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Abstract 
This thesis describes the impact of high energy density nutritional supplement drinks 
(HENSDs) on appetite regulation, energy intake and cardiovascular risk factors in lean 
healthy females. It also explores the impact of Solid Ready-To-Use Foods (RTUF) and a 
milk based Liquid Ready-To-Use proprietary Supplement (LRUS) on weight gain and 
appetite in mild to moderate underweight children from Pakistan. The thesis consists of a 
literature review (Chapter 1), general methods (Chapter 2), three experimental chapters 
(Chapter 3- Chapter 5), each describing an independent research study, and a general 
discussion and conclusion chapter (Chapter 6). 
Accumulating evidence suggests that oral HENSDs increases energy intake and are 
beneficial for the treatment of malnutrition. Their effectiveness however, may be 
diminished by acute suppression of appetite. Therefore, the first experimental study aimed 
to investigate the extent to which the consumption of the HENSD in the fasted state 
reduces energy intake during a consecutive breakfast and lunch and whether this reduction 
relates to changes in appetite and metabolic appetite regulators. Twenty three young 
females with BMI of 18.2 ± 0.8 kg/m
2 
consumed either a HENSD or a low energy drink 
(PLACEBO) after fasting, in a single blind randomized cross-over study. Appetite was 
tracked, and blood taken, prior to the intake of the supplement and 240 minutes afterwards. 
Energy intake was recorded during an ad libitum buffet breakfast served 60 minutes and an 
ad libitum buffet lunch served 240 minutes post supplementation. Energy intake during the 
breakfast was significantly higher in the PLACEBO than in the HENSD trial. No 
significant difference was found in energy intake during the lunch between the two trials. 
When energy provided by supplements was added to energy intake during breakfast and 
lunch, the energy intake in the HENSD trial was significantly higher. The net effect was 
that total energy intake was increased by 1.07 ± 0.34 MJ in the HENSD trial. During the 
pre-breakfast, feelings of hunger and a desire to eat were significantly lower; satiety and 
fullness were significantly higher in the HENSD trial. After breakfast, none of the appetite 
measures differed between the trials regardless of plasma PYY, CCK, and insulin 
concentrations being significantly higher in the HENSD trial.  
The second experimental study investigated the time scale of compensation after HENSD 
supplementation. Over a five day period, energy intake was measured after the 
supplementation during the evening meal, and during the ad libitum breakfast, lunch and 
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dinner consumed on the consecutive day. Since, consumption of HENSD due to the 
promotion of energy was expected to promote positive energy balance, this study also 
aimed to investigate the impact of HENSD supplementation on cardio-metabolic risk 
factors. Twenty-three young healthy females with a BMI of 18.7 ± 1.2 kg/m
2
 participated 
in a single blind randomised, controlled, crossover study. Participants consumed either 
HENSD or a PLACEBO for five days in the evening. Participants were asked to record 
their dietary intake during the days of supplementation. On the sixth day plasma lipids, 
insulin and glucose concentrations were measured in the fasted state and at 30, 60, 90 and 
120 minutes after the ad libitum buffet breakfast and lunch. The findings showed that the 
average daily energy intake was significantly higher in HENSD trial and that consumption 
of HENSDs in the evening induced immediate and short-lasting reduction in energy intake. 
Fasting plasma concentrations of insulin and HOMA (IR) were significantly higher in the 
HENSD as compared to the PLACEBO trial. No significant differences were detected in 
fasting plasma concentrations of TAG, total-, HDL- and LDL-cholesterol between the 
HENSD and the PLACEBO trials.  
  
The third experimental study explored the efficacy of RTUFs and LRUS in promoting 
weight gain and their effect on appetite regulation in mild to moderate malnourished 
children. An open labelled randomized controlled trial was conducted in primary schools 
of Pakistan. Sixty eight mild to moderate underweight children aged 8.2 ± 1.2 years were 
randomly allocated to receive either RTUF or LRUS providing 500 kcal/ day in addition to 
regular diet in their school for four weeks. The children‘s height, weight, and skinfolds 
were measured before supplementation and at the end of the supplementation. The children 
marked visual analogue scale questionnaires before the provision of the first and the last 
supplement. The findings from this study indicated that after four weeks of 
supplementation the average weight gain, change from the baseline in weight-for-age Z 
score (WAZ), height-for-age Z score (HAZ) in the RTUF and LRUS were not significantly 
different between the two groups. The difference in the appetite measures before the 
provision of the first and the last supplement between the two groups were also not 
significantly different. The total extra energy supplied for 4 weeks would have been 
expected to lead to an excess gain of 2kg. Thus, at least 2/3 of the energy ingested 
appeared to have been compensated by less intake at other times. 
 
Based on the data obtained the following conclusions have been drawn: 
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 Following oral intake of HENSDs, the appetite suppressive action of the metabolic 
and hormonal appetite modulators is short lived.  
 
 HENSDs consumption for five consecutive days in the evening induced 
compensation, which happens immediately, disappears quickly and is short-lived 
which allows only partial compensation for the energy provided by HENSD. 
 
 Short-term supplementation with HENSD is safe in relation to the impact on 
cardiometabolic risk factors such as plasma concentration of fasting and 
postprandial lipids but can be expected to reduce insulin sensitivity. 
 
 RTUF and LRUS given to the community has similar impact on improving the  
nutritional status in mild of moderate underweight children but the overall rate of 
weight gain was lower than expected. 
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1 Introduction and Literature Review 
1.1 Malnutrition 
1.1.1 Prevalence, causes and consequences 
Malnutrition is a condition in which nutrients such as proteins, vitamins, 
minerals and energy are deficient or in excess (imbalance). This causes severe 
measurable adverse effects on body composition, function and clinical 
outcomes (Meier and Stratton 2008, Nieuwenhuizen, Weenen et al. 2010). 
There are the controversies and confusion regarding the definition of 
malnutrition and its recognition. There is no universally accepted definition of 
malnutrition (Alberda, Graf et al. 2006). According to the World Health 
Organization (WHO) malnutrition is defined  as “The cellular imbalance 
between the supply of nutrients and energy and the body’s demand for them to 
ensure growth, maintenance, and specific functions” (Alberda, Graf et al. 
2006). 
 
It is suggested that for defining malnutrition, deficiencies of energy, protein, 
fat free mass, and function should be included, and for the operational 
definition BMI, involuntary weight loss and nutritional intake should be 
incorporated. Malnutrition can be explained as either over or under-nutrition 
with inflammation (Meijers, van Bokhorst-de van der Schueren et al. 2010). In 
this context, we are using under-nutrition. The WHO cites malnutrition as the 
single greatest threat to the world‘s public health (Nieuwenhuizen, Weenen et 
al. 2010). One out of twelve people is malnourished worldwide. According to 
estimates, 148 million children in the world are underweight, out of which 78 
million are from South Asia and 36 million are from Sub-Saharan Africa. 
Approximately 19 million are severely malnourished (Walton and Allen 
2011). Undernutrition is a direct cause of about 300,000 deaths per year and is 
indirectly responsible for about half of all the deaths in young children 
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(Nemer, Gelband et al. 2001, Black, Morris et al. 2003, Müller, Garenne et al. 
2003). 
 
Developed world 
 
Malnutrition is a common condition affecting millions of individuals in the 
developed world. Its victims are not age specific. In hospitalized patients, 
almost 50% are affected by under-nutrition, and the incidence further increases 
with an increase in the duration of hospital stay. Fifty-five percent of elderly 
people are undernourished when they are hospitalized (Milne, Avenell et al. 
2006). In Australia, the rate of malnutrition in hospitals is between 30-40% 
(NICE 2006). In the UK more than 3 million people are malnourished or at 
risk of malnutrition of which 1.3 million people were aged over 65 years (Elia, 
Russell et al. 2010, Cawood, Elia et al. 2011).  Ninety-three percent of these 
malnourished people are living in the community, 5% in care homes and 3% in 
hospitals or in other NHS settings (Elia, Russell et al. 2010, Stratton and Elia 
2010).   
 
Hospital admissions  at risk of malnutrition range from10-60%  and 15-30% of 
outpatients are at risk of malnutrition (Stratton and Elia 2010). The risk of 
death is directly related to the degree of malnutrition (Pelletier, Frongillo Jr et 
al. 1993, Black, Morris et al. 2003, Müller and Krawinkel 2005). Disease 
related malnutrition is prevalent across all health settings, including: hospitals, 
social care settings and sheltered homes (Cawood, Elia et al. 2011). Over the 
last ten years the prevalence of acute malnutrition in  hospitalized children in 
the UK, France, Germany and USA varied from 6-14% while in Turkey its 
prevalence was up to 40% (Joosten and Hulst 2011). 37% of the 
institutionalized elderly in European countries are malnourished (Manders, de 
Groot et al. 2009). According to a campaign Fight Against Malnutrition, it is 
estimated that about 5% of the European Union population is at risk of 
developing malnutrition (Ljungqvist, van Gossum et al. 2010). The British 
20 
 
 
 
 
Association of Parenteral and Enteral Nutrition (BAPEN) estimate that this 
corresponds to 20 million people (Ljungqvist, van Gossum et al. 2010). 
 
It has been estimated that disease-related malnutrition costs more than £13x 
10
9 
annually to the UK (Stratton 2005, Elia and Russell 2009, Elia and Stratton 
2009, Elia, Russell et al. 2010, Stratton, Hébuterne et al. 2013). In several 
countries around Europe, for example, the Netherlands, Ireland and Germany, 
similar calculations have been done at the national level (Rice and Normand 
2012). In England and Wales, in 2007, the cost of nutrition prescriptions was 
£157x10
6
. Of this, about £99x10
6
 was for oral nutritional supplements 
(Stratton and Elia 2010). On average the under-nourished hospitalized patients 
incurred 19% more cost to the hospital as compared to the well-nourished 
patients. Some studies have found that the treatment cost associated with 
malnutrition is 75% or even 300% higher (Nieuwenhuizen, Weenen et al. 
2010). According to one study it was found that the treatment of malnourished 
patients costs more than twice that of treating non-malnourished patients 
(Guest, Panca et al. 2011). 
 
Developing world 
 
Malnutrition is a highly pervasive and damaging condition in  low and middle 
income countries, and is prevalent in community settings (Black, Allen et al. 
2008). Childhood malnutrition and under nutrition is common in low and 
middle-income countries. According to UNICEF 129 million children (25%) 
under 5 years of age in these countries are underweight and approximately 195 
million children (28%) are stunted (Imdad, Sadiq et al. 2011). According to 
the UN, malnutrition kills 10 children every minute (Blössner and de Onis 
2005). WHO estimates, that by 2015, the worldwide prevalence of 
malnutrition will be 17.6%, and 29% of the population will have stunted 
growth due to under nutrition. Not surprisingly in the low income countries 
112 million (20%) out of 556 million children under 5 years of age are 
underweight and 36 million (6.4%) are suffering from moderate wasting 
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(Golden 2009, Michaelsen, Hoppe et al. 2009).  The data from 139 countries 
showed that about 10.2 % of the deaths are attributable to wasting, and wasted 
children have a three times higher risk of death compared to well nourished 
children (Black, Allen et al. 2008, Huybregts, Houngbé et al. 2012). South 
Central Asia has the highest estimated point prevalence (19%) of moderate 
acute malnutrition, and the highest absolute number of affected children (30 
million) (Lazzerini, Rubert et al. 2013). In South Asian countries, the most 
prevalent public health issue is malnutrition among children under five years 
of age. It is documented that more than 50 percent of the world‘s malnourished 
children are residing in Pakistan, India and Bangladesh (Gillespie and Haddad 
2003, Hirani 2012).  
  
The major underlying cause of malnutrition and its determinants is poverty 
(Müller and Krawinkel 2005, Imdad, Sadiq et al. 2011). In a given population 
the degree and distribution of malnutrition depends upon many factors, such as 
socio-economic, political, seasonal, climatic, sanitation conditions, educational 
level, food production,  prevalence of infectious diseases, breast feeding 
habits, and non-availability of health services (Brabin and Coulter 2003, 
Young, Borrel et al. 2004, Müller and Krawinkel 2005, Grover and Ee 2009, 
Imdad, Sadiq et al. 2011). Poor dietary intake along with repeated infections 
especially in the underprivileged population is the main contributor to 
malnutrition. Inadequate calorie intake due to less dietary intake or decreased 
diet assimilation, stress due to critical acute illness, or chronic inflammation 
extensive burns or postoperative sepsis, gastrointestinal disease, mixed 
metabolic abnormalities like AIDS, cancer or chronic liver diseases  are 
considered to be important etiological factors for malnutrition (Alberda, Graf 
et al. 2006, Imdad, Sadiq et al. 2011). 
 
Despite the high global prevalence of malnutrition, it remains under-treated, or 
undetected. This causes an enormous detrimental effect on the health of each 
individual and imposes a financial burden on both the individual and the health 
care system (Cawood, Elia et al. 2011). Malnourished children are at increased 
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risk of mortality and morbidity as compared to well-nourished children. There 
is an increased risk of death with increasing severity of malnutrition (Imdad, 
Sadiq et al. 2011). 
 
Figure 1.1: Causes and consequences of malnutrition 
 
Malnutrition predisposes the body to the risk of different diseases, and also 
causes severe adverse outcomes of disease in a variety of ways (Cawood, Elia 
et al. 2011). Disease related malnutrition is very harmful physiologically and 
clinically, by delaying recovery from illnesses and impairing the quality of life 
(Stratton and Elia 2007). If malnutrition is not treated or inefficiently treated, it 
will lead to poor quality of life of the patients, increase complications, delay 
recovery from diseases, result into more use of healthcare facilities, more 
health care expenses and more rehabilitation needs (Alberda, Graf et al. 2006, 
Nieuwenhuizen, Weenen et al. 2010, Stratton and Elia 2010, Cawood, Elia et 
al. 2011). Malnutrition leads to severe adverse metabolic events which  
compromise the body‘s  immunity,  impairs body function, composition and its 
ability to acclimatize, recover and to survive (Alberda, Graf et al. 2006, 
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Cawood, Elia et al. 2011). Malnutrition also has severe adverse effects on the 
cognitive development of children, decreased productivity, reduced ability to 
work and small adult physique (Imdad, Sadiq et al. 2011). Taking into 
consideration the enormous costs of malnutrition, a condition that is largely 
preventable and treatable, a timely identification followed by the most 
suitable, effective, efficient, evidence-based treatment is recommended 
(Stratton and Elia 2010). 
 
1.1.2 Nutritional supplements and their use in the treatment of 
malnutrition in developing countries 
Interventions to prevent protein energy malnutrition include food 
supplementation, dietary diversification and fortification of salt with iodine 
(Müller and Krawinkel 2005). Other preventive measures include maternal 
nutritional education, reduction in the price of food items, high immunization 
coverage and correct management of infectious diseases (Müller and 
Krawinkel 2005). In the majority of cases of malnutrition, energy intake is low 
therefore supplements may be given to provide extra energy and 
macronutrients which in turn increases the body weight (Lawson, Doshi et al. 
2000). 
Supplements are products which are used in conjunction with a diet containing 
vitamins, minerals,  proteins and amino acids to enhance the diet (Maughan, 
Depiesse et al. 2007). Oral nutritional supplements are usually multinutrient 
mixtures containing macronutrients (proteins, carbohydrates and fats) and 
micronutrients (minerals, vitamins and trace elements). The oral nutritional 
supplements are energy dense, mostly containing 1.5kcal/ml to 2.4kcal/ml 
(Stratton and Elia 2010). They are usually available in liquid form or in 
powder form which is mixed with whole milk before drinking (Stratton and 
Elia 2010). Usually, the supplements available in liquid form are ready to use. 
Health Care professionals find them convenient to administer in hospital and 
community settings (Stratton and Elia 2010). A variety of supplements are 
available which may be nutritionally complete or incomplete (lacking some of 
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essential micronutrients or fatty acids) and may be modular (containing only 
one or two energy sources). Specialised supplements are also available for 
treating malnourishment in specific diseases such as cancer, diabetes, hepatic  
or renal diseases (Stratton and Elia 2007). High-energy nutritional supplement 
drinks (HENSDs) have substantially higher energy content and are 
supplemented with a large variety of micronutrients. For example, 
Scandishake
®
, a mainstream dairy HENSD has 2.5 kcal/ml, 5% protein, 13% 
fat, and 61% carbohydrates, 230 mg of phosphorus and an osmolarity of 880 
mOsmol/L.  
In the 1960‘s supplements were first used for prevention of malnutrition in 
Guatemala, where children under 3 years of age, and pregnant women, were 
provided with either a moderate energy supplement (90kcal/ 100 ml), or, a low 
energy supplement (33kcal/100 ml). It was found that the nutritional 
interventions were associated with greater improvement in height, weight and 
mental development of the children (Rivera and Habicht 2002). In low and 
middle-income countries, moderate acute malnutrition was treated by 
providing food supplements to improve dietary habits (Lazzerini, Rubert et al. 
2013). Two main categories of food supplements include lipid based nutrient 
supplements (with high lipid content as ready- to- use foods and blended food 
supplements which are food mixtures for example corn-soy blends, or wheat-
soy blends that can be cooked at home to make porridge or soup (Lazzerini, 
Rubert et al. 2013).    
 
According to the WHO, recommendations for the treatment of malnutrition, 
during the nutritional rehabilitation phase the children should receive an 
energy and protein dense diet fortified with vitamins and minerals, to promote 
rapid weight gain. For this purpose, a solid, ready-to-use-food (RTUF), has 
been developed which is made up of peanut butter (Diop, Dossou et al. 2003).  
RTUF was developed as an alternative to the F-100 formula or milk oil 
formula to be used in the hospitals and nutritional rehabilitation centres after 
initiation of cure (Brewster 2006). In RTUF, the skimmed milk was replaced 
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by groundnut paste and lacto-serum. RTUF is an energy dense paste which 
does not require cooking and can be stored for several months (24 months 
shelf life) without spoiling (Briend 2001, Ashworth 2006). These RTUF have 
low osmolarity and can be eaten directly from the silver foil package by the 
child without the addition of water or milk which reduces risk of bacterial 
contamination (Diop, Dossou et al. 2003, Lazzerini, Rubert et al. 2013). In 
hospital settings the major limitation of RTUF is that it cannot be administered 
easily through a naso-gastric tube (Brewster 2006). RTUF have the following 
salient features: good nutritional characteristics, low cost, resistant to bacterial 
contamination, long shelf life, does not need refrigeration, highly palatable, 
does not require any further processing,  prior feeding and its consistency is 
suitable for feeding infants and children (Ciliberto, Sandige et al. 2005, 
Brewster 2006).  
 
Malnutrition is a potentially preventable disease and is a chief contributor to 
child mortality and the overall global disease burden (Black, Allen et al. 2008, 
Hendricks 2010). Childhood malnutrition is associated with a number of socio-
economic and environmental factors such as poverty leading to inadequate 
food intake, lack of access to food, poor hygienic practices, lack of sanitation, 
poor health, recurrent infections and large family size (Golden 2009, Babar, 
Muzaffar et al. 2010).  
 
Pakistan is the world‘s seventh most populous country and 45% of its 
population is under 15 years of age. Evidence suggests that malnutrition in 
children between 5-12 years is high in Pakistan and is a very serious 
impediment in the development of the nation (Mian, Ali et al. 2002, Pappas, 
Agha et al. 2008). In Pakistan, 23.9% of  the population lives below the 
poverty line and 38% of all children under 5 years of age are underweight 
(Pappas, Agha et al. 2008, Akram, Arif et al. 2010). According to National 
Health Survey of Pakistan, one out of three children is malnourished, 6.2-8.3 
million (30-40%) Pakistani children have stunting (low height for their age), 
and more than 2.9 million (> 14%) children have wasting (low weight for their 
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height) (Gillespie and Haddad 2003, Mujib, Kazmi et al. 2006). In Pakistan, 
there is a complex interplay between poverty, hunger and uncomplicated 
malnutrition coupled with un-acceptable treatment cost to the family. In such 
circumstances, the family does not consider uncomplicated malnutrition as a 
health problem. That is why health care is approached only when the problem 
is associated with co-morbidities, which lead to increased mortality.       
 
Malnutrition is identified using standard deviation scores (Z-scores), which are 
a statistical measure identifying how body weight and height compares to 
reference values. The World Health Organization (WHO) Global Database on 
Child Growth and Malnutrition uses a Z-score cut off point of <-2SD to 
classify undernutrition and a cut-off of >+2 SD to classify overweight in 
children (Wang and Chen 2012). Moderate acute malnutrition (MAM) is 
defined as  weight- for-height Z-score (WHZ) <-2 and ≥-3 without oedema 
(Chang, Trehan et al. 2013). Children with MAM are at three times greater 
risk of deaths as compared to the well-nourished children and are prone to 
morbidity from infectious diseases and suffer from delayed cognitive and 
physical development (Black, Allen et al. 2008, Chang, Trehan et al. 2013). 
Worldwide 11% of the children under 5 years of age are suffering from MAM 
(Black, Allen et al. 2008). It is estimated that in developing countries 32% 
(178 million) of children had weight-for-age Z score (WAZ) of less than -2 
(Black, Allen et al. 2008). A mildly underweight child with (WAZ) between -
1.0 and -2.0 have twice the risk of death as compared with WAZ >-1.0, and the 
relative risk increases to five times and eight times for the moderately 
underweight ( WAZ between -2.0 and -3.0) and severely underweight children 
(WAZ <-3.0), respectively (Caulfield, de Onis et al. 2004, Thakwalakwa, 
Ashorn et al. 2010). More detailed information regarding the use of RTUF in 
community settings in low- and middle-income countries in children is 
explained later in this chapter.  
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1.1.3 Use of nutritional supplements in developed countries 
As major cause of malnutrition is reduced dietary intake, in 2006 the National 
Institute for Health and Clinical Excellence (NICE) recommended an increase 
in dietary intake using a variety of nutrition support strategies including oral 
nutritional supplements, artificial nutritional support and dietary counselling. 
All these strategies are aimed to reverse inadequate food intake by increasing 
energy intake and to improve awareness, knowledge, practices and attitudes 
related to healthy diet (Cawood, Elia et al. 2011, Lazzerini, Rubert et al. 
2013). Inadequate energy, protein and micronutrient intake mostly occurs in 
disease related malnutrition as appetite is poor due to diseases and  patients  
ingest less food with less proteins and less nutrients, and in some cases protein 
requirements are also higher and there is the need for more protein to 
encourage damaged tissues repair and to facilitate body repletion (Cawood, 
Elia et al. 2011). 
 
The current evidence suggests that the nutritional supplements have several 
beneficial effects (Table 1.1). A number of meta-analyses and systematic 
reviews indicate the beneficial clinical outcomes while using nutritional 
supplements (Stratton and Elia 2007, Cawood, Elia et al. 2012). There is a 
significant reduction in the rates of complications like pressure ulcers, surgical 
wound healing, chronic obstructive airways disease, liver diseases and 
infections with the use of nutritional supplements in hospitals (Olofsson, 
Stenvall et al. 2007), community (Tidermark, Ponzer et al. 2004) and in both 
hospitals and community settings (Stratton and Elia 2007, Botella-Carretero, 
Iglesias et al. 2008, Cawood, Elia et al. 2012). In the majority of cases the 
liquid ready to use multi-nutrient nutritional supplements with a reported 
intake of 1.05-2.52 MJ/d (250- 600kcal) were used. The use of nutritional 
supplements during peri-operative periods have constantly indicated fewer 
complications including major complications, infectious complications and 
intra-abdominal/thoracic complications before, during and after hospitalization 
(Stratton and Elia 2010, Cawood, Elia et al. 2011). 
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 In elderly patients with a range of diseases: respiratory, acute illnesses, hip 
fracture, gastrointestinal diseases, and cancer were reported to have improved 
functional outcomes with the use of nutritional supplements (Norman, 
Kirchner et al. 2008, Norman, Pirlich et al. 2011, Piantadosi, Visvanathan et 
al. 2011). Functional outcomes include handgrip strength, physical and mental 
health, walking distance and activities of daily life, quality of life and mobility 
(Bourdel-Marchasson, Barateau et al. 2000,Stratton,Green et al. 2003, 
Cawood, Elia et al. 2011).  
The systemic review and meta-analysis by Cawood et al 2012 assessed thirty-
six randomized controlled trials (n=3790) and a series of meta-analysis of high 
protein oral nutritional supplements provided evidence that oral nutritional 
supplements produce clinical, nutritional and functional benefits. This 
systemic review and meta-analysis reported that an overall mean weight 
change was greater in the supplement group (2.1kg; -1.3 to 11.0 kg) as 
compared to the control group (-1.6kg; -2.4 to 2.7 kg) (Cawood, Elia et al. 
2012). Studies have also reported information regarding the beneficial impact 
of the nutritional supplements on body composition including the triceps 
skinfolds, mid upper arm circumference, fat mass measured by DEXA and 
bone mineral density (Gariballa, Forster et al. 2006, Gariballa and Forster 
2007, Norman, Kirchner et al. 2008, Cawood, Elia et al. 2012).  
Studies have shown that the improvement after the supplementation in total 
energy intake, body weight and body functions, occurs more commonly in 
those patients with a BMI of less than 20kg/m
2
 compared to those with a BMI 
of more than 20kg/m
2
 (Stratton and Elia 2000). Some of the studies have 
shown that in older adults the nutritional supplements have improved the 
proteins, vitamins, minerals and energy intake (Gray-Donald, Payette et al. 
1994, Turic, Gordon et al. 1998, Edington, Barnes et al. 2004). It is also found 
from the meta-analysis that the oral nutritional supplements also reduce the 
length of hospital stay and readmission rates thus improving the health 
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economy (Stratton, Green et al. 2003, Norman, Kirchner et al. 2008, Cawood, 
Elia et al. 2011, Stratton, Hébuterne et al. 2013). 
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Table 1.1 A summary of studies, assessing the beneficial clinical and functional outcomes of the oral nutritional supplement. 
 
Systemic 
Review 
Study 
design 
Patient group  Settings Interventions No. of trials/No. 
of Patients 
Significant benefits to clinical and functional 
outcomes with supplements 
(Stratton, 
Hebuterne 
et al. 2013) 
Systemic 
review and 
meta-
analysis 
Adults of any 
nutritional 
characteristics 
(mostly elderly 
patients) 
Community 
settings 
All ONS types, 
energy density 
1.00–2.48 kcal/ml, 
(475 to 1200 
kcal/day) for 6wks 
- 1 yr, 
Systematic review 
(9 RCT, n = 1190) 
 
Meta-analysis ( 6 
RCT, n = 852) 
Hospital (re)admission: Significant reductions 
with ONS vs. routine care (OR 0.59, 95% CI 0.43–
0.80, P = 0.001) 
(Collins, 
Elia et al. 
2013) 
Systemic 
review and 
meta-
analysis 
Stable patients 
with a diagnosis 
of COPD 
All settings ONS and ETF 12 RCT (n = 448) Respiratory muscle strength:  
Significantly improved with ONS  
(pressure +3.86 standard error (SE) 1.89 cm H2O, P 
= 0.041; maximal 
expiratory mouth pressure +11.85 SE 5.54 cm H2O, 
P = 0.032) 
 Handgrip strength: Significantly improved (+1.35 
SE 0.69 kg, P = 0.05) with ONS and ETF 
Weight gains: Weight gain of ≥2 kg with ONS. 
QoL: Improved with supplementation  
(Cawood, 
Elia et al. 
2012) 
Systemic 
review and 
meta-
analysis 
Elderly with hip 
fractures, 
pressure ulcers,  
COPD, cancer, 
gastro-intestinal 
disease, and a 
range of critical 
and acute 
illnesses 
Hospital and 
community 
settings 
ONS energy 
densities (0.75–
3.85 kcal/ml) and 
the percentage 
energy from 
protein ranged 
from 20–54% (149 
to 995 kcal/day) 
36 RCT (n=3790) Complications: ONS significantly reduced the 
incidence of complications (pressure ulcers, 
wounds, non healing fracture, infections, or a 
combination of complications) compared to control 
(OR 0.68 (95% CI 0.55–0.83). 
Functional: ONS improved grip strength (1.76 kg 
(95%CI 0.36–3.17) 
Energy Intake: ONS increased intake of protein (p 
< 0.001) and energy (p < 0.001)  
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Improvements in weight: ONS significantly 
improve weight   
Readmissions: ONS, significantly reduce hospital 
readmissions compared to control (OR 0.59 (95% 
CI 0.41–0.84). 
(Norman, 
Pirlich et 
al. 2011) 
RCT Malnourished  
with benign Gl 
disease 
Hospital  ONS 
(~200ml/day)  
for 3 months 
n= 114 QoL: Improved with ONS 
Cost effective: Treatment is cost effective 
according to international benchmarks  
(Norman, 
Kirchner 
et al. 2008) 
RCT Patients with 
benign GI 
disease 
Hospital 
setting 
ONS ( 200 ml) per 
day (nutritionally 
complete, 150 kcal 
and 10 g protein/ 
100 ml, 27% 
energy from 
protein) for three 
months compared 
with DC 
n= 80 The following outcome measures significantly 
improved with ONS as compared to DC 
Energy intake: Total energy  and protein intake 
(p<0.0001) 
Hand-grip 
Strength: 26.1 ± 11.3–31.5±10.1 kg, (p<0.0001)  
Peak flow: 329.2 ± 124.0–388.9 ± 108.4 l/min( p 
=0.004 
QoL: Improved  
Hospital readmissions: Significantly less (p = 
0.041). 
(Olofsson, 
Stenvall et 
al. 2007) 
RCT Patients with 
femoral neck 
fracture aged ≥ 
70 years  
Hospital 
Settings 
Nutritional and 
protein drinks (400 
ml/day) and 
protein-enriched 
meals for at least 4 
days 
postoperatively 
during 
hospitalization. 
n=157 Post-operative complications:  
a) Fewer patients in the intervention group 
developed post-operative delirium (46 patients in 
the intervention group vs. 54 patients in the control 
group, p=0.022).  
b)The number of days with delirium was 
significantly fewer (p<0.001) in intervention group 
c) Significantly less number of patients developed 
decubitus ulcers in intervention group 
d) Hospitalization period was shorter in intervention 
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group (p = 0.019) 
(Botella-
Carretero, 
Iglesias et 
al. 2008) 
RCT Geriatric patients 
aged ≥ 65 years 
submitted to 
surgery 
for hip fracture 
Hospital 
settings 
2 types of ONS: 
a) 37.6 g of protein  
(500 kcal/ day) 
b) 36 g of protein 
(152 kcal/day) 
n=90 Small effect of ONS on serum albumin was 
detected in patients with post-surgical 
complications. 
 
 
 
(Stratton 
and Elia 
2007) 
Review of 
reviews 
Gastrointestinal 
surgical patients 
All settings –
mostly 
hospitalized 
patients  
ONS (single 
nutrient and multi-
nutrient) 250-600 
kcal/day for 7 
days-10 weeks 
18 RCT (n=907 ) 
of ONS and ETF 
6RCT (n=418) of 
ONS 
 
Mortality: Significantly lower in supplemented 
group with OR 0.61 ( 95% CI 0.48-0.78). 
Morbidity: Supplements significantly reduced 
postoperative complications including wound and 
lung infections, postoperative ileus, unresolved 
peritonitis and wound dehiscence with OR 0.37 
(95% CI 0.26-0.53). 
(Gariballa 
and 
Forster 
2007) 
Prospective
, double-
blind, 
placebo-
controlled 
trial 
Acutely ill 
elderly patients 
aged ≥ 65 years 
Hospital 
setting 
ONS (995 
kcal/day) 
(carbohydrate 45%, 
fat 35% and protein 
20%) and 100% of 
the Reference 
Nutrient Intakes for 
6 weeks 
 
 
n=225 Nutritional status: Serum 
albumin concentration, red-cell folate and plasma 
vitamin B12 concentrations significantly improved 
in the supplement group as compared to placebo 
group. 
Symptoms of depression:  In the supplement 
group there was a significant increase in the number 
of patients with no symptoms of depression and a 
decrease in those with symptoms of mild or severe 
depression as compared to placebo group.  
(Milne, 
Avenell et 
al. 2006) 
Meta-
analysis 
Older people 
aged ≥ 65 years 
(excluding 
critically ill 
patients and 
All settings Commercial ready-
made ONS and 
other milk-based 
supplements 175-
1000 kcal/day 
55 trails( n 
=9187) 
Mortality: Improved 
survival with supplementation in : 
a) Undernourished people (17 trials; 2093 
participants) (Peto OR, 0.73 [CI, 0.56 -0.94]) 
b) People aged ≥75 years (18 trials; 1611 
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patients 
recovering from 
cancer treatment) 
Duration of 
Supplementation : 
10 days – 18 
months 
 
participants) (Peto OR, 0.64 [CI, 0.49 - 0.85]),  
c) Ill people (22 trials; 6630 participants) (Peto OR, 
0.86 [CI, 0.74 - 1.00]). 
Morbidity and Complications: In hospitalized 
patients supplements significantly decrease 
complications 
(Peto OR, 0.72 [CI, 0.53 to 0.97]) like infective 
complications, incomplete wound healing etc. 
(Gariballa, 
Forster et 
al. 2006) 
RCT Patients aged 65 
-92 years. 
Hospital 
setting 
ONS (995 
kcal/day)  and 
100% of the 
Reference Nutrient 
for 6 weeks 
n=445 Readmission: 29% patients in the supplements 
group were readmitted to the hospital compared 
with 40% in the placebo group (adjusted hazard 
ratio 0.68 [95% CI 0.49-0.94]). 
Mean Length of hospital stay: was 9.4 days in 
supplement group compared with 10.1 days in 
placebo group. 
Nutritional Outcomes: Serum albumin 
concentration increased significantly in the 
supplement group 
(Stratton, 
Bircher et 
al. 2005) 
Systemic 
review and 
meta-
analysis 
Patients with 
chronic kidney 
disease receiving 
maintenance 
dialysis 
Any setting ( 
hospital, 
outpatient or 
home) 
ONS and enteral 
tube feeding 
18 studies: RCT 
(n=5), non-RCTs 
(13) 
Biochemical outcomes: Enteral nutritional support 
increased serum albumin concentration by 0.23g/dl. 
Energy Intake: Increased total energy intake 
Clinical outcome: May improve clinical outcomes 
(Stratton, 
Ek et al. 
2005) 
Systemic 
review and 
meta-
analysis 
Patients with, or 
at risk of 
developing, 
pressure ulcers 
All settings –
mostly 
hospitalized 
elderly, post-
surgical 
patients. 
ONS (250–500 
kcal/day) 
 
Duration of 
supplementation: 
2–26 weeks 
15 studies: RCT 
(n=8),CCTs 
(n=1),CTs (n=1) 
and cohort studies 
(n=5) 
Prevention of pressure ulcers: ONS were 
associated with significantly lower incidence of 
development of pressure ulcers compared to routine 
care with OR 0.75(95% CI 0.62-0.89, n=1224) 
Healing of  existing pressure ulcers: A tendency 
of improved wound healing 
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(Stratton 
2000) 
(Stratton 
and Elia 
2000) 
Systemic 
review 
Patients with 
specific diseases  
Community 
settings 
ONS (were used in 
80% of the studies) 
with energy density 
(3·25–16·0 kJ/ml), 
ranged from 
< 0·42 MJ/d to > 
10·5 MJ/d.  
Duration of 
supplementation: 1 
week 
-over 2 years. 
84 trials; 45 RCT 
(n=1728) and 
non-39 RCT 
(n=842). Studies 
grouped according 
to disease: 
COPD (n=14), 
Crohn‘s disease 
(n=9), cystic 
fibrosis (n=11), 
elderly (n=12), 
HIV and AIDS 
(n=15); liver 
disease (n=2), 
malignancy 
(n=15); other 
conditions (n=6). 
Weight change: The mean percentage weight 
change of patients receiving ONS (2·93 %) was 
greater than that of the control patients (1·15 %).  
Patients with a mean 
BMI < 20 kg/m2 had a greater percentage weight 
change (4·7 % of the body 
weight) than patients with a mean BMI > 20 kg/m2 
(2·4 % of the body weight). 
Total energy intake:  
Mean increase in energy intake = 67 % of the 
energy of the ONS consumed), which varied 
considerably according to the disease state and the 
BMI of patients. 
Functional benefits:  
COPD patients: Improved muscle strength, 
walking distance and well-being.  
Children with cystic fibrosis: Improved growth 
performance. 
Elderly: reduced falls and increased activities of 
daily living 
(Lauque, 
Arnaud-
Battandier 
et al. 2000) 
RCT Elderly people 
aged ≥ 65 years 
Community 
setting ( 
private 
nursing 
home) 
ONS (300-500 
kcal/day) for 60 
days 
n=88 ONS improved: 
a) Mini-nutritional assessment score: in subjects 
at risk of malnutrition and in malnourished subjects 
(from 13.9± 2.6 to 17.1 ± 3.9). 
b) Weight gain: (1.4 ± 0.5kg) in subjects at risk of 
malnutrition and  (1.5 ± 0.4kg) in malnourished 
subjects.  
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Abbreviations: ONS, Oral nutritional supplements; RCT, Randomized controlled trial; ETF, Enteral tube feeding; OR; Odds ratio; CI, 
Confidence interval; CCTs, Controlled clinical trials; CTs, Clinical trials; GI disease, Gastrointestinal disease; COPD, Chronic obstructive 
pulmonary disease; QoL,  Quality of life; DC, dietary counselling. 
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Stratton found that the energy from the supplements was additional to that 
taken from the habitual food intake with an increase in mean energy intake to 
67% of the energy consumed by the nutritional supplements although this 
contribution varied with the disease state and BMI of the patients. In the 
patients with a BMI <20 kg/m
2
 the proportion of supplement energy additional 
to the food intake was approximately 79% compared to 28% in those with a 
BMI greater than 20kg/m
2
.
 
The individuals with a BMI <20 kg/m
2
 showed 
more improvement in the total energy intake, body weight and the body 
function compared to the individuals with a BMI >20 kg/m
2 
(Stratton 2000, 
Stratton and Elia 2007). 
The evidence suggests that there was slight suppression of normal food intake 
with the oral nutritional supplements but they effectively increased the total 
energy and nutritional intake (Stratton, Green et al. 2003, Stratton 2005, 
Milne, Avenell et al. 2006, Stratton and Elia 2007, Cawood, Elia et al. 2011, 
Hubbard, Elia et al. 2012). In one prospective randomized trial based on 
interviews with patients about their dietary habits and appetite, no significant 
difference was found in appetite between the two groups; one on the 
nutritional supplement, and another without the supplement, in older non-
demented females with hip-fracture (Carlsson, Tidermark et al. 2005). Studies 
have also found that there was significantly more protein and energy intake 
with the supplements (Edington, Barnes et al. 2004), and there was no 
significant reduction in food intake (Norman, Kirchner et al. 2008).  A multi-
centre trial to look at the effects of nutritional supplements in critically-ill 
elderly patients found that, whilst oral nutritional supplements increased 
energy and protein intake of elderly patients, the actual intake was low 
compared to what was expected (Bourdel-Marchasson, Barateau et al. 2000). 
Another study found that there was slight decrease in the voluntary intake of 
food in the supplement group compared to controls but the total energy intake 
including the supplement was significantly higher in the supplement group 
(Lauque, Arnaud-Battandier et al. 2000).  
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A recent meta-analysis suggested that the consumption of oral nutritional 
supplements could increase the daily energy intake by a mean of 375 kcal/d 
(Hubbard, Elia et al. 2012). However, another systematic review suggested 
that this translated into an average total weight gain of only 1.7 kg, with wide 
variability (Cawood et al 2012). A rare longer term trial in children and 
adolescents with cystic fibrosis showed no net gain in BMI (Poustie et al 
2006). The difference between the intake and the net weight gain thus must 
reflect some degree of energy compensation. It is important to study how 
consumption of HENSD affects energy intake during subsequent meals. 
No study has formally assessed the impact of high energy nutritional 
supplement drinks on appetite sensations (such as hunger, satiety, fullness or 
desire to eat), however a range of anecdotal observations were documented 
ranging from stimulation of appetite to loss of appetite (Stratton 2000, Stratton 
and Elia 2000). As energy content, nutrient composition, concentration of 
electrolytes and osmolarity (i.e. gastric emptying speed and gastrointestinal 
absorption) are well-established regulators of appetite, it is important to 
consider how consumption of HENSD affects energy intake during subsequent 
meals. Although existing evidence suggests the clinical beneficial effects of 
nutritional supplements, it is imperative to perform further research to 
determine the mechanisms responsible for the partial compensation of the 
energy provided by the nutritional supplements.  
1.1.4 Specially formulated therapeutic foods for treatment of 
moderate acute malnutrition in children from low- and 
middle-income countries  
Moderate acute malnutrition (MAM) affects approximately 10% of the 
children under five years of age in low and middle income countries. Different 
approaches have been used for the nutritional recovery of the children in these 
settings such as  lipid based nutrient supplements (food with high energy 
density and high lipid content) or blended foods (dry food mixtures without 
high lipid content), which can be provided in a low dose or full dose as a 
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supplement to their habitual diet (Müller and Krawinkel 2005, Lazzerini, 
Rubert et al. 2013). The provision of these supplements to MAM children 
increased the recovery rate by 29% and significantly improved weight-for- 
height as compared to standard care (Lazzerini, Rubert et al. 2013).  
 
An early study by Walker et al (1991) performed on stunted children (< -2 SD 
of the National Centre for Health Statistics (NCHS) reference) aged 9-24 
months, were randomly assigned to four groups: a nutritional supplement 
group (milk based supplement providing 750 kcal per day), psychosocial 
stimulation group, both the supplement and stimulation group and a control 
group for 12 months. Supplementation significantly increased weight, head 
circumference, mid upper arm circumference and triceps skinfold in the first 6 
months, but no significant increase was reported in the subsequent six months. 
In this study dietary intake was measured by two 24 hour dietary recalls before 
the intervention and then after 6 months of the intervention. The baseline 
dietary intakes were similar in the stunted and non stunted children, while at 6 
months, dietary intake was significantly reduced in the supplement group 
(Walker, Powell et al. 1991). Lack of further improvement in weight, head 
circumference, mid upper arm circumference and triceps skinfold in the last 
six months of the study might be due to decreased food intake or/and to a 
decline in the intake of the supplement. The compliance of subjects in taking 
the supplements was not measured in this study.  
 
On the other hand, a study by Gershoff et al, (1988) observed no demonstrable 
changes in anthropometric indices as a result of high caloric supplementation 
(300 kcal) provided to pre-school children, in Thailand, from December 1981 
to October 1983. No impact of supplementation on the anthropometric indices 
of the children in the intervention group was thought to be due to increased 
physical activity and reduced intake of habitual food, although neither were 
not measured in that study (Gershoff, McGandy et al. 1988). The disparity of 
the results in these studies may be due to differences in the energy density of 
the supplements provided and duration of the intervention. 
39 
 
 
 
 
 
The WHO recommends that during treatment of malnutrition in the nutritional 
rehabilitation phase, children should receive an energy and protein dense diet 
fortified with vitamins and minerals to promote rapid weight gain. This phase 
of rehabilitation requires 3-4 weeks and is usually carried out in hospital or 
residential therapeutic centres and the mother has to stay with the child (Diop, 
Dossou et al. 2003). This has some limitations as there are more chances of 
cross-infections and secondly it is unfavourable for other family members 
(Collins 2001). Therefore, community based rehabilitation is suggested as an 
alternative (Ashworth and Khanum 1997).  
 
Ready to use foods in the treatment of severe malnutrition 
 
For this purpose, a solid ready to use food (RTUF) has been developed which 
is made up of peanut butter (Diop, Dossou et al. 2003).  RTUF was developed 
as an alternative to the F-100 formula ( a liquid milk based diet, recommended 
by WHO during the rehabilitation phase of the treatment of severe 
malnutrition, which has high energy and protein content, 100 energy units/100 
mL, 418 J; 135-200 mL/kg body weight/24 hours and 2.9 g proteins/100 ml) or 
milk oil formula to be used in the hospitals and nutritional rehabilitation 
centres after initiation of the cure (Brewster 2006). In RTUF, the skimmed 
milk was replaced by groundnut paste and lacto-serum. RTUF is an energy- 
dense paste which does not require cooking and can be stored for several 
months (24 months shelf life) without spoiling (Briend 2001, Ashworth 2006). 
These RTUF has low osmolarity and can be eaten directly from the silver foil 
package by the child without the addition of water or milk which reduces the 
risk of bacterial contamination (Diop, Dossou et al. 2003). 
 
Systemic reviews and randomized controlled trials have showed that RTUFs 
are very effective and safe in the treatment of severe malnutrition in the 
children (Briend, Lacsala et al. 1999, Collins and Sadler 2002, Dossou, Ndour 
et al. 2003, Sandige, Ndekha et al. 2004, Ciliberto, Sandige et al. 2005, 
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Brewster 2006, Bhutta, Ahmed et al. 2008, Gera 2010). Although these 
systemic reviews assessed the efficacy and effectiveness of therapeutic 
nutritional products in the treatment of severe acute malnutrition they cited 
different studies (Ashworth 2006, Gera 2010). In a systemic review of thirty 
three community based rehabilitation studies 5 trials utilized RTUF and found 
them to be very effective (Ashworth 2006). In another review of two systemic 
reviews, 7 randomized controlled trials and 7 observational studies, it was 
revealed that home based management of uncomplicated severe acute 
malnutrition with RTUF was as effective as F-100 and was more effective than 
home based dietary therapies (Gera 2010).  
 
A randomized controlled trial conducted on 60 severely malnourished 
Senegalese children, in a therapeutic feeding centre, compared RTUF with F 
100 formula (high energy milk) and demonstrated that the increase in energy 
intake (808 vs. 573 kJ/kg/day) and weight gain (15.6 vs.10.1g/kg/day) 
achieved by the supplementation with RTUF was significantly higher in 
comparison to changes induced by the consumption of a traditional high-
energy drink based on milk (F-100). This study provided evidence that RTUF 
is superior to F 100 for the management of severe malnutrition during the 
rehabilitation phase for the rapid catch up growth (Diop, Dossou et al. 2003). 
A controlled comparative clinical effectiveness trial in Malawi on 1178 
malnourished children compared home based therapy with RTUF with 
standard in patient therapy and demonstrated better weight gain (3.5 compared 
with 2.0 g/kg/day), lower relapse rates (8.7% compared with 16.7%) and lesser  
rates of cross infection with RTUF (Ciliberto, Sandige et al. 2005).  
 
A study on 282 HIV negative Malawian children of greater than 1 year of age 
compared RTUF with two home based treatments (RTUF supplement and 
blended maize soy flour). After two weeks of hospital treatment, the children 
were monitored fortnightly for 6 months. The RTUF group had rapid gain in 
weight (5.2 g/kg/day compared to 3.1g/kg/day) and rapid recovery from 
wasting (WHZ >0 in 35 days compared to 56 days) as compared to the home 
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based treatment with maize/soy and RTUF supplement groups (Manary, 
Ndkeha et al. 2004). The better outcomes with RTUF in these studies were 
related to fivefold higher energy density of RTUF than F-100 and maize/soy 
(Brewster 2006). In the developing world, due to prevalence of childhood 
under-nutrition, local production of RTUF is needed in order to make the 
therapy more widely available. Therefore, Sandige et al (2004) conducted a 
study on 260 severely malnourished Malawian children, to compare a locally 
produced RTUF with imported RTUF, and observed a similar weight gain 
with the imported RTUF (5.2 g/kg/day) and locally produced RTUF (4.8 
g/kg/day). This is evidence that both locally produced and imported RTUF 
have similar efficacy and effectiveness (Sandige, Ndekha et al. 2004). 
Recently a study demonstrated that a whey protein based RTUF in which all 
the dried skimmed milk is replaced by whey protein concentrate, is an 
effective, cheaper alternative to the milk based RTUF (Bahwere, Banda et al. 
2014). 
 
Ready to use foods in the treatment and prevention of moderate 
malnutrition 
 
RTUF have also been used to supplement the dietary intake of the moderately 
malnourished (Kuusipalo, Maleta et al. 2006, Defourny, Seroux et al. 2007, 
Matilsky, Maleta et al. 2009, Nackers, Broillet et al. 2010, Patel, Sandige et al. 
2011), as shown in Table 1.2. RTUF was found to be effective in preventing 
malnutrition in non-wasted children in areas of food insecurity (Defourny, 
Minetti et al. 2009, Isanaka, Nombela et al. 2009, Isanaka, Roederer et al. 
2010, Huybregts, Houngbé et al. 2012). It has been recommended that the 
nutritional intervention to prevent malnutrition might be more effective than 
the curative treatment of malnutrition (Ruel, Menon et al. 2008). A cluster-
randomized trial of children aged 6-60 months, found that 3 months of 
supplementation with 1 packet of RTUF per day (500 kcal/day) reduced the 
incidence of wasting and severe wasting over a period of 8 months of follow-
up. Although, a significant reduction in the incidence of wasting was observed 
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in the intervention group, no difference in mortality was found between the 
intervention and control group (Isanaka, Nombela et al. 2009). Here it is worth 
mentioning that two different growth standards were used in that study. For 
inclusion, NCHS growth standards were used while for the analysis outcomes 
WHO growth standards were used. In the WHO growth reference the 
estimates of wasting tend to decrease (de Onis, Garza et al. 2007) and the use 
of WHO growth reference for analysis of outcomes may have showed 
exaggerated improvements in weight for height. 
 
Similarly, Defourny et al (2009) evaluated a large scale distribution of ready-
to-use food (RUF 1000kcal/day), during the 2007 hunger gap in Maradi 
region, Niger and reported that the incidence of severe acute malnutrition 
remained extremely low. Recovery rates were higher in approximately 60,000 
moderately malnourished children who received a blanket supplementation 
(Defourny, Minetti et al. 2009). Although it is important to mention here that, 
the moderate malnourished children consisted of a group with severe 
malnutrition without complications.  
 
Similarly, Grellety et al (2012), performed a non-randomized 4- months cohort 
study on 2238 children, aged 6-23 months, and found a positive effect on 
anthropometric status as presented in Table 1.2 and prevention of wasting by 
RUSF (250 kcal/day) supplementation. However, no difference in length gain 
was observed between the two groups. In the intervention group, fewer 
initially non-wasted children also developed moderate wasting compared to 
the group (without supplementation) (Grellety, Shepherd et al. 2012). 
Although the baseline anthropometry of the children was not significantly 
different between the two groups, the children in the intervention group had 
slightly lower mean weight-for- length (Table 1.2). They were younger, and 
came from larger families, which might have increased the chances of sharing 
the supplement and could have an impact on the findings of this study. 
Likewise, Huybregts et al (2012) performed a cluster-randomized controlled 
pragmatic intervention study on 6-36 months, non-wasted children (WHZ ≥ 80 
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% of NCHS reference median and absence of bilateral pitting oedema) from 
city Abache. The intervention group was provided with 46 grams of ready–to-
use supplementary food (RUSF =247 kcal) daily for 4 months. It was found 
that the intervention group had significantly higher gain in height-for-age Z 
score, haemoglobin concentration accompanied by reduction in fever episodes, 
and lower risk of diarrhoea, compared to control group, at the end of the study. 
However, no significant differences were detected in weight increase, mean 
change in WHZ, between the two groups. The provision of RUSF packets in 
the intervention group did not result in a reduction in cumulative incidence of 
wasting. Compared to baseline mean WHZ increased slightly in both arms 
while mean HAZ was slightly lower in both arms. This study could not 
establish clear evidence that addition of RUSF to the household food ration 
was effective in the prevention of acute malnutrition (Huybregts, Houngbé et 
al. 2012).  In this study, a general food ration was also provided to both 
groups, which might dilute the effects of the intervention, and may be a 
possible reason for not finding the effect of the supplementation on nutritional 
status of the children in the intervention group. 
 
For treating children with MAM, besides RTUF, other supplements, such as 
fortified blended flours, like corn-soy blend and corn-soy blend plus oil, and 
milk (CSB++) are also used (Chang, Trehan et al. 2013). The evidence 
regarding the comparison of the efficacy of RTUF with the corn-soy blend in 
children with MAM has conflicting results. The majority of the studies 
reported higher recovery rates with RTUF compared to the corn-soy blend 
(Matilsky, Maleta et al. 2009, Nackers, Broillet et al. 2010, Thakwalakwa, 
Ashorn et al. 2010, Patel, Sandige et al. 2011, Karakochuk, van den Briel et al. 
2012). However, other studies demonstrated that CSB++ and RTUF are 
equally effective (LaGrone, Trehan et al. 2012).  
 
A randomized clinical effectiveness trial in rural Malawi, on moderately 
wasted children ( WHZ <-2 but ≥ -3 ), found that 8-week intervention with 
milk/peanut fortified spread, soy peanut fortified spread, or corn soy blend, 
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each providing 314 kJ/kg/day, had higher and faster recovery rates with the 
fortified spread groups compared to CSB group. However, no difference was 
detected in the rates of the length gain among three groups, and 8% of children 
in each group developed severe malnutrition (Matilsky, Maleta et al. 2009). 
Karakochuk et al (2012) performed a cluster randomized effectiveness trial on 
1125 Ethiopian children aged 6–60 months with moderate acute malnutrition 
(MAM) (WHZ between -2 and -3). They reported that after 16 weeks of 
supplementation with Ready-to-use supplementary food (RUSF) 92 g (500 
kcal) and  corn-soy blend (CSB) 300g (1413 kcal) daily resulted in the higher 
recovery rate with RUSF, however this difference was not statistically 
significant (Karakochuk, van den Briel et al. 2012). 
 
Likewise, Patel et al (2011) found greater rates of weight gain 3.1g/kg/day, 
higher recovery rates and lower relapse rates with RTUF than corn/soy blend 
(1.4g/kg/day), after 8 weeks of supplementation. Nackers et al (2010) 
performed a field randomized trial in Niger. Four hundred and fifty one 
children aged between 6 to ≥ 36 months measuring 65 to <110 cm, with 
moderate acute malnutrition (WHM% between 70% and <80% of the NCHS 
median) were randomized to receive either RUTF (Plumpy‘ Nut 1000 
kcal/day) or CSB premix (1231 kcal/day). Two hundred and fifteen children 
were recruited in RTUF group and 236 in the corn/soy-blend (CSB-based- 
premix). Children were assessed weekly until their recovery (discharge 
criteria: WHM % ≥ 85% for 2 consecutive weeks). Children who recovered 
after the intervention were additionally followed up for 6 months.  
 
Although RUTF group resulted in higher weight gain, higher recovery rates 
(79% versus 64% in the CSB group) and shorter length of stay as compared to 
the CSB group, during follow up, height and height-for-age gains were similar 
in both groups. Also, and one fifth of the cured children relapsed (Nackers, 
Broillet et al. 2010). On the other hand, a study by Lagrone et al (2012) 
reported that 12 weeks of supplementation with 75kcal of either soy whey 
RUSF, soy RUSF and CSB++ are equally effective and there were no 
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significant differences in the recovery rate of the children in each group 
(LaGrone, Trehan et al. 2012).  During the 12-months following period, this 
study demonstrated that only 63% of children who recovered from the MAM 
remained well-nourished, 17% relapsed to MAM and 10% developed severe 
acute malnutrition (Chang, Trehan et al. 2013).   
 
Limitation of existing research on moderate acute malnutrition 
 
The majority of the existing evidence on the use of community based 
management of uncomplicated, moderately acute malnutrition, has emerged 
from the studies conducted in Africa in emergency settings. There is little 
evidence exploring the impact of RTUF with other commercially available 
milk-based proprietary supplement in settings where food is available, and 
nutritional habits, nutritional education and sanitation are the main 
determinants of malnutrition. There are no studies on MAM from Asia where 
MAM is mainly prevalent (Lazzerini, Rubert et al. 2013). Furthermore, while 
assessing the impact of the supplementation on child nutritional status, other 
factors should also be taken into account, including appetite suppression, 
replacement of habitual food intake and compliance to the intervention. There 
is a need to generate more evidence regarding the efficacy of RTUF and other 
locally available, ready-to-use supplements in non-emergency settings, 
particularly in Pakistan. 
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Table 1.2 Studies assessing the comparison of effectiveness of specially formulated therapeutic foods for the treatment 
malnutrition in children.  
 
 
 
Study Study 
Design 
Study 
participant 
Intervention 
duration 
Results 
1. (Huybregts, 
Houngbé et 
al. 2012) 
City of 
Abache 
Central Africa 
Cluster 
RCT 
n=1,038, non-
wasted 
children (≥ 80 
% of NCHS 
reference) 
between 6-36 
mths.  
 
RTUF 
(Plumpy‘ Doz) 
= 247 kcal/day 
for 4 mths 
                                                  
                                      
 
Intervention 
(n= 598)                
Control 
(n=440) 
P value 
WHZ (SD)                 -1.05 (0.93)           -1.09 (0.95)  
Intervention effect 
(95%CI) WHZ 
 
-0.002 (-0.03,0.03)                            0.89 
 
HAZ (SD)                  -1.79 (1.46)           -2.06 (1.39) 
 
 
Intervention 
effect(95% CI) HAZ              
 
0.03 (0.01,0.04)                              <0.001 
Prevalence of stunting   
(%)(n)             
46.2 (276)           52.3 (230) 
 
 
MUAC (cm)(SD)       14.3 (1.1)               14.1 (1.2)       
Intervention 
effect(95% CI) MUAC   
 
0.01(-0.02,0.04)                                 0.49 
 
2. (Thakwalak
wa, Ashorn 
et al. 2012) 
Malawi 
RCT Underweight 
(WAZ< -2)   
age 6-15 mths 
12 wks an 
average daily 
71 g CSB= 
1188kJ or 43g 
LNS =920kJ 
and no 
supplement 
(control) group.  
 LNS 
(n=99)       
CSB 
(n=106)         
Control 
( n=77) 
P value 
Weight(kg) (SD)    0.75 (0.41)    0.68(0.50)     0.63(0.40)       0.21 
 Length (cm) (SD)    3.6 (1.3)       3.3(1.3) 3.4(1.2) 0.29 
 MUAC (cm) (SD)    0.4 (0.7)       0.3(0.9)        0.3(0.8)          0.74                       
    WAZ(SD) -0.12 (0.60)    -0.13 (0.71)   -0.13(0.61) 0.40                        
    WHZ(SD)             -0.10(0.64)     -0.14 (0.81) -0.25(0.71) 0.40                    
      HAZ(SD)                0.02 (0.47)     -0.02 (0.47) 0.06 (0.44)    0.45 
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3. (Bahwere, 
Banda et al. 
2014) 
Malawi 
RCT n=600  
age 6 -59 
mths  
SAM 
(MUAC 
<11.0 cm or 
pitting edema 
+1 or +2).  
  
 P-RTUF and 
WPC-RTUF 
=175kcal/kg. 
till recovery 
(weight gain of 
at least 15%, 
MUAC 
>11.0cm) 
 WPC-RUTF       
(n=308)          
 
P-RUTF 
(n=292) 
average weight gain 
(g/kg/d)          
3.1                   2.9 
recovery rate                                   84.8%              84.2% 
 
defaulter rate                                   12.2%              12.2% 
 
Mortality rate                   1.6%                                0.7% 
 
In both groups recovery rate exceeds the SPHERE minimum standards of > 
70%.                           
4. (Bisimwa, 
Owino et al. 
2012) 
Demographic 
republic of 
Congo 
Prospecti
ve, non 
blinded, 
RCT  
n=1331full 
term born 
infants 
(gestational 
age >37 
weeks)  when 
became 4–5 
mths.  
 
RUCF 280 kcal 
or UNIMIX 275 
kcal daily for 
six mths.  
                                        RUCF         UNIMIX          P value 
                                      (n= 656)       (n=675) 
Weight gain (kg)       1.2 (1.2,1.3)     1.3 (1.3, 1.4)       0.08 
Underweight                   20%              18%                  0.42 
Stunting                            48%              46%                 0.31 
Length gain (cm)     5.2 (5.0, 5.3)      5.4 (5.3, 5.6)       0.039       
MUAC gain (mm)    5.3 (4.6, 6.1)    5.2 (4.5, 6.0)        NS           
Diff  HAZ               -1.1 (-1.2, -1.0)    1.0 (-1.1, -0.9)    NS 
Diff WAZ               -0.3 (-0.4, -0.2)   0.3 (-0.3, -0.2)     NS 
Diff WHZ                0.1 (0.0, 0.2 )    1 (0.0, 0.2)            NS 
5. (LaGrone, 
Trehan et al. 
2012) 
Malawi 
Prospecti
ve, RCT  
n= 2712 
 MAM (WHZ 
<-2 and  ≥ -3) 
children aged  
6-59 mths 
75 kcal/ kg/day  
of CSB ++, 
locally 
produced  soy 
RUSF or an 
imported 
soy/whey 
RUSF for ≤ 12 
wks 
                                  CSB++        Soy RUSF       Soy/whey RUSF     
                                  ( n=888)         (n= 906)                ( n=918) 
Weight gain (g/kg/d)   3.1±2.4
1
       3.4 ± 2.6                3.6 ± 2.8 
 Length gain (mm/d)    0.13±0.46    0.13±0.44            0.15 ±0.47  
MUAC gain(mm/d)     0.13±0.40
1    
0.13±0.43             0.21±0.44 
 WHZ                          -1.68±0.67    -1.61±0.63           -1.59±0.60 
 Recovered %(n)          85.9 (763)     87.7 (795)            87.9 (807) 
Develop SAM % (n)       6.6 (59)
1
      5.2 (47)                  4.2 (39) 
Continue MAM % (n)     0.9 (8)        0.6 (5)                     0.9 (8) 
 
1 
SG from soy/whey RUSF. 
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6. (Karakochuk
, van den 
Briel et al. 
2012) 
Ethiopia 
Cluster 
randomiz
ed 
effective
ness trial. 
n=1125 age 
6–60 mths 
with MAM ( 
WHZ 
between -2 
and -3) 
92 g RUSF  
 =500 kcal  
300g CSB  
=1413 kcal 
daily for 16 wks 
                                          RUSF          CSB           P value 
                                       (n= 351)      (n=698) 
Recovery rate % (n)        73 (265)      67 (482)         0.056 
Defaulted % (n)                2 (7)           2 (12)              NS 
Non responsive % (n)       24 (86)       30 (216)          NS 
Met sphere target               No             No 
 
 
7. (Singh, Kang 
et al. 2010) 
India 
RCT n=128, 
18-59 mths 
children with 
WAZ of  ≤-
2SD.  
 
RTUF 50g/ 
child /day (550 
cal/ 100 g) 
HCCM  
( 187 calories/ 
100ml)  
                                        RTUF             HCCM                P value 
                                        (n= 51)             (n=45) 
Weight gain (kg)    0.54 (0.44-0.65)     0.38 (0.25-0.51)      0.047    
 
 
8. (Nackers, 
Broillet et al. 
2010) 
South Niger 
Field 
Randomi
zed trial 
 MAM 
(WHM% 
between 70% 
and <80% of  
the NCHS 
median) age 6 
to ≥ 36 mths.   
RTUF =1000  
kcal/d or CSB 
=1231 kcal/day. 
until  recovery ( 
WHM% ≥  85% 
for 2 wks).  
                                       RTUF                   CSB              P value 
                                       (n= 215)              (n=236) 
 
Weight gain(g/kg/d)       5.67 ± 3.02      4.59 ± 2.59        <0.001 
MUAC gain (mm/d)       0.37 ± 0.29     0.32 ± 0.24          0.11 
LOS (weeks)                  4 (2-16)           6 (2-16)            <0.001 
Recovered % (n)            79.1(170)        64.4 (152)         <0.001 
Non responder % (n)       6.0 (13)          8.9 (21)               0.25 
9. (Thakwalak
wa, Ashorn 
et al. 2010) 
Malawi 
Clinical 
randomiz
ed trial 
n=182 
underweight 
children ( 
WAZ <-2) 
between  6-15 
mths  
 43g/day LNS 
=1189 kJ, 71 
g/day CSB 
=921kJ control 
group= No 
supplement.  
                                LNS          CSB            Control           P value 
                               (n=99)      (n=106)           ( n=77) 
 
Weight(kg)       0.62 ± 0.47    0.51±0.35     0.47 ± 0.35         0.11               
 Length (cm)      3.4 ± 1.1       3.5 ± 1.1        3.3 ± 1.2            0.60               
 MUAC (cm)      0.2 ± 0.8      -0.1 ± 0.6       0.0 ± 0.6            0.06             
    WAZ               0.02 ± 1.11
1
  -0.31 ± 0.59     -0.32±0.54        0.03                  
     WHZ             -0.34 ± 0.77   -0.58 ± 0.76     -0.55±0.73        0.16              
    HAZ               0.29 ± 1.07     0.14 ± 0.37      0.11 ± 0.42       0.29               
 
1
 LNS vs Control SG 
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10. (Phuka, 
Thakwalakw
a et al. 2009) 
Malawi 
RCT 6 -18 mths 
with low 
(WAZ < -2.0)  
50g/d FS  or  
71 g/day LP for 
12 wks.  
                                               LP              FS              P value 
                                           (n=86)            (n=90)    
    Weight(kg)                 0.84 ± 0.46      0.89 ± 0.38        NS     
      Length (cm)             2.65 ± 1.1         2.50 ± 1.3          NS 
     MUAC (cm)              0.3 ± 0.8          0.4 ± 0.8            NS 
    WAZ                          0.22 ± 0.69      0.29 ± 0.51         NS 
     WHZ                         0.39 ± 0.85      0.52  ± 0.63        NS 
    HAZ                          -0.08  ±0.41      -0.13 ± 0.42        NS 
 
11. (Patel, 
Sandige et al. 
2011) 
Malawi 
Controlle
d clinical 
effective
ness trial  
Weight for 
height <85% 
but>80% of 
the 
international 
standard.  
7 kg of 
RTUF/mth and 
50 kg of 
CSB/mth for 8 
wks 
                                                    RTUF        CSB            P value 
                                                  (n= 331)         (n=41) 
Rate of weight gain (g/kg/d)        3.1±2.7      1.4±2.5       <0.001   
Rate of height gain (mm/d)        0.28±0.27    0.17± 0.21    0.003 
Rate of MUAC gain (mm/d)      0.30±0.31     0.18±0.29    0.02 
 
12. (Defourny, 
Minetti et al. 
2009) 
Maradi 
Evaluatio
n of large 
scale 
distributi
on of 
nutrition
al 
suppleme
nt on 
preventio
n of 
wasting. 
n= 60,000 
 age between 
6-36 mths 
with a height 
between 60 
and 85 cm  
Six monthly 
distribution of  
RTUF) 
1000kcal/day 
for children  < 
8kg and 1500 
kcal/day for 
children> 8kg 
                                            RTUF            No RTUF       P value 
                                              (n= 3,362)      (n=2,949) 
 
Weight gain (g/kg/d)            5.1 ± 4.6          5.5 ± 4.7          0.005 
LOS (days)                           44.4 ± 29.8      44.4 ± 29.6      0.951 
Cured % (n)                           92.3 (3054)     90.1 (2621)    0.003 
Died % (n)                             1.8 (60)            2.2 (65)          0.23 
Non respondent % (n)            1.1 (37)            1.4 (41)          0.30 
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13. (Isanaka, 
Nombela et 
al. 2009) 
Niger 
Cluster 
randomiz
ed trial  
n= 3533 
children aged 
6-60 months 
with weight 
for height 
80% or more 
of the NCHS 
reference.  
RTUF 
(92g(500kcal/da
y) for three 
months 
                                     RTUF         No RTUF        P value 
                                     (n= 1671)      (n=1862) 
Rate of    WHZ                                                       <0.001 
 
WHZ differences between groups at baseline= -0.10 z (-0.23-0.03) 
WHZ differences between groups at end =      0.12 z (0.02-0.21) 
 HAZ differences between groups at baseline = -0.06z (-0.18-0.06) 
HAZ differences between groups at end =        0.08 (-0.18-0.06) 
 
↓ incidence of wasting with RTUF =36% (17%-50%)                                                     
 
↓incidence of severe wasting with RTUF =58% (53%-68%) 
14. (Matilsky, 
Maleta et al. 
2009) 
Malawi 
Randomi
zed 
clinical 
effective
ness trial 
1362 
moderately 
wasted 
children  
WHZ <-2 but 
≥ -3 
Milk/ peanut 
FS=314kj/kg/da
y, 
Soy/peanut FS 
=314kj/kg/day 
or CSB for 8 
wks. 
  
                               Milk /Peanut FS     Soy/Peanut FS      CSB 
                                   (n=465)                   (n=450)             (n=447) 
Recovered % (n)        79 (369)               80 (360)            72  (323) 
Remained wasted % (n)  8 (35)                7 (29)               15 (67) 
WHZ at discharge      ~1.6 ± 0.7             ~ 1.7 ± 0.7       ~1.8 ± 0.8 
HAZ at discharge      ~ 2.7 ± 1.3              ~2.6 ± 1.5       ~ 2.8 ± 1.9 
Duration of                14 (14,42)               14 (14,42)      28 (14,56) 
 Supplementation (days) 
15. (Phuka, 
Maleta et al. 
2008) 
Malawi 
RCT  n=182 age 
between 5.5-
6.69 mths  
One year of 
daily 
supplementatio
n with 50 g 
(FS50) =256 
kcal,  
25g FS 
(FS25)=127kcal 
or 71 g  
LP=282 kcal 
                                  LP          FS50           FS25                 P value 
                               (n=61)        (n=61)         ( n=60) 
 
    Weight(kg)      2.37±0.60     2.47±0.77     2.37 ± 0.61       0.66 
    Length (cm)    12.7± 1.7      13.5 ± 2.9      13.2 ± 2.9         0.23 
     MUAC (cm)   1.1±0.9        1.0±1.1           1.0±0.8             0.64 
    WAZ              -1.29 ± 0.63  -1.18±0.90      -1.32 ±0.65       0.53 
     WHZ              -0.98 ±0.83  - 1.05±0.86     -1.13±0.75        0.62 
    HAZ                -0.74 ±0.95    -0.59 ± 1.22     -0.64 ±0.8       0.71 
 
16. (Adu-
Afarwuah, 
Lartey et al. 
2007) 
Ghana 
Commun
ity based 
randomiz
ed trial 
All infants 
attending 
weight 
monitoring 
session were 
potentially 
eligible.  
Complementary 
foods with SP = 
1sachet/d NT= 
1 tablet/d or NB 
=20g/d from 6-
12 months of 
age.  
NB group had a significantly higher WAZ (-0.49 ± 0.54)  
 LAZ (-0.20 ± 0.54) as compared to NT group (WAZ:-0.67 ± 0.54; LAZ: -0.39 
± 0.54)  
                         SP            NT            NB                 NI        
                       (n=96)     (n=101)     ( n=97)         (n=81) 
 WAZ       -0.53±1.1
a,b
   -0.88±1.1
a
   -0.40±1.1
b
     -0.74 ± 1.1
a,b
 
  HAZ      -0.40 ±1.0       -0.44±1.0    -0.14 ± 1.0    -0.40 ± 1.0 
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   WHZ     -0.45±1.1
a,b        
-0.89±1.1
a     
 -0.43±1.1
b
    -0.74±1.1
a,b 
 
Values in the same row with different superscripts are significantly different 
P<0.05 
17. (Kuusipalo, 
Maleta et al. 
2006) 
Malawi 
RCT  n= 128  
6-17 mths 
underweight 
infants 
(WAZ<-2, 
WHZ greater 
than -3).  
12 wks 
supplementatio
n 1 of 8 
supplements, 
nothing, 5, 25, 
50, or 75 g/day 
milk based 
fortified spread 
(FS), or 25, 50, 
or 75 g/day soy-
based fortified 
spread. 
 Change in WAZ score, HAZ, and WHZ score was not significantly different 
between the groups. 
Average gain in weight and height  
was higher among infants receiving FS (daily 25 to 75 g) than among those 
receiving only 0 to 5 g FS. The maximum weight gain was 0.83 kg with 50g of 
milk base fortified spread 
 
                                      
18. (Ciliberto, 
Sandige et al. 
2005) 
Malawi 
Controlle
d, 
comparat
ive 
clinical 
effective
ness trial 
n=1178 
children aged 
between 10-
60 mths with 
wasting 
(WHZ < -2)  
 Home based 
therapy with 
RTUF (260g 
plastic jar/day) 
for 8 weeks.  
Standard 
therapy (F100).  
                                                             F100           RTUF      
                                                             (n= 186)      (n=992) 
Rate of weight gain (g/kg/d) 4 wks    2.0 ± 6.9       3.5 ± 3.7* 
 Rate of height gain (mm/d) 8 wks    0.12± 0.29     0.19±0.59* 
 Rate of MUAC gain (mm/d) 4wks  0.23±0.33       0.32±0.41* 
Children died %(n)                              5.4 (10)         3.0 (30) 
Children relapsed % (n)                      16.7 (31)        8.7 (87)* 
 
19. (Manary, 
Ndkeha et al. 
2004) 
Malawi 
RCT n=282  
children > 1 
year old 
discharged 
from nutrition 
unit were 
systematicall
y allocated to 
treatment 
RTUF, blended 
maize/soy flour 
=730kJ/kg/d, or 
RTUF 
supplement=21
00 kJ/d 
Recovery WHZ 
>0. provided  
                                                 RTUF       RTUF-S       Maize/soy 
                                                 (n=69)        (n=96)          ( n=117) 
 
Average weight gain (g/kg/d)        5.2*        3.1              3.1 
Children likely to reach WHZ>0    95%      78%          78% 
                                                 (1.1%-1.3%) 
20. (Sandige, 
Ndekha et al. 
2004) 
RCT  n=260 with 
severe 
malnutrition 
Imported RTUF 
or local 
RTUF=175 
                                         Local RTUF            Imported RTUF      
                                              (n= 135)                    (n=125) 
Weight gain (g/kg/d)            5.2 ± 4.6                 4.8 ± 4.0 
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Maawi kcal/kg/d) till 
they reach 
WHZ> -0.5 or  
after 16 wks 
Height gain (mm/d)             0.33 ± 0.29              0.24 ±0.23 
 MUAC gain (mm/d)           0.35 ± 0.30               0.36 ± 0.31 
 
 
 
21. (Diop, 
Dossou et al. 
2003) 
Senegal 
Open-
labeled 
randomiz
ed trial 
n=70 severely 
malnourished 
(WFH Z 
score < -2) 
age 6-30 mths  
The children 
received either 
3 meals of F100 
or 3 meals of 
RTUF daily ad 
libitum 
                                                          F100              RTUF      
                                                        (n= 30)             (n=30) 
Rate of weight gain (g/kg/d)   10.1 ( 8.7, 11.4)  15.6 (13.4, 17.8)*                     
                                                                                     
Average duration of          17.3 (15.6,19.0)        13.4(12.1, 14.7)*     
 rehabilitation                                                                           
Daily energy intake           573± 201                   808 ±280*  
( kJ /kg body wt/d )   
 
 
                                                                                                      
22. (Yebyo, 
Kendall et al. 
2013) 
Ethiopia 
A 
retrospec
tive 
cohort 
study 
n= 628 age 6-
59 mths 
treated for 
SAM 
(MUAC < 
110 cm or 
weight for 
height ratio 
<70%) 
Plumpy‘Nut 
sachets 
according to 
their body 
weight 
Weight gain= 5.24 (4.98, 5.63) gm/kg/day.  
Recovery rate =61.78%, 
 Defaulter rate=13.85% 
Mortality rate= 3.02% 
Weight increase= 21.4% 
Mean length of stay under intervention = 6.48 weeks (95% CI=6.25, 6.72). 
The overall  rate of weight gain  and recovery rate < sphere standards   
 
 
 
 
23. (Grellety, 
Shepherd et 
al. 2012) 
Niger 
Cohort 
study 
n=2238  age 
6 -23 mths 
between  60 - 
80 cm in 
length   
RUSF 
(Plumpy‘Doz) 4 
x325 g pots (4 
pots = 1 mth) 
for 4 mths. 
                                 
 
RUSF   
(n= 1400)                
Control 
(n=838) 
    P value 
 
  Weight (g) 395 (364-425)         327 ( 281-372)         0.05 
  Length (cm)      2.7 (2.6-2.8) 2.8 (2.6-2.9)             0.24 
  WHZ                -0.2 (-0.2-0.2)         -0.3 (-0.4-0.3)          0.006 
  MUAC (mm) -2.8 (-3.2-2.3)         -4.0( -4.7-3.3) 0.002 
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Abbreviations: RCT, randomized control trial; P-RTUF, Peanut based RTUF; WPC-RTUF, whey protein concentrate RTUF; RUCF, 
Lipid based ready to use complementary foods; UNIMIX , fortified corn soy blend porridge;  LNS, lipid based nutrient supplement; 
SAM, severe acute malnutrition; MUAC, mid-upper arm circumference; RTUF, ready-to-use therapeutic food; WAZ, weight-for-
height Z-score;  HAZ, height-for-age Z-score; WHZ,  weight-for-height Z- score;  WLZ,  weight-for-length Z- score;  LAZ,  length-
for-age  Z- score;  CSB, corn-soy blend; CSB++, corn-soy blend ―plus-plus‖;  LNS, A lipid-based nutrient supplement;  RUSF, ready-
to-use supplementary food; FS, fortified spread;  LP, micronutrient- fortified maize-soy flour ; PPN, peanut-based ready-to-use 
therapeutic food;  HCCM , High Calorie Cereal Milk; NB, Nutributter; NT, Nutritabs; SP, Sprinkle powder;  NI,  non intervention; 
LOS, Length of stay; SG, significantly different; NS, Not statistically significant; Diff, Difference;    , change; wks, weeks; months, 
mth.
24. (Isanaka, 
Roederer et 
al. 2010) 
Niger 
Cohort 
study 
n=1645 
 age 6-36 
mths   
RUSF= 247 
kcal / day for 6 
mths, RTUF 
=500 kcal /day 
for 4 mths. 
 RUSF RTUF 
Reduction in wasting          46% (6%-69%)        59% (17%-80%) 
Incidence of wasting NS NS 
Incidence of severe wasting NS NS 
Reduction in incidence of stunting  ↓           
 
25. (Ali, 
Zachariah et 
al. 2013) 
Cross-
sectional 
semi-
structure
d 
question
naire 
survey 
Care givers 
and 
community 
health 
workers of 
malnourished 
children age 
6-59 mths  
149 care givers 
interviewed  
Expressed problems with acceptability = 60% 
Perceived child dissatisfaction with taste = 43%   
 Attributed side effects to PPN = 64% 
Children took PPN willingly = 48%   
Needed encouragement or had to be forced = 47% children completely rejected 
PPN after 3 weeks = 5% 
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1.2 Appetite regulation in relation to energy provision 
1.2.1 Principles of appetite regulation 
The internal driving force for food ingestion is called appetite. Appetite has 
two definitions; a) covers the entire field of food intake, motivation, selection 
and preference, and, b) refers particularly to the qualitative features of eating, 
sensory characteristic or responsiveness to the environmental stimulation 
which can be contrasted with conditions based on eating in response to 
physiological stimuli or energy deficit (Blundell, De Graaf et al. 2010).  
 
Appetite is divided into three components i.e. hunger, satiation and satiety 
(Mattes, Hollis et al. 2005). Hunger is a motivational state that enhances food 
intake and reflects the body state in which metabolic fuels for example free 
fatty acids and glucose, are low and is a principal variable that connotes the 
drive to eat (Blundell, De Graaf et al. 2010). Satiation is the process that leads 
to the termination of eating and it takes place when food is being eaten.  It 
governs the size and duration of the meal. It is also called as intra-meal satiety 
(Blundell, De Graaf et al. 2010). Following meal initiation, hunger subsides 
and satiation is dominant. Then, satiation feelings contribute to eating 
cessation and a period of eating abstinence begins.  
 
The feelings that determine the inter-meal fasting period is known as satiety, it 
is the process which leads to the inhibition of further eating. It reduces the 
feelings of hunger and increases fullness after the meal has finished (Mattes, 
Hollis et al. 2005, Blundell, De Graaf et al. 2010, Geraedts, Troost et al. 
2011). Satiety is influenced by a number of factors such as food mass, 
palatability, energy density and glycaemic index (Halton and Hu 2004). 
Satiety is a complex interaction of behavioural, psychological and 
physiological mechanisms (Halton and Hu 2004). Satiety leads to increase in 
fullness and a decline in hunger after  the meal has finished (Blundell, De 
Graaf et al. 2010). 
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Appetite control is a complex process that involves the interaction between the 
central and peripheral organs. This influences the short term feeding 
behaviour, as well as the long term adaptive process that responds to the 
energy input and energy expenditure (Delzenne, Blundell et al. 2010). A 
number of different physiological, psychological, cultural, emotional and 
social factors interact in a very intricate manner. This influences the sensations 
of hunger, satiety and desire to eat (Melanson, Westerterp-Plantenga et al. 
1999, Flint, Raben et al. 2000). Therefore, appetite control is a complex 
process, and it involves both central and peripheral organ interaction 
(Delzenne, Blundell et al. 2010) and is a combination of neuro-endocrine, 
behavioural, and psychological influences which are involved in controlling 
the appetite and food intake (Huda, Wilding et al. 2006). 
 
 
Figure.1.2 Schematic diagram of appetite regulation by central appetite circuits 
and circulating factors.  
Abbreviations: ARC- Arcuate Nucleus, NPY-  Neuropeptide Y, AgRP - Agouti-Related 
Peptide, CART- Cocaine Amphetamine Regulated Transcripts, POMC-
proopiomelanocortin,  DVC- Dorsal Vagal Complex, consisting of dorsal motor 
nucleus, AP- Area Postrema and NTS- Nucleus Tractus Solitarius  
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1.2.2 Role of gut peptides in appetite control 
There are numerous peptides and hormones produced by the gut and the 
pancreas. These include peptide YY (PYY), cholecystokinin (CCK), ghrelin 
and a glucagon -like peptide 1 (GLP-1) which regulate the food intake and 
directly influences satiety and hunger (Huda, Wilding et al. 2006, Crespo, 
Cachero et al. 2014).  
 
In this section, the role of ghrelin, PYY and CCK is discussed in detail. 
Gastrointestinal hormones which regulate acute satiety are GLP-1, Peptide 
YY, Oxyntomodulin and glucose-dependent inhibitory polypeptide (Wynne, 
Stanley et al. 2005). In 1912, stomach contractions were thought to be 
involved in regulating appetite. In 1975, the duodenum was considered as the‖ 
pituitary of gastrointestinal tract‖, as it controls gut hormones (Le Roux and 
Bloom 2005). After the discovery of gut peptides in the hypothalamus and 
presence of hypothalamic hormones in the gut, the relationship between the 
gut and brain became evident (Cowley, Smith et al. 2003). Endocrine cells are 
scattered throughout the gut mucosa, which ensure the diverse and important 
endocrinological capacity of the gut. Nutrients in contact with the gut mucosa 
release gut hormones, which regulate different gastrointestinal functions. 
Examples of these are; motility, secretion, absorption and positive feedback to 
the central nervous system in response to the nutrients‘ availability. All these 
factors play an important role in regulating the food intake. 
 
Ghrelin 
Ghrelin is the only endogenous peripheral hormone that has powerful 
orexigenic properties (appetite stimulant; which induces hunger and increases 
food intake). In 1996, the growth hormone secretagogue (GHS) receptor was 
identified, and surprisingly ghrelin was discovered as an endogenous ligand 
for the GHS receptor in the stomach (Kojima, Hosoda et al. 1999). Ghrelin is a 
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28- amino acid peptide released primarily by the oxyntic glands of the gastric 
mucosa, and from the duodenum, ileum, caecum and colon (Sakata, Tanaka et 
al. 2002, Huda, Wilding et al. 2006, Crespo, Cachero et al. 2014). Ghrelin was 
also isolated from tissues of the hypothalamus (Cowley, Smith et al. 2003), 
anterior pituitary gland (Korbonits, Bustin et al. 2001), lungs (Volante, 
Fulcheri et al. 2002), pancreas (Volante, AllÌa et al. 2002), kidneys, adrenal 
glands, thyroid, placenta, gonads, lymphatic tissue, myocardium, adipose 
tissues, and the bones (Huda, Wilding et al. 2006). This widespread 
distribution of ghrelin may explain its many endocrine and non-endocrine 
effects. 
 
 
 
Figure 1.3 Schematic presentation of principal sites of gastrointestinal peptides 
and their role in appetite regulation. Modified from (Cummings and Overduin 
2007) 
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Table 1.3. Main Neuropeptides and Peripheral Appetite Regulating hormones and their Role in Appetite Regulation 
Neuropeptides and 
Neurotransmitters 
Main site of 
synthesis/ 
production 
Action on appetite Other functions Effect of peripheral 
peptides on food 
intake 
Anorexigenic 
factors 
    
PYY Ileum and colon 
(gastrointestinal L 
cells) 
 Inhibition of gastric emptying 
 Increases absorption of fluid and 
electrolytes from ileum after meal 
 May acts as ―illeal brake‖ 
 Direct appetite suppressing effect on brain 
by activation of anorexigenic POMC 
neurons and inhibition of NPY neurons 
 Inhibits bile acid secretion 
 Inhibits secretion of digestive 
enzymes 
 Inhibits gall bladder emptying 
 
↓ 
CCK Duodenum and 
proximal jejunum 
 Inhibits gastric emptying 
 Appetite suppressing action on brain 
(hypothalamus through neural pathway to 
 Stimulates gallbladder contraction 
 Stimulates release of digestive 
enzymes 
↓ 
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(Intestinal I cells) brain stem). 
 CCK1 receptors are present in the areas of 
CNS involved in food regulation such as  
dorsomedial hypothalamus, NTS and AP  
 Stimulates pancreatic enzyme 
secretion  
 Regulates nutrient delivery rate from 
stomach to small intestine 
 CCK has numerous effects on 
memory, analgesia, sexual behaviour, 
anxiety and seizure threshold 
 May be involved in long-term body 
weight regulation. 
GLP-1 Ileum and colon 
(gastrointestinal L 
cells) 
 Inhibits gastric emptying 
 Important role in ―illeal brake‖ 
 Direct appetite suppressing action on brain. 
It exert its effects via GLP-1 receptors 
containing neurones of NTS project to 
POMC/CART neurones in arcuate nucleus 
and to dorsomedial and para-ventricular 
nucleus. The central effect of GLP-1 are 
 Stimulates glucose dependent insulin 
secretion and inhibits glucagon 
release 
 
↓ 
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mediated through AP and ascending brain 
stem pathway.  
Oxyntomodulin Ileum and colon 
(gastrointestinal L 
cells) 
 Delays gastric emptying 
 Inhibit gastric acid secretion 
 Glucose dependent insulin release ↓ 
Pancreatic 
Polypeptide 
Peripheries of 
pancreatic islets 
(endocrine type F 
cells) 
 Stimulation of gastrointestinal motility 
 Stimulation of gastric acid secretion 
 Inhibit pancreatic exocrine function 
 Inhibit gall bladder contraction 
↓ 
Leptin Adipocytes  Signals the brain stem and arcuate nucleus 
of hypothalamus when fat stores are low 
 Regulate body weight and energy 
homeostasis. It inhibits NPY and AgRP 
and activates α-MSH. It also acts  on IGF-
1 and growth hormone 
 Involved in neuroendocrine response to 
 Expression of NPY and  AgRP  is up-
regulated in leptin deficiency due to 
fasting 
 Regulation of lipid metabolism 
 Regulation of inflammatory response 
 Glucose homeostasis 
 Puberty and ovulation 
↓ 
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starvation  Fetal growth and metabolism 
 Bone metabolism 
Orexigenic 
Factors 
    
Ghrelin Gastric mucosa      
( X/A like cells) 
 Direct appetite stimulating effect. It 
stimulates neurons expressing AgRP and 
NPY, which are orexigenic peptides. 
 Increase gastric emptying 
 It also increases gastric motility gastric 
acid secretion and pancreatic exocrine 
secretion 
 Powerful releasing stimulator of 
growth hormones from anterior 
pituitary gland 
 It  also influences secretion of other 
endocrine hormones like cortisol and 
insulin 
↑ 
Orexin A and B Cell bodies of 
lateral 
hypothalamic area 
 Excitatory neuropeptides 
 Appetite stimulating neuropeptides 
 ↑ 
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Abbreviations: Cholecystokinin, CCK; neuropeptide Y, NPY; agouti-related peptide, AgRP; peptide YY, PYY; glucagon-like peptide 1, GLP-1; 
insulin like growth fator-1, IGF-1; Growth hormone, GH;  proopiomelanocortin, POMC; α-melanocyte-stimulating hormone, α-MSH; area 
postrema, AP; nucleus tractus solitaries, NTS
NPY Arcuate nucleus of 
hypothalamus 
 Stimulate food intake  Decrease energy expenditure ↑ 
AgRP Arcuate nucleus of 
hypothalamus 
 Stimulate food intake 
 
 ↑ 
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Ghrelin has numerous physiological effects on the human body due to its 
extensive expression in various tissues (Table 1.3). Through GHSR-1a 
activation, it is a powerful releasing stimulator of growth hormones from the 
anterior pituitary gland. Ghrelin also influences the secretion of the other 
endocrine hormones such as cortisol (Takaya, Ariyasu et al. 2000) and insulin 
(Wierup, Svensson et al. 2002, Date, Toshinai et al. 2005). The most 
important function of ghrelin is the regulation of food intake and energy 
balance. Ghrelin also increases gastric motility, gastric acid secretion and 
pancreatic exocrine secretion (Masuda, Tanaka et al. 2000, Asakawa, Inui et 
al. 2001). After binding to its receptors GHSR-1a, it stimulates neurons 
expressing AgRP and NPY, which are orexigenic peptides (Crespo, Cachero et 
al. 2014).  
 
 
Figure 1.4 Schematic presentation of the role of ghrelin in appetite regulation  
 
Ghrelin secretion from the stomach is largely dependent upon the nutritional 
state. Under fasting conditions before a meal ghrelin, plasma concentration is 
highest, suggesting its role in meal initiation (Cummings, Purnell et al. 2001). 
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Its level decreases tremendously after a meal (within 15-20 minutes of food 
intake) and again, its plasma concentration increases before the next meal after 
gastric emptying (Cummings, Foster-Schubert et al. 2005). Ghrelin responses 
are dose dependently associated to the amount of calories ingested. They are 
also dependent on the type and composition of the macronutrient ingested 
(Callahan, Cummings et al. 2004).  
 
Ghrelin is more effectively suppressed by proteins and carbohydrates as 
compared to isocaloric-rich fat meals (Blom, Lluch et al. 2006, Foster-
Schubert, Overduin et al. 2008). Prolonged suppression of ghrelin after 
consumption of dietary proteins is found in many studies showing relationship 
between higher satiety and high protein intake (Latner and Schwartz 1999, 
Bowen, Noakes et al. 2006).  
 
 
Figure 1.5 Schematic presentation of ghrelin release in response to food intake 
 
Plasma ghrelin levels are higher in lean people, low in obese people, and its 
level increases with the loss of weight in obesity (Hansen, Dall et al. 2002). 
There is a difference in appetite regulation and ghrelin in overweight and lean 
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subjects (Hellstrom, Geliebter et al. 2004). In obese subjects fasting ghrelin 
levels are reduced (Tschöp, Weyer et al. 2001) and post-prandial ghrelin levels 
are not suppressed in obese subjects, which demonstrates that ghrelin may be 
involved in obesity (English, Ghatei et al. 2002). Moreover, intravenous 
administration of ghrelin in obese subjects resulted in the consumption of more 
food showing that obese subjects are not resistant to ghrelin (Druce, Wren et 
al. 2005). On the other hand, ghrelin levels rises when weight loss is 
associated with cachexia and anorexia (Shimizu, Nagaya et al. 2003, Itoh, 
Nagaya et al. 2004). 
 
An understanding of the fundamental role of ghrelin, in appetite regulation, in 
humans, comes mainly from two independent clinical trials. One in which 
synthetic ghrelin was intravenously administered to the subjects and then 
appetite and food intake was measured prior to, during and after infusion 
which was then compared with the infusion of placebo (saline). In other trials, 
the ghrelin was investigated in pre-load studies in which ghrelin 
concentrations were studied prior to, during and after consumption of a pre-
load, and then compared with the reference product. In healthy subjects 
intravenous administration of ghrelin caused 28% increase in energy intake 
from ad libitum buffet breakfast, and increased the subjective ratings of hunger 
(Wren, Seal et al. 2001).  
 
Similarly, intravenous infusion of ghrelin in lean and obese humans has shown 
increased energy intake from buffet meals. In healthy lean and obese 
individuals intravenous administration of ghrelin at doses of 1 
pmol/kg/min(low dose) and 5 pmol/kg/min (high dose) increased the mean 
energy intake by  36.6 ±9.4% on the low dose day and 70.1± 15.5% on the 
high dose day in obese subjects. In the lean subjects, the mean increase in 
energy intake was 20.2 ±10.8% on the low dose day and 20.1±10.6% on the 
high dose day (Druce, Neary et al. 2005, Druce, Wren et al. 2005), 
demonstrating its relevance to food intake behaviour (Delzenne, Blundell et al. 
2010).  
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Studies have documented, that after ghrelin infusion, the palatability of the 
food was increased (Druce, Wren et al. 2005). Moreover, ghrelin 
administration increased the neural response to food pictures, particularly in 
areas, involved in the hedonic values of visual cues (Malik, McGlone et al. 
2008).  
 
The pre-load studies also demonstrated that suppression of ghrelin resulted in 
decreased energy intake from subsequent an ad libitum buffet meal. In lean 
and obese subjects, it was observed that high protein and adequate protein 
meals resulted in decreased energy intake by approximately 14 and 22% 
respectively from subsequent an ad libitum buffet meal, which was associated 
with the suppression of ghrelin (Brennan, Luscombe-Marsh et al. 2012). In 
overweight male subjects, consumption of a glucose based liquid pre-load, 
compared with lactose, resulted in higher ad libitum energy intake and an 
earlier return of ghrelin to pre-prandial concentrations (Bowen, Noakes et al. 
2006).  
 
There are some studies where this is not the case. This suggests that ghrelin 
suppression may postpone initiation of the next meal. However, evidence also 
suggests that ghrelin levels are conditioned by the habitual patterns of meals 
and rises in anticipation of a meal (Frecka and Mattes 2008). On the other 
hand, studies have documented that time-blinded spontaneous meal requests 
are directly related to the caloric content of the previous meal and not to the 
ghrelin response. When the macronutrient distribution, volume and all other 
features are kept constant, and the caloric content of meals is varied, the 
duration and depth of prandial ghrelin suppression are dose-dependently 
associated to the number of calories ingested (Callahan, Cummings et al. 
2004). Therefore, it can be suggested that large meals suppresses both ghrelin 
and hunger more comprehensively as compared to small meals. Additionally, 
the degree of the consequent pre-prandial recovery of ghrelin levels has also 
been reported to correlate with the number of calories consumed in the 
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subsequent meal (Callahan, Cummings et al. 2004, Cummings 2006). All the 
above studies provide evidence of ghrelin as a meal initiator.   
 
Peptide tyrosin-tyrosin  
Peptide tyrosin-tyrosin (PYY) was first isolated from porcine jejunal mucosa 
by Tatemoto and his colleagues (Huda, Wilding et al. 2006). Peptide YY is a 
thirty-six amino acid linear peptide synthesized and released from endocrine 
cells (L-cells) of the intestine (ileum and colon) (Delzenne, Blundell et al. 
2010, Crespo, Cachero et al. 2014). Peptide YY is present throughout the 
gastrointestinal tract, but its highest concentration is present in the distal 
segment of gastrointestinal tract, i.e. ileum, colon and rectum. It is also found 
in the pancreas and hypothalamus. Peptide YY is a member of the PP fold 
peptide family and is co-secreted with glucagon like peptide 1 (Huda, Wilding 
et al. 2006, Cooper 2014). PYY affects gastrointestinal tract motility and 
inhibits gastric acid secretion, pancreatic enzyme secretion and gall bladder 
emptying (Pittner, Moore et al. 2004, Wren and Bloom 2007, Cooper 2014). It 
may act as part of the ―ileal brake‖ by slowing down gastric emptying and 
intestinal transit so that nutrients, fluid and electrolytes absorption from the 
ileum increases after a meal (Huda, Wilding et al. 2006).  
 
The ileal brake is the primary inhibitory feedback mechanism to control meal 
transit through the gastrointestinal tract to optimise nutrient digestion and 
absorption (Maljaars, Peters et al. 2008). Activation of the ileal brake leads to 
reduced frequency of antral and duodenal peristaltic waves. It stimulates an 
increase in pyloric sphincter pressure which contributes to delayed gastric 
emptying (Fone, Horowitz et al. 1990). Moreover, ileal brake activation also 
reduces the frequency of jejunal contractions (percentage of jejunal 
contractions and distance of propagation) which contributes to an increased 
small intestinal transit time. In addition to that, ileal brake activation has been 
shown to decrease the meal stimulated secretion of pancreatic enzymes, 
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inhibits gastric acid secretion and also reduces bile acid output in a dose 
dependent manner (Keller, Holst et al. 2006, Maljaars, Peters et al. 2008).   
 
Plasma PYY levels are  lowest in the fasted state in the morning, rise after 
breakfast, increase further after lunch, and peak a few hours after the evening 
meal (Delzenne, Blundell et al. 2010, Crespo, Cachero et al. 2014). PYY is 
secreted into the circulation after the intake of food and its levels are elevated 
within 30 minutes of food reaching the small intestine (Batterham, Cohen et 
al. 2003, Crespo, Cachero et al. 2014). This suggests neural regulation of PYY 
in the intestine as most PYY is released from the small intestine and colon in 
advance of the arrival of the nutrients to this region of the intestine. The 
highest plasma concentration of PYY occurs postprandially, one hour after the 
meal (Batterham, Cowley et al. 2002, Batterham, Cohen et al. 2003), and its 
levels remain high for about 6 hours after the meal (Batterham, Cohen et al. 
2003, Crespo, Cachero et al. 2014).  
 
The increase in PYY levels is directly proportional to caloric intake (Degen, 
Oesch et al. 2005, Crespo, Cachero et al. 2014). The size of the meal is also 
important in relation to the PYY response (Degen, Oesch et al. 2005, Le Roux, 
Batterham et al. 2006). As HENSD supplements are energy rich and 
provide2.49 MJ of energy, and increase the caloric intake, it is therefore 
important to determine how HENSD supplementation impacts on PYY levels.  
 
PYY release is stimulated more by fat intake than protein and carbohydrate 
meals with similar energy content (Onaga, Zabielski et al. 2002, Huda, 
Wilding et al. 2006, Cooper 2014). Protein rich meals cause the greatest 
elevation in PYY levels compared to other macronutrients (Batterham, 
Heffron et al. 2006, Crespo, Cachero et al. 2014).  
 
Evidence for the causal role of PYY in appetite regulation in humans mainly 
comes from two independent clinical trials; one in which synthetic PYY was 
exogenously administered to the subjects and then appetite was measured 
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(appetite ratings and or ad libitum food intake after fixed time period) prior to, 
during and after infusion which was then compared with the infusion of a 
placebo (saline). In other clinical trial the PYY was investigated in pre-load 
studies in which serum PYY concentrations were studied prior, during and 
after consumption of test meals and then compared with the reference product 
(Mars, Stafleu et al. 2012).  
 
Peripheral administration of PYY1-36 in both rodents and man, inhibited food 
intake for several hours (Batterham, Cowley et al. 2002, Challis, Pinnock et al. 
2003). Similarly, a study by Sloth et al (2007) on 12 lean and 12 obese males 
observed a decreased energy intake of 19% during lunch. This was compared 
to PYY1-36 and a 22% decrease in the energy intake after saline infusion. A 
statistically significant lower rating of perceived ability to eat were observed 
after both PYY3-36 and PYY1-36 infusion but no significant differences were 
observed in other ratings of appetite (Sloth, Holst et al. 2007). The effect of 
exogenous administration of PYY3-36 was also studied in both lean and obese 
subjects. After 2 hours of  intravenous infusion of  PYY3-36  the energy intake 
at an ad libitum  buffet was decreased by 30% in obese subjects and 31% in 
lean subjects (Batterham, Cohen et al. 2003). Lower fasting plasma levels of 
PYY have been reported in obese people in comparison with lean subjects 
(Batterham, Cohen et al. 2003, Le Roux, Batterham et al. 2006). Several other 
studies have also demonstrated reduction in energy intake following 
exogenous PYY administration (Degen, Oesch et al. 2005, Neary, Small et al. 
2005). 
 
All the above mentioned exogenously administered PYY studies demonstrate 
that the intravenous infusion of PYY reduced food intake. However, evidence 
regarding the role of endogenously produced PYY on energy intake is less 
conclusive and is less frequently studied (Cooper 2014). Duocet et al (2008) 
observed no association between ad libitum energy intake and PYY levels in 
twenty-five pre-menopausal women (Doucet, Laviolette et al. 2008).  Guo et 
al (2006) observed that fasting and postprandial PYY levels were not 
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associated with the ad libitum food intake over 24 hours in twenty-nine non-
diabetic subjects (Guo, Ma et al. 2006). However, in a study to evaluate the 
impact of barley β-glucans on short-term appetite and satiety related 
hormones, it was found that β-glucan enriched bread (βGB) resulted in a 16% 
higher total AUC of the PYY response, resulting in 19% reduction of energy 
intake at an ad libitum lunch subsequent to βGB, as compared to the control 
bread (Vitaglione, Lumaga et al. 2009). There is also controversy regarding 
the role of endogenous PYY on appetite control. With some studies showing 
that plasma PYY is positively correlated with the feelings of fullness and 
inversely related with the feelings of hunger (Guo, Ma et al. 2006), while other 
studies report that PYY levels were not correlated with the feelings of fullness 
and hunger (Cooper, Watras et al. 2011, Heden, Liu et al. 2013, Kozimor, 
Chang et al. 2013). The fact that higher endogenous PYY levels are not always 
associated with a decreased energy intake, or subjective ratings of fullness, or 
hunger, highlights the fact that appetite control is a very complex process. 
When food is ingested, numerous physiological, hormonal, social and 
psychological processes are triggered in an intricate in a very complex manner. 
Therefore, it can be said that PYY is just one piece, which contributes to the 
complex process of appetite control. 
 
HENSD are energy-rich supplements, rich in both carbohydrates and fats. 
Therefore, it is imperative to investigate how the intake of HENSD impacts on 
post-prandial PYY levels, and how this contributes to the appetite regulation 
and energy intake during the consecutive meal. 
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Figure 1.6 Schematic presentation of the effects of peptide YY (PYY) on 
gastrointestinal system 
 
Cholecystokinin  
Cholecystokinin (CCK) was discovered by Ivy and oldberg in 1928. It is a 
hormone that contracts the gall bladder (Huda, Wilding et al. 2006). In 1973, 
Gibbs and his colleagues discovered that CCK had effects on the appetite and 
it was the first gut hormone found which had this property. CCK is a gut 
hormone found mainly in the duodenum and jejunum. CCK is also present in 
parts of brain, for example, the amygdala, cortex, hippocampus, thalamus, 
hypothalamus, septum, dorsal hindbrain and basal ganglia, and acts as a 
neurotransmitter (Huda, Wilding et al. 2006, Delzenne, Blundell et al. 2010, 
Crespo, Cachero et al. 2014).  
The main effect of CCK on the gastrointestinal system is to facilitate nutrient 
absorption, stimulate gall bladder contraction, enhance pancreatic enzyme 
secretion and slow gastric emptying. The nutrient delivery rate from the 
stomach to the small intestine is regulated by CCK (Wren and Bloom 2007, 
Delzenne, Blundell et al. 2010, Zac-Varghese, Tan et al. 2010) (Table 1.3). 
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Cholecystokinin levels increase 10-30 minutes after the initiation of a meal. 
The levels fall gradually and require 3-to-5 hrs to return to baseline levels. 
Proteins and fats (rather than equal calories of carbohydrates) have been 
shown to stimulate the CCK release (Delzenne, Blundell et al. 2010). 
It has been reported that fasting CCK levels were higher in obese women 
compared to lean women. In anorexia nervosa fasting CCK levels were found 
to be lowered (Baranowska, Radzikowska et al. 2000). Results of another 
study are at variance (Milewicz, Bidzinska et al. 2000). In one study on 
Prader-Willi Syndrome (PWS), which is characterised by hyperphagia, it was 
found that the fasting CCK levels were not significantly different from non 
PWS obese subjects, which suggests that CCK may not be associated with the 
hyperphagia of this PWS (Butler, Carlson et al. 2000). 
 
Figure 1.7 Schematic presentation of the effects of Cholecystokinin on 
gastrointestinal system 
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As with PYY, evidence for the causal role of CCK in appetite regulation 
comes mostly from two types of clinical trials, infusion studies and pre-load 
studies. Intravenous administration of physiological doses of CCK in humans 
reduces food intake and also enhances the perception of fullness (Crespo, 
Cachero et al. 2014). Several studies have been performed regarding the 
impact of CCK on appetite. A study by Ballinger et al (1995) observed a 
statistically significant reduction of 20% in food intake, after administration of 
CCK-8. This produced a similar plasma concentration to that of the meal 
(Ballinger, McLoughlin et al. 1995). Similarly, an infusion of CCK-33 also 
reduced food intake in the subsequent meal by 20% (Lieverse, Jansen et al. 
1994). Brennan et al (2005) also demonstrated that exogenous administration 
of CCK-8 in the nine healthy males increased the subjective rating of fullness, 
decreased ratings of desire to eat and subsequent energy intake at  the ad 
libitum buffet meal (Brennan, Feltrin et al. 2005). Exogenous administration of 
CCK-8 in  ten healthy men reduced energy intake during an ad libitum buffet 
meal, and reduced the desire to eat after 90 minutes of the intravenous 
administration of CCK-8 (Brennan, Little et al. 2008).  
Evidence also suggests that the intravenous administration of CCK-8 in 
healthy older adults also suppressed energy intake significantly at a subsequent 
ad libitum buffet meal by 11% (Tai, Feinle-Bisset et al. 2010). This indicates 
that CCK has a fundamental role in appetite regulation (Delzenne, Blundell et 
al. 2010). Generally, all these studies provide a consistent picture that CCK 
suppresses food intake. The suppression of food intake varied considerably 
between 0% and 63% depending upon the subject characteristics, dose and 
other experimental conditions. For the appetite suppressing impact of CCK a 
full stomach is considered to be a necessary condition, which indicates that the 
delayed gastric emptying may be the possible mechanism by which CCK 
suppresses appetite (De Graaf, Blom et al. 2004).  
Evidence regarding the role of the endogenously produced CCK on the energy 
intake and appetite is controversial, with some demonstrating, that the higher 
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CCK levels, compared to the reference, was associated with decreased energy 
intake during an ad libitum meal, and decreased ratings of hunger and 
increased fullness (Hall, Millward et al. 2003, Pasman, Blokdijk et al. 2003). 
While some studies demonstrated no effect of CCK on satiety (Sanggaard, 
Holst et al. 2004) another demonstrated the opposite effect (Zijlstra, Mars et 
al. 2009). Hall et al 2005 demonstrated that there was significantly less energy 
intake from the ad libitum buffet meal after 90 minutes, after whey protein, 
compared to casein pre-load, with a 60% increase in the plasma CCK and  
greater subjective feeling of satiety (Hall, Millward et al. 2003). In another 
pre-load study, performed on overweight subjects, it was observed that the 
higher responses of CCK were correlated with satiety, but had no impact on 
energy intake (Bowen, Noakes et al. 2006).  
The exogenous administration of CCK may achieve concentrations above 
physiological values (the increase in blood levels may be larger than that 
which can be evoked by food) and therefore we see a link between CCK, 
appetite and food intake. However, the higher endogenous CCK levels are not 
always associated with increased subjective ratings of fullness, or decreased 
hunger, or decreased energy intake, which identifies the fact, that when food is 
ingested numerous physiological processes are triggered, including hormonal 
responses which interact in a very complex manner. Therefore, we can say that 
CCK is just a single factor, which also contributes to the complex process of 
appetite control. 
So far, there are no studies on CCK and PYY responses after HENSD 
supplementation, and therefore contribution of their responses to the partial 
energy compensation seen with supplementation remains to be investigated. 
1.2.3 Role of glucose and insulin in appetite regulation 
There are many theoretical ideas regarding hunger, meal initiation and control 
of food which were preceded by the concept that glucose intake and its 
utilization plays central role in regulating the energy balance of the body, and 
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in control of satiety and hunger (Campfield and Smith 2003, Flint, Gregersen 
et al. 2007). In 1955, Mayer proposed the glucostatic theory, whereby 
increases in the concentration of blood glucose levels increases the satiety 
feelings, whereas decreased levels of blood glucose concentration produces the 
opposite effect. Mayer postulated that post-prandial hyperglycemia and 
increased glucose utilization in gluco-sensitive sites of brain leads to decreased 
feeling of hunger and termination of food intake (a period of satiety). Mayer 
postulated that the reduced glucose utilization (metabolic hypoglycemia) point 
at which the peripheral arteriovenous difference of blood glucose becomes 
negligible, and glucose is not entering ―metabolizing cells‖ was the point for 
meal initiation (Flint, Gregersen et al. 2007).  
After the glucostatic theory, numerous studies were performed to look at the 
impact of decreased intracellular glucose concentration as the meal initiation 
stimulus (Anderson and Woodend 2003,Campfield and Smith 2003, Flint, 
Gregersen et al. 2007). In the 1980s, experiments were performed on free 
feeding rats, with continuous computerized monitoring of blood glucose 
levels. It was found that transient decline in blood glucose levels, was 
associated with meal initiation (Thorens 2008). This decline in blood glucose 
concentration did not predict meal size or timing of  meal termination (Flint, 
Gregersen et al. 2007). However, studies have found that the changes in blood 
insulin and glucose concentrations ran parallel to changes in visual analogue 
scale scores of fullness (Lemmens, Martens et al. 2011). 
Whether only blood glucose levels are associated with short-term regulation of 
appetite is still unclear. It is also controversial that decline in blood glucose 
concentration before meal is the causal factor for initiation of meal. Some 
studies demonstrated that decrease in blood glucose concentration causes meal 
initiation (Anderson and Woodend 2003, Campfield and Smith 2003). One 
other study demonstrated that there is no significant role of blood glucose 
levels on short term regulation of appetite (Porte Jr, Baskin et al. 2002, Flint, 
Gregersen et al. 2007). Some studies have shown that the concentrations of 
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blood glucose levels, following a meal, are inversely associated with 
subjective measures of appetite and food intake (Anderson, Catherine et al. 
2002), while another study found no association between satiety and blood 
glucose concentrations after raising the blood glucose concentrations by 
intravenous infusion (Lavin, Wittert et al. 1996). It has been postulated that the 
potential impact of insulin as a satiety signal may require increased blood 
glucose concentrations (Blaak, Antoine et al. 2012). Moreover, along with 
post-prandial glucose concentration there are numerous factors which co vary, 
making it difficult to determine that whether it is only blood glucose or other 
factors that are responsible for promoting the satiety effect (Holt, Brand et al. 
1996, Raben, Holst et al. 1996).  
In one study, 18 healthy adults were housed in a room isolated from time cues. 
Blood glucose concentration was monitored continuously (blood withdrawn 
from antecubital vein at the rate of 25µl/min) following an overnight fast over 
2-6 hours period. It was found that both meal request and changes in hunger 
were preceded by brief transient decrease in the blood glucose levels. This 
association between changes in hunger rating, meal request and decline in the 
blood glucose levels was significant. No changes were found in hunger rating 
associated with stable blood glucose levels (Campfield, Smith et al. 1996).  
Similarly Dewan et al (2004) demonstrated that hypoglycemia induced by 
exogenous insulin, significantly increased the feelings of hunger over a 20 
minutes interval, and also increased food intake at the successive test meal in 
healthy men (Dewan, Gillett et al. 2004). The relatively early and sharp 
decline in the blood glucose levels seems to be very important in the early 
return of the appetite and hunger and disappearance of satiety (Niwano, 
Adachi et al. 2009). Evidence from previous studies demonstrates that glucose 
may be used as a biomarker of satiety in certain conditions. The evidence 
suggests that high concentrations of glucose in the blood are associated with 
lower appetite, however, absolute glucose concentrations have a complicated 
relation to appetite (De Graaf, Blom et al. 2004). A study by Arumugam et al 
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(2008) also demonstrated link between postprandial changes in blood glucose 
levels and appetite changes supporting the glucostatic theory (Arumugam, Lee 
et al. 2008). 
Glucose triggers insulin secretion by β cells of the pancreatic islets of 
Langerhans (Thorens 2008, Crespo, Cachero et al. 2014). It has been 
suggested that insulin is involved in short term appetite regulation (Flint, 
Gregersen et al. 2007, Blaak, Antoine et al. 2012). Insulin secretion increases 
rapidly after food intake and acts to control blood glucose levels (Benelam 
2009). Studies have demonstrated that, in normal weight subjects, the 
concentration of insulin before a test meal are inversely related to subsequent 
ad libitum energy intake (Speechly and Buffenstein 2000) while this 
association is not found in obese people (Speechly and Buffenstein 2000).  
From one meta-analysis it seems that the postprandial insulin response is one 
of the best predictors of ad libitum energy intake and satiety (Flint, Gregersen 
et al. 2007). In order to clarify the role of blood glucose and insulin in short 
term regulation of appetite, Flint et al 2007, conducted a meta-analysis on 
seven single test meal studies on healthy or overweight subjects conducted in 
their department, having individual participant data on blood glucose, insulin 
and subjective appetite sensations, using visual analogue scales (Flint, 
Gregersen et al. 2007). The results from this meta-analysis suggested that in 
healthy subject‘s insulin, but not glucose, is associated with short-term 
regulation of appetite. However, this relationship is disrupted in obese or 
overweight subjects. Therefore, this study does not support a significant role 
for blood glucose in short term appetite regulation. However, it has been 
postulated that the portable effect of insulin as a satiety signal might require 
increased blood glucose concentrations.  
Studies have demonstrated that both insulinemic and glycemic response are 
associated with the subjective feelings of hunger, and /or satiety and appetite 
irrespective of age, sex and weight. The relative sharp and early decline of 
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blood glucose below the baseline may be a key to the earlier return of hunger 
and appetite and earlier disappearance of satiety (Niwano, Adachi et al. 2009). 
Therefore, the presence of both hyperglycaemia and hyperinsulinaemia may be 
essential to inhibit appetite and food intake (Blaak, Antoine et al. 2012). 
Several mechanisms may be involved if insulin acts as a short-term satiety 
signal (Flint, Gregersen et al. 2007). Insulin could act directly on the 
hypothalamic area through insulin receptors (Verdich, Toubro et al. 2001) as 
central insulin receptors plays an important role in appetite regulation (Porte 
Jr, Baskin et al. 2002). A central insulin effect could be mediated indirectly 
through its interaction with other satiety inducing  hormones like peptide YY, 
CCK and GLP-1 (Schwartz and Morton 2002, Flint, Moller et al. 2004). Blood 
insulin and glucose levels are known to stimulate leptin production (Crespo, 
Cachero et al. 2014). Leptin levels are negatively correlated with food intake 
and appetite, when subjects are not in energy balance, while the leptin 
relationship with appetite during energy balance is less clear. When subjects 
are not in energy balance, leptin is appropriate as a long term biomarker of 
satiety. However, leptin cannot act as a simple short term satiety biomarker 
(De Graaf, Blom et al. 2004). Some of the studies have shown that insulin may 
affect the intracellular ATP levels in the liver by altering the transport of 
energy yielding substrate to the liver (Flint, Gregersen et al. 2007). According 
to Flint et al 2007, the insulin infusion studies do not reflect normal 
circumstances. The intravenous infusion of insulin glucose is also infused 
concomitantly in order to prevent hypoglycemia. As a result of which, insulin 
effect on the energy status of  the liver could be bypassed (Flint, Gregersen et 
al. 2007). 
 
Since insulin and glucose levels may contribute to the suppression of appetite 
prior to a consecutive meal, thus diminishing energy intake in response to the 
HENSD supplementation. Therefore, research is required to investigate 
whether blood glucose and insulin levels contribute to the appetite suppressive 
action of HENSD supplementation prior to a consecutive meal.  
79 
 
 
 
 
1.2.4 Role of thermogenesis in appetite regulation  
Diet induced thermogenesis (DIT) is the increase in the energy expenditure 
above basal fasting levels consequent to meal consumption, and it  reflects the 
amount of energy required for the processing, digestion, absorption and 
storage of the food consumed per day (Westerterp 2004, Tentolouris, Pavlatos 
et al. 2008, Tentolouris, Alexiadou et al. 2011, Ravn, Gregersen et al. 2013). 
The two main determinants of DIT are the nutrient composition of food and 
the level of energy intake. DIT is increased by increasing the carbohydrate or 
protein content of food and by increasing energy intake (Westerterp-Plantenga, 
Wijckmans-Duijsens et al. 1997, Westerterp 2004). There are two distinctive 
components of DIT: a) obligatory component which is involved in the 
postprandial nutrient metabolism and comprises of all the energy expenditure 
involved in the breakdown, digestion and storage of the nutrients in the body, 
and  b) a facultative component which is partly mediated through the increased 
sympathetic nervous system activity, and could be determined by means of 
sensory characteristics of food (van Baak 2008).  
 
DIT is commonly expressed as a percentage and accounts for 10-15 % of the 
total daily energy expenditure (Donahoo, Levine et al. 2004, Westerterp 2004, 
Scott and Devore 2005, Tentolouris, Alexiadou et al. 2011). However, in 
studies, it varies considerably between individuals and between specific 
groups of individuals (Nagai, Sakane et al. 2005, Petzke and Klaus 2008) and 
also varies depending upon the macronutrient composition of the meals 
(Westerterp 2004, Scott and Devore 2005, Compher, Frankenfield et al. 2006, 
Tentolouris, Alexiadou et al. 2011). There is convincing evidence that protein 
exerts more thermic effect (20-30% of the energy content of the protein 
consumed) as compared to fats (0-5%) and carbohydrates (5-10 %) 
(Tentolouris, Pavlatos et al. 2008, Acheson, Blondel-Lubrano et al. 2011, 
Tentolouris, Alexiadou et al. 2011).  
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Raben et al (2003) found that protein and alcohol produce greater effects on 
thermogenesis, compared to carbohydrates and fats. However, this study did 
not find significant differences in the appetite rating and food intake after 
ingestion of these macronutrients with equal energy. Therefore this study did 
not support the relationship between macronutrient oxidation hierarchy and the 
satiety hierarchy (Raben, Agerholm-Larsen et al. 2003). There are 
controversies regarding the thermic effect of fat and carbohydrate in the 
studies comparing high carbohydrate and high fat meals with a constant 
protein content. Some studies observed significantly higher thermogenic 
responses after high carbohydrate meals (Rasmussen, Larsen et al. 2007) while 
others found no significant differences between both the meals (Verboeket-
Van De Venne and Westerterp 1996, Labayen, Forga et al. 1999).  
 
DIT, as has been suggested previously, is one of the mechanisms that 
influence appetite sensations including hunger, satiety and energy intake. 
Studies have demonstrated that increased DIT has been directly associated 
with reduced hunger and increased fullness (Luscombe, Clifton et al. 2003, 
Raben, Agerholm-Larsen et al. 2003, Lejeune, Westerterp et al. 2006). 
Borbeck postulated thermostatic hypothesis in which he postulated that the 
changes in visceral, skin and core temperature could stimulate behaviours that 
alter energy balance and match energy expenditure, energy intake and body fat 
mass over a prolonged period of time. Therefore, hypothermia and reduced 
thermogenesis and its metabolic effects initiates  food intake, while on the 
other hand postprandial hyperthermia leads to feeding cessation and satiety 
(Campfield and Smith 2003, Stratton, Hébuterne et al. 2013) .  
 
Westerterp-Plantenga et al (1999) proposed that the basis of the association 
between DIT and satiety may be that the increased energy expenditure at rest 
after intake of food causes increased oxygen consumption and body 
temperature. This may give rise to the body feeling deprived of oxygen and 
could be translated into the feeling of satiety  (Ravn, Gregersen et al. 2013).  
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Several studies have measured DIT and the appetite responses to a specific 
meal (Raben, Christensen et al. 1994, Westerterp-Plantenga, Wijckmans-
Duijsens et al. 1997, Crovetti, Porrini et al. 1998, Westerterp-Plantenga, 
Rolland et al. 1999, Raben, Agerholm-Larsen et al. 2003, Keogh, Lau et al. 
2007, Leidy, Mattes et al. 2007, Ravn, Gregersen et al. 2013). Some of these 
studies (de Graaf, Hulshof et al. 1992, Raben, Agerholm-Larsen et al. 2003, 
Keogh, Lau et al. 2007, Leidy, Mattes et al. 2007, Ravn, Gregersen et al. 
2013) did not find any significant differences in the DIT, appetite, or both 
among their comparative test meals. Therefore, from these studies it is difficult 
to form a relationship between DIT and postprandial appetite.  
 
While there are some studies (Raben, Christensen et al. 1994, Westerterp-
Plantenga, Wijckmans-Duijsens et al. 1997, Crovetti, Porrini et al. 1998, 
Westerterp, Wilson et al. 1999) that have found a significant correlation 
between the postprandial subjective ratings of satiety and DIT, while 
comparing meals of the different compositions. A significant relationship 
between DIT and the postprandial AUC for satiety was found by Westerterp-
Plantenga et al (1997) while comparing a full-fat lunch (41% fat, 44% 
carbohydrate and 15% protein) and isoenergetic reduced fat lunch (26% fat, 
59% carbohydrate and 15% protein) and a reduced -fat reduced- energy lunch 
(26% fat, 58% carbohydrate and 15% protein) (Westerterp-Plantenga, 
Wijckmans-Duijsens et al. 1997).  
 
Similarly, Crovetti et al (1998) examined the association between appetite 
sensations and the thermic effect of food after three isoenergetic meals, a high 
protein meal (HP) (68% of energy from protein), high carbohydrate meal (HC) 
(69% of energy from carbohydrate) and high fat meal (HF) (70% energy from 
fat). There was highest thermogenesis with the HP meal and it determined the 
highest fullness, while no differences in the appetite sensations and the thermic 
effect between the carbohydrate and the fat meals were detected. A significant 
positive correlation  was found between DIT and the postprandial area under 
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the curve (AUC) for fullness, but no correlation was detected between the 
desire to eat and satiety and DIT (Crovetti, Porrini et al. 1998).  
 
A recent individual participant data meta-analysis found no association 
between the DIT and satiety (Ravn, Gregersen et al. 2013). According to a 
review by Veldhorst et al (2008) in a single meal, the acute satiating impact of 
protein is present when the content of 25-81% of energy is from protein 
(Veldhorst, Smeets et al. 2008). In a Ravn et al (2013) the protein intake was 
approximately 16% of the energy from protein and may be too low to trigger a 
satiating effect. De Graff et al (2004) suggested that the rise in body 
temperature resulting from the DIT might be a biomarker of satiety and 
satiation. They proposed that DIT and body temperature are dependent on the 
nutrient oxidation and may indicate an integrative measure of energy balance 
(De Graaf, Blom et al. 2004).(De Graaf, Blom et al. 2004). Since HENSD are 
energy rich supplements, their consumption can be expected to significantly 
enhance thermogenesis and thus contributes to the suppression of appetite 
prior consecutive meal, and thus diminish impact of supplements on promotion 
of energy intake. Thus further investigation is imperative to find out whether 
DIT contributes to the appetite suppressive action of HENSD supplementation 
prior consecutive meal. 
 
1.2.5  Role of Gastric emptying in appetite regulation 
Gastric emptying is a complex process, which is determined by the 
coordinated gastric and proximal intestinal motor activity, myogenic, neural 
and hormonal factors (Malagelada and Azpiroz 2010).  
Evidence from previous studies suggests that gastric emptying is associated 
with appetite, energy intake (Sepple and Read 1989, Jones, Doran et al. 1997, 
Sturm, Parker et al. 2004, Nair, Brennan et al. 2009) and glycaemic control 
(Horowitz, Edelbroek et al. 1993, Wishart, Horowitz et al. 1998, Beckoff, 
MacIntosh et al. 2001). The role of gastric emptying in appetite control is 
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complex (Janssen, Vanden Berghe et al. 2011). Very few studies directly 
investigated the relationship between gastric emptying and appetite (Janssen, 
Vanden Berghe et al. 2011).  
Physiological delay in gastric emptying, or artificially induced delayed gastric 
emptying, was found to be associated with increased subjective feelings of 
fullness and satiety and cessation of food intake (Hunt 1980, Di Lorenzo, 
Williams et al. 1988, Wisén and Hellström 1995). A delayed rate of gastric 
emptying is observed in patients with anorexia nervosa (Dubois, Gross et al. 
1979). Some studies have documented rapid rate of gastric emptying in obese 
subjects (Johansson and Ekelund 1976). Gastric distension influences the 
appetite as it triggers stretch and tension mechanoreceptors, which transmit 
information to the brain (Grundy 2002, Powley and Phillips 2004). There is a 
strong relationship between antral distension and sensation of fullness. This 
suggests that a slower rate of gastric emptying, and hence increased gastric 
distension, might predispose to satiety. Previous studies have demonstrated 
that increased gastric distension due to delayed gastric emptying is related with 
the delayed return of hunger and increased satiety (Geliebter 1988). Similarly, 
another study found a significant correlation between the time required for 
90% of the food to empty and increased postprandial hunger ratings (Sepple 
and Read 1989). Experiments using ultrasonographic and scintigraphic 
techniques have found that satiety and satiation are inversely correlated to  
gastric emptying (Hveem, Jones et al. 1996). Gastric emptying is inversely 
correlated with the caloric content of the food (Calbet and MacLean 1997).  
Existing evidence suggests that in response to the varying combination of 
intraduodenal fat and/or carbohydrate, inter- related gastrointestinal factors 
like glucagon-like peptide -1 (GLP-1), CCK and PYY are released which 
provides feedback inhibition of gastric emptying and suppresses the energy 
intake (Feinle, O'Donovan et al. 2003, Seimon, Feltrin et al. 2009, Seimon, 
Lange et al. 2010, Little and Feinle-Bisset 2011). The studies on humans 
suggests that the fat slows down the rate of gastric emptying, suppresses the 
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appetite and stimulates the secretion of CCK, which is dependent upon the 
digestion of triglycerides to fatty acids (Matzinger, Degen et al. 2000, Feinle, 
Rades et al. 2001, Feinle, O'Donovan et al. 2003). Intra-duodenal infusion of 
fat in healthy subjects slows gastric emptying, reduces hunger and  food intake 
(Lieverse, Jansen et al. 1994, Chapman, Goble et al. 1999) and  these effects 
are in part mediated by CCK (Fried, Erlacher et al. 1991, Lieverse, Jansen et 
al. 1994). Moreover, gastric emptying is also influenced by the individual‘s 
characteristics like age, sex and time of the day.  
In addition to gastric distension, the presence of nutrients in the small intestine 
is also vital for satiety. In response to intestinal nutrients numerous gut 
peptides are released that act directly by entering the bloodstream, and 
indirectly through the vagus nerve, to inhibit appetite (Cummings and 
Overduin 2007, Savastano and Covasa 2007). After eating, CCK , PYY and a 
glucagon-like peptide-1 (GLP-1) are released (Huda, Wilding et al. 2006, 
Wren and Bloom 2007). Both PYY and GLP-1 show a biphasic response to 
meal ingestion (Cummings and Overduin 2007). It is proposed that duodenal 
nutrients initiate a humoral and/or neural signal to the distal gut which 
contributes to their early release (Pilichiewicz, Chaikomin et al. 2007), then 
followed by direct nutrient stimulation of the distal gut (Cummings and 
Overduin 2007). During early postprandial period, more rapid gastric 
emptying is directly associated with increases in plasma CCK (Nguyen, Fraser 
et al. 2007), PYY (Nguyen, Fraser et al. 2007) and GLP-1.  
Evidence suggests that a threshold rate of gastric emptying exists which should 
be exceeded to stimulate the release of GLP-1. Upon release GLP-1, CCK and 
PYY in turn inhibit gastric emptying (Camilleri 2009). However, the inhibition 
of gastric emptying is not essential for the control of food intake by intestinal 
stimulation (Ritter 2004). On the other hand, ghrelin accelerate the rate of 
gastric emptying (Levin, Edholm et al. 2006). However, a more rapid gastric 
emptying is associated with the lower postprandial ghrelin concentrations 
(Blom, Lluch et al. 2006), which in turn is correlated with a reduced appetite 
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(Heath, Jones et al. 2004). All these findings suggest that a slow rate of gastric 
emptying might enhance and prolong gastric distension, delay or reduce 
release of PYY, CCK, and GLP-1 and reduce ghrelin suppression.  
Gastric distension by the food may play a vital role in the feelings of fullness. 
Reduced sensations of hunger, after a meal, may result from nutrient 
interaction with receptors in the small intestine (Näslund, Hellströrn et al. 
2001). Moreover, factors like the inter-meal interval also influence the relative 
contribution of the intestinal and gastric signals to appetite control. Differences 
in the initial versus subsequent rate of gastric emptying (Little, Russo et al. 
2007) might explain why accuracy in compensation for prior energy intake 
reduces as the time interval to the subsequent meal increases, thus showing the 
importance of considering the temporal pattern and the kinetic of gastric 
emptying in relation to appetite control. From the current literature it appears 
that there is a vital integrative relationship between gastric emptying and gut 
peptides in appetite control. 
There is no evidence about how gastric emptying is influenced by HENSD 
supplementation, therefore further research is necessary to find out how gastric 
emptying impacts on the compensation induced by HENSD supplementation. 
 
1.2.6 Appetite regulation and amendments in energy intake 
after high energy nutritional supplement drinks 
There are no studies investigating the impact of specific nutritional 
supplements use in the treatment of malnutrition on appetite and appetite 
hormones. So far, the role of metabolic and hormonal appetite modulators in 
amendments of energy intake after high energy nutritional supplements was 
investigated only in tube feeding studies (Stratton and Elia 1999, Stratton, 
Stubbs et al. 2008).  
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Stratton et al performed a study on six healthy men who received 3 days of 
bolus tube feeding (6.93 ± 0.38MJ/day of 4.18kJ/mL multinutrient feed). For 
two days before and after tube feeding placebo boluses (<0.4MJ/day) were 
provided by the tube. Bolus tube feeding significantly increased the total 
energy intake as compared with the placebo periods before and after tube 
feeding. Overall, oral food intake was significantly reduced with the bolus tube 
feeding as compared to the placebo periods. With bolus tube feeding the 
suppression of food intake was equivalent to 39.7% of the total tube feed 
energy infused leaving 60.3% additive to oral energy intake. During three days 
of bolus tube feeding the oral energy intake significantly declined by 15%. 
Therefore, in total only 40% of the tube feed energy was additive. No 
significant differences were detected in the first hour VAS rating, except for 
the preoccupation with the thoughts of food rating, which was significantly 
different during the bolus tube feeding. Significant increase in some of the 
putative satiety mediators like insulin, leptin, glucagon, resting energy 
expenditure and respiratory exchange rates and reduction in ghrelin was 
observed with the bolus tube feeding (Stratton, Stubbs et al. 2008).   
The intermittent delivery of tube feeding as bolus reflected a physiological 
liquid meal-like pattern. This was regardless of the variety of significant 
metabolic and hormonal changes involved in satiation. However, this induced 
only partial compensation for energy provided by the bolus (Stratton, Stubbs et 
al. 2008). However, studies on continuous tube feeding suggested that the 
continuous tube feeding did not suppress appetite and food intake (Stratton, 
Stubbs et al. 2003).  A study conducted by Stratton et al (2003) on six healthy 
subjects showed that 3 day administration of liquid feeds (6.9 MJ) containing a 
mixture of macro and micronutrients, continuously for 12- 24 hours, 
irrespective of whether the feed was administered diurnal or nocturnal, had 
remarkably little impact on appetite sensations (measured by visual analogue 
scale) and on the potential metabolic and hormonal mediators of appetite. 
Although there was a marked increase in total energy intake during tube 
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feeding, and a reduction in the oral energy intake equivalent to <40% of the 
tube feed energy (Stratton, Stubbs et al. 2003).  
Studies have demonstrated that distressing appetite sensations may occur even 
when all the nutrient requirements were fulfilled by  enteral tube feeding, or by 
parenteral nutrition (Stratton and Elia 1999). Moreover, enteral tube feeding 
and parenteral nutrition appears to only partially suppress oral food intake. 
Therefore,  when nutritional supports are used to supplement food intake, an 
increase in total energy intake is observed (Stratton 2001). Indeed, tube 
feeding delivers nutrients directly into stomach and thus by-passes the sensory 
aspects of oral consumption and the cephalic phase response. In addition, one 
bolus of tube feeding provides nearly twice as much energy in comparison to 
typical oral high-energy supplement (Stratton and Elia 1999, Stratton, Stubbs 
et al. 2008). However, interaction between appetite, food intake, and the 
metabolic and hormonal mediators of appetite and satiety, following tube 
feeding and oral supplementation, can be different.  
Impaired adjustment of energy intake due to previous ingestion has also been 
reported by studies investigating satiating effects of liquid beverages. These 
studies report weak satiating effects of these beverages and suggest that the 
liquid calories are not well perceived by the body (DiMeglio and Mattes 2000, 
Mattes 2006, Drewnowski and Bellisle 2007). This suggestion receives 
support from the evidence available from pre-load and appetite regulation 
studies. These studies report that preloads consumed in liquid form, elicit 
greater postprandial hunger and lower fullness sensations, more rapid gastric-
emptying and attenuated insulin and glucagon-like peptide release, and lower 
ghrelin suppression, than do preloads consumed in solid form. This is related 
to a lower energy intake during the consistent meal (Cassady, Considine et al. 
2012). Therefore, HENSD supplements may permit enhancement in daily 
energy intake, due to diminish appetite responses. Further research is required 
to more fully understand the impact of oral nutritional supplements on the 
putative measures of appetite, metabolic and hormonal variables, and appetite 
sensations, and to investigate the mechanisms which are related to partial 
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compensation for the energy provided by high-energy nutritional supplements, 
and which permit an increase in energy intake. 
 
1.3 Impact of acute changes in energy intake and 
energy balance on plasma lipids, glycaemia and 
insulinemia  
1.3.1 Insulin resistance 
Insulin is very important anabolic hormone and is vital for appropriate tissue 
development, growth, and maintenance of body glucose homeostasis. Insulin 
is secreted by the β cells of the pancreas located in the islets of Langerhans, in 
response to elevated levels of glucose and amino acids after meal (Pessin and 
Saltiel 2000, Shulman 2000, Thorens 2008, Crespo, Cachero et al. 2014). 
Insulin regulates glucose homeostasis at several sites; it reduces the hepatic 
glucose output (decreases gluconeogenesis and glycogenolysis) and increases 
the rate of glucose uptake, mainly into striated muscle and adipose tissue. 
Insulin also has an effect on the lipid metabolism, increases lipid synthesis in 
both liver and fat cells, and attenuates the release of fatty acid from 
triglycerides in fat and muscle (Shulman 2000). Insulin resistance occurs when 
normal circulating concentration of insulin are insufficient to regulate all these 
processes properly (Pessin and Saltiel 2000).  
Insulin resistance is described as a condition in which greater concentration of 
insulin is required than normal to elicit a given metabolic response to glucose 
(Frayn 2002). Therefore, insulin resistance is characterized by decreased 
insulin ability to promote peripheral glucose disposal and suppress hepatic 
glucose production. As a result, a higher concentration of insulin in the blood 
is required to clear glucose. Insulin resistance is a growing worldwide 
problem, which develops progressively over the years, if unchecked 
predisposes to type 2 diabetes mellitus and CVD (Haag and Dippenaar 2005, 
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Reaven 2012). Insulin resistance is tightly coupled with obesity and 
cardiovascular pathology (Eckel, Grundy et al. 2005, Li, Fu et al. 2014).  
Initially, insulin resistance is reflected by hyper-insulinaemia in response to 
food, if untreated, progresses to the stage where hyper-insulinaemia and hyper-
glycaemia both are experienced in response to food (Kendrick 2003). If the 
individuals suffering from the latter stage are not treated, insulin resistance 
will progress to next stage in which fasting insulin and glucose levels are 
elevated (Kendrick 2003). If all the former stages are not adequately dealt 
with, it results into type 2 diabetes (Kendrick 2003).  
In type 2 diabetes, initially the pancreas is able to secrete insulin effectively 
although it is characterised by the resistance of the body tissue to insulin 
impact. However, constant high insulin demand can eventually cause β cell 
failure assisting the transition starting from insulin resistance to diabetes. 
Increased risk of cardiovascular disease is independently associated with low 
insulin sensitivity (Rutter, Meigs et al. 2005). Studies have highlighted the role 
of hyper-insulinaemia (insulin resistance) as a major determinant for the 
development of cardiovascular events (Bonora, Kiechl et al. 2007) in pre-
diabetic women who developed type 2 diabetes later on (Hu, Stampfer et al. 
2002) and in established type 2 diabetic patients (Bonora, Formentini et al. 
2002). Insulin resistance is not only a key cofounder of type 2 diabetes, CVD 
risk, but is also associated with other metabolic disorders such as 
dyslipidaemia (Chahil, Reyes et al. 2008, Li, Fu et al. 2014), chronic low 
grade inflammation (Pradhan, Cook et al. 2003) and obesity (Ritchie and 
Connell 2007). Therefore, insulin resistance is a generalized metabolic 
disorder which is characterized by ineffective insulin function in liver, skeletal 
muscle, vascular endothelium and adipocytes (Haag and Dippenaar 2005). All 
these changes are the consequence of insulin resistance and contribute to 
insulin resistance so it is difficult to separate the causes from effects. 
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1.3.2 Lack of adipose tissue and insulin resistance  
The metabolic consequences of having too little fat (lipodystrophy) are 
astonishingly similar to those of having too much fat (obesity) (Vatier, Bidault 
et al. 2013). Adipose tissue is a crucial metabolically active site of hormone 
synthesis and energy balance (Havel 2004, Harwood Jr 2012). Adipose tissue 
produces adipocytokines, which have both paracrine and endocrine functions, 
so adipose tissue has the ability to influence other tissues such as skeletal 
muscle and liver through tissue derived hormones and the dynamic flux of 
fatty acids. An increase in adipose tissue compartment is associated with  
enhanced lipolysis and increased non-esterified fatty acids (NEFA) in the 
circulation, which is suggestive of adipose tissue insulin resistance (Delarue 
and Magnan 2007).  
Elevated levels of NEFA in the circulation induces chronic skeletal muscle 
insulin resistance through decreased insulin stimulated glucose uptake and 
carbohydrate oxidation (Boden and Shulman 2002). In insulin resistance 
adipose tissue fails to suppress lipolysis in response to insulin which may lead 
to inappropriate NEFA release during the postprandial state producing 
additional ‗lipid overflow‘ to skeletal muscle and liver (Arner 2005). 
Moreover, NEFA induce hepatic insulin resistance which is regarded as 
unchecked hepatic glucose production (Roden, Stingl et al. 2000). However, in 
insulin resistance the NEFA concentrations are not always elevated, therefore 
lipotoxicity may be associated with decreased fat oxidative capacity of the 
target organs (Corpeleijn, Saris et al. 2009).  
On the other hand, post-prandial NEFA concentrations may have a 
comparatively greater impact on insulin sensitivity. An increased 
concentration of circulating NEFA in response to the dietary fat may be 
associated with ‗lipid overflow‘ (Jackson, Wolstencroft et al. 2005). Visceral 
adipose tissue is supposed to have greater influence on insulin sensitivity as 
compared to subcutaneous fat (Macor, Ruggeri et al. 1997, Boyko, Fujimoto et 
al. 2000). An enlarged visceral adipose tissue compartment may elevate total 
91 
 
 
 
 
circulating NEFA (Arner 2002). This may impact the skeletal muscles insulin 
resistance (Corcoran, Lamon-Fava et al. 2007), and may increase NEFA 
delivery to liver through splanchnic circulation (Basu, Basu et al. 2001). This 
may cause pancreatic beta call toxicity (Taylor 2008) and may be a source of 
pro-inflammatory adipokines. This in turn promotes insulin resistance by 
directly acting on insulin signalling, and indirectly by the induction of 
endothelium dysfunction (Kahn, Hull et al. 2006, Montecucco, Steffens et al. 
2008). Adipose tissue hormones also contribute to insulin sensitivity, plasma 
leptin concentrations are directly associated with the adipose tissue mass 
(Mantzoros, Magkos et al. 2011). Plasma adiponectin levels are inversely 
associated with adipose tissue mass (Arita, Kihara et al. 1999). In obesity, pre-
diabetic states and type 2 diabetes, the circulating adiponectin levels are lower 
(Pellme, Smith et al. 2003, Kowalska, Straczkowski et al. 2008).  
Deficiency of adipose tissue as in lipodystrophy (either total or partial) is also 
associated with insulin resistance (Freitas and Carvalho 2013). Interestingly, 
the same pattern of TAG accumulation and insulin resistance is observed in 
lipodystrophy as shown in the Figure 1.5.  
Figure 1.8 Loss of normal buffering action of adipose tissue against daily 
influx of dietary fat in obesity and lipodystrophy Modified from (Frayn 2001) 
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Human lipodystrophy, whether partial or total is an insulin resistant state and 
is usually associated with type 2 diabetes (Garg 2004). The metabolic 
consequences of having too little fat (lipodystrophy) are similar to those of 
having too much fat (obesity) (Vatier, Bidault et al. 2013). The normal role of 
adipose tissue is to buffer the daily influx of dietary fat in the circulation in the 
post-prandial period. This is similar to the roles of the skeletal muscle and 
liver in buffering the post-prandial glucose flux. Adipose tissue provides 
buffering action by increasing TAG clearance and by suppressing the release 
of non-esterified fatty acids into the circulation. If this buffering action is 
impaired then extra adipose tissues (liver, skeletal muscle and pancreatic beta 
cells) are exposed to excessive flux of fatty acid leading to insulin resistance 
(Frayn 2001, Frayn 2002).  
In obesity, the buffering action of adipose tissue is impaired through defects in 
the ability of adipose tissue to respond to dynamic postprandial situation. The 
buffering action of adipose tissue is also impaired in lipodystrophy. There is 
not enough adipose tissue to provide necessary buffering capacity. Therefore, 
the phenotype with regard to insulin resistance is similar in both deficiency 
and excess of adipose tissue and other tissues are exposed to an excessive flux 
of fatty acids (Frayn 2002). This results in fatty acid accumulation (in the form 
of TAG) and interference with insulin mediated glucose disposal (Frayn 2001). 
Lipodystrophies are characterized by the selective loss of body fat in an insulin 
resistant state (Garg 2011, Vatier, Bidault et al. 2013). It remains unclear 
whether very lean individuals, due to low adipose tissue mass, have impaired 
insulin sensitivity. Nor is it clear how supplements expected to promote 
positive energy balance impact insulin sensitivity in those with low adipose 
tissue mass. 
1.3.3 Insulin resistance and dyslipidaemia 
It has been suggested that insulin resistance and dyslipidemia may have a 
reciprocal, positive feedback correlation, and may reinforce each other. Low 
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HDL-C and hypertriglyceridemia are associated with insulin resistance, 
whereas the consequences of insulin resistance also involve dyslipidemia. This 
vicious cascade of events accentuates the development of insulin resistance 
(Li, Fu et al. 2014). In insulin resistance, three major components of 
dyslipidaemia occurs; a) elevated triglyceride levels, b) decreased HDL  
cholesterol (HDL-C), and c) compositional changes in LDL (Howard 1999). 
Triglyceride and HDL-C may be a causal factor of insulin resistance, rather 
than LDL-C (Li, Fu et al. 2014). The Framingham Heart Study supports this 
idea. It demonstrated that low HDL-C and hypertriglyceridemia were more 
prevalent in type 2 diabetic patients as compared to the normal population, 
whereas high LDL-C did not differ significantly between the two groups. 
From this it can be demonstrated that low HDL-C and hypertriglyceridemia 
may be the causal factors of type 2 diabetes and numerous studies support this 
inference (von Eckardstein and Sibler 2011, Drew, Rye et al. 2012, Mineo and 
Shaul 2012, Li, Fu et al. 2014).  
 HDL can enhance insulin secretion from β cells, and also augment insulin 
sensitivity in the target tissues such as muscles, adipose tissues and liver. 
Moreover, HDL has a positive effect on β cell survival (Li, Fu et al. 2014). A 
few of the benign effects of HDL may be due to its ability to suppress 
inducible fatty acid synthase and nitric oxide synthase. Other effects can be 
attributed to the role of HDL on cholesterol homeostasis. It was also found that 
the primary apolipoprotein moiety of HDL, APOA-I induces the 
phosphorylation of AMP kinase, which facilitates the glucose uptake into 
myocytes and inhibits gluconeogenesis in hepatocytes (von Eckardstein and 
Sibler 2011). Recent evidence shows that HDL also regulates the storage of fat 
in adipocytes. All these properties of HDL signify that, HDL plays a role in β 
cell function and insulin resistance. There is a substantial heterogeneity 
between the HDL sub-classes ranging from small HDL to large HDL 
subclasses. Usually, a  larger HDL sub-class illustrates more favourable effects 
on  insulin sensitivity (Filippatos, Rizos et al. 2013).  
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There is a strong inverse relationship between HDL and VLDL levels which 
suggests that VLDL also plays a role in insulin resistance. VLDL may have 
direct and indirect influence on insulin sensitivity. The exact mechanism by 
which hypertriglyceridemia and low HDL-C could lead to  insulin resistance is 
still unclear. However, three generally accepted mechanisms known to induce 
insulin resistance are inflammation, lipotoxicity and endoplasmic reticulum 
stress (Glass and Olefsky 2012, Samuel and Shulman 2012). Evidence 
suggests that higher serum triglycerides levels may provoke a substantial 
amount of fatty acids to be deposited in cells resulting into ectopic lipid 
storage. Therefore, following dyslipidaemia, lipotoxicity may be the major 
causal mechanism in insulin resistance (Drew, Rye et al. 2012). However, it is 
also suggested  that even in the absence of lipotoxicity, dyslipidaemia may 
directly causes inflammation, endoplasmic reticulum stress or some other 
mechanisms may lead to insulin resistance (Li, Fu et al. 2014).  
Many studies have documented the mechanisms by which insulin resistance 
causes increased VLDL and plasma free fatty acid levels. Insulin resistance 
stimulates cholesterol synthesis and lipogenesis. Therefore, excess amounts of 
free fatty acids are produced in the adipose tissue. Then,  free fatty acid  are 
transferred to the liver, which consequently leads to the overproduction of 
VLDL, higher plasma triglycerides and a decline in HDL-C levels through the 
action of  cholesterol ester transfer protein (CETP) and increased HDL-C 
clearance by the kidney (Reaven 2012). The LDL role in insulin resistance is 
less clear, but if it plays a role in insulin resistance, it may be a very modest 
one. Despite the fact that, LDL does not seem to amend insulin sensitivity, it 
has the capability to affect β-cell function, as it has been found that elevated 
levels of plasma LDL promotes β-cell loss (Brunham, Kruit et al. 2008).  
1.3.4 Impact of acute changes in energy balance on fasting and 
post-prandial lipaemia 
Fasting and postprandial triglyceride concentrations are linked closely to 
energy balance. A long-term positive energy balance can lead to weight gain 
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and an elevated levels of plasma triglyceride concentrations (Terán-Garcı́a, 
Després et al. 2004). A study on twelve pairs of monozygotic twins found that 
a positive energy balance achieved by overfeeding of 4.2 MJ (1000kcal) above 
the daily energy needs, 6 days a week, for a period of 100 days significantly 
increased body weight, fat mass, plasma TAG levels, VLDL-TAG, LDL 
cholesterol whereas HDL-cholesterol levels decreased significantly. This 
suggests that a chronic positive energy balance is associated with significant 
weight gain. Adiposity has a detrimental impact on plasma lipoproteins levels 
and most likely on CHD risk (Terán-Garcı́a, Després et al. 2004). Similarly, 
another study on healthy male subjects demonstrated that overfeeding by 
4.2MJ per day above their individual energy requirement for 100 days resulted 
in undesirable changes in adiposity and HDL-C levels (Terán-García, Després 
et al. 2008).   
 
A negative energy balance associated with weight loss induces a decline in 
plasma triglyceride concentrations. Studies have demonstrated that 
hypocaloric diets lower post-prandial triacylglycerolemia during the period of 
active weight loss, with more improvement seen when diet is low in 
carbohydrates (Sharman, Gómez et al. 2004, Volek, Sharman et al. 2004). 
 
Mittendorfer et al (2003) observed that the rate of VLDL-TAG measured with 
the stable isotope tracer technique, was decreased by approximately 40% in six 
lean women and seven obese women after modest weight loss of 10% 
(Mittendorfer, Patterson et al. 2003). However, studies have shown that even a 
single day of diet induced energy deficit also reduces the postprandial TAG 
concentrations (Maraki, Magkos et al. 2010). This suggests that the observed 
decline in the post-prandial TAG concentrations after low carbohydrate diets 
in weight loss studies mentioned by Volek et al (2004) and Sharman et al 
(2004)  may be due to acute negative energy balance than the weight loss 
itself.  
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A few studies have assessed postprandial lipemia after weight stabilization 
following weight loss of 5 kg (Abbasi, Chen et al. 2008), or 10 kg (James, 
Watts et al. 2003), induced by several weeks on a hypocaloric diet. But these 
did not significantly influence  postprandial plasma TAG concentrations after 
2 weeks (Abbasi, Chen et al. 2008) or 4 weeks (James, Watts et al. 2003) of 
weight stabilization i.e. when the impact of diet induced acute negative energy 
balance was no longer present . On the other hand, 10% weight loss followed 
by ≥ 4 weeks of weight maintenance decreased the plasma TAG 
concentrations (Maraki, Aggelopoulou et al. 2011). The inconsistency of these 
results may be attributed to the fact that the different approaches were used to 
induce weight loss. 
 
Many studies have investigated the acute impact of reduction in energy intake 
on the plasma triglyceride concentrations, through moderate dietary 
restrictions, and, or, increasing the energy expenditure through single bout of 
exercise. Studies have shown that an acute moderate energy deficit, 
independent of its origin (exercise, diet or combination of both), decreases 
fasting and post-prandial triacylglycerolemia in females (Maraki, Magkos et 
al. 2010). Accumulating evidence suggests that a single bout of aerobic 
exercise reduces fasting and postprandial TAG concentration the next day 
(Gill and Hardman 2000, Harrison, O'Gorman et al. 2009, Maraki, Magkos et 
al. 2010), and is more evident when  accompanied with a negative energy 
balance (Harrison, O'Gorman et al. 2009).  
 
On the other hand a recent study Bellou et al (2013b), found no impact of 
acute dietary energy restriction of the equivalent energy deficit, of 
approximately 2MJ, on the very low density lipoprotein (VLDL) (Bellou, 
Siopi et al. 2013). This study failed to observe any changes in VLDL-TAG 
kinetics, might be due to the energy deficit being inadequate in these 
participants (Bellou, Maraki et al. 2013). While on the other hand, a study by 
Yamada et al (2008) found that a negative energy balance achieved by 
reduction in the dietary energy intake for a short period of 5 days (energy 
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deficit of 4428 ± 250 kcal/ 5 days) can decrease the fasting plasma triglyceride 
concentrations (Yamada, Kurasawa et al. 2008).  
 
Combining different types of energy deficit (light exercise with mild 
hypoenergetic diet) have also shown to reduce the postprandial lipemia. 
Maraki et al (2009), performed two oral fat tolerance tests in the morning on 
eight healthy sedentary pre-menopausal women, once after a single bout of 
light exercise (100 min at 30% of peak oxygen consumption, net energy 
expenditure 1.04 MJ) coupled with mild restriction in the energy intake (1.39 
MJ), and once after resting, coupled with iso-energetic feeding (control) on the 
preceding day. Fasting plasma TAG concentrations and TAG in the TAG –rich 
lipoproteins were 18% and 34% lower respectively after the exercise plus diet, 
as compared to the control. Postprandial plasma TAG and TRL-TAG 
concentrations were 19 and 27% less after the exercise plus diet, than the 
control (Maraki, Christodoulou et al. 2009). 
 
Since supplementation with HENSD is expected to promote energy intake and 
induce a positive energy balance, evidence on the impact of positive energy 
balance on triglyceride metabolism will be discussed in the following text. 
There is some evidence regarding the acute impact of positive energy balance, 
independent of changes in body weight and composition, on triglyceride 
metabolism. A positive energy balance induced by an increase in dietary 
energy intake also impacts upon plasma triglyceride concentrations (Hill, 
Peters et al. 1990, Faeh, Minehira et al. 2005, Bortolotti, Kreis et al. 2009, 
Brøns, Jensen et al. 2009). The impact of short term overfeeding on 
triglyceride metabolism is inconclusive. The majority of the studies on dietary 
macronutrient content were manipulated with the dietary energy intake. Many 
studies reported an increase in VLDL-TAG concentrations after 4 to 7 days of 
consuming hyper-caloric high carbohydrate diet (Ngo Sock, Lê et al. 2010, 
Sobrecases, Lê et al. 2010). Studies about overfeeding with high fat diet 
lowered VLDL-TAG concentrations (Brøns, Jensen et al. 2009, Sobrecases, 
Lê et al. 2010). The impact of hypercaloric diet on TAG concentration appears 
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to be dependent upon the macronutrient content that is ingested to excess. 
Whereas, some studies found no impact of hypercaloric feeding on VLDL-
TAG concentrations in healthy women (Bellou, Maraki et al. 2013) and in 
obese subjects (Smith, Magkos et al. 2013).  
 
A recent study by Bellou et al (2013) found that there was no effect on basal 
VLDL-TAG metabolism when a positive energy balance was induced by an 
acute dietary energy surplus of approximately 3MJ, as compared to an iso-
caloric diet (providing estimated daily energy needs for weight maintenance), 
or hypocaloric diet (providing estimated daily energy needs for weight 
maintenance minus 3MJ). The additional energy required to achieve a positive 
energy balance was provided by asking the subjects to consume two high-
calorie (6kJ/ml) fibre-free energy drinks; the percentage energy from 
macronutrients was 50% from carbohydrates, 35% from fat, and 15% from 
protein. While an acute negative energy balance achieved by an acute dietary 
energy deficit of approximately 3MJ leads to hypotriglyceridemia i.e., 
decreased in fasting plasma VLDL-TAG concentrations by approximately 
26%, owing to 21% decline in hepatic VLDL-TAG secretion rate, and 12% 
increase in the plasma clearance rate of VLDL-TAG, than isocaloric feeding 
(Bellou, Maraki et al. 2013).  
 
Therefore, it can be presumed that an induction of acute positive energy 
balance in a manner mimicking free living conditions (over consumption of all 
macronutrients) has no impact on VLDL-TAG secretion and clearance 
(Bellou, Maraki et al. 2013). Smith et al ( 2013) performed a study to find out 
whether the increased energy intake (and resulting positive energy balance) 
per se contributes to abnormalities in the VLDL-TAG metabolism, or whether 
they develop a secondary to elevated free fatty acid release from the adipose 
tissues and insulin resistance in obese people. They found that one day of 
moderate overfeeding (30% excess energy intake) has no impact on the hepatic 
and adipose tissue fatty acid metabolism in obese men. Using isotope-labeled 
tracer methods, 8 obese men were studied on two occasions in a randomized 
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cross over design once after they consumed balanced diet that provided 30% 
excess calories (hypercaloric diet) and another occasion, after they consumed a 
balanced diet providing estimated daily energy needs for weight maintenance 
(isocaloric diet). Total plasma TAG and VLDL-TAG were not different in the 
isocaloric and hypercaloric conditions, while VLDL-apoB-100 concentrations 
was significantly different after  hypercaloric but not isocaloric feeding 
(Smith, Magkos et al. 2013).  
 
Similarly, a study by Despres et al (1987) on six pairs of male monozygotic 
twins found that an acute positive energy balance achieved by the ingestion of 
4.2 MJ (1000 kcal) above individual daily energy needs, from a mixed diet 
(percentage energy from macronutrients was 50% energy from carbohydrates, 
35% energy from fat and 15% energy from protein), for 22 days, significantly 
increased the total serum cholesterol and LDL-cholesterol, and had no impact 
on the serum triglyceride levels (Després, Poehlman et al. 1987). In a similar 
study, Mc Devitt et al (2001) found no significant difference in the plasma 
concentrations of TAG after 96 hours of dietary treatment, in eight lean and 
five obese women. The dietary treatment comprised of two overfeeding 
treatments and a control treatment. In the control treatment, the energy intake 
was calculated as basal metabolic rate multiplied by a fixed constant of 1.3, 
and the participants were fed to the nearest 0.5 MJ/day. The two overfeeding 
treatments provided 50% more energy as compared to the control treatment. 
The overall macronutrient composition of the overfeeding treatment was 42% 
of energy as fat, 50% of energy as carbohydrate and 8% of energy as protein 
(McDevitt, Bott et al. 2001).  
 
In summary, the evidence from the previous studies reported changes in the 
VLDL-TAG concentrations following hypercaloric feeding for a few days 
(resulting in mild weight gain), with specific macronutrients, such as 
carbohydrate or fat (Hill, Peters et al. 1990, Minehira, Bettschart et al. 2003, 
Faeh, Minehira et al. 2005, Brøns, Jensen et al. 2009, Ngo Sock, Lê et al. 
2010, Sobrecases, Lê et al. 2010). These studies demonstrated that excess 
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carbohydrate intake  of  mainly fructose (Minehira, Bettschart et al. 2003, 
Faeh, Minehira et al. 2005, Sobrecases, Lê et al. 2010) increases VLDL-TAG 
concentrations, whereas excess fat intake decreases VLDL-TAG 
concentrations (Bortolotti, Kreis et al. 2009, Brøns, Jensen et al. 2009, 
Sobrecases, Lê et al. 2010). However, overfeeding with both fat and 
carbohydrate had no impact on VLDL-TAG concentrations (McDevitt, Bott et 
al. 2001, Sobrecases, Lê et al. 2010, Bellou, Maraki et al. 2013), which 
demonstrate that the increased caloric intake in a mode mimicking free living 
conditions (that is over-consumption of all the macronutrients) has no impact 
on basal VLDL-TAG metabolism (Bellou, Maraki et al. 2013). However 
further research is required to verify the validity of the results when linking 
plasma lipids to an acute positive energy balance. In this thesis, the impact of 
HENSD supplementation (which provides 2.49 MJ excess energy above the 
habitual diet) via mixed overfeeding (46% energy from carbohydrate, 46% 
from fat and 8% from proteins) for five days will be investigated.  
 
1.3.5 Acute modification of the macronutrient composition: 
impact on plasma lipids and insulin sensitivity 
The impact of acute positive energy balance on the TAG, HDL, VLDL-TAG, 
insulin and glucose levels depends upon the macronutrient that is ingested in 
excess. Several studies have confirmed that high carbohydrate (CHO) diets 
have detrimental impact on the risk of CVD. A dietary excess in 
carbohydrates, particularly fructose, for a short duration of 4-6 days increases 
the total plasma triglyceride concentrations and VLDL-TAG concentrations 
(Minehira, Bettschart et al. 2003, Faeh, Minehira et al. 2005, Ngo Sock, Lê et 
al. 2010). In healthy sedentary individual‘s high CHO low fat diet have shown 
to increase the fasting and postprandial TAG concentrations and reduced 
HDL- cholesterol (Koutsari, Malkova et al. 2000, Roberts, Bickerton et al. 
2008, Culling, Neil et al. 2009).  
The detrimental impact of high carbohydrate intake on plasma lipids has been 
reported in iso-energetic controlled trials. Study by Koutsari et al (2000) found 
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that a high carbohydrate diet (68% energy from CHO) consumed for three 
days by nine normolipidemic men significantly increased both the fasting and 
postprandial TAG, decreased fasting HDL-cholesterol, decreased plasma 
glucose levels, and had no impact on the serum insulin response as compared 
to an isoenergetic high fat diet (66% energy from fat) (Koutsari, Malkova et al. 
2000).  Similarly, in Robert et al (2008), by applying stable isotope tracer 
technique showed that both the fasting and postprandial TAG concentrations 
were significantly increased after a high CHO diet as compared to high fat diet 
(Roberts, Bickerton et al. 2008). Likewise, Culling et al (2009), observed that  
the short term TAG raising impact of high CHO diet depends upon the nature 
of the CHO, with a greater impact of a sugar rich than a complex CHO rich 
diet (Culling, Neil et al. 2009). This provides evidence that different types of 
CHO produce a difference in the lipid profile and could be important in 
preventing the risk of CVD. 
Evidence suggests that the replacement of saturated fat with an increased CHO 
intake (particularly refined CHO) can aggravate atherogenic dyslipidaemia. 
This is associated with an increased TAG and small LDL particles and reduced 
HDL-cholesterol (Siri-Tarino, Sun et al. 2010). In a study by Arefhosseini et 
al (2009), twelve healthy postmenopausal women were advised to increase 
their proportions of energy derived from CHO and reduce their fat intake for 4 
weeks. It was found that by increasing the CHO energy intake, by up to 50% 
the results were a in the reduction of body weight, significant increase in 
fasting TAG concentration, and significant decrease in HDL cholesterol, 
favouring an increased risk of CVD (Arefhosseini, Edwards et al. 2009). 
The detrimental impact of high carbohydrate intake on plasma lipids has been 
reported in hypercaloric studies. In a study by Sevastianova et al (2012), 
sixteen overweight subjects were placed on high carbohydrate hypercaloric 
diet (> 1000kcal with 98% of energy from carbohydrates) for three weeks and 
thereafter on a hypocaloric diet for 6 months. During 3 weeks of carbohydrate 
overfeeding body weight increased by 2%, fasting serum concentrations of  
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triglycerides increased significantly, whereas HDL cholesterol decreased 
significantly (Sevastianova, Santos et al. 2012). Faeh et al (2005) also 
observed, a significantly increased plasma TAG concentrations by 79% in 
their fructose overfeeding study (diet supplemented with 3g/kg/day fructose 
resulting in hyperenergetic diet (800-1,000 kcal/day), for six days (Faeh, 
Minehira et al. 2005). Similarly Le et al (2006) found that in seven healthy 
subjects high fructose supplementation (1.5g fructose.kg body wt
-1
.d
-1
) within 
one week significantly increased the fasting VLDL-TAG (72%) and total 
triacylglycerol (36%) concentrations (Lê, Faeh et al. 2006). Sobrecases et al 
(2010) studied thirty healthy male subjects to assess the effect of 7-day high 
fructose diet (Fruc: +3.5gfructose/kg fat-free mass/day, +35% energy), 4-days 
high fat diet (Fat; + 30%energy as saturated fat) or a 4- days high fructose high 
fat diet (Fruc fat:+3.5g fructose/kg fat-free mass/day, +30% energy as fat,+ 
65% total energy) on intrahepatocellular lipid. It was found that hypercaloric 
high fructose diet  increased VLDL –TAG concentrations (+ 58%) whereas 
VLDL-TAG concentrations decreased after high fat diet (-22%) while no 
changes were observed after high fructose high fat diet (Sobrecases, Lê et al. 
2010).   
Evidence regarding carbohydrate overfeeding studies has conflicting results on 
fasting plasma glucose and serum insulin concentrations. Some studies 
reported an increase in the concentration of both insulin and glucose 
(Silbernagel, Machann et al. 2011) some in insulin only (Lê, Ith et al. 2009, 
Sobrecases, Lê et al. 2010) or in glucose only (Lê, Faeh et al. 2006), and 
others found no change in insulin or glucose levels (Ngo Sock, Lê et al. 2010). 
A study by Kolteman et al (1979) found that the consumption of high 
carbohydrate diet (75% energy from CHO) for 2 weeks in 10 healthy males 
improved insulin sensitivity, increase the ability of insulin to stimulate glucose 
removal from the plasma (Kolterman, Greenfield et al. 1979). These findings 
were not confirmed by other studies. A study conducted by Borkman et al 
(1991) on eight healthy subjects found that a high CHO diet (more than 50% 
energy from CHO) for three weeks had no impact on fasting blood glucose and 
103 
 
 
 
 
serum insulin concentration, and thus did not enhance the insulin sensitivity 
(Borkman, Campbell et al. 1991). These findings were supported by another 
study by Garg et al (1992) in which no impact on  the glycemic control or 
insulin sensitivity was detected when 8 men with mild non insulin dependent 
diabetes consumed a high carbohydrate diet (60% energy from CHO) for a 
period of 21 days (Garg, Grundy et al. 1992).  
Conversely, postprandial hyperinsulemia was found by  Coulston et al (1983) 
in 11 healthy individuals on high CHO diet (60% energy from CHO) for 10 
days which was not present when individuals were on the control diet (40% 
energy from CHO)  (Coulston, Liu et al. 1983). Ngo Sock et al (2010) studied 
eleven healthy men in a randomized order after 7 days of the hypercaloric diet 
enriched with either fructose (3.5g fructose/kg fat free mass per day, +35% 
energy intake) or glucose (3.5g fructose/kg fat free-mass per day, +35% 
energy intake) showed a significant increase in the fasting VLDL-TAG ( high 
fructose diet: 59% and high glucose diet 31%), while no changes were 
observed in the fasting glucose and insulin concentrations as compared to 
weight maintenance controlled diet (Ngo Sock, Lê et al. 2010). Similarly, 
Silbernagel et al (2011) observed that post-prandial TAG, fasting and post-
prandial concentration of LDL were significantly increased in response to 2 
weeks consumption of 25% of energy as fructose, and high fructose corn 
syrup, but not with the consumption of glucose in forty-eight younger, normal 
weight and overweight subjects. AUC for 24-hour glucose and 24-hour insulin 
and the post meal insulin peaks were significantly higher in the participants 
consuming glucose, significantly lower in the subjects consuming fructose 
while it remains unchanged in the subjects consuming high fructose corn syrup 
(Silbernagel, Machann et al. 2011). 
Evidence regarding fat overfeeding studies has also conflicting results on the 
total plasma triglyceride and VLDL concentrations. Some studies reported 
decrease in the concentration of the both plasma triglycerides and the VLDL 
(Bortolotti, Kreis et al. 2009, Brøns, Jensen et al. 2009, Sobrecases, Lê et al. 
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2010), some reported significant increase in the plasma triglyceride (van der 
Meer, Hammer et al. 2008) while other reported no impact of high fat diet on 
plasma triglyceride (Schrauwen‐Hinderling, Kooi et al. 2005, Westerbacka, 
Lammi et al. 2005).  
Fat and fructose have an opposite effect on the plasma triglycerides indicating 
a complex interaction between these two nutrients classes (Sobrecases, Lê et 
al. 2010). A study on 10 subjects found that after 4 days of hyper-caloric high 
fat diet, the total triglycerides and VLDL-TAG concentrations were reduced as 
compared to the control diet. While high fat diet has no impact on the plasma 
insulin and glucose levels (Bortolotti, Kreis et al. 2009).  Likewise, Brons et al 
(2009) investigated the effects of 5 days high fat (60%) overfeeding (+50%) 
versus a control diet (50% of the energy coming from CHO, 35% from fat and 
7.5% from protein), on the glucose and insulin metabolism of twenty-six 
young healthy volunteers. They found that a high fat- high calorie- diet 
(containing 50% extra energy, where 60% energy is from fat, 32.5% from 
CHO and 7.5% from protein) decreased the fasting plasma TAG, LDL- and 
VLDL- cholesterol concentration. Whereas HDL- cholesterol was increased 
compared to the control diet. Fasting glucose levels were significantly higher 
while borderline increase in the insulin levels were observed in high-fat high-
calorie diet (Brøns, Jensen et al. 2009).  
Van der Meer et al (2008) found that after a 3-day high-fat high-energy diet 
(total energy intake was approximately 4732 kcal/d: 69% fat, 20% 
carbohydrate and 11% protein) the plasma triglyceride, plasma NEFA, and 
postprandial plasma insulin concentrations were significantly higher. While 
the plasma glucose levels remained unchanged (van der Meer, Hammer et al. 
2008). Westerbacka et al (2005) placed 10 overweight apparently healthy 
women on two successive 2-week isocaloric diets (16% and 56% energy from 
fat) in a randomized cross- over study. No significant changes were observed 
in the fasting plasma triglycerides, LDL-, HDL-cholesterol and fasting plasma 
105 
 
 
 
 
glucose concentrations. However, fasting plasma insulin concentrations were 
significantly higher during the high fat diet (Westerbacka, Lammi et al. 2005).  
The impact of acute positive energy balance achieved by overfeeding with 
both carbohydrate and fat has controversial findings on plasma glucose and 
insulin levels. Some studies reported an increase in the concentration of both 
insulin and glucose (Tam, Viardot et al. 2010, Bellou, Maraki et al. 2013), 
some insulin only (Sobrecases, Lê et al. 2010, Cornford, Hinko et al. 2012) 
and others found no change in insulin or glucose levels (Després, Poehlman et 
al. 1987, McDevitt, Bott et al. 2001).  
A study performed by Bellou et al (2013) found that acute  positive energy 
balance of approximately 3MJ during hypercaloric diet significantly increased 
the fasting plasma glucose concentration, but not after an acute negative 
energy balance of approximately 3MJ (hypocaloric diet) or isocaloric diet 
(zero energy balance). Serum insulin levels were significantly higher after the 
hypercaloric diet than after the hypocaloric diet while no difference was 
detected between the hypercaloric and the isocaloric diet (Bellou, Maraki et al. 
2013). Similarly a study conducted by Tam et al (2010) on thirty six healthy 
individuals found that, after 28 days of overfeeding by 1,250 kcal/day above 
baseline energy requirements (45% fat, 40% carbohydrate and 15% protein), 
there was a significant increase in both fasting insulin and glucose 
concentrations (Tam, Viardot et al. 2010).  A study by Cornford et al (2012), 
on healthy non-obese subjects, found that after two-weeks, over-feeding 
(approximately 4000 kcal/day (50% carbohydrate, 35% fat and 15%protein) 
doubled fasting plasma insulin concentrations. As a result the HOMA(IR) was 
also significantly elevated, although fasting plasma glucose concentration was 
well maintained (Cornford, Hinko et al. 2012).   
Similarly, an overfeeding study conducted by Adochio et al (2009) also found 
that,   5-days of 40% overfeeding of  a high carbohydrate ( 60% carbohydrate, 
20% fat) diet induced fasting insulin levels, but had no impact on fasting 
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glucose levels (Adochio, Leitner et al. 2009).  In one study,  no change in 
insulin and  glucose responses were detected after a short term caloric excess 
of daily surplus of 4.2 MJ (1000 kcal) for 22 days (Després, Poehlman et al. 
1987). 
Studies have shown that short- term over feeding with modest weight gain, 
increases plasma insulin concentrations and induced insulin resistance (Tam, 
Viardot et al. 2010, Brands, Swat et al. 2013). Brands et al (2013) 
demonstrated that in lean healthy men the positive energy balance induced by 
short term over feeding (1.4 × caloric intake from eucaloric diet), resulted in 
weight gain, induced whole-body insulin resistance, fasting and glucose 
stimulated hyperinsulinaemia. The surplus energy was provided by liquid 
drink that contained 36.8g carbohydrates, 12g protein and 11.2g fat (300 kcal 
per 200ml). The mechanisms responsible for hyperinsulinaemia may be 
explained by the combined effect on the increased insulin secretion and 
decreased insulin clearance (Brands, Swat et al. 2013). A study conducted by 
Erdmann et al (2008) demonstrated that hyperinsulinaemia after modest 
weight gain was explained by the hepatic clearance only and did not observe 
any difference in the insulin secretion (Erdmann, Kallabis et al. 2008).   
The difference in the Brands et al (2013) and Erdmann et al (2008) study 
might be due to the difference in study design. Erdmann et al (2008) studied 
their subjects after a hypercaloric diet of 3-4 months with a weight stable 
period of 4 weeks; however, Brands et al studied their subjects during a 
hypercaloric diet. This implies that during hypercaloric feeding insulin 
secretion is enhanced and insulin clearance is reduced, whereas during weight 
stability after weight gain, only insulin clearance is increased. Increased 
insulin secretion is related to the insulin resistance induced elevated glucose 
concentrations, and to increased dynamic β-cell responsitivity (higher response 
to a change in glucose concentrations). Though glucose sensitivity of the β-
cells did not change. The impact of hypercaloric diet on dynamic insulin 
responsitivity index indicates that the hypercaloric feeding enhances β-cell 
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response  (Brands, Swat et al. 2013). However, it is worth mentioning here 
that during a hypocaloric diet, insulin sensitivity, insulin clearance, glucose 
stimulated insulin secretion and the dynamic β-cell responsitivity returned to 
baseline. These findings suggest that the metabolic disturbances in the early 
phase of hypercaloric intake, with intentional weight gain, are entirely 
reversible by a caloric restriction (Brands, Swat et al. 2013).  
Overfeeding studies have demonstrated that, during hypercaloric state fasting 
glucose concentrations did not increase significantly, while fasting insulin 
secretions increased (Brands, Swat et al. 2013, Smith, Magkos et al. 2013). As 
fasting glucose concentrations were mostly determined by endogenous glucose 
production (Turner and Holman 1976),  it might be possible that the increase 
in portal insulin inhibited the increase in the glucose concentration by reducing 
glucose output. The stable glucose concentrations might represents a new 
steady state at the expense of higher basal insulin secretion (Brands, Swat et 
al. 2013). 
To sum up the literature, the isocaloric high carbohydrate diets, particularly 
fructose, for a short duration of 4-6 days increases the total plasma triglyceride 
concentrations and VLDL-TAG, and have no impact on the fasting plasma 
glucose and serum insulin concentrations. The overfeeding study with an 
excess fat intake (decreased carbohydrate diet) reduces total plasma 
triglyceride and increases insulin and glucose concentrations. Therefore, 
further research is required to look at the impact of acute positive energy 
balance induced by HENSD supplementation for five days, on fasting plasma 
insulin and glucose concentrations. 
1.4 Aims and objectives 
Accumulating evidence suggests that multi-nutrient, oral high-energy 
nutritional supplements (HENSDs), increases energy intake, and are beneficial 
for the treatment of malnutrition. Their effectiveness, however, may be 
diminished by the acute suppression of appetite. The existing knowledge of the 
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hormonal and metabolic effects of HENSD is mostly based on the work done 
in tube feeding studies. However, interaction between appetite, food intake, 
metabolic and hormonal mediators of appetite and satiety, following tube 
feeding, and oral HENSD can be different. Therefore, further studies are 
required to investigate the mechanisms which are related to the partial 
compensation for the energy provided by HENSD and which causes an 
increase in energy intake.  
 
Furthermore, there is a need to investigate if supplementation in the evening, 
for a longer duration, induces a positive energy balance and also investigate 
the time scale of compensation after the HENSD supplementation for five 
consecutive days. Since, the energy intake with consumption of HENSD is 
expected to promote a positive energy balance; there is a need to investigate 
the impact of HENSD supplementation on the cardio-metabolic risk factors.  
 
Studies have shown that the nutritional supplements such as Solid ready to use 
food (RTUFs) are very effective in the treatment of severe malnutrition in 
children. Community-based management of acute malnutrition using RTUF 
has been associated with higher recovery rates, greater weight gain and lower 
case fatalities. However, there is little evidence from exploring the impact of 
RTUF and milk based ‗Liquid Ready To Use‘ proprietary Supplement (LRUS) 
on weight gain in mild to moderate underweight children from Asia. 
Therefore, the main aims and objectives of the following research were as 
follows: 
 
 To investigate the level of energy intake compensation in lean adult 
women following HENSD consumption and find out how it relates to 
responses of a range of hormonal and metabolic appetite regulators. 
(Chapter 3).  
 To investigate the impact of HENSD supplementation on proxy 
measure of gastric emptying and to evaluate the extent by which the 
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supplementation-induced increase in energy-intake is diminished by 
the thermogenic effect (Chapter 3).   
 To investigate the impact of supplementation of HENSD in the 
afternoon for 5 consecutive days on energy intake and to find out 
whether it has any detrimental impact on plasma lipids, glycaemia and 
insulinaemia Chapter 4). 
 To explore the efficacy of RTUF and LRUS in promoting  weight gain 
and appetite regulation in mild to moderate underweight children  
between the ages of 5-10 years from Pakistan (Chapter 5).  
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2 General Material and Methods 
2.1 Participants 
The experimental studies described in chapter 3 and 4 of this thesis 
involved healthy women with a body mass index of 17- 20 kg/m
2
. Both 
experimental studies were approved by the College of Medicine, 
Veterinary and Life Sciences, University of Glasgow, Research Ethics 
Committee and were performed in accordance with the Helsinki 
Declaration.  
The eligible inclusion criteria for the subjects to participate in the 
experiments described in chapter 3 and 4 were: females aged between 18-
35 years, generally in good health, and with a BMI of less than 20kgm
-2
. 
All the participants were non-smokers, had stable weight for one month 
prior to the study, not pregnant, having a regular menstrual cycle, were 
not on any medication or any nutritional supplement, and were not 
following a special diet. The participants were recruited by word of mouth 
in the campus of the University of Glasgow, at Yorkhill hospital and in 
the University gym. The subjects who agreed to take part in the study 
were provided with the detailed volunteer information sheet (Appendix 
IIa, b) regarding the study, to take away before making their decision.  
The volunteer information sheet described all the details of the purpose of 
the study, inclusion criteria for the study, screening procedures of the 
study, what the participant would to do prior to the study, experimental 
tests involved in the study, possible benefits for taking part in the study 
and possible disadvantages and risks of taking part in the study. It was 
essential for all the subjects who agreed to take part in the study to attend 
a screening visit at the metabolic room of the Human Nutrition 
department of Yorkhill Hospital. During this visit they were screened by 
detailed medical history (Appendix IVa) to exclude chronic illnesses, 
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eating disorders and any major gastrointestinal surgery. This was done by 
them completing a health questionnaire describing the subjects past 
illnesses, present illnesses and the health status and family history of any 
diseases. Furthermore, anthropometric measurements were also taken 
prior to the study, to make sure that the participants fulfilled the inclusion 
criteria of the study. All the subjects were provided with written, informed 
consent (Appendix IIIa, b). Ethics documents for chapter 3, 4 and 5 are 
shown in (Appendix I a, b, c).  
2.2 Anthropometry and body composition 
2.2.1 Height and Weight Measurement 
The height of the participants was measured with a portable stadiometer 
(Seca, Leicester, UK), using a stretch stature method. The stature is the 
maximum distance from the ground to the uppermost point of the skull 
when the position of head is held in the Frankfort plane position (Marfell-
Jones, Stewart et al. 2006). The participants height were measured 
barefooted, with their back placed against a fixed backboard, and their 
arms placed in a position lateral to their body. The head was positioned 
adjacent to the backboard, in such a way that the line of eyesight was 
perpendicular to the backboard. When the volunteer was properly 
positioned and was relaxed then the measurement was carried out. The 
headboard was lowered on the top of head with slight pressure to 
compress the hairs. The researcher applied mild upwards pressure below 
the angle of mandible and the measurement was performed to the nearest 
of 0.01m. The same height scale was used by the researcher throughout 
the experimental study.  
Body mass was measured with the help of a digital scale (TBF-300, 
TANITA, Cranlea, UK). The weight of the participants was measured 
wearing lightweight cloths but without shoes. Prior to taking the 
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measurements, extraneous clothing and jewellery were removed. The 
participants stood with both feet placed flat on the balance, without socks, 
and with arms positioned laterally along the side of the body. The 
measurements were performed to the nearest of 0.01kg. To calculate their 
of BMI, the derived values of height and weight were used (Marfell-
Jones, Stewart et al. 2006).  
2.2.2 Body Composition 
Body-fat mass and fat-free mass was measured with bioelectrical 
impedance scales (TBF-300, TANITA, Cranlea, UK). Two pressure 
contacts (footpad electrodes) were incorporated into the platform of the 
Tanita scales. The participant‘s measurements were taken in a standing 
position with bare feet in contact with the electrodes. Tanita scales 
determine the opposition to the flow of electric current through the body 
tissues i.e. bioelectrical impedance, which is then used to estimate the 
total body water. Total body water is then used to calculate fat-free body 
mass, and through difference in body weight, body fat is estimated.  
2.3 Ad libitum Meals 
Ad libitum buffet meals consisted of a wide variety of standardised foods, 
and were presented at about three times in excess from what participants 
were expected to consume. For the ad libitum breakfast a variety of 
breakfast cereals such as corn flakes, fruit & fibre or chocolate-flavoured 
cereals were offered. Milk (semi-skimmed, skimmed and whole cream), 
croissants, jam (apricot, mixed fruit jam, black-current), butter, apple and 
orange juice were presented. Banana and apples were also offered (Figure 
2.1). The ad libitum lunch included two filled white bread sandwiches, 
two filled whole meal bread sandwiches, mixed leaf salad, yoghurt, 
banana, grapes and apple-juice or orange-juice (Figure 2.2). Before 
offering meals to the participants, all foods were weighed and the left-
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overs from the meal were weighed to estimate the amount of food 
consumed. Water was available throughout the trial. Reading and 
watching television were not allowed during ad libitum meals as these 
activities could influence the food intake (de Castro 2000). 
 
Figure 2.1 Ad libitum Breakfast 
 
The ad libitum buffet meals were identical in the HENSD and PLACEBO 
trials, containing the same energy and macronutrient contents and providing a 
variety of carbohydrate, fat and protein content. The food was cut into smaller 
pieces in order to eliminate the portion related cues. Furthermore all the ad 
libitum meals were served in a standardised setting, serving the same type of 
food in the same dishes (coloured), scheduling meals at the same time, and on 
the same table in order to avoid any bias in the eating behaviour. The 
participants were given 30 minutes to consume their meal and were advised to 
eat according to their appetite until they were satisfied and were comfortably 
full. Moreover, additional food was also available if desired. The researchers 
were not present when the participants consumed the ad libitum buffet meals 
in order to curtail any potential influence by the presence of the researcher on 
the feeding behaviour. The participants were blinded to the actual purpose of 
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ad libitum buffet meals i.e. measurement of the food intake, and were instead 
informed that biomarkers in the blood will be investigated for the food 
consumed. This approach avoided conscious eating and reduced the potential 
bias that could take place if the participants were aware of the fact that food 
consumption was being monitored (de Castro 2000). As the effects of social 
context on eating behaviour and patterns is very complex and different 
psychological processes, cognitive and emotional believes and restrains 
influence the volume and type of food eaten. Furthermore, the presence of 
observers can induce people to discontinue eating (Herman, Roth et al. 2003, 
Herman and Polivy 2005, Hetherington, Anderson et al. 2006). 
 
 
 
Figure 2.2  Ad libitum Lunch 
 
2.4 Energy Intake Measurement 
The researcher weighed all food and drinks offered and left-over during the ad 
libitum buffet breakfast and the ad libitum buffet lunch, with an electronic 
kitchen scales (Salter Housewares Ltd., Tonbridge, U.K.) to estimate the 
amount of food being consumed. The type and the amount of each food item 
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were then entered into the dietary software Windiets 2005 (The Robert Gordon 
University, Aberdeen, Scotland, UK), a computerized version of McCance and 
Widdowson’s The Composition of Foods (Krebs 2002), by way of calculating 
the energy and macronutrient intake during the ad libitum buffet breakfast and 
lunch. These values included intake during the ad libitum breakfast, intake 
during the ad libitum lunch, and intake of meals, including either the HENSD 
or PLACEBO. The macronutrient intake (CHO, protein and fat) for each ad 
libitum meal and the macronutrient intake, together with the supplements, 
were also taken into consideration. Three researchers carried out this analysis 
of dietary intake independently to reduce inputting errors and researcher bias. 
Then the mean values of each of their results were taken into account to 
enhance the accuracy of the results.  
2.5 Subjective Appetite Sensations      
Visual analogue scales (VAS) are most commonly used for the assessment of 
subjective appetite sensations. VAS helps to evaluate a subject‘s desire to eat 
by reporting hunger, desire to eat, prospective food consumption, satiety and 
fullness rating (Flint, Raben et al. 2000). The feelings of prospective food 
consumption and the desire to eat are considered as the initial phase of the 
drive to eat. Eating related stimuli such as smell of food, view of food etc can 
trigger these feelings and motivate eating even when subject is satiated.   
Visual analogue scales consist of lines of the same length (usually 100mm) 
with words at each end of the line, which describe extremes such as I am not 
hungry at all/ I have never been hungrier. The negative respective feelings are 
anchored on the left and positive feelings on the right. The subjects were 
requested to rate their appetite sensations including hunger, satiety, fullness, 
prospective food consumption and the desire to eat by making a vertical line at 
the point which corresponded to their feeling. The measurements were 
quantified by measuring a distance on the line from left end to the mark (Flint, 
Raben et al. 2000). Visual analogue scales are more accurate and sensitive 
116 
 
 
 
 
with in subject comparison then  to the comparison between the subjects (Flint, 
Raben et al. 2000). VAS questionnaire used in the study is presented in 
Appendix V. 
For a subjective measure of the appetite response, the total area under the 
curve (AUC) was calculated using the Trapezium Rule. The time averaged 
AUC was calculated as total AUCs divided by the total duration of observation 
time (240 minutes). Time averaged AUC was measured for hunger, satiety, 
fullness, prospective food consumption and desire to eat for both PLACEBO 
and HENSD trials. AUC was calculated by the equation:  
[(a+b)/ 2 x Time] 
(a=trapezium 1), (b=trapezium 2) 
The time-averaged AUC was calculated which provided a measure of the 
average value over the period of observation.  
2.6 Resting Metabolic Rate and Diet Induced 
Thermogenesis 
The resting metabolic rate (RMR) and diet-induced thermogenesis were 
measured by indirect calorimetry, with a computerised open-circuit ventilated 
hood system (Oxycon Pro, Jaeger GmbH, Hoechberg, Germany). The Oxycon 
Pro consisted of a high-speed paramagnetic oxygen sensor and an infrared 
carbon dioxide analyser. A transparent ventilated plastic hood which was 
connected to the gas mixing chamber by a flexible plastic tube. It had a bi-
directional digital volume sensor consisting of an amplifier, Triple V and a 
pressure transducer, and a gut mixing chamber, turbine and twin tubing. 
Before the start of each test the volume calibration was completed. For volume 
calibration, a 3-liter syringe was connected to the assembly of Triple V. Six 
complete pumps of the syringe was repeated so that the percentage difference 
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between the recent and previous volume calibration was less than 1 % (James 
Carter et al 2002). 
For gas calibration, and delay time calibration, the Jaeger Oxycon Pro had an 
automatic calibration process. For gas calibration 16% Oxygen and 5% carbon 
dioxide was introduced to Oxycon Pro through a gas cylinder. The automatic 
process was repeated until the existing and prior data, delay time and offset 
were within 1 % (Carter and Jeukendrup 2002). 
The RMR of the participant was measured in the morning at 8.30 am in the 
metabolic suite, after 12 hours of fasting and abstinence from physical activity, 
for two days prior to the main trial. The metabolic suite of the Yorkhill 
Hospital was a quiet, semi-dark room, where background noise was kept to a 
minimum. It had a thermo-neutral environment (21-24
0
 C). Before starting the 
main trial in the metabolic room, the subjects were asked to lie in a supine 
position with straight legs and arms placed straight on the side. Then after 
10min, the transparent ventilated plastic hood was placed over the subject‘s 
head. The ventilated hood was connected to the gas-mixing chamber through 
corrugated plastic tubes and the ventilation was run by means of a flow 
volume sensor unit through the system. The rate of Oxygen consumption 
(VO2) and rate of carbon dioxide production (VCO2) were recorded, at 
intervals of 1 minute. Measurements were recorded for 10 minutes prior to 
placing the canopy on the participant and these measurements were called pre-
drift. Then, 20 minutes of measurements were recorded with the participant 
inside the canopy. After that, 10 minutes of measurements were taken when 
the participant was outside the canopy, which acts as a post-drift. Then mean 
of pre-drift and post drift was taken for the correction of drift. Throughout the 
experiment, participants were closely monitored so that talking, excess 
movement and sleeping would be avoided.  
VO2 and VCO2 were continuously recorded when the participant was outside 
the canopy for calculating the pre-drift. The participants lay down after meals 
and the canopy was placed on them for 20 minutes. After 20 minutes, the 
118 
 
 
 
 
participants came out of the canopy for 10 minutes during which they were 
allowed to perform their sanitary activities.  
The mean values obtained from VO2 and VCO2 were corrected for the drift by 
taking the mean of the pre-drift and post-drift values. Then these values were 
used to calculate respiratory exchange ratio and rate of energy expenditure by 
using the indirect calorimetry equations described by Frayn and Macdonald 
(Frayn and Macdonald 1997) . 
Rate of fat oxidation (g/min) = (VO2 – VCO2)/ 0.57 
Rate of carbohydrate oxidation (g/min) = (1.40× VCO2 – VO2)/ 0.30 
Rate of energy expenditure (kJ/min) = (rate of carbohydrate oxidation×15.6) + 
(rate of fat oxidation× 39). 
  
Figure 2.3 Oxycon Pro (Oxycon Pro, Jaeger GmbH, Germany) with ventilated 
hood system  
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2.7 Blood sampling and Plasma Preparation 
On the days of the main experimental trial, venous blood samples were 
collected from the participants. Participants arrived in the morning at the 
metabolic room after an overnight fast. After recording the resting-metabolic 
rate measurement, the participant rested in a supine position and was informed 
about the intravenous cannulation. Then an indwelling 18G cannula (Venfoln, 
BOC, Helsingbourg, Sweden) was inserted into the antecubital vein of the 
forearm. Fasting or baseline venous blood sample was collected into a 10 ml 
ethylenediamine tetra-acetic acid (EDTA) Vacutainer
TM
 tube (BD Vacutainer 
Systems, Plymouth, UK). About 10mls of venous blood was collected at 0, 30, 
60, 120, 150, 180, 210 and 240 minutes during the entire period of study.  
 
Figure 2.4 Intravenous cannulation during experimental trials 
 
Blood samples for the analysis of insulin, glucose, plasma lipids 
concentrations and for the measurement of plasma paracetamol levels (as an 
indirect measure of gastric emptying) were centrifuged at 4
0
C, 3000 rpm for 
15mins in a refrigerated centrifuge. After centrifugation the plasma 
supernatant was aspirated using a pipette and then 0.3ml of plasma aliquoted 
into three labelled 2ml Eppendorf (Alpha laboratories Ltd, UK) and frozen at -
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80
0
C for the analysis. The blood samples used for the determination of gut 
peptides were split into two aliquots: a) 1ml of blood was aliquoted into three 
Eppendorf tubes each containing 80μl aprotonin (0.4TIU/ 500KIU) (Sigma-
Aldrich, UK). Then samples were centrifuged in a smaller centrifuge machine 
for 4mins at maximum 14000 rpm. Subsequently, 300μL of plasma was 
aliquoted into 3 Eppendorf tubes labeled for CCK/ PYY. Immediately all the 
aliquoted samples were frozen at -80
0
C until assayed.  
2.8 Plasma Analysis 
2.8.1 Glucose Analysis 
Plasma glucose concentrations were determined in the Exercise Physiology 
Laboratory, Western Infirmary, University of Glasgow by the enzymatic 
calorimetric method using commercially available glucose analysis kits. 
Glucose analysis kits consist of reagents (Glucose HK CP Reagent ABX 
Pentra, Horiba ABX, France) and the analysis was performed on the 
spectrophotometric analyser an automated Roche Cobas Mira (Horibra ABX, 
Montpellier, France). The precision and accuracy of the assays was monitored 
with quality control sera (Horiba ABX, Montpellier, France). The analysis of 
all the samples from each subject were carried out on a single run and in 
duplicate with the co-efficient of variation of less than 3%. The glucose 
determination principle is based on the calorimetric reaction 
Where HK is hexokinase and G-6-PDH is glucose-6-phosphate-dehydrodenase 
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2.8.2 Insulin Analysis 
Insulin analysis was performed in the Steroid II laboratory, at the Human 
Nutrition, Royal Hospital for Sick Children Yorkhill, University of Glasgow. 
Quantitative insulin analysis was performed by using a commercially available 
Enzyme-linked immunosorbent assay (ELISA) kit with pro-insulin (Mercodia 
AB, Uppsala Sweden) with less than 0.01% cross-reactivity. For analysis 
Interassay and intrassay coefficient of variance were 3.4% and 3.6%. Mercodia 
insulin ELISA is based on the principle of solid phase two-site enzyme 
immunoassay. Monoclonal antibodies were directed against the antigenic 
determinants of insulin molecules in a ‗sandwich‘ technique. Insulin present in 
the samples reacts with the per-oxidase conjugated anti-insulin antibodies, and 
these anti-insulin anti- bodies then bound to the micro-titration well. Unbound 
enzymes labelled anti-bodies are then removed by simple washing step. Bound 
conjugates are detected by their reaction with 3, 3‘, 5, 5‘-tetramethylbenzidine 
(TMB). Finally, the acid was added to stop the reaction and to get a 
calorimetric end point which was read spectrophotometrically. 
Before use, all samples and reagents were brought to room temperature. 
Sufficient micro-plate wells were prepared to accommodate the Calibrators 
and samples in the duplicate. Plasma samples (25μL) and Calibrators (25μL) 
were poured into appropriate assay wells. Then 100-μL of freshly prepared 
enzyme conjugate was added to each well. Afterwards, incubation of the plates 
for one hour at room temperature (18-25
0
C) was done on a plate shaker (700-
900 rpm). Insulin in the samples during incubation period reacts with 
peroxidase-conjugated anti-insulin antibodies and these anti-insulin antibodies 
attach to the plate wells. Using an automated and wash buffer solution (700 
μL), the plates were washed and dried six times to eliminate any unbound 
enzyme labelled antibody. After that 200μL of 3, 3‘, 5, 5‘-
tetramethylbenzidine (TMB) was added to the wells to detect bound 
conjugates in the well. To permit the reaction between bound conjugates and 
TMB, the plates were again incubated for 15 min at room temperature. The 
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reaction was stopped after incubation in each well by adding 50 micronlitres of 
stop solution containing 0.5M sulphuric acid. Then the plate was placed again 
on the shaker for 5 seconds approximately to ensure the proper mixing. 
According to the conjugate-substrate complex concentration a yellowish tint 
colour developed. Subsequently by means of a Plate reader the optical density 
of every well was read. By comparing the optical density of the samples to the 
standard curve for every plate insulin concentration in the samples was 
determined. The coefficients of variation for assay were <5%.  
All the samples from one subject were analysed in a single run. Quality control 
sera (Mercodia Diabetes Antigen Control (Low, High)/human) (Mercodia AB, 
Uppsala Sweden) was used to determine the precision and accuracy of assays.    
2.8.3 Human Peptide YY Analysis 
Human Peptide YY analysis was performed in the Steroid II laboratory, at the 
Human Nutrition, Royal Hospital for Sick Children Yorkhill, University of 
Glasgow. For determination of PYY concentrations in all the samples 
commercially available ELISA kit (Millipore 96-well plate, Cat. # 
EZHPYYT66K) was used according to the manufacturer‘s instructions. 
 
This is a ―Sandwich‖ ELISA, used for non- radioactive quantification of 
Human PYY molecule in the plasma and serum. Its sensitivity is 1.4pg/ml for 
20μl sample. It involves binding the PYY molecules (PYY1-36 and PYY3-36) 
in the sample by the rabbit anti-human PYY lgG. The resulting complex was 
then immobilized to the microtiter plate wells which were coated with the anti-
rabbit IgG antibodies. Simultaneously, a second biotinylated antibody was 
bound to the PYY molecules.  At this step unbound materials were removed 
by washing the wells, followed by conjugation of the immobilized biotinylated 
antibodies with horseradish peroxidase.  Unbound enzymes labelled anti-
bodies were removed by washing. The quantification of immobilized 
antibody-enzyme conjugates was done in the presence of the substrate TMB 
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by monitoring horseradish peroxidase activities. In the last step acid was added 
to stop the reaction and to get a calorimetric end point where the blue colour of 
the assay turned to yellow. Afterwards enzyme activity was measured with a 
spectrophotometer (Thermo Scientific multi-scan spectrum). The automated 
analyser for the specific assay was set up at two wavelengths; one at 450 nm 
for the increased absorbency and other at 590nm for correction. The increasing 
absorbance was then directly proportional to the amount of PYY; therefore, a 
standard curve was formed (by using reference standards with known 
concentrations) to calculate the PYY concentrations. 
 
2.8.4 Cholecystokinin Analysis 
Cholecystokinin (CCK) analysis was performed in the Steroid II laboratory, at 
the Human Nutrition, Royal Hospital for Sick Children Yorkhill, University of 
Glasgow. Cholecystokinin (CCK) was analysed by using an Enzyme 
Immunoassay kit (EIA kit) (Phoenix, Pharmaceuticals, Inc., Burlingame, CA, 
USA) according to the manufacturer‘s instructions. 
This EIA kit was based on the principle of ―competitive‖ enzyme 
immunoassay. The immunoplate provided in the kit was pre-coated with the 
secondary antibody while the non-specific binding sites were blocked. The 
secondary antibody bound to the Fc fragment of the primary antibody whereas 
Fab fragment binds was bound competitively by the peptide standards and 
biotinylated peptide or targeted peptides in the samples. Streptavidin-
horseradish peroxidise (SA-HRP) catalyzed the substrate solution. The 
biotinylated peptide interacts with SA-HRP. There was a competitive binding 
of biotinylated peptide with the peptide antibody of the samples (primary 
antibody) or with the standard peptide. The intensity of yellow colour was 
directly proportional to the biotinylated peptide SA-HRP complex and was 
inversely proportional to the amount of peptides in the samples or standard 
solutions. A standard curve of known concentration was developed 
accordingly and an unknown concentration of the samples was determined by 
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extrapolation of the standard curve. For analysis inter-assay and intra-assay 
coefficient of variance were < 6.6% and <5.4% respectively. 
 
2.8.5 Gastric Emptying 
The paracetamol (acetaminophen) absorption test was used to assess the 
gastric emptying. The paracetamol absorption test was based on the 
pharmacokinetic principle (Clements, Heading et al. 1978) that gastric 
emptying was the rate-limiting step in the absorption of paracetamol because 
the paracetamol was not  absorbed in the stomach but was completely and 
rapidly absorbed from the small intestine after passage through the pylorus 
(Kim, Myung et al. 2000). Therefore, the plasma paracetamol had been shown 
to correlate with the rate of gastric emptying. 
On the morning of the experimental trial, after the baseline measurements, 
following the supplement intake, two paracetamol tablets (1000mg with 100ml 
of water) were given to the participants. Then, venous blood samples were 
collected at 0, 30, 60, 120, 150, 180, 210 and 240 minutes during the entire 
period of study for measuring plasma paracetamol concentrations. 
For assessment of gastric emptying plasma paracetamol concentrations were 
assayed by using Acetaminophen Assay kits (Cambridge Life Sciences, 
Cambridge, U.K.). An enzyme specific for amide bond of acylated aromatic 
amines was used for the cleavage of the paracetamol molecule and produced 
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p-aminophenol. The p-aminophenol reacted with o-cresol in ammoniacal 
copper solution, which gave a blue color. The instructions of the kit were 
followed and an alternative protocol was used for this assay, which has been 
validated by Cambridge Life Sciences and allowed the use of reduced 
volumes.  
The accuracy of the paracetamol absorption test greatly depends on the 
absorptive index used (Willems, Quartero et al. 2001). Several 
pharmacokinetic parameters have been used as the rate metrics in the 
paracetamol absorption test such as a fixed-time concentration, maximal 
plasma concentration (Cmax), the time of maximal plasma concentration 
(Tmax), and the area under the curve (AUC). However, the most appropriate 
index for the paracetamol absorption remains inconclusive (Willems, Quartero 
et al. 2001). The AUC is considered as an accurate estimation of the rate of 
paracetamol absorption (Willems, Quartero et al. 2001). A study by Nimmo et 
al (1975) also obtained a significantly high correlation (r = 0.94) between 
AUC and Scintigraphy (Nimmo, Heading et al. 1975). 
We calculated the total areas under the curves of concentration versus time 
(AUC) using the trapezium rule for plasma paracetamol concentrations. AUC 
from 0-60 minutes (AUC60) were calculated on responses at 0, 30, and 60 
minutes and AUC from 0-180 minutes were calculated using values at 0, 30, 
60, 120, 150 and 180 minutes.  
2.8.6 Cholesterol Analysis 
The determination of total cholesterol was performed on an automated Roche 
Cobas Mira Plus spectrophotometric analyser (Cobas Mira Plus (ABX 
Diagnostics, France), by enzymatic calorimetric method using commercially 
available kits (Cholesterol CP Reagent, ABX Pentra, Horiba ABX, France). 
All samples from each participant were analyzed on a single analyser run. The 
accuracy and precision of the assays were monitored using quality control sera 
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(Roche diagnostics GmBH, Mannheim, Germany. Randox laboratories 
Limited Co., Antrim Ireland, Wako chemicals GmBH, Germany). The 
quantitative determination of cholesterol is usually done for screening 
purposes and can be performed by an enzymatic photometric test ―CHOD-
PAP‖. The principle of the cholesterol determination is based on the 
calorimetric equation as follows: 
 
 
2.8.7 Triglyceride Analysis 
The measurement of plasma triglycerides was performed on an automated 
Roche Cobas Mira Plus spectrophotometric analyser (Horiba ABX, 
Montpellier, France) using a commercially available kit (Triglcerides CP 
Reagent ABX Pentra, Horiba ABX, France). All samples from each participant 
were performed on a single analyser run. The principle of enzymatic 
determination of triglycerides was based on the following colorimetric 
equation; 
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2.8.8 High-density lipoprotein Analysis 
The measurement of high-density lipoprotein (HDL) was performed on an 
automated Roche Cobas Mira Plus spectrophotometric analyser (Horiba ABX, 
Montpellier, France) using the commercially available kit (HDL Direct 
Reagent ABX Pentra, Horiba ABX, France). All samples from each participant 
were performed on a single analyser run. The principle of enzymatic 
determination of HDL was based on the following colorimetric equation; 
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The above methods were used to obtain the values of plasma TAG, HDL-
cholesterol, and the total cholesterol. LDL-cholesterol within the plasma was 
then calculated by using the standardized formula (Friedewald, Levy et al. 
1972);  
 
LDL-cholesterol = (Total cholesterol – HDL cholesterol – Total triglyceride) / 
2.19 
 
2.9 Statistical Analysis 
 The Anderson-Darling test was used to determine the normality of the data 
using Minitab 16 statistical software. Depending upon the distribution of the 
data, parametric or nonparametric analyses were applied. Time-averaged AUC 
for subjective measures of appetite, for energy intake, and for post-meal 
energy expenditure were calculated using trapezium rule. Statistical 
129 
 
 
 
 
significance was accepted for P-values of less than 0.05. Differences in energy 
intake between both trials were tested for pre-breakfast, pre-lunch and over the 
whole duration of the trial. All the data was presented as Means ± SE. All the 
analysis of the data was carried out using the Minitab software (Minitab Inc., 
State College, Pensylvania). Please refer to each experimental chapter for 
detailed information regarding the calculation of sample size and the statistical 
analysis of the respective experimental chapter. 
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3 Effects of high energy nutritional 
supplement drinks on appetite, appetite 
hormones, postprandial energy 
expenditure & energy intake 
3.1 Introduction 
Studies in the published literature suggest that oral multi-nutrient high-energy 
liquid supplements (HENSD) can improve energy intake and thus increase 
body weight and have a variety of clinical and functional benefits in 
malnourished patients, and patients at risk of becoming malnourished (Stratton 
and Elia 2007, Stratton and Elia 2010, Cawood, Elia et al. 2011, Hubbard, Elia 
et al. 2012, Stratton, Hebuterne et al. 2013). Studies have demonstrated that 
HENSD supplementation increases daily energy intake (Huynh, Devitt et al. 
2014). A recent meta-analysis of 8 RCTs (total patients: n = 771) revealed that, 
due to consumption of oral nutritional supplements daily energy intake 
increased by a mean of 375 kcal/d (Hubbard, Elia et al. 2012). Thus, the oral 
nutritional supplements, (typically containing a mixture of protein, 
carbohydrate and fat and some micronutrients, and providing from 6·3 kJ/ml 
to 10·1 kJ/ml per typical serving of 125–220 ml) form an integral part of the 
management of malnutrition (Stratton and Elia 2010). 
It is obvious that the ability of oral HENSD to promote an increase in the daily 
energy intake and induce a positive energy balance is related to incomplete 
energy compensation and lack of adjustment of energy intake due to previous 
ingestion. The standard explanation for lack or diminished compensation can 
be based on the results from studies which report weak satiating effects of soft 
drinks, and their inability to induce precise compensation for the energy 
provided. This suggests that liquid calories are not perceived by the body 
(DiMeglio and Mattes 2000, Mattes 2006, Drewnowski and Bellisle 2007). In 
addition, contrary to expectations, the higher energy preloads were associated 
with less compensation (Almiron‐ Roig, Palla et al. 2013). The mechanisms 
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responsible for little suppression of food intake following oral intake of 
HENSD remain to be investigated. 
Current evidence indicates that the postprandial release of insulin and 
gastrointestinal factors such as peptide YY(Le Roux and Bloom 2005), 
Cholecystokinin (CCK) (Simpson, Parker et al. 2012), provide inhibitory 
feedback that suppresses appetite and food intake. Postprandial release of CCK 
also slows gastric emptying (GE) and by this mechanism contributes further to 
energy intake suppression (Kleibeuker, Beekhuis et al. 1988, Konturek, 
Kwiecien et al. 1990). So far, the role of metabolic and hormonal appetite 
modulators, in amendment of energy intake, due to malnutrition treatment has 
been investigated only in tube-feeding studies (Stratton and Elia 1999, 
Stratton, Stubbs et al. 2008). The intermittent delivery of tube- feeding as a 
bolus, reflecting a physiological liquid meal-like pattern,  regardless of  the 
variety  of significant metabolic and hormonal changes involved in satiation, 
induce only partial compensation for the energy provided by the bolus 
(Stratton, Stubbs et al. 2008). Indeed, tube feeding delivers nutrients directly 
into the stomach, and thus bypasses the sensory aspects of oral consumption 
and cephalic-phase response. In addition, one bolus of tube feeding provides 
nearly twice as much energy in comparison to a typical oral high-energy 
supplement (Stratton and Elia 1999, Stratton, Stubbs et al. 2008). However, 
interaction between appetite, food intake, metabolic and the hormonal 
mediators of appetite and satiety, following tube- feeding and oral 
supplementation can be different. 
This study aimed to confirm that consumption of oral HENSD induces only a 
partial suppression of ad libitum food intake. In addition, study  investigated 
impact of HENSD supplementation on the proxy measure of gastric emptying 
which is most probably an important mediator of both appetite and the energy 
intake (Jones, Doran et al. 1997, Sturm, Parker et al. 2004) and evaluate extent 
by which supplementation induced increase in the energy intake is diminished 
by thermogenic effect.   
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3.2 Material and Methods 
Participants 
Twenty-three healthy women with a mean (±SD) age of 24.4 ± 2.8 years 
(range: 18-35 years) with a body mass index (BMI) in (kg/m
2)
 of 18.6 ± 0.9 
kg/m
2
 (range:
 
17-20 kg/m
2
) and body fat mass in (kg) of 9.1 ± 3.3 were 
recruited into this study. We have chosen ―underweight‖ healthy women 
(BMI: 17-20 kg/m
2
) to simulate relative under-nutrition. This allows a 
sampling regime and study design which would not be ethical in a paediatric 
patient group. Participants were recruited by means of advertisement leaflets 
on notice boards at the university and word of mouth in the campus of the 
University of Glasgow and in other public places. All the participants were 
non-smokers, had stable weight for one month prior to the study, not pregnant, 
having a regular menstrual cycle, were not on any medication or any 
nutritional supplement, and were not following a special diet. Before enrolling 
in the study participants underwent a screening visit which included height and 
weight measurement and filling out a detailed health screen questionnaire 
regarding the participant‘s health, to exclude chronic illness, eating disorders 
and gastrointestinal operations, which could interfere with the results of the 
study. All participants were required to give written, informed consent. The 
study was approved by the College of Medical Veterinary and Life Sciences, 
University of Glasgow, Research Ethics Committee.  
Study Design  
This study used a single blind crossover design with two randomly sequenced 
experimental trials, separated by 4 weeks. A schematic representation of the 
study design is shown in Figure 3.1.  
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Figure 3.1 Schematic representation of the study design  
 
On the morning of the experimental trial, participants reported to the metabolic 
investigation room between 0800 and 0900 after a 12 hour fast. Height (Seca, 
Leicester, UK) body mass and body fat (TBF-300, TANITA, Cranlea, UK), 
and resting metabolic rate (RMR) were measured. A venous cannula was then 
inserted and after an interval of 10 min, a base-line blood sample was 
obtained. Subsequently an appetite questionnaire was completed. Then, within 
10 minutes, the study participants were asked  to consume 240 ml of either 
high energy liquid mainstream nutritional supplement (Scandishake, 
Chocolate, Nutricia) prepared with full fat milk (HENSD trial), or a  low 
calorie drink  made up with skimmed milk, cocoa and sweeteners (PLACEBO 
trial).  
 
 
 
 
Time (min) 
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Table 3.1 Energy (MJ) and proportion (percentage) from carbohydrate (CHO), 
fat and protein provided by PLACEBO and HESND drink. 
 
    PLACEBO HENSD 
       CHO (g) 11.3g 68.8g 
        Fat (g) 1.3g 30.4g 
       Protein (g) 9g 11.9g 
Energy (MJ) 0.38 2.49 
          Energy from CHO (%)   48 46 
         Energy from Fat (%) 13 46 
         Energy from Protein (%) 39 8 
 
Abbreviations: CHO, Carbohydrates 
The participants were blinded to the preload drink, and they were not told 
which chocolate drink they would consume. The order in which drinks were 
provided was randomly allocated. Each participant was allocated an 
alphanumeric subject code by the researcher. A block method of 
randomization was used to randomly allocate participants for taking the 
HENSD or PLACEBO drink first (Block size of 3 was taken). The first block 
participants were given HENSD drink and next block was given PLACEBO 
first. The HENSD and PLACEBO drinks had the same colour, volume, flavour 
and texture and were not distinguishable. Following supplement intake, two 
paracetamol tablets (1000mg with 100ml of water) were given to the 
participants. The participants marked further appetite questionnaires and blood 
samples were collected at 30 and 60 min after supplement intake, while the 
metabolic rate was measured every minute for the duration of 20 minutes after 
each blood sample. In the 60 minutes following the preload drink an ad libitum 
buffet style breakfast was served to the participants. 
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Subsequently appetite questionnaires were completed, blood samples were 
collected at 120, 150, 180, 210 and 240 minutes and metabolic rate was 
recorded as explained previously in Chapter 2.   
 
Measurement of food and energy intake 
All food and drink items (excluding water) were covertly weighed before and 
after each breakfast and lunch using the standard electronic kitchen scales 
(accurate to ±1 g). The macronutrient and energy intake with and without 
macronutrients and energy provided by the supplements, was calculated over 
the whole experimental trial using the dietary software Windiets 2005 (The 
Robert Gordon University, Aberdeen, Scotland, UK). The calculations on 
energy and macronutrient intake were independently conducted by two 
researchers and mean values of each of their results was taken into account to 
enhance the accuracy of results.  
Appetite Measurements 
Visual Analogue Scale (VAS) questionnaires, with a line of 100 mm (Flint, 
Raben et al. 2000) were used throughout the trial for measuring the appetite 
sensations of the participants. Participants were asked to express their feeling 
of hunger, satiety, fullness, prospective food consumption and the desire to eat 
on 100mm lines by placing a vertical mark on the horizontal line at a point, 
which corresponds to their feelings at that time. The lines were anchored by 
negative respective feeling words (I am not hungry at all) on the left and by 
positive feeling words (never being hungrier) on the right respectively. 
Quantification of the measurement was made by measuring distance from the 
left end of the line to the participant‘s mark.  
Metabolic Rate 
Metabolic rate was measured by means of computerised open-circuit 
ventilated hood system (Oxycon Pro, Jaeger GmbH, Hoechberg, Germany). 
The rate of oxygen consumption (VO2) and rate of carbon dioxide production 
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(VCO2) were recorded at every minute for the duration of 20 minutes. Then 
these values were used to calculate the rate of energy expenditure by using the 
indirect calorimetry equations described by Frayn and Macdonald (Frayn and 
Macdonald 1997). 
Blood Analysis 
Venous blood samples were collected into a 10 ml ethylenediamine tetra-
acetic acid (EDTA) Vacutainer tube (BD Vacutainer Systems, Plymouth, UK). 
Blood samples used for the analysis of insulin and glucose were centrifuged at 
4
0
C, 3000 rpm for 15mins in a refrigerated centrifuge. After centrifugation the 
plasma supernatant was aspirated and frozen at -80
0
C until analysed. The 
blood samples used for the determination of gut peptides were aliquoted into 
three Eppendorf tubes each containing 80μl Aprotonin (0.4TIU/ 500KIU) 
(Sigma-Aldrich, UK). As 0.6 TIU activity per ml of the blood is provided by 
80l of Aprotonin. Each bottle contains 4.4 TIU activity per mg protein and 
for 1.7 mg/protein per ml it has7.84 TIU activity per ml (1.7 mg x 4.4 TIU), 
thus 0.6 TIU activity will be supplied by 80l of Aprotonin (0.6 TIU x 
1ml/7.48 TIU). Then samples were centrifuged in a smaller centrifuge 
machine for 4mins at maximum 14000 rpm. Subsequently 300μL of plasma 
was aliquoted into three Eppendorf tubes labelled for CCK/ PYY. 
Blood glucose analysis was performed on a spectro-photometric analyser 
which was an automated Roche Cobas Mira (Horibra ABX, Montpellier, 
France) with co-efficient of variation < 3%. Quantitative insulin analysis was 
performed using commercially available Enzyme-linked immunosorbent assay 
(ELISA) kit (Mercodia AB, Uppsala Sweden). For analysis, the inter-assay 
and intra-assay coefficients of variance were 3.4% and 3.6%. The PYY were 
measured according to the manufacturer‘s instructions using Millipore ELISA 
kit (Merck, Millipore, Bioscience Division, UK), with an inter-assay 
coefficient of variance of < 7.6% and an intra-assay coefficient of variance of 
< 4%. Cholecystokinin (CCK) was also analysed using ELISA kit (Phoenix, 
Pharmaceuticals, Inc., Burlingame, CA, USA). For analysis, inter-assay and 
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intra-assay coefficients of variance were < 6.6% and <5.4% respectively. For  
the assessment of gastric emptying, plasma paracetamol concentrations were 
assayed by using Acetaminophen Assay kits (Cambridge Life Sciences, 
Cambridge, U.K.). The instructions of the kit were followed and an alternative 
protocol was used for this assay which had been validated by Cambridge Life 
Sciences, which allowed the use of reduced volumes.  
Calculations and Statistical Analysis  
The Anderson-Darling test was used to determine the normality of the data and 
it was found that the data was normally distributed.  
For the subjective measure of appetite responses (hunger, satiety, fullness, 
prospective food consumption and desire to eat), plasma concentration of 
glucose, insulin, peptide YY and CCK the total areas under the curve (AUC) 
were calculated using the Trapezium Rule. Paired t-test was used to identify 
the differences between the PLACEBO and the HENSD trials. For subjective 
measure of the appetite responses (hunger, satiety, fullness, prospective food 
consumption and desire to eat), glucose levels, insulin levels and appetite 
hormones, the total areas under the curve (AUC) were calculated using the 
Trapezium Rule. Then time averaged AUC was calculated as total AUCs 
divided by the total duration of observation time (240 minutes).   
The time-averaged AUC was calculated for the pre-breakfast (60 minutes), 
pre-lunch (150 minutes) and over the entire duration of the trial (240 minutes). 
This provided a measure of the average value over the period of observation. 
AUC for pre-breakfast (0-60min) values were calculated on the responses at 0, 
30, and 60 time points. The AUC for pre-lunch values were calculated using 
values at 60, 90, 120, and 240. The calculated AUC were divided by time of 
observation to obtain the time averaged AUCs. 
We calculated the total areas under the curves of concentration versus time 
(AUC) using the trapezium rule for plasma paracetamol concentrations. AUC 
from 0-60 minutes (AUC60) were calculated on responses at 0, 30, and 60 
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minutes and AUC from 0-180 minutes were calculated using values at 0, 30, 
60, 120, 150 and 180 minutes.  
The metabolic rate pre-breakfast and pre-lunch energy expenditure and energy 
expenditure (EE) for the whole duration of the trial (240 minutes) was 
calculated in (kJ/min). After that the pre-breakfast increase in the energy 
expenditure (kJ) above RMR was calculated for a period of 60 minutes. Then 
pre-lunch increase in EE was calculated for 150 minutes and again for the 
whole duration of the trial (240 minutes). This was calculated by subtracting 
the mean value of energy expenditure rate (pre-breakfast, pre-lunch and over 
the full trial) from RMR and then multiplied by the time of observation. The 
percentage increase in energy expenditure above the resting metabolic rate was 
calculated for pre-breakfast, pre-lunch and for the whole duration of the trial. 
All the data was presented as means ± SE. All the analysis of the data was 
carried out using the Minitab16 statistical software (Minitab Inc., State 
College, Pennsylvania).  
3.3 Results 
Energy Intake 
Data on energy and macronutrient intake during the HENSD and PLACEBO 
trials are presented in Figure 3.2 and Table 3.2.  
.  
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Figure 3.2  Energy provided by preload drinks and energy intake during ad 
libitum breakfast and ad libitum lunch in HENSD and PLACEBO trials.  
a
 Significant (P=0.001) difference during breakfast between HENSD and 
PLACEBO trials; 
b
Significant (P=0.006) difference in summary energy intake 
between HENSD and PLACEBO. 
Energy intake during the ad libitum breakfast was significantly (P=0.001) 
lower in the HENSD compared with the PLACEBO trial, but no significant 
difference between the two trials was found in the energy intake during the ad 
libitum lunch. Due to energy intake reduction during breakfast in the HENSD 
trial, energy intake during the breakfast and lunch combined was also 
significantly (P=0.005) lower in the HENSD than the PLACEBO trial. In the 
HENSD trial, the suppression of energy intake was equivalent to 43 ± 14 % 
(1.07± 0.34MJ) of energy provided by the supplement. Thus, total energy 
intake calculated as a sum of energy intake during breakfast and lunch, and 
energy provided by supplements was significantly (P=0.006) higher in the 
HENSD than the PLACEBO trial.  
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Table 3.2 Energy from carbohydrate (CHO), protein and fat intake in HENSD 
and PLACEBO trial   
 
Meal 
 
HENSD PLACEBO 
Breakfast  Energy (MJ) 1.92 ± 0.17 2.89 ± 0.23** 
 
    CHO (g)    80 ± 8     113 ± 1* 
     Protein (g)    11 ± 1     16 ± 1* 
     Fat (g)     12 ± 1     21 ± 2** 
Lunch Energy (MJ) 2.16 ± 0.16 2.27 ± 0.20 
 
      CHO (g)     69 ± 5      72 ± 7 
       Protein (g)     22 ± 2      24 ± 2 
       Fat (g)     18 ± 1.6      18 ± 1.9 
Breakfast +              
Lunch 
Energy (MJ) 4.09 ± 0.26 5.16 ± 0.32** 
 
      CHO (g)     150 ± 11       186 ± 13** 
       Protein (g)     33 ± 3       40 ± 3* 
        Fat (g)      30 ± 2       40 ± 3** 
Breakfast + 
Lunch + 
Supplement 
Energy (MJ) 6.58 ± 0.26 5.54 ± 0.32** 
 
     CHO (g)      219 ± 11      197 ± 13 
      Protein (g)      45 ± 3       50 ± 3 
       Fat (g)      60 ± 2       41 ± 3** 
Values are presented as Mean ± SE. Significantly different (*P<0.05, ** 
P>0.001) from HENSD 
 
Appetite Responses 
Responses of appetite measures during the HENSD and the PLACEBO trials 
are presented (Figure 3.3).  
In the fasted state, VASs for hunger, desire to eat, fullness, and satiety were 
not significantly different between the HENSD and the PLACEBO trials. 
During the pre-breakfast period (0-60 min) mean VASs for hunger  (HENSD, 
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41 ± 4 mm; PLACEBO, 52 ± 4 mm, P = 0.03) and desire to eat (HENSD, 46 ± 
4 mm; PLACEBO, 62 ± 4 mm, P= 0.007), were significantly lower, and for 
satiety (HENSD, 46 ± 4 mm; PLACEBO, 34 ± 4 mm, P=0.03) and fullness 
(HENSD, 46 ± 4 mm; PLACEBO, 32 mm ± 4 mm, P=0.006) significantly 
higher in the HENSD than the PLACEBO trial. During the pre-lunch period 
(60-240 min), mean VASs for hunger (HENSD, 28 ± 3 mm; PLACEBO 30 ± 
3 mm, P=0.61), desire to eat (HENSD 48 ± 4 mm; PLACEBO, 53 ± 5 mm, 
P=0.28), fullness (HENSD 64 ± 3 mm; PLACEBO, 62 ±  3 mm, P=0.43), and 
satiety (HENSD 64 ± 3 mm; PLACEBO, 60 ±  3 mm, P=0.15) were not 
significantly different between the HENSD and the PLACEBO trials. 
Metabolic Rate 
The resting metabolic rate, measured before consumption of the supplement 
was not significantly different between the two trials (HENSD, 3.1± 0.1 
kJ/min; PLACEBO 3.2 ± 0.1 kJ/min). Energy expenditure (EE) above resting 
metabolic rate (RMR) after supplement intake during the pre-breakfast period 
(0-60 min) and pre-lunch period (60-240 min) in the HENSD and the 
PLACEBO trials is presented (Figure 3.4). The percentage increase in energy 
expenditure during the pre-breakfast period, was measured for 60 minutes after 
consumption of the supplements (HENSD, 15.5 ± 4.03%; PLACEBO, 4.84 ± 
3.85%, P=0.03) and during 180 min of pre-lunch period (HENSD, 33.87 ± 
6.2%; PLACEBO, 21.71± 3.78%, P=0.03) was significantly higher in the 
HENSD than the PLACEBO trial. The amount of energy expended above the 
resting metabolic rate during the pre-breakfast period, measured for 60 
minutes after consumption of the supplements (HENSD, 27.54 ± 5.24 kJ; 
PLACEBO, 10.73± 6.3 kJ, P=0.04), during 180 min of pre-lunch period 
(HENSD, 142.97 ± 19.11 kJ; PLACEBO, 95.91± 16.11 kJ, P=0.01) and during 
the whole duration (0-240 min) of the experimental trials (HENSD, 296.6 ± 
37.8 kJ; PLACEBO, 171.8± 40.0 kJ, P=0.003) was significantly higher in the 
HENSD trial with difference in energy expended above the metabolic rate 
between trials being 124.74 ± 35.95 kJ.  
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Figure 3.3 Measures of hunger, satiety, fullness, and desire to eat in the fasted 
state (0 min), during pre-breakfast period (0-60 min) and pre-lunch periods 
(60-240 min) in HENSD and PLACEBO trials  
The preloads were consumed immediately after the fasting measurements. 
Values are presented as mean ± SE.  
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Figure 3.4: Energy expenditure (EE) above resting metabolic rate (RMR) after 
supplement intake during pre-breakfast period (0-60 min) and pre-lunch 
periods (60-240 min) in HENSD and PLACEBO trials.  Values are expressed 
as mean ± SE. 
 
Metabolic and Hormonal Responses 
Metabolic and hormonal responses during the HENSD and PLACEBO trials 
are presented in (Figure 3.5., Table 3.3). Mean concentration of plasma 
glucose during pre-breakfast (HENSD, 6.37 ± 0.25 mmol/l; PLACEBO, 5.51 ± 
0.18 mmol/l, P=0.0001) was significantly higher in HENSD than the 
PLACEBO trial. During pre-lunch period (HENSD, 6.76 ± 0.21 mmol/l; 
PLACEBO, 6.09 ± 0.29 mmol/l, P=0.06) mean concentration of the plasma 
glucose was not significantly different between HENSD and PLACEBO trial.  
During the pre-breakfast period, mean concentration of plasma insulin 
(HENSD, 30.27 ± 7.03 mU/l; PLACEBO, 7.94 ± 1.43 mU/l, P=0.006), CCK 
(HENSD, 2.2 ± 0.19 ng/ml; PLACEBO, 2.0 ± 0.22 ng/ml, P=0.04) and peptide 
YY (HENSD, 112 ± 10 pg/ml; PLACEBO, 76 ±9 pg/ml, P=0.006) were 
significantly higher in the HENSD trial then the PLACEBO trial. During the 
pre-lunch period, the mean concentration of plasma insulin (HENSD, 62.71 ± 
13.47 mU/l; PLACEBO, 36.74 ± 6.13 mU/l, P=0.01), CCK (HENSD, 2.43 ± 
0.17 ng/ml; PLACEBO, 2.06 ± 0.13 ng/ml, P=0.001) and peptide YY 
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(HENSD, 136 ± 8 pg/ml; PLACEBO, 101 ± 11 pg/ml, P=0.006) were also 
significantly higher in the HENSD than the PLACEBO trial.  
Table 3.3: Time-averaged AUC for responses of glucose, insulin, peptide YY 
(PYY), cholecystokinin (CCK) during pre-breakfast, pre-lunch period and 
during the entire period of trial. Values are presented as Mean ± SE. (n=9) 
 
Time points HENSD PLACEBO P-Values 
Glucose (mmol/L)   
 
    Pre-breakfast 6.37 ± 0.25 5.51 ± 0.18 0.0001* 
    Pre-lunch 6.76 ± 0.21 6.09 ± 0.29 0.06 
    Over 240 mins 6.66 ± 0.17 5.95 ± 0.24 0.01* 
Insulin (mU/L)   
 
     Pre-breakfast 30.27 ± 7.03 7.94 ± 1.43 0.006* 
      Pre-lunch 36.74 ±  6.13 62.71 ± 13.47 0.018* 
      Over 240 mins 38.93 ± 7.71 29.54 ± 4.86 0.05* 
PYY (pg/ml)    
    Pre-breakfast 112 ± 10 76 ± 9 0.006* 
    Pre-lunch 136 ± 8 101 ± 11 0.006* 
    Over 240 mins 130 ± 8 95 ± 10 0.003* 
CCK (ng/ml)    
     Pre-breakfast 2.2 ± 0.19 2.0 ± 0.22 0.04* 
     Pre-lunch 2.43 ± 0.17 2.06 ± 0.13 0.001* 
     Over 240 mins 2.39 ± 0.17 2.05 ± 0.15 <0.0001 
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Figure 3.5: Plasma concentration of glucose, insulin, cholecystokinin (CCK), peptide YY 
(PYY) in the fasted state (0 min), during pre-breakfast period (0-60 min) and pre-lunch 
periods (60-240 min) in HENSD and PLACEBO trials.  
Values are expressed as mean ± SE. 
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Gastric emptying was a little faster in the PLACEBO trial as compared to HENSD trial. 
Time taken to reach peak plasma paracetamol concentration in PLACEBO trial was 120 
minutes whereas time taken to reach peak plasma paracetamol concentration in HENSD 
trial was delayed until 150 minutes (Figure 3.6).   
 
Figure 3.6: Plasma concentration of paracetamol in fasted state (0 min), from 0-60 minutes 
(AUC60) and from 0-180 minutes (AUC180) in HENSD and PLACEBO trials.  
Values are expressed as mean ± SE. 
 
AUC of the plasma paracetamol concentration from 0-60 minutes (AUC60) (HENSD, 816 
± 224µl/ml; PLACEBO, 1556 ± 146µl/ml, P=0.01) and from 0-180 minutes (AUC180) 
(HENSD, 8508 ± 551µl/ml; PLACEBO, 10979 ± 637µl/ml, P=0.008) was significantly 
lower in the HENSD trial than the PLACEBO trial.  
Table 3.4 The area under plasma paracetamol concentration-time curve from 0-60 minutes 
(AUC60) and the area under plasma paracetamol concentration-time curve from 0-180 
minutes (AUC180) in HENSD and PLACEBO trials. Values are presented as Mean ± SE. 
(n=9) 
 
Time points HENSD PLACEBO P-Values 
Paracetamol (µl/ml)   
 
(AUC60) 816 ± 224 1556 ± 146 0.01* 
(AUC180) 8508 ± 551 10979 ± 637 0.008* 
 
 
-20
0
20
40
60
80
100
0 30 60 120 150 180 210 240
P
ar
ac
e
ta
m
o
l(
μ
l/
m
l)
Time(min)
PLACEBO
HENSD
 
 
3.4 Discussion 
This study demonstrated that the metabolic and hormonal appetite regulators following 
HENSD consumption responded in a way, which is expected to facilitate the suppression 
of appetite and energy intake. Regardless of this, suppression of energy intake was only 
partial and is evident during the first meal. Inability to induce precise compensation for the 
energy provided by the HENSD even in circumstances of enhanced satiety hormones 
suggests that calories provided by the HENSD are not fully perceived by the body, which 
justifies this type of supplement for the treatment of malnutrition.  
Due to higher energy provision with the HENSD in comparison to PLACEBO during pre-
breakfast period, we observed that PYY, CCK, insulin and glucose levels were higher 
which is in consistence with findings from other studies (Lieverse, Jansen et al. 1993, 
Verdich, Toubro et al. 2001, De Graaf, Blom et al. 2004, Degen, Oesch et al. 2005, 
Stratton, Stubbs et al. 2008). The appetite suppressing impact of the elevated levels of 
CCK becomes evident by suppression of food intake during the breakfast in the HENSD 
trial. Since the studies on humans showed that intravenous administration of  CCK 
suppresses food intake by 19% in a test meal (Lieverse, Jansen et al. 1993, De Graaf, Blom 
et al. 2004) and it also induced a significant decrease in the feelings of hunger whereas 
fullness feelings tended to be increased (Degen, Matzinger et al. 2001).  Intravenous 
infusion of PYY was shown to suppress the food intake by approximately 30%, while the 
subjective feelings of hunger and fullness were in line with a decline in food intake during 
the breakfast (Batterham, Cowley et al. 2002, Batterham, Cohen et al. 2003). Insulin also 
had an appetite suppressing impact, and its levels immediately before ad libitum meals 
were inversely correlated with the energy intake in lean subjects (Verdich, Toubro et al. 
2001).  
Appetite after preload before breakfast coincided with all hormonal appetite regulators 
including CCK, PYY, insulin and glucose. We found that 40% of the energy provided by 
HENSD was compensated for by eating less during the breakfast in the HENSD trial. Our 
findings were similar to the previous studies in which liquid preloads interventions 
reported, energy compensation levels of 75% or less (Mattes 2006, Mattes and Campbell 
2009, Almiron‐Roig, Palla et al. 2013). In one of these studies food intake with bolus 
feeding was equivalent to 39.7 % of the tube feed energy infused and the food energy 
intake was declined by 15% (Stratton, Stubbs et al. 2008).  
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During the pre-lunch period, which started after breakfast and lasted for 180 minutes, 
appetite measures and energy intake during lunch were not different between the trials 
regardless of participants of the study in HENSD trial after breakfast being in more 
positive energy balance. Conversely, concentration of hormonal appetite regulators during 
pre-lunch period such as CCK, PYY and insulin were significantly higher in the HENSD 
trial. 
Therefore, it seems that dissociation between appetite measures and  the expected action of 
these appetite regulators is in contradiction with some studies (French, Murray et al. 1993, 
Delzenne, Blundell et al. 2010), but in consistence with other studies (Woo, Kissileff et al. 
1984, Doucet, Laviolette et al. 2008) which found that appetite scores were not related to 
CCK concentration (De Graaf, Blom et al. 2004) PYY concentration (Doucet, Laviolette et 
al. 2008) and insulin concentration (Gielkens, Verkijk et al. 1998). 
 
Having no difference in the energy intake during lunch most likely was related to the 
gastric emptying. It has been found that the mechanism by which CCK suppresses appetite 
is by slowing the gastric emptying (Kleibeuker, Beekhuis et al. 1988, Konturek, Kwiecien 
et al. 1990, Melton, Kissileff et al. 1992). Since gastric emptying is one of the most 
important appetite regulator (Jones, Doran et al. 1997, Sturm, Parker et al. 2004), we also 
measured the rate of gastric emptying. We found that gastric emptying coincides with 
appetite and food intake induced after HENSD supplementation. Gastric emptying was 
slower in HENSD trial, and energy intake and appetite was lower during pre-breakfast 
period while during pre-lunch period no difference in gastric emptying coincides with no 
difference in energy intake and appetite measures. Therefore, short-lived impact of 
HENSD on gastric emptying may be a central facilitator in increase in the energy intake 
during the lunch period. Thus having no appetite and energy intake suppression during 
second meal consumed during 240 minutes after HENSD intake played an important role 
in the promotion of positive energy balance. Therefore having short-lived action of 
HENSD on energy regulation can be very important for promotion of energy intake. 
The thermic effect of food is another potential appetite and energy intake regulator 
(Crovetti, Porrini et al. 1998, De Graaf, Blom et al. 2004). Previous evidence demonstrated 
that higher diet induced thermogenesis was correlated with reduced feelings of hunger and 
higher values for fullness (Luscombe, Clifton et al. 2003, Raben, Agerholm-Larsen et al. 
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2003, Lejeune, Westerterp et al. 2006). We aimed to link the appetite responses and the 
energy intake during meals following HENSD consumption with the thermic effect of 
food. Increased energy expenditure above the resting metabolic rate during the pre-
breakfast period also coincided with reduced feelings of hunger and desire to eat, but 
higher values for satiety, and fullness as found by other studies (Luscombe, Clifton et al. 
2003, Raben, Agerholm-Larsen et al. 2003, Lejeune, Westerterp et al. 2006). The 
enhanced thermic effect of food was significant after the intake of HENSD and after 
breakfast, but energy intake was suppressed during breakfast. We found 15% increase in 
energy expenditure after the HENSD supplementation, as compared to the thermic effect 
for proteins (20-30%), carbohydrates (5-10%) and fat (0-3%) (Tappy 1996, Raben, 
Agerholm-Larsen et al. 2003). The participants ate less during breakfast; the enhancement 
in the energy expenditure lasted longer and was found to be 34% during the 180 minutes of 
the pre-lunch period, suggesting that the effects of these supplements might be more 
prolonged.  It has been found that the postprandial rise in energy expenditure lasts for 
several hours (Reed and Hill 1996). In spite of the increased energy expenditure during the 
pre-lunch period in the HENSD trial, we did not observe any significant difference in the 
appetite measures and ad libitum energy intake during the lunch. Findings that showed an 
increase in the metabolic rate was not related to appetite measures during the pre-lunch 
period. This is not surprising, since other studies have also demonstrated that subjective 
sensations of hunger, satiety, fullness or prospective food consumption are sometimes, but 
not always, related to energy expenditure (Raben, Agerholm-Larsen et al. 2003). We found 
that diet-induced thermogenesis was 269kJ (64kcal) over 240 minutes after the 
consumption of HENSD and approximately 171kJ (41kcal) after the consumption of the 
PLACEBO, a difference of 98kJ (23kcal). Therefore, the total energy intake on the day of 
the HENSD trial was significantly higher even when corrected for post-prandial energy 
expenditure (EE). 
Energy compensation is the adjustment of energy intake provoked by the previous 
ingestion of supplement (Almiron‐Roig, Palla et al. 2013). Inter-meal interval (IMI) is one 
of the strongest contributors to the level of compensation (Almiron‐Roig, Palla et al. 
2013). In  lean subjects, satiety hormones regulated the IMI (Chapelot, Aubert et al. 2000). 
We considered an IMI of 60 minutes in our study as a physiological factor. A minimum 
interval of 20 minutes is required for the initial absorptive effect of the preload to influence 
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the energy level (Booth, Toates et al. 1976) and it is speculated that short intervals allows 
the detection of orosensory and gastric effects (Blundell, De Graaf et al. 2010). 
The results of this study are highly reliable and accurate as the energy intake was measured 
under strict laboratory conditions and all foodstuffs were measured by the researcher. 
Three researchers analyzed the energy and macronutrient intake increasing the validity of 
results. In this study while calculating energy expenditure the values were corrected by 
taking the mean of both pre and post drift and it was the first study in which the energy 
expenditure was measured in this way. In order to measure the appetite and metabolic 
responses of the females in the same phase of menstrual cycle, both the trials were set apart 
by four weeks or according to the duration of the menstrual cycles as appetite control and 
energy intake vary considerably across menstrual cycle (Buffenstein, Poppitt et al. 1995). 
This study has some limitations; firstly, the trial was set for a short duration of time under 
laboratory conditions so short term impact of the preload drink might not be representative 
of clinical settings where HENSDs are prescribed daily. Therefore, this trial might not 
effectively reflect the long-term effects of HENSD. Additionally participants remained 
sedentary in the metabolic suite for the whole duration of the trial which was not  in 
accordance with habitual interaction (Poppitt, McCormack et al. 1998). Moreover, the 
accuracy of self-reported appetite responses like hunger, satiety and fullness depends on 
the participant‘s ability to provide representative responses. Due to the expenses involved 
in the measurements of appetite regulating hormones, and difficulty in obtaining blood 
samples from some of the participants, data on PYY, CCK, glucose levels and insulin 
levels were obtained for only nine participants. However, despite of these numbers of 
participants we were able to find statistically significant differences between HENSD and 
the PLACEBO trials. In fact, during the pre-breakfast period time averaged AUC in case of 
PYY, CCK, insulin and glucose was significantly higher. The current findings apply to 
healthy under-weight women and may not necessarily be generalized to the malnourished 
population so the results should not be over-interpreted. 
In summary our study suggest that only partial compensation for energy provided by 
HENSD may be at least, in part, explain why the suppressive action of metabolic and 
hormonal appetite regulators was short lived.  
 
151 
 
 
 
 
3.5 Conclusions 
In this study we found that in underweight healthy young females with a BMI of less than 
20kg/m
2
 the consumption of ultra HENSD at 60 minutes allows an increase in energy prior 
to  breakfast, reduced hunger, increased satiety, increased post prandial energy expenditure 
and enhanced blood glucose, increased insulin and PYY concentrations, which all 
suppressed appetite. This increase in satiety leads to partial compensation for energy 
consumed by HENSD as compared to the PLACEBO, and 43% of the energy provided 
was compensated by eating less during the breakfast. Furthermore, this suppression of 
appetite is short lived and has its greatest impact on energy intake during the breakfast. 
Therefore, the daily energy provision in the HENSD trial remained much higher even 
when corrected for the increase in post- prandial energy expenditure. Consequently 
HENSD does not induce full compensation for energy provided and can be expected to 
increase daily energy intake, thus the improving nutritional status of lean females. 
However, the overall benefit of HENSD is lower than expected. 
. 
 
152 
 
 
 
 
 
 
Figure 3.7 Schematic presentation of the results, showing the impact of 
HENSD supplementation on partial reduction in energy intake during ad 
libitum buffet breakfast and having no impact on energy intake during ad 
libitum buffet lunch  
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4 Impact of High Energy Nutritional 
Supplement Drink (HENSD) consumed for 
five consecutive days on appetite, energy 
intake and cardio-metabolic risk factors in 
underweight females 
4.1 Introduction 
The evidence suggests that high energy nutritional supplement drinks ( 
HENSDs) can improve energy intake and prevent or correct disease associated 
under-nutrition and improve clinical outcomes (Stratton and Elia 2007, 
Stratton and Elia 2010, Cawood, Elia et al. 2011, Hubbard, Elia et al. 2012, 
Stratton, Hebuterne et al. 2013). Many studies demonstrated that provision of 
HENSD to malnourished patients increased their energy intake, promoted 
rapid recovery, reduced morbidity and improved their quality of life (Potter, 
Langhorne et al. 1998, Milne, Potter et al. 2005, Stratton and Elia 2007, 
Vanderkroft, Collins et al. 2007, Nieuwenhuizen, Weenen et al. 2010, 
Philipson, Thornton et al. 2013, Stratton, Hebuterne et al. 2013). 
In our previous study (chapter 3) we found that in slim young females, 
HENSD consumed 60 minutes before breakfast reduced hunger, increased 
satiety, and enhanced blood glucose, insulin and peptide YY (PYY) 
concentrations which all are known as appetite suppressors (Huda, Wilding et 
al. 2006, Wren and Bloom 2007). This increase in satiety and potential 
appetite regulators led to compensation for energy consumed by HENSD. 
However, the compensation was only partial, although energy intake during 
the ad libitum breakfast was significantly lower in the HENSD than the 
PLACEBO trial. When energy provided by supplements was added to the 
energy intake from breakfast and lunch, the energy intake in the HENSD trial 
was significantly higher. We also found that in the HENSD trial energy 
provision remained higher even when corrected for the increase in post-
prandial energy expenditure. Thus, in a well-controlled study we demonstrated 
that in young, healthy, slim women, consumption of HENSD in the morning 
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does not induce full compensation for energy provided by this drink. We 
concluded that the compensation for the energy provided by HENSD 
supplementation happens immediately and disappears quickly and increases 
daily total energy intake. Therefore, HENSD might be beneficial for the 
treatment of malnutrition.  
In clinical practice, high-energy supplements are usually provided in the 
evening, rather than prior to breakfast, and prescribed for several days or 
weeks. Therefore, from a practical point of view, it is important to find 
whether enhancement in daily energy intake can also be achieved when 
HENSD is consumed on a day-by-day basis and when intake of supplements 
takes place in the evening. There is a need to investigate if supplementation in 
the evening induces positive energy balance and to confirm the findings from 
our first study that compensations with HENSD supplementation happens 
immediately, disappears quickly and is short lived (Fatima, Gerasimidis et al. 
2013).  
Therefore, this study aimed to investigate the time scale of compensation after 
HENSD supplementation for five days by measuring energy intake after 
supplementation during the evening meal, and during the ad libitum breakfast, 
lunch and dinner consumed on the consecutive day. Since, consumption of 
HENSD due to promotion of energy intake is expected to promote positive 
energy balance which as discussed in chapter 1 may have deleterious effects in 
the malnourished, , this study also aimed to investigate the impact of HENSD 
supplementation on cardio-metabolic risk factors.  
 
Evidence from data originating from previous studies investigating the impact 
of acute negative energy balance achieved through moderate dietary 
restrictions and/or increasing energy expenditure through a single bout of 
exercise on reducing lipoprotein metabolism, insulin and glucose 
concentrations are available in abundance (Maraki, Magkos et al. 2010, 
Maraki and Sidossis 2010, Bellou, Siopi et al. 2013). However, evidence 
relating to an acutely induced positive energy balance in relation to 
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postprandial lipid profiles, insulin and glucose concentrations is lacking. A 
positive energy balance induced by an increase in dietary energy intake 
impacts on plasma triglyceride, insulin and glucose concentrations (Hill, Peters 
et al. 1990, Faeh, Minehira et al. 2005, Bortolotti, Kreis et al. 2009, Brøns, 
Jensen et al. 2009). Bortolotti et al (2009) in a cross-over study observed that 
after 4 days of either hypercaloric high fat diet, hypercaloric high fat high 
protein diet, or an isocaloric diet (control). The total LDL-cholesterol and 
HDL-cholesterol concentrations were significantly higher in both high fat diet 
and high fat high protein diet. However, total triglycerides and VLDL-TAG 
were slightly reduced with a high fat diet as compared to the control diet, 
while a high fat diet had no impact on plasma insulin and glucose levels 
(Bortolotti, Kreis et al. 2009). Likewise, Brons et al (2009) investigated the 
effects of a 5 day high fat (60%) overfeeding (+50%) versus a control diet 
(50% of the energy coming from CHO, 35% from fat and 7.5% from protein) 
in twenty-six young healthy volunteers. They found that a high fat- high 
calorie- diet (containing 50% extra energy, where 60% energy is from fat, 
32.5% from CHO and 7.5% from protein) decreased fasting plasma TAG, 
LDL- and VLDL- cholesterol concentration. Whereas HDL- cholesterol was 
higher than the control diet. Fasting glucose levels were significantly higher 
while borderline increase in insulin levels were observed on the high fat high 
calorie diet (Brøns, Jensen et al. 2009).  
 
The impact of short term overfeeding on triglyceride metabolism is uncertain 
since it is difficult to distinguish between changes in energy intake and 
changes in the macronutrient composition. Some studies reported elevated 
VLDL-TAG concentrations after 4 to 7 days of consuming hypercaloric high 
carbohydrate diet (Ngo Sock, Lê et al. 2010, Sobrecases, Lê et al. 2010) while 
overfeeding studies with high fat diet found that VLDL-TAG concentrations 
were reduced (Brøns, Jensen et al. 2009, Sobrecases, Lê et al. 2010). Other 
studies found no impact of hypercaloric feeding on very low density 
lipoprotein triglyceride (VLDL-TAG) concentrations in healthy women 
(Bellou, Maraki et al. 2013), and in obese subjects (Smith, Magkos et al. 
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2013). A study conducted by Bellou et al (2013) found that a single day with a 
positive energy balance induced by overfeeding (surplus of approximately 
3MJ), with a mixed diet (balanced diet), did not have an acute effect on 
VLDL-TAG concentration. Two high-calorie fibre-free energy drinks (6kJ/ml) 
provided the surplus energy (Bellou, Maraki et al. 2013). Smith et al (2013) 
confirmed the results from Bellou et al (2013), and demonstrated that a single 
day of an acute positive energy balance achieved by increasing the daily 
energy intake by 30% and providing 55% energy from carbohydrate, 30% 
from fat and 15% from proteins in both normal and overweight subjects had no 
impact on the VLDL-TAG concentrations (Smith, Magkos et al. 2013).  
 
The impact of acute positive energy balance achieved by overfeeding with a 
mixed diet (balanced diet) produced controversial findings of effects on 
plasma glucose and insulin levels. Some studies reported an increase in the 
concentration of both insulin and glucose (Tam, Viardot et al. 2010, Bellou, 
Maraki et al. 2013), some insulin only (Sobrecases, Lê et al. 2010, Cornford, 
Hinko et al. 2012) and others found no change in insulin or glucose levels 
(Després, Poehlman et al. 1987, McDevitt, Bott et al. 2001).  
 
The evidence from previous studies demonstrated that, by manipulating the 
macronutrient composition and keeping the intervention isocaloric there was a 
detrimental impact on the postprandial lipid responses. Koutsari et al (2000) 
found that a high carbohydrate diet (68% energy from CHO) consumed for 
three days by nine normolipidemic men significantly increased both fasting 
and postprandial TAG, decreased fasting HDL-cholesterol, decreased the 
plasma glucose levels, and had no impact on serum insulin response in 
comparison with an isoenergetic high fat diet (66% energy from fat) (Koutsari, 
Malkova et al. 2000).  Similarly, Robert et al (2008) found that when eight 
healthy individuals consumed either an isocaloric high CHO diet (75% energy 
from CHO), or, a high-fat low-carbohydrate diet (40% of energy from fat) for 
three days, a stable isotope tracer technique showed that both fasting and 
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postprandial TAG concentrations were significantly increased after the high 
CHO diet as compared to high-fat diet (Roberts, Bickerton et al. 2008). 
 
 Likewise, in a randomized crossover study by Culling et al (2009), eight non-
diabetic subjects consumed three isoenergetic diets: high fat (50% energy from 
fat), high sugar and high starch (70% energy from CHO) each for three days. 
On day 4, following each dietary period fasting TAG concentrations were 
highest following a high sugar diet and lowest when following a high fat diet. 
There were no significant differences between high-fat and high-starch diet. 
Fasting glucose levels were not affected by the prior diet but, the postprandial 
glucose concentrations were significantly higher after the high-fat diet as 
compared to high-sugar diet. It was suggested  by this study, that  the short 
term TAG raising impact of high CHO diet depends upon the nature of the 
CHO, with a greater impact of a sugar rich than a complex CHO rich diet 
(Culling, Neil et al. 2009).  
 
These isocaloric studies showed that, by manipulating the macronutrient 
composition of the intervention, there was a detrimental impact on 
postprandial lipids and insulin, the intervention with isocaloric high 
carbohydrate diet significantly increased the postprandial TAG concentrations. 
The high-fat diet had no impact on postprandial TAG concentration but had a 
detrimental impact on glucose homeostasis. However, further research is 
necessary to verify these results when linking postprandial TAG 
concentrations, plasma insulin and plasma glucose concentrations to induce a 
positive energy balance.  
 
Therefore, this study aimed to investigate the impact of 5 days of 
supplementation with HENSD, in the evening, on the energy intake following 
HENSD supplementation, and during the consecutive day.  We also aimed to 
find out if consumption of HENSD in the evening for five days has a 
detrimental impact on the plasma lipids, glycaemia and insulinaemia.  
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4.2 Material and Methods 
Participants 
The participants of this study were twenty-three healthy females with a mean 
(±SD) age of 25 ± 5 years (range: 18-34 years) with a BMI in (kg/m
2)
 of 18.7 ± 
1.2 (range:
 
17-20 kg/m
2
) and body fat mass in (kg) of 8.5 ± 3. The participants 
had a stable weight for one month prior to the study, had regular menstrual 
cycle and were not on medication, nutritional supplements and were not 
following specific diets. Participants were recruited from the campus of the 
University of Glasgow or from other public places. All participants gave 
written informed consent. The study was approved by College of Medical 
Veterinary and Life Sciences, University of Glasgow, Research Ethics 
Committee.  
Study Design 
This was a single blinded, randomised, controlled, crossover study. 
Participants commenced upon two experimental trials of a high-energy 
nutritional supplement drink (HENSD) and PLACEBO trial, lasting for six 
days. The trials were conducted in a counter balance order and were separated 
by at least 7 days of wash out period. During each evening for five days, 
participants came to the metabolic suit at Yorkhill hospital, and consumed a) 
HENSD (Scandishake, Chocolate, Nutricia) made up with 240g of full fat 
milk, according to the manufacturer instructions (Nutricia, 2009) b) 
PLACEBO (a low calorie drink prepared with 240 g of skimmed milk, 4g of 
cocoa and 2 sweeteners). The participants were blinded in relation to the drink 
offered and the drinks were consumed under supervision of the researcher, 
ensuring compliance. The order in which drinks were provided was randomly 
allocated. The PLACEBO and HENSD drinks had the same volume, colour, 
texture and flavour and were not distinguishable. The researcher allocated an 
alphanumeric subject code to each participant. Then block method of 
randomization was used to randomly allocate participants for taking HENSD 
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and PLACEBO drink first (Block size of 3 was taken). First block participants 
were given HENSD drink and next block was given PLACEBO first, and so 
on. The energy content (MJ) and the percentage energy from the macronutrient 
content of the HENSD and the PLACEBO are presented in Table 4.1.  
Table 4.1Energy (MJ) and proportion (percentage) from carbohydrate (CHO), 
fat and protein provided by PLACEBO and HESND drink. 
 
 PLACEBO HENSD 
CHO (g) 11.3 68.8 
Fat (g) 1.3 30.4 
Protein (g) 9 11.9 
Energy (MJ) 0.38 2.49 
Energy from CHO (%) 48 46 
Energy from Fat (%) 13 46 
Energy from Protein (%) 39  8 
 
Abbreviations: CHO, Carbohydrates 
After supplementation, the participants were allowed to go home and consume 
their evening meal at home. Participants recorded their dietary intake during 
the four days of supplementation. The participants were asked to record, in 
detail, the weight of all the food consumed and any leftover after eating, for 
four days. They were asked to document the weight of each item of food 
separately and time of their consumption. The participants were provided with 
the food diary, oral and written instructions on how to keep their dietary record 
and the electronic scales (Salter Housewares Ltd., Tonbridge, U.K.) to weigh 
their food accurately. The researchers of the study inspected the dietary 
records to make sure the dietary records were completed with sufficient 
details. 
On day six, the participants were requested to come to the metabolic 
investigation suite at Yorkhill Hospital at ~ 08:30am in a fasted state. 
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Participant height was measured with a portable stadiometer (Seca, Leicester, 
UK). Body weight and fat mass was measured to the nearest 0.01 kg using a 
digital bioelectrical impedance scale (TBF-300, TANITA, Cranlea, UK). 
Approximately 10-15 minutes were given to the participant to rest and 
acclimatize with the environment. Then a venous cannula was inserted and, 
after an interval of 10 min, a base line blood sample was obtained and the 
participants were asked to mark the appetite questionnaire regarding their 
appetite sensations. Then an ad libitum buffet breakfast was served and 
following breakfast, blood samples were collected and appetite questionnaires 
were completed at 30, 60, 90 and 120 minutes. An ad libitum buffet lunch and 
ad libitum buffet dinner was provided three and seven hours after breakfast, 
respectively. After lunch, blood samples were collected and appetite was 
evaluated in the same manner as after breakfast. The amount of food offered 
and leftover during the ad libitum buffet breakfast, ad libitum buffet lunch, and 
ad libitum buffet dinner was recorded by the researcher. A schematic 
representation of the study design is shown in Figure 4.1.  
 
 
Figure 4.1 A schematic presentation of the study design 
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Anthropometry and Body Composition 
The height of the participants was measured with a portable stadiometer (Seca, 
Leicester, UK) using a stretch stature method. Body weight and fat mass were 
measured using a bioelectrical impedance scale (TBF-300, TANITA, Cranela, 
UK) to the nearest 0.01kg.  
Ad libitum Buffet Meals 
This study offered ad libitum buffet meals to the participants in order to 
provide them an opportunity to self-select from a large variety of normal every 
day food,  and to ensure that the voluntary food intake were not constrained by 
the choice or quantity. Ad libitum buffet meals consisted of a wide variety of 
standardised foods and were presented about 3 times in excess from what 
participants were expected to consume. In the ad libitum breakfast,  a variety 
of breakfast cereals (corn flakes, fruit & fibre or coco pops), milk (semi-
skimmed, skimmed and whole cream), croissants, jam (apricot, mixed fruit 
jam, black-current), butter, juice (apple and orange) and fruits (apple, banana, 
pineapple and grapes) were offered. The ad libitum lunch included two filled 
white bread sandwiches, two filled whole meal bread sandwiches, mixed leaf 
salad, yogurt (plain, flavoured), fruits (apple  banana, grapes) and juice (apple, 
orange, and blackcurrant). In the ad libitum dinner, participants selected the 
meal of their choice from the cafeteria at the Yorkhill Hospital. This was then 
served with fruits (apple, banana, grapes and pineapple), yogurt (plain, 
flavoured) and juice (apple, orange, and blackcurrant) (Figure 4.2). Before 
offering meals to the participants, all foods were weighed and recorded by the 
researcher, at the end of each meal the leftovers were weighed and recorded 
again to calculate the energy intake. The total food intake during the ad libitum 
buffet breakfast, lunch, dinner, and the left over after the intake was weighed 
with an electronic kitchen scale, accurate to 1g.  
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Throughout the trial water was available ad libitum. During ad libitum meals 
reading, listening music and watching television were not allowed as all these 
activities might influence the food intake (de Castro 2000). The ad libitum 
buffet meals served during HENSD and PLACEBO trials were identical, 
containing the same energy and macronutrient contents, and provided a variety 
of carbohydrate, protein and fat. In order to eliminate the portion related cues 
the food offered was cut into smaller pieces. Additionally all the ad libitum 
meals were served in standardised settings for example, scheduling meals at 
the same time, on the same table, and the same type of food was served in the 
same coloured dishes to avoid any bias in the eating behaviour. The 
participants were allowed 30 minutes to consume their meals. The participants 
were given advice to eat according to their appetite until they are comfortably 
full and satisfied. The participants were left alone during the consumption of 
ad libitum buffet meals, in order to curtail any potential impact of the presence 
of the other person on the feeding behaviour, as the presence of observers may 
induce subjects to discontinue eating (Herman, Roth et al. 2003, Herman and 
Polivy 2005, Hetherington, Anderson et al. 2006). The participants were not 
aware of the actual purpose of ad libitum buffet meals (measurement of food 
intake) and were instead told that the biomarkers of blood will be investigated 
for the food consumed. This approach avoids the potential bias and conscious 
eating that  might occurs if the participants were aware of the reality that the 
consumption of food was being monitored (de Castro 2000). 
. 
 
Figure 4.2  Ad libitum buffet breakfast, lunch and dinner 
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Dietary Intake Analysis 
The energy intake was measured by calculating the weight of all the foods 
served and left over from the ad libitum breakfast, ad libitum lunch and ad 
libitum dinner in the metabolic suite. Then the data was analysed by using the 
dietary software Windiets 2005 (The Robert Gordon University, Aberdeen, 
Scotland, UK) by two researchers and average values of each of their results 
was taken into account. These values included the energy and macronutrient 
intake during ad libitum breakfast, ad libitum lunch, ad libitum dinner and 
total intake of all the meals. Energy and macronutrient intake during four days 
of dietary record before and after the provision of a drink was also analysed by 
two researchers.  
Appetite Profile 
The appetite profile of the participants was  assessed by using a validated 
Visual Analogue Scale (VAS) questionnaires (100 mm) throughout the trial 
(Flint, Raben et al. 2000).  The VAS were anchored with negative feeling 
words, ―not at all‖ at one end and a positive feeling word ―extremely‖ at the 
other end. Participants were instructed to mark the horizontal line with a 
vertical line at a point that most accurately reflects their feeling of hunger, 
fullness, satiety, desire to eat and prospective food consumption at that time.  
Plasma preparation and Blood Analysis 
Venous blood samples were collected into a 10 ml ethylenediamine tetra-
acetic acid (EDTA) Vacutainer tube (BD Vacutainer Systems, Plymouth, UK). 
Blood samples were centrifuged at 4
0
C, 3000 rpm for 15mins in a refrigerated 
centrifuge. After centrifugation the plasma supernatant was aspirated and 
frozen at -80
0
C until analysed. Blood samples were used for the analysis of 
plasma lipids, insulin, and glucose concentrations.  
 
The analytical measurements of plasma lipid concentrations of the assay were 
carried out by Roche Cobas Mira (Horibra ABX, Montpellier, France) through 
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a calorimetric method using commercially available kits (ABX Pentra). The 
precision and accuracy of the assays were monitored by quality controls 
(Roche Diagnostics GmBH, Mannheim, Germany. Randox Laboratories 
Limited Co., Antrim Ireland, Wako Chemicals GmBH, Germany). The values 
for plasma TAG, HDL-cholesterol and total cholesterol were measured with a 
calorimetric method. LDL-cholesterol concentration was calculated  by using a 
standardised formula (Friedewald, Levy et al. 1972); 
 
 (Total cholesterol – HDL cholesterol – Total triglyceride) / 2.19 
 
Blood glucose analysis was performed on an automated Roche Cobas Mira 
(Horibra ABX, Montpellier, France) with co-efficient of variation < 3%. 
Quantitative insulin analysis was performed by using the commercially 
available Enzyme-linked immunosorbent assay (ELISA) kit (Mercodia AB, 
Uppsala Sweden). For analysis inter-assay and intrassay coefficient of 
variance were 3.2% and 3.4%.  
The homeostasis model assessment of insulin resistance (HOMAIR) was used 
to measure the insulin resistance. HOMA(IR) score calculate an estimated 
insulin resistance by using the following formula (Matthews, Hosker et al. 
1985): 
HOMA (IR) = Fasting glucose *Fasting insulin/22.5 
Statistical Analysis  
All the data was analysed using Minitab16 statistical software (Minitab Inc., 
State College, Pensylvania). The normality of the data was determined by 
using the Anderson-Darling test.  
For the pre-breakfast, pre-lunch, and pre-dinner appetite responses, the time 
averaged area under the appetite measure versus time curve (AUC) was used 
as a summary measure. The AUCs for TAG, insulin and glucose vs. time 
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curves were calculated using time averaged values for pre-lunch, pre-dinner 
and over the whole postprandial periods. Then a paired t-test was used to 
detect any statistical difference between the PLACEBO and the HENSD trials. 
Any significant differences in fasting plasma TAG concentration, total-, HDL-
, LDL- cholesterol, insulin and glucose were also analyzed through a paired t-
test. The energy and macronutrient intake was recorded for four days of 
supplementation and on the day following five days of supplementation, 
results were compared using a paired t-test. As the body weight and fat mass 
data was not distributed normally, a Mann-Whitney test was performed. All 
the data obtained was presented as means ± SE, significance was set at P<0.05. 
4.3 Results 
Energy Intake and Appetite 
The average daily energy intake (MJ) and the percentage energy intake from 
carbohydrate (CHO), protein and fat during four days of supplementation with 
and without addition of the energy and macronutrients provided by HENSD 
and PLACEBO is presented in (Table 4.2). 
The average daily energy intake during four days of supplementation without 
the energy provided from a supplement was significantly lower in HENSD as 
compared to the PLACEBO trial. The average daily energy intake after 
consumption of a drink in the evening meal was significantly lower in HENSD 
than PLACEBO trial. This may reflect that an immediate compensation 
happens after the intake of HENSD due to which energy intake during the 
evening meal was lower in HENSD trial. While before the provision of 
supplement drink, no significant difference was found in the energy intake 
during four days of supplementation. During HENSD supplementation, the 
suppression of energy intake was equivalent to 43 ± 19 % (1.07± 0.47MJ) of 
energy provided by the supplement. However, during four days of 
supplementation the average total energy intake including energy provided by 
the drink was significantly higher in HENSD (HENSD, 9.2 ± 0.3MJ; 
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PLACEBO, 8.2 ± 0.4MJ, P=0.03) than PLACEBO trial. The averaged daily 
energy intake (MJ) total, before and after provision of the drink during four 
days of supplementation are shown in (Figure 4.3).  
Table 4.2 Averaged daily energy intake (MJ) and macronutrient intake during 
4 days of supplementation with and without energy and macronutrients 
provided by HENSD and PLACEBO drinks. Values are presented as Mean ± 
SE (n=21) 
 HENSD PLACEBO 
Without Drink 
  
Energy Intake (MJ) 6.8 ± 0.3* 7.7 ± 0.3 
Carbohydrate (g) 217 ± 11 237 ± 13 
Protein (g) 57 ± 3** 70 ± 4 
Fat (g) 61 ± 6 70 ± 4 
Energy from CHO (%) 54 ± 3 51 ± 3 
Energy from Fat (%) 34 ± 3 34 ± 2 
Energy from Protein (%) 14 ± 1 15 ± 1 
With Drink   
Energy Intake  (MJ) 9.2 ± 0.3* 8.2 ± 0.4 
Carbohydrate (g) 286 ± 11* 249 ± 13 
Protein (g) 69 ± 3* 79 ± 4 
Fat (g) 91 ± 6** 71 ± 4 
Energy from CHO (%) 52 ± 2 51 ± 3 
Energy from Fat (%) 37 ± 2 33 ± 2 
Energy from Protein (%) 12 ± 1* 17 ± 1 
Significantly different (*P<0.05, ** P>0.001) from HENSD 
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During four days of supplementation, the daily average consumption of 
carbohydrates (CHO) and fat without the supplementation drink was not 
significantly different between PLACEBO and the HENSD trial. When the 
CHO and fat provided by the supplementation drink was added then the 
consumption of carbohydrate and fat was significantly higher in the HENSD 
compared to the PLACEBO trial. The consumption of protein from the diet 
alone and after addition of protein from the supplementation drink was 
significantly higher in the PLACEBO trial days.  
 
 
*Significant difference in energy intake after drink (P<0.05)  
Figure 4.3 Averaged total daily energy intake (MJ), including energy intake 
before and after supplementation, and energy provided by supplements in 
HENSD and PLACEBO trials. 
The energy intake (MJ) and percentage energy intake from macronutrients 
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during experimental trial conducted on the day following five days of 
supplementation are given in Table 4.3. Energy intake during ad libitum 
breakfast, ad libitum lunch, ad libitum dinner and total energy intake was not 
significantly different between the HENSD and the PLACEBO trials. 
Similarly, no significant difference was found in the carbohydrate, fat and 
protein intake during ad libitum breakfast, lunch and dinner between HENSD 
and PLACEBO trials.  
Table 4.3 Energy Intake (MJ) and energy intake from macronutrients during 
ad libitum breakfast, lunch, and dinner on the day following five days of 
supplementation. Values are presented as Mean ± SE (n=21) 
 
Meal  HENSD PLACEBO 
Breakfast 
Energy Intake 3.19 ± 0.21 3.19 ± 0.18 
   CHO (g) 128 ± 7 129 ± 7 
    Protein (g) 17 ± 1 17 ± 1 
    Fat (g) 23 ± 3 24 ± 3 
Lunch Energy Intake 2.65 ± 0.21 2.52 ± 0.19 
 CHO (g) 81 ± 7 77 ± 6 
 Protein (g) 28 ± 3 27 ± 3 
 Fat (g) 24 ± 3 22 ± 2 
Dinner Energy Intake 2.97 ± 0.24 2.90 ± 0.25 
 CHO (g) 100 ± 10 97 ± 8 
 Protein (g) 23 ± 2.4 22 ± 2.5 
 Fat (g) 26 ± 3 27 ± 3 
Total Energy Intake 8.93 ± 0.53 8.75 ± 0.49 
 CHO (g) 310 ± 20 301 ± 15 
 Protein (g) 68 ± 5 66 ± 5 
 Fat (g) 72 ± 5 73 ± 6 
Results obtained from the data on the subjective measures of appetite sensation 
over time, using VAS questionnaires between the HENSD and the PLACEBO 
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trial on the day following five days of supplementation are shown in (Table 
4.4; Figure 4.4). 
Time-averaged area under the curve for appetite measurement over the time 
was used to detect statistical differences between HENSD and the PLACEBO 
trials. Time-averaged area under the curve was calculated for values on the 
appetite responses over the time obtained during pre-breakfast (0-30min), pre- 
lunch (30-120 min) and pre- dinner (180-270 min) period. No significant 
difference was detected in any of the appetite responses during the pre-
breakfast, pre-lunch, pre-dinner period on the day following five days of 
supplementation between HENSD and the PLACEBO trials. 
Plasma Glucose, Insulin and Lipids  
Fasting and postprandial plasma glucose, insulin and triglycerides (TAG) 
concentrations in the HENSD and the PLACEBO trials are presented in 
(Figure 4.5 and Table 4.5).  
Fasting plasma concentration of insulin (P= 0.01) and HOMA (IR) (P= 0.01) 
were significantly higher in HENSD as compared to the PLACEBO trial. 
Fasting plasma glucose levels were not significantly different between 
HENSD and the PLACEBO trials. The mean concentration of plasma glucose 
and insulin evaluated as time averaged areas under concentration versus time 
response during the postprandial period (pre-lunch and pre-dinner period), 
were not significantly different between HENSD and the PLACEBO trial.  
No significant differences were detected in fasting plasma concentration of 
TAG, total-, HDL- and LDL-cholesterol between HENSD and the PLACEBO 
trials. Postprandial TAG concentrations were also not significantly different in 
the HENSD and the PLACEBO trials.  
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Table 4.4: Time-averaged area under the curve (AUC) for responses of hunger, 
satiety, fullness, prospective food consumption and desire to eat during pre-
breakfast, pre-lunch and pre-dinner period. Data is presented as Mean ± SE. 
 
 HENSD PLACEBO 
Hunger (mm) 
  
Pre-breakfast 38 ± 3 38 ± 3 
Pre-lunch 27 ± 3 29 ± 3 
Pre-dinner 20 ± 3 22 ± 3 
Satiety (mm)   
Pre-breakfast 57 ± 3 54 ± 3 
Pre-lunch 71 ± 3 68 ± 3 
Pre-dinner 78 ± 3 76 ± 3 
Fullness (mm)   
Pre-breakfast 55 ± 3 55 ± 2 
Pre-lunch 70 ± 3 68 ± 3 
Pre-dinner 79 ± 3 77 ± 3 
Prospective food consumption (mm)   
Pre-breakfast 59 ± 2 56 ± 2 
Pre-lunch 68 ± 3 67 ± 2 
Pre-dinner 77 ± 3 73 ± 3 
Desire to eat (mm)   
Pre-breakfast 39 ± 3 42 ± 3 
Pre-lunch 29 ± 3 32 ± 3 
Pre-dinner 21 ± 3 24 ± 3 
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Figure 4.4: Responses of hunger, satiety, fullness and desire to eat on the trial 
day. 
Ad libitum breakfast and ad libitum lunch were provided at 120 and 270 
minutes respectively. 
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Figure 4.5  Plasma concentration of glucose, insulin and triglycerides (TAG) 
in the fasted state (0 min) and postprandial period in HENSD and PLACEBO 
trials. Values are expressed as Mean ± SE 
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Table 4.5: Fasting plasma insulin, glucose, triglycerides (TAG), total-, HDL-, 
LDL-cholesterol and postprandial responses of glucose, insulin and TAG. 
Values are expressed as Mean ± SE 
 
 
HENSD PLACEBO 
Fasting Insulin (mU/L) 5.19 ± 0.56*
 
3.47 ± 0.27 
Fasting Glucose (mmol/L) 4.72 ± 0.19 4.55 ± 0.29 
HOMA (IR) 1.08 ± 0.13*
 
0.68 ± 0.05 
Fasting Total Cholesterol (mmol/L) 5.56 ± 1.13 5.30 ± 1.04 
Fasting HDL-Cholesterol (mmol/L) 1.76 ± 0.31 1.62 ± 0.29 
Fasting LDL-Cholesterol (mmol/L) 3.39 ± 0.84 3.23 ± 1.01 
Fasting TAG (mmol/L) 0.88 ± 0.30 0.83 ± 0.27 
Insulin  AUC (mU/L) 24.22 ± 3.67 26.24 ± 4.11 
Glucose  AUC (mmol/L)  5.46 ± 0.21 5.51 ± 0.34 
TAG AUC (mmol/L) 0.97 ± 0.35 0.99 ± 0.38 
Values are presented as Mean ± SE (n=11). *Significantly different (P<0.05) 
from HENSD. Postprandial concentrations are presented as AUCs (time-
averaged areas under concentrations vs. time curves). 
Body weight and Fat Mass  
The body weight and fat mass measurements were taken before and after five 
days of supplementation in HENSD and the PLACEBO trials. There was no 
significant difference in the magnitude of change in the body weight (mean 
difference 0.1 (95% confidence interval -0.30 to 0.40), P = 0.67) and fat mass 
(mean difference 0.4 (95% confidence interval -0.50 to 1.40), P = 0.37) 
between the HENSD and the PLACEBO trials.  
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4.4 Discussion 
This study aimed to measure the immediate impact of HENSD provided to 
slim healthy women in the evening, for five consecutive days, on energy 
intake, and on appetite sensations and the energy intake on the consecutive 
day. Impact of supplementation on cardio-metabolic risk factors was also 
assessed in this study. The obtained data confirmed that consumption of 
HENSDs for five consecutive days in the evening induced immediate 
compensation for energy provided and that the modifying impact of 
supplement on energy intake was short-lived. Furthermore, HENSD 
supplementation for five consecutive days in the evening significantly 
increased the total energy intake regardless of partial compensation. It 
demonstrated that HENSD supplementation for five consecutive days 
increased the fasting plasma insulin concentrations and HOMA (IR) but have no 
impact on the fasting plasma lipids, postprandial lipemia, insulinaemia and 
glycaemia.  
 
During four days of the supplementation with HENSD the averaged total 
energy intake including the energy provided from the drink was significantly 
higher (1.06 ± 0.47 MJ). Increased energy with supplementation has been 
observed in other studies (Lauque, Arnaud-Battandier et al. 2000, Stratton and 
Elia 2000, Norman, Kirchner et al. 2008, Stratton, Stubbs et al. 2008, 
Manders, de Groot et al. 2009, Stratton and Elia 2010, Hubbard, Elia et al. 
2012, Huynh, Devitt et al. 2014) and in our previous study we have also found 
that HENSD supplementation is beneficial for increasing the energy intake 
(Fatima, Gerasimidis et al. 2013). Previous studies have demonstrated that 
energy provision by the oral nutritional supplements is additive to that taken 
from habitual food, which produces a mean increase in the energy intake 
equivalent to 67% of the energy from the supplement consumed. However, the 
proportion of energy provided by supplement that was additional to the 
habitual food intake varied considerably from an average increase of 79% in 
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patients with BMI < 20kg/m
2
 as compared to  28% increase in those with BMI 
> 20kg/m
2
(Stratton and Elia 2000).  
 
During five days of supplementation, acute suppression of energy intake 
immediately after HENSD supplementation has been observed in the evening 
meal. We observed that 43% of the energy provided by HENSD was 
compensated by eating less during the evening meal after HENSD 
supplementation. Previous studies have also reported energy compensation 
(Mattes 2006, Stratton, Stubbs et al. 2008, Mattes and Campbell 2009, 
Almiron‐Roig, Palla et al. 2013) and in our previous study we have found that 
exactly the same 43% of energy was compensated by eating less during 
breakfast after HENSD supplementation (Fatima, Gerasimidis et al. 2013). 
However, it is worth mentioning that a significant decrease in the energy 
intake of the evening meal was seen during four days after consumption of the 
HENSD, no differences in the energy intake during the ad libitum breakfast, 
lunch and dinner was observed on the consecutive day.  
 
This suggests that the provision of the HENSD in the evening for five 
consecutive days suppressed intake only immediately during the evening meal, 
and did not suppress appetite on the following day. Therefore, it can be 
concluded that the appetite suppressive action of HENSD is short lived and 
induced only an acute compensation, as it did not impact energy intake the 
next day. The findings of this study are consistent with our previous study 
(Fatima, Gerasimidis et al. 2013) in which we observed partial compensation 
for the energy provided by the HENSD due to acute appetite suppression, 
which was only short lived as it occurs only in the meal that followed the 
HENSD consumption. In this study, we did not measure appetite hormones but 
in our previous study we found that energy intake was related to appetite. 
Appetite measures reflect better energy intake rather than appetite hormones. 
Measuring the appetite hormones may not be quantitatively related to satiety. 
(Delzenne, Blundell et al. 2010). Therefore, in this study for this reason and 
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due to appetite hormone measurements being very expensive we did not 
measure appetite hormones.  
 
No suppression of energy intake on the next day after five days of HENSD 
supplementation coincides with the measurement of appetite sensations during 
the pre-breakfast, pre-lunch and pre-dinner period that too demonstrated no 
significant difference in the appetite sensations of hunger, satiety, fullness, 
prospective food consumption and desire to eat.  
 
We appreciate that the measurement of the energy intake in the dinner during 
five days of supplementation was conducted at home as representative of 
actual eating behavior. Later on, subjects remained in the laboratory for further 
measurement of the energy intake during ad libitum breakfast, lunch and 
dinner the following day. Evidence from the previous studies have shown that 
the correlation was significantly high between the energy intake evaluated 
from 4 day ad libitum energy intake in the laboratory and 4 day dietary records 
kept at home. In that study, no difference in body weight was observed during 
either condition, which suggests that food consumed in a laboratory setting 
under controlled conditions is a reasonable approximation of the energy intake 
measured under free living conditions (Obarzanek and Levitsky 1985). 
Moreover, in our study the free-living conditions also provided time flexibility 
for dinner, which varies considerably between the individuals and is not 
possible under the laboratory conditions.  
 
In our study, we found no difference in the magnitude of change in body 
weight and fat mass between HENSD and the PLACEBO trials. Here it is 
worth mentioning that the duration of supplementation lasted only for 5 days, 
which was expected to increase the weight of the body by 300 grams only. 
That value is within the range of the mistake of the measurements moreover 
43% compensation was also observed during HENSD supplementation. 
Increased body weight may be observed if HENSD supplements were 
provided for a longer duration. 
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The present study indicated that five days of positive energy balance induced 
by the HENSD supplementation does not have an acute impact on fasting and 
the postprandial lipid profiles. The results in this study are corroborated with a 
study conducted by Bellou et al (2013), which demonstrated that the acute 
positive energy balance achieved by hypercaloric feeding with a dietary 
energy surplus of 2.91 ± 0.32 MJ from a mixed diet does not affect VLDL-
TAG concentration and metabolism in healthy women (Bellou, Maraki et al. 
2013). Likewise a study by Smith et al (2013) found that only one day of  
hypercaloric feeding (total energy intake exceeded the total daily energy 
requirement by 30% (from mixed diet) had no impact on VLDL-TAG 
secretion and plasma clearance rates, VLDL-apoB-100 plasma clearance rate, 
and free fatty acid rate of appearance in plasma in  overweight/obese men 
(Smith, Magkos et al. 2013). Another study by Sobrecases et al (2010) 
demonstrated that a short term hypercaloric diet in healthy male subjects with 
a mixture of fat and fructose combined resulted in no significant changes in 
VLDL TAG concentrations (Sobrecases, Lê et al. 2010).  
 
However, studies have also reported the effect of hypercaloric feeding on 
VLDL-TAG metabolism but they have examined the impact of hypercaloric 
feeding with increase in a specific macronutrient like carbohydrate or fat (Hill, 
Peters et al. 1990, Minehira, Bettschart et al. 2003, Faeh, Minehira et al. 2005, 
Brøns, Jensen et al. 2009, Ngo Sock, Lê et al. 2010, Sobrecases, Lê et al. 
2010). These studies demonstrated that excess carbohydrate intake mainly 
fructose (Minehira, Bettschart et al. 2003, Faeh, Minehira et al. 2005, 
Sobrecases, Lê et al. 2010) increased VLDL-TAG concentrations, whereas 
excess fat intake decreased the VLDL-TAG concentrations (Bortolotti, Kreis 
et al. 2009, Brøns, Jensen et al. 2009, Sobrecases, Lê et al. 2010). However, 
overfeeding with a mixed diet (balance diet containing all macronutrient) had 
no impact on VLDL-TAG concentrations (McDevitt, Bott et al. 2001, 
Sobrecases, Lê et al. 2010, Bellou, Maraki et al. 2013, Smith, Magkos et al. 
2013). Findings from the overfeeding studies using a mixed diet are in 
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agreement with the results of our study. We have induced a positive energy 
balance by provision of HENSD with the energy surplus of 2.49 MJ (46% of 
energy from carbohydrate, 46% from fat and 8% from protein) showing that 
the positive energy balance achieved by increased caloric intake in a way 
mimicking free-living conditions (over consumption of all macronutrients) has 
no impact on fasting and the postprandial lipid profile.  
 
The results from our study demonstrated a significant increase in fasting 
insulin concentrations and HOMA (IR) after only five days of overfeeding 
with HENSD supplementation. This confirmed that insulin resistance develops 
very rapidly during a period of positive energy balance irrespective of the 
macronutrient composition of the diet. However, we found no impact of 
HENSD supplementation on fasting plasma glucose concentrations. Our 
finding is in accord with previous studies showing that one day of moderate 
mixed meal overfeeding (30% excess energy intake) significantly increased 
the plasma insulin concentrations, but had no impact on the plasma glucose 
concentrations (Smith, Magkos et al. 2013). Our results are also in line with a 
recent study  performed by Bellou et al 2013 which showed that hypercaloric 
feeding with a dietary energy surplus of 2.91±0.32 MJ increased plasma 
insulin levels (Bellou, Maraki et al. 2013). The findings from our study 
suggest that the deleterious effects of positive energy balance achieved by 
overfeeding on insulin homeostasis manifests rapidly. These results indicate 
that insulin resistance is sensitive to acute (5 days) moderate increase in the net 
energy balance, whereas lipid/ TAG metabolism are not. This increase in 
fasting insulin levels could be simply because of the higher carbohydrate load 
ingested during the HENSD supplementation, the mechanisms for this finding 
needs to be investigated further.  
  
In our study, we found that acute positive energy balance did not impact on 
plasma glucose concentrations. Our findings are consistent with the findings 
from other overfeeding studies. Overfeeding studies have demonstrated that 
during a hypercaloric state, fasting glucose concentrations did not increase 
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significantly, while fasting insulin secretions increased (Brands, Swat et al. 
2013, Smith, Magkos et al. 2013). As fasting glucose concentrations are 
mostly determined by endogenous glucose production (Turner and Holman 
1976), it might be possible that an increase in portal insulin inhibits an 
increase in the glucose concentration by reducing the glucose output. The 
stable glucose concentrations may represent a new steady state at the expense 
of higher basal insulin secretion (Brands, Swat et al. 2013). 
 
The strengths of this study include the participant‘s attendance, as none of the 
participants were eliminated due to the non-compliance of supplementation.  
All participants consumed both HENSD and the PLACEBO supplements in 
the presence of the researchers. This study being a blinded randomized control 
trial, it was expected that the participants would not be able to identify whether 
they were taking the supplement or the PLACEBO. This is endorsed by the 
fact that 61% of participants were unable to correctly guess about the type of 
drink they were given. This also ensures that there was no psychological 
influence on the food choices during the four days of dietary record.  
 
The results of this study are highly reliable and accurate as on the day of main 
trial the energy intake was measured under strict laboratory conditions and all 
food stuffs were measured by the researchers. Two researchers analyzed the 
energy and macronutrient intake and the mean of the combined values were 
used for statistical analysis which further increased the validity of the results.  
Moreover the under and over-reporters were excluded from the study by using 
Goldberg cut offs, which was also confirmed by Johnson (Johnson 2002). 
Since it is implausible that habitual energy intake could be <1.35X BMR or 
>2.0 X BMR (Goldberg, Black et al. 1991). The reported four days dietary 
records of the participants were not included for statistical analysis if the 
reported energy intake was greater than basal metabolic rate (BMR) multiplied 
by 2.0 (over-reporter) or less than BMR multiplied by 1.35 (under-reporter).  
On this basis, dietary records of two participants were excluded, based on the 
suspected over-reporting (one participant) and under-reporting (one 
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participant). Moreover, this study was a randomised crossover study, in which 
each participant acted as her own control thus minimising the number of 
exterior confounding factors, which is vital while considering the results as the 
impact of confounding factor are considerably reduced and the findings are 
weighted more significantly than to other study designs.  
 
Like other studies, our study has several limitations. Firstly, we studied only 
healthy, lean young females; therefore, it remains unclear that whether similar 
responses to the HENSD supplementation for a few days would occur in other 
study populations (i.e. healthy lean men, obese men, obese women and 
children). Thus, we cannot generalize our results for obese women, healthy 
and obese men, or hypertriglyceridemic subjects. Secondly, the positive 
energy balance achieved by the HENSD supplementation was relatively 
moderate and only for five days, therefore it remains unclear whether a longer 
duration of supplementation or different degrees of supplementation would 
result in similar responses or not.  Furthermore, on day six, for the dinner, the 
participants had a free choice for their meal from the cafeteria of Yorkhill 
Hospital. Consequently, all twenty-three participants consumed different food 
with different composition and consistency. This introduced some limitation to 
the accuracy of the analysis during dinner as energy composition and 
macronutrient intake of the dinner was only estimated and was not hundred 
percent. Although this was expedient, as cooking facilities were not available 
at Yorkhill Hospital and it was necessary to provide participants the food 
which they could enjoy.   
 
Future research is required to investigate the impact of longer duration of 
supplementation or different degrees of supplementation with HENSD on 
lipoprotein, glucose and insulin metabolism in healthy and obese subjects. The 
detrimental impact of continuous supplementation should also be considered; 
as an acute short-term positive energy balance was found to enhance insulin 
resistance, which if unchecked may predisposes to type 2 diabetes mellitus and 
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CVD even in malnourished or very thin people (Martin, Warram et al. 1992, 
Haag and Dippenaar 2005, Reaven 2012). 
 
4.5 Conclusion 
In summary, the results from our study confirm that regardless of 
compensation the provision of HENSD can be expected to increase the daily 
energy intake most likely because compensation for the energy provided is 
immediate, short lived and has no impact on the appetite and the energy intake 
during the next day. A positive energy balance induced by the HENSD 
supplementation can be expected to reduce insulin sensitivity but have no 
impact on the fasting lipids and the postprandial lipemia, insulinaemia and 
glycaemia.  
 
 
Figure 4.6 Schematic presentation of results showing that the provision of 
HENSD supplements induces positive energy balance which is expected to 
reduce insulin sensitivity but have no impact on postprandial lipaemia, 
insulinaemia and glycaemia   
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5 Limited effectiveness of Solid Ready-To-Eat 
and a Liquid Ready-To-Drink Supplements in 
Mild to Moderate Underweight Children from 
Pakistan 
5.1 Introduction 
Malnutrition is, potentially, a preventable condition and is the main contributor 
to child mortality and the overall burden of global disease (Black, Allen et al. 
2008, Hendricks 2010). In developing countries childhood malnutrition is 
associated with numerous socio-economic and environmental factors such as 
poverty, poor hygienic practices, lack of sanitation, recurrent infections, poor 
health and large family size (Golden 2009, Babar, Muzaffar et al. 2010). 
Malnutrition is a highly pervasive and damaging condition in low and middle 
income countries (Black, Allen et al. 2008). Not surprisingly in low income 
countries 112 million out of 556 million children (20%) under 5 years of age 
are underweight and 36 million (6.4%) are suffering from moderate wasting 
(Golden 2009, Michaelsen, Hoppe et al. 2009). Malnutrition is the most 
prevalent health issue in South Asian countries which are predominantly 
classified as middle income countries. It is the most prevalent public health 
issue among children under five years of age (Hirani 2012). It is documented 
that more than 50 percent of the world‘s malnourished children reside in 
Pakistan, India and Bangladesh (Gillespie and Haddad 2003, Hirani 2012).  
As it has been discussed in Chapter 1, children who are exposed to insufficient 
food intake and recurrent infections can easily enter into a vicious cycle of 
increased susceptibility to infections, weight loss, stunting and ever worsening 
nutritional status. Food interventions aim to reverse inadequate food intake. 
There are different strategies to address malnutrition with prepared foods for 
the nutritional recovery of malnourished children for example providing lipid-
based nutrient supplements (RTUF) or blended foods to complement the usual 
diet.   
183 
 
 
 
 
Studies from the published literature suggests that  RTUFs are very effective 
and safe in the treatment of severe malnutrition in children (Briend, Lacsala et 
al. 1999, Collins and Sadler 2002, Dossou, Ndour et al. 2003, Sandige, 
Ndekha et al. 2004, Ciliberto, Sandige et al. 2005, Ashworth 2006, Brewster 
2006, Bhutta, Ahmed et al. 2008, Gera 2010). There is evidence to 
demonstrate  that home based management of uncomplicated severe acute 
malnutrition with RTUF is as effective as F-100, and more effective compared 
to home based dietary therapies (Gera 2010). Some studies have demonstrated 
a higher increase in energy intake (808 vs. 573kJ/kg/day) and weight gain 
(15.6 vs.10.1g/kg/day) achieved by supplementation with RTUF compared to 
the changes induced by consumption of a traditional high-energy drink based 
on milk (F-100) (Diop, Dossou et al. 2003). A clinical effectiveness trial 
demonstrated better weight gain (3.5 compared with 2.0 g/kg/day), lower 
relapse rates (8.7% compared with 16.7%) and lesser  rates of cross infection 
with RTUF (Ciliberto, Sandige et al. 2005).  
RTUFs have been used to supplement the dietary intake of moderately 
malnourished children (Kuusipalo, Maleta et al. 2006, Defourny, Seroux et al. 
2007, Matilsky, Maleta et al. 2009, Nackers, Broillet et al. 2010, Patel, 
Sandige et al. 2011). These studies define moderate malnutrition differently; 
Nackers et al 2010 defined moderate acute malnutrition as WHM % between 
70% and < 80% of the NCHS median and compared RTUF with CSB. Patel et 
al 2011 defined children at risk of malnutrition as weight-for -height < 85% 
but > 80% of the international standard and their primary outcomes were 
recovery and rate of weight gain. Maltisky et al 2009, defined moderate 
malnutrition as WHZ <-2 but ≥ -3, and recovery rates (defined as having WHZ 
>-2) were compared among three intervention groups i.e. milk/peanut fortified 
spread (FS), soy/peanut FS and CSB. RTUF have been found to be effective in 
preventing onset of malnutrition in non-wasted children from the areas of food 
insecurity (Defourny, Minetti et al. 2009, Isanaka, Nombela et al. 2009, 
Isanaka, Roederer et al. 2010, Huybregts, Houngbé et al. 2012). It has been 
recommended that nutritional intervention to prevent malnutrition might be 
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more effective than the curative treatment of malnutrition (Ruel, Menon et al. 
2008). 
A recent review by Lazzerini et al 2013 evaluated the safety and effectiveness 
of specially-formulated food products for children with MAM in low- and 
middle-income countries. This review included eight randomized controlled 
trials, enrolling 10,037 children. In this review seven studies compared lipid –
based nutrient supplements (LNS) to blended foods, two of the studies 
compared complementary LNS to blended foods, three studies compared 
specific blended foods (enriched blended foods CSB++) to other LNS and one 
study compared enriched blended food CSB++ to other blended foods. When 
LNS were compared to any blended foods, it significantly improved the 
number of children who recovered (RR 1.10, 95% CI 1.04-1.16; 6367 
children, 5 trials), and reduced the number of non-recovering children (RR 
0.53, 95% CI 0.40-0.69; 4537 children, 3 trials). LNS slightly improved the 
nutritional status of the recovered children with improved weight gain, weight-
for-height, and mid-upper arm circumference (MUAC), and this improvement 
was regarded as modest as it came from moderate quality evidence. However, 
the comparison between LNS and blended foods did not show significant 
difference in mortality (RR 0.93, 95% CI 0.54-1.62; 6367 children, 5 trials), 
progression to severe acute malnutrition (RR 0.88, 95%CI 0.72 -1.07; 4537 
children, 3 trials), or the number of defaulters (drop outs) from the nutritional 
programme (RR 1.14, 95% CI 0.62-2.11; 5107 children, 4 trials).  
Only one study reported more children with vomiting when given LNS 
compared to blended food (RR 1.43, 95% CI 1.11-1.85; 2712 children, 1 trial). 
Enriched blended foods resulted in similar outcomes to LNS (4758 children, 3 
trials) (Lazzerini, Rubert et al. 2013). The findings from this review 
demonstrated that both LNS and blended foods are effective in the treatment 
of the children with MAM although there are no studies evaluating the impact 
of improving adequacy and quality of local diet/home diet in the settings 
where food in available. However, Lazzerini et al 2013 also points to the fact 
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that there are ―limitations in the completeness of evidence and its 
generalizability‖     
Similarly Lenters et al 2013 reviewed five studies investigating the impact of 
RTUF compared to CSB in moderately malnourished children under 5 years of 
age. Two of the studies were cluster randomized controlled trials and three 
were RCTs. This review found no significant difference in mortality and 
height gain between those children who received RTUF compared to those 
given CSB. Although, the children in the RTUF group were more likely to 
recover (RR: 1.11, 95% CI 1.04-1.18) and the non-response rate was also 
significantly lower in the RTUF group (RR: 0.65, 95% CI 0.47-0.90) 
compared to the CSB group. Children in RTUF group had a greater gain in 
MUAC (0.04 mm/day) (MD: 0.04, 95% CI 0.01 - 0.07) and an average weight 
gain of 0.61 g/kg/d than CSB group.  
Although, this difference was statistically significant, it may not be an 
adequate difference to be clinically important.  Lenters et al 2013, in their 
systemic review and meta-analysis observed considerable variations among 
the trials reviewed and that the effectiveness of overall treatment approaches 
for MAM was inconclusive. The authors concluded that the evidence 
generalization must be treated with caution due to gaps in their ability to 
estimate effectiveness (Lenters, Wazny et al. 2013). 
The majority of the existing evidence on the use of community based 
management of uncomplicated severe acute malnutrition has emerged from 
studies conducted in Africa in emergency settings (Gera 2010). There are no 
studies from Asia exploring the effectiveness of RTUF and other industrialised 
foods in the treatment of children with moderate acute malnutrition (MAM), 
where MAM is most prevalent (Lazzerini, Rubert et al. 2013). There is a need 
to generate more evidence regarding the efficacy of RTUF and other locally 
available ready to use the supplements in non-emergency settings particularly 
in a Pakistani context. 
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Moreover, there is no evidence comparing the impact of RTUF and the 
proprietary liquid supplements on weight gain in mild to moderate 
malnourished children between the ages of 5-10 years. 
The proposed study aimed: 
 
 To explore the efficacy of RTUF and LRUS in promoting the weight 
gain and appetite regulation in mild to moderate underweight children 
between the ages of 5-10 years from Pakistan. 
5.2 Material and Methods 
Participants 
The participants of this study were primary school children between the age of 
5-10 years, with a mild to moderate malnutrition weight for age Z score 
(WAZ) (between -2 and -1 Z score). Before enrolling in the study, the 
participants underwent a screening visit, which included height and weight 
measurement. These anthropometric measurements were used to calculate Z-
scores using the WHO standards. Children with mild to moderate malnutrition 
WAZ (between -2 and -1 Z-score) were selected for the study. A detailed 
health screen questionnaire was filled in by the participant parent/carer 
regarding participant‘s health to exclude chronic illness, eating disorders, any 
specific food intolerance (e.g., peanut allergy) and gastrointestinal operations, 
which could interfere with the results of the study.  
Setting 
This study was conducted in the primary school of the district of Abbottabad 
located in the Hazara region of Khyber Pakhtunkhwa province in Pakistan. 
Abbottabad is situated 50 kilometres northeast of the capital Islamabad.  
Recruitment and the follow up for the study were started in June and the 
intervention was started on the day of recruitment. The eligible children were 
identified by the researcher, on the basis of anthropometric status. 
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Anthropometric measurements were taken on day 1, day 14 and day 29, with a 
window of 2 days after planned date allowing for weekends and holidays.  
Study Design 
This study was an open labelled randomized controlled trial. The children 
were randomly allocated by computerized randomization using free software 
(Research Randomiser) (Urbaniak and Plous 2011) to receive either solid 
ready to use food (RTUF) or liquid ready to use supplement (LRUS). Height, 
weight, biceps and triceps skinfolds and mid-upper-arm circumference of the 
children were measured before the supplementation (baseline), two weeks 
after initiation of the supplementation and at the end of the supplementation. 
The children were provided with these supplements in their school for four 
weeks and were asked to consume the supplements in addition to their habitual 
diet. The supplements were delivered to the children by the researcher. The 
children were asked to keep the empty bottles/sachet of the supplements with 
them after drinking/eating, which were collected by the main researcher the 
same day in the afternoon in order to check the compliance. Any leftover in 
the bottle or sachet was also recorded.  
The appetite questionnaires were marked by the children before the provision 
of the first and the last supplement. Visual Analogue Scale (VAS) 
questionnaires with a line of 100 mm (Flint, Raben et al. 2000) were used for 
measuring appetite sensations of the children before provision of first and last 
supplement. Furthermore, the parents/carers were requested to attend 
structured interview regarding the appetite of their child once before the start 
of supplementation and once at the end of the study. Moreover, the 
parents/carers were also encouraged to continue the regular habitual diet of 
their children. The children who were screened (n=128) and did not meet the 
criteria for recruitment (WAZ > -1 SD) were measured for the height and 
weight again after four weeks and acted as a control group (CG). The 
questions were also asked from the parents/carers of the children to obtain the 
information about their socio-demographic characteristics. The children who 
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were provided with the supplements were followed after mean (±SD) 7.13 ± 
3.14 months when they were off the supplements. 
Interventions 
The energy, micronutrient and macronutrient contents of RTUF and LRUS are 
presented in Table 5.1. RTUF is a mixture of peanut, sugar, milk powder, 
minerals, vitamins and vegetable oil. It does not require cooking and is a 
microbiologically safe product and can be stored in the household conditions 
for several months (Isanaka, Nombela et al. 2009, Ali, Zachariah et al. 2013). 
RTUF and LRUS looked different; therefore, the study was not blinded. LRUS 
(Fortini, Strawberry, Nutricia) was a strawberry flavoured ready to drink sip 
feed available in 200 ml bottles with a flexible straw, and RTUF (Plumpy‘ 
Nut; Nutriset, Malaunay, France) was individually packaged in airtight alu-foil 
sachet, looked like a thick paste and tasted like a slightly sweater peanut 
butter. Daily the children in RTUF group were provided with one sachet of 
RTUF (92 g, 500 kcal/d), and the children in LRUS group were provided with 
two bottles of LRUS (60ml of LRUS was removed daily from one of the two 
bottles in order to provide nearly 500 kcal/ day). 
Measurements 
All the measurements were performed by the same researcher. For each 
skinfold measurement two measurements were taken and the mean of both 
were considered for the accuracy of results. 
Height Measurement  
Height was measured with a portable stadiometer (Seca, Leicester, UK) using 
the stretch stature method. The stature is the maximum distance from the 
ground to the uppermost point of the skull when the position of head is held in 
Frankfort plane position (Marfell-Jones, Stewart et al. 2006). The 
measurements were performed to the nearest 0.01m. The same height 
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stadiometer was used throughout the study and the same researcher performed 
all the measurements. 
 Table 5.1 Comparison of nutritional composition of RTUF and LRUS 
 
 Per 100 g  Distributed Per day 
 RTUF LRUS  RTUF  
(92 g) 
LRUS 
(340ml)  
 
    Energy (kcal) 
 
545 
 
150 
 
500          
 
510 
    Energy( kJ) 2281 630 2093 2142 
Macronutrients     
     Protein (g) 13.6 3.4 12.5 11.56 
     Carbohydrates (g) 35.0 18.8 32.2 63.92 
     Fat g 35.7 6.8 32.9 23.12 
Minerals     
    Sodium (mg) 189 67                           <189 227.8 
    Potassium (mg) 1111 140 1051 476 
    Calcium (mg) 320 84 276 285.6 
    Phosphorus (mg) 394 75 276 255 
   Magnesium (mg) 92 17          84.6 57.8 
    Zinc (mg) 14 1.5 12.9 5.1 
    Iron ( mg) 11.5 1.5 10.6 5.1 
RTUF, solid ready to use food; LRUS, liquid ready to use supplement 
Weight Measurement  
Weight was measured with a regularly calibrated electronic scale (Seca 861, 
Hamburg, Germany). The weight of the children was measured wearing light 
weight clothes without shoes. Prior to the measurements extraneous clothing 
were removed. The children stood with both feet placed flat on the balance and 
arms positioned laterally along the side of the body. The measurements were 
performed to the nearest 0.1kg. 
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Mid upper arm circumference (nearest mm) 
Mid upper arm circumference was measured with a mid upper arm 
circumference (MUAC) measuring tape which were colour coded (green, 
yellow and red) to indicate nutritional status. The measurements were 
performed on the left upper arm while the arm was relaxed and hanging down 
the side of the body. 
 
 
 
 
 
 
 
 
Figure 5.1 Holtain skinfold calliper and a mid upper arm circumference 
(MUAC) measuring tape  
Skinfold Measurement 
Triceps, biceps and sub scapular skinfolds were measured using Holtain 
skinfold calliper (Holtain LTD, Crosswell, United Kingdom) to the nearest 
0.2mm. For measuring triceps skinfold the child was asked to bend the left arm 
at 90
0
 at the elbow and place his/her forearm across the body. Then the 
Acromion process at the outer-most edge of the shoulder and tip of the 
Olecranon process of the ulna were located and the distance between the two 
was measured with the help of the measuring tape. Then the mid-point in line 
with the elbow and Acromion process was marked. After that the child‘s arm 
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was extended so that it hung loosely at the side. Using the thumb and 
forefinger a vertical fold of skin and underlying fat 1cm above the marked 
mid-point was grasped. Afterwards the skinfold was gently pulled away from 
the underlying muscle and calliper jaws were applied at right angles exactly at 
the marked mid-point. While taking the measurements the skinfold were held 
in the fingers. Two measurements were taken and the mean of both were 
considered for the accuracy of results. 
 For measuring biceps, skinfolds at the level of the mid-point between the 
Acromion process (bony tip of shoulder) and the proximal and lateral border 
of  the radius bone (approximately the elbow joint), on the mid-line of the 
anterior surface of the arm (over the biceps muscle) was marked. Then the 
child was asked to relax his/her arm with the palm of the hand facing forwards. 
Then using thumb and forefinger a vertical fold of skin was grasped at the land 
mark, and calliper jaws were applied.  
 For measuring sub scapular skinfold the lower most tip of the scapula was 
marked. The skinfold was picked up obliquely following the natural skin 
contour and the calliper jaws were applied.     
Appetite Measurement 
Children were asked to rate their appetite on Visual Analogue Scale (VAS) 
questionnaires along a line of 100 mm. Children were asked to express their 
feeling of hunger, satiety, fullness, prospective food consumption and desire to 
eat by placing a vertical mark on the horizontal 100 mm line at a point which 
corresponds to their feelings at that time. The lines were anchored by negative 
respective feeling words (I am not hungry at all) on the left and by positive 
feeling words (never being hungrier) on the right. Quantification was made by 
measuring the distance from the left end of the line to the child‘s mark.  
Structured interviews 
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In depth structured interviews were conducted with the parents/carers of the 
children who received RTUF and LRUS once before the start of 
supplementation and once at the end of the study. The main researcher led the 
structured interviews and each interview lasted for approximately 35 minutes. 
In each discussion, the parents/carers were asked questions regarding the 
appetite of their children before the start of supplements and after 
supplementation, acceptability of supplements, taste of supplement and any 
changes observed by them in their children after 4 weeks of the 
supplementation. 
Calculations and Statistical Analysis  
The Anderson-Darling test was used to determine the normality of the data. 
Power calculations were based on data available from the previous study 
(Diop, Dossou et al. 2003). We used the standard deviation (STDEV) for the 
difference in weight gain (which was measured by calculating the weight gain 
expressed in (g/kg/d) between solid ready to eat supplement and liquid ready 
to drink supplement groups, the main outcome of this study. We found that at 
80 % power, considering STDEV of 0.7, 32 subjects in each group will allow 
us to detect a mean difference of 0.5kg between two groups. This number of 
participants should be sufficient to detect differences in other outcomes of the 
study. The difference between the body weight, MUAC, biceps, triceps, and 
sub scapular measurements at the baseline and after 28 days of 
supplementation between two groups was determined by using unpaired t test. 
The differences in the socio-demographic characteristics and structured 
interviews between the RTUF and LRUS groups were determined by using 
Chi-square test and significance was set at P<0.05. 
Ethics 
The study was approved by College of Medical Veterinary and Life Sciences, 
University of Glasgow, Research Ethics Committee and the Research Ethics 
Committee of Ayub Medical College Abbottabad. Approval from the 
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principals of the school was received prior to the start of the study. The 
purpose of the study and study protocols were explained to the principals and 
parents/carers in local language. The parents/carers of all the participants were 
required to give written informed consent after clarification that their refusal 
would have no effect on how the child is treated in the school by the teachers 
and support staff. 
 
5.3 Results: 
A total of 239 children were eligible, 165 were excluded as they did not meet 
the inclusion criteria, 146 weight for age Z score (WAZ > -1SD) while 19 
(WAZ < -2SD). A total of 74 children were eligible for the study, 2 refused 
enrolment, and 4 were excluded on the basis of health screen. A total of 68 
children were enrolled in the study; 34 received RTUF and 34 received LRUS 
The children who were screened (n=128) and did not meet the criteria for 
recruitment (WAZ > -1 SD) were measured for height and weight again after 
four weeks and acted as a control group as presented in figure 5.3.  
 
Socio-demographic data 
A total of 63 parents/carers (RTUF =32, LRUS= 31) were asked about socio-
demographic characteristics. The socio-demographic characteristics are 
summarized in Table 5.2, which demonstrates that the parents of the 
supplement group earned little money, spent small amounts on food items; 
mothers were illiterate, had more children and had more people living in one 
small house. However, no statistically significant differences were detected in 
any of the socio-demographic characteristics between the RTUF and LRUS 
groups. 
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Figure 5.2 Flow chart of children‘s course throughout the trial  
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Table 5.2 Socio-demographic characteristics of the parents of schoolchildren 
who were provided with RTUF and LRUS.  
 
Characteristics RTUF 
(n=32 ) 
No (%) 
LRUS 
(n=31) 
No (%) 
P value 
Father‟s Occupation 
      Skilled 
      Unskilled 
 
20 ( 62.5) 
12  ( 37.5) 
 
20 (64.5) 
11 ( 35.5) 
 
0.538 
Mother‟ Occupation 
      Employed 
      Unemployed 
 
5  (15.6) 
27  (84.4) 
 
7 (22.6) 
24  (77.41) 
 
0.35 
Father‟s Income (PKR per month) 
        Up to 9000 
         9000-18000  
         >18000 
 
25 (78.1) 
6 (18.7) 
1 (3.1) 
 
23 (74.2) 
8 (25.8) 
0 
 
0.508 
Money Used on Food monthly (PKR 
per month) 
        <3000 
         3000-6000 
 
24 (75) 
8 (25) 
 
23 (74.2) 
8 (25.8) 
 
0.580 
Mother‟s Educational level 
      Not educated     
      Incomplete primary (1-4 yrs) 
      Complete primary (5 yrs) 
      Incomplete secondary ( 6-10yrs) 
      Complete secondary ( 11yrs) 
      University (≥ 12yrs) 
 
19 (59.4) 
3 (9.4) 
4 (12.5) 
6 (18.7) 
0 
0 
 
17 (54.8) 
3 (9.7) 
2 (6.4) 
8 (25.9) 
0 
1 (3.2) 
 
0.727 
House Ownership 
     Owned by the family 
      Rented 
 
16 (50) 
10 (31.2) 
 
17 (54.8) 
9 (29.0) 
 
0.924 
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      Shared 6 (18.7) 5 (16.1) 
House construction 
       Pakkah (cemented) 
       Kacha (made of mud) 
       Semi Pakkah 
 
22 (68.7) 
7 (21.9) 
3 (9.4) 
 
17 (54.8) 
9 (29.0) 
5 (16.1) 
 
0.503 
Total number of rooms in the house 
       0-3 
       4-6 
      >6 
 
22 (68.75) 
9 (28.1) 
1 (3.1) 
 
25 (80.6) 
5 (16.1) 
1 (3.2) 
 
0.517 
No. of siblings 
      0-3 
      4-6 
      >6 
 
6 (18.7) 
15 (46.9) 
11 (34.4) 
 
7 (22.6) 
21 (67.7) 
3 (9.7) 
 
0.06 
No. of Family members residing in the 
house 
        0-5 
        6-10 
        >10 
 
2 (6.2) 
15 (46.9) 
15 (46.9) 
 
3 (9.6) 
15 (48.4) 
13 (41.9) 
 
0.849 
Water source 
       Tap water 
       Hand pump 
       Wells 
       Spring 
 
12 (37.5) 
8 (25) 
5 (15.6) 
7 (21.9) 
 
15 (48.4) 
5 (16.1) 
5 (16.1) 
6 (19.3) 
 
0.780 
Type of Bathroom 
      Flush system 
      Laterine 
      Open space 
 
7 (21.9) 
25 (78.1) 
0 
 
5 (16.1) 
25 (80.6) 
1 (3.2) 
 
0.517 
Garbage disposal 
     In the dump 
 
0 
 
0 
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     Outside the house 
     Inside the house 
32 (100) 
0 
31 (100) 
0 
 
Nutritional Characteristics 
At the beginning of the trial the mean (±SD) age of the children (range: 5-10 
years) (RTUF, 8.45 ± 1.22 years; LRUS, 8.19 ± 0.86 years, P = 0.30), weight-
for-age Z score (WAZ) (RTUF, -1.33 ± 0.28; LRUS, -1.35 ± 0.29, P = 0.86) 
and body mass index Z score (BMI Z score)  (RTUF, -1.43 ± 0.73; LRUS, -
1.58 ± 0.61, P = 0.37) were not significantly different between the RTUF and 
LRUS groups. The baseline nutritional characteristics of the children at 
enrolment are presented in the Table 5.3. 
 
The weight, height weight-for-age Z score (WAZ), and height-for-age Z 
(HAZ) score and BMI Z score at baseline, 14, and 28 days of supplementation 
and during the follow up in the RTUF and LRUS groups, are presented in 
Table 5.4 and Figure 5.4. Compared with baseline there was a significant 
increase in mean (±SD) weight gain (g/kg/day) in RTUF (0.96 ± 0.48 
g/kg/day) and LRUS group (1.10 ± 0.69 g/kg/day), after four weeks of 
supplementation, however the difference in the mean weight gain (g/kg body 
weight/day) was not significantly different between RTUF and LRUS groups 
(0.96 compared with 1.10 g/kg/day difference: 0.14; 95% CI: -0.45, 0.11 
g/kg/day, P = 0.33) (Table 5.5). 
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 Table 5.3 Nutritional characteristics of children on enrollment 
 
Characteristics Control group 
(n=128) 
RTUF 
(n=34) 
LRUS 
(n=34) 
Age (years) 8.73 ± 0.86
b 
8.45 ± 1.22 8.19 ± 0.86 
Female/ Male n (%) 124/4 ( 97/3) 30/4 (88/12) 33/1 (97/ 3) 
Height (cm) 136.20 ± 8.71
a, b 
126.31 ± 7.22 124.5 ± 4.32 
Weight (kg) 28.60 ± 5.18
a, b 
21.61 ± 2.72 20.77± 2.12 
BMI (kg/m
2
) 15.37 ± 1.67
a, b 
13.85 ± 0.98 13.52 ± 0.78 
WAZ (SD) 0.16 ± 0.72
a, b 
-1.33 ± 0.28 -1.35 ± 0.29 
HAZ (SD) 0.87 ± 1.05
a, b 
-0.51 ± 0.66 -0.54 ± 0.56 
BMI Z score (SD) -0.48 ± 0.87
a, b 
-1.43 ±0.73 -1.58 ±0.61 
Skinfold Z score - -0.79 ± 0.51 -0.95 ± 0.57 
MUAC (cm) - 15.81 ± 1.03 15.56 ± 0.82 
Triceps (mm) - 7.62 ± 1.34 7.46 ± 1.46 
Sub scapular (mm) - 5.36 ± 0.79 5.03 ± 0.89 
 
Abbreviations: RTUF, Solid ready to use food; LRUS, liquid ready to use 
supplement; CI, confidence interval; WAZ, weight-for-age Z-score; HAZ, 
height-for-age Z-score; BMI Z score, body mass index Z- score; MUAC,  mid 
upper arm circumference; 
a 
Significantly different from RTUF group. 
b 
Significantly different from LRUS group. P < 0.05 (Student’s t test). 
 
Similarly there was a significant change in WAZ after 4 weeks of 
supplementation in the RTUF group (from -1.33 ± 0.28 to -1.21 ± 0.29, 
P<0.0001) and the LRUS group (from -1.35 ± 0.29 to -1.20 ± 0.31, P<0.0001). 
When the difference in change in WAZ after 28 days of supplementation in the 
RTUF group (RTUF: 0.12 compared with LRUS: 0.15; difference: 0.03; 95% 
CI:-0.03, 0.08) and the LRUS group was compared it was not significantly 
different. Likewise, when changes in WAZ, HAZ, and skinfold Z score were 
compared between RTUF and LRUS groups, no significant differences were 
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found between the two groups (Table 5.5). In the control group, a significant 
increase in height was observed after 28 days; however, no significant 
differences were detected in weight, WAZ, HAZ, and BMI Z score after 28 
days (Table 5.4). A statistically significant lower mean weight gain (g/kg/day) 
and change in WAZ was detected in the control group as compared with the 
RTUF and LRUS groups (Table 5.5). Thirty two children in the RTUF group 
and 29 in LRUS group were followed after mean (±SD) 7.13 ± 3.14 months 
when they were off the supplements (Table 5.4). During follow up height and 
weight gain were similar in both RTUF and LRUS groups. No significant 
differences were detected in WAZ, HAZ, BMI Z-score; skinfold Z score when 
the end of supplementation was compared with the follow up (Table 5.4; 
Figure 5.4).  
 
The changes in nutritional characteristics of mildly wasted (BMI Z<-1) and 
mildly stunted (HAZ < -1SD) children of the supplemented group after four 
weeks of supplementation with the control group were also compared (Table 
5.6). A statistically significant difference was detected in changes in WAZ, 
HAZ and BMI Z score when mildly wasted children of the supplement group 
(RTUF + LRUS) was compared with the control group after 28 days of the 
baseline measurements. However, when the mildly stunted children of the 
supplemented group after four weeks of supplementation was compared with 
control group after 28 days of baseline measurements a statistically significant 
difference was detected only in changes in WAZ (Table 5.6). 
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Table 5.4 Nutritional Characteristics after 4 weeks of supplementation 
 
Characteristics Control group RTUF LRUS 
 Baseline After 28 days Before 
Supplementation 
After 
Supplementation 
Follow up 
(n=32) 
Before 
Supplementation 
After 
Supplementation 
Follow up 
(n=29) 
Weight (kg) 28.60 ± 5.18 28.94 ± 5.51 21.78 ± 2.57 22.36 ± 2.67* 23.27 ± 2.75
a 20.97 ±  1.81 21.62 ± 1.94* 22.80 ± 1.94
a 
Height (cm) 136.20 ± 8.71 136.64 ± 8.60* 126.31 ± 7.22 127.00 ± 7.25* 129.85 ± 6.83
a 
124.50 ± 4.32 125.18 ± 4.41* 128.70 ± 5.01
a 
WAZ (SDS) 0.16 ± 0.72 0.15 ± 076 -1.33 ± 0.28 -1.21 ± 0.29* -1.31 ± 0.33
 -1.35 ± 0.29 -1.20 ± 0.31* -1.25 ± 0.36
 
HAZ (SDS) 0.87 ± 1.05 0.86 ± 1.05 -0.51 ± 0.66 -0.47 ± 0.65* -0.52 ± 0.54 -0.54 ± 0.56 -0.50 ± 0.57* -0.51 ± 0.59 
BMI-Z score (SDS) -0.48 ± 0.87 -0.49 ± 0.86 -1.43 ± 0.73 -1.45 ± 0.73* -1.56 ± 0.74 -1.58 ± 0.61 -1.39 ± 0.60* -1.47 ± 0.76
 
MUAC (cm) - - 15.81 ± 1.03 16.30 ± 1.12* 16.27 ± 1.15 15.56 ± 0.79 16.00 ± 0.83* 16.04 ± 0.87 
Triceps (mm) - - 7.62 ± 1.34 7.91 ± 1.27* 7.69 ± 1.27 7.46 ± 1.46 7.89 ± 1.42* 7.63 ± 1.26 
Sub scapular (mm) - - 5.36 ± 0.79 5.73 ± 0.84* 5.44 ± 0.96 5.03 ± 0.89 5.35 ± 0.90* 5.16 ± 0.82 
Skinfold Z score 
(SD) 
- - -0.79 ± 0.51 -0.62 ± 0.47* -0.80 ± 0.57 -0.95 ± 0.57 -0.75 ± 0.54* -0.92 ± 0.54 
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Abbreviations: RTUF, Solid ready to use food; LRUS, liquid ready to use supplement; CI, confidence interval; WAZ, weight-for-age Z-score; 
HAZ, height-for-age Z-score; BMI Z-score, body mass index Z- score.
*
Significantly different from baseline; a Significantly different from the end of 
supplementation, P < 0.001 (Student’s t test).   
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Table 5.5 Comparison of gain in anthropometric outcomes of children receiving 4 weeks supplementation between RTUF and LRUS groups 
 Control  
(n=128) 
RTUF 
(n=34) 
LRUS 
(n=34) 
P value Difference between RTUF and 
LRUS 
(95% CI) 
Rate of weight gain (g/kg/day) 0.30 ± 1.64
a, b 
0.96 ±  0.48 1.10 ± 0.69 0.33 0.14 ( -.45, 0.11) 
Weight gain (kg) 0.26 ± 1.54 0.59 ±0.30 0.65 ± 0.42 0.48 0.06 (-0.244, 0.12) 
Height gain (cm) 0.44 ± 0.86 0.69 ± 0.49 0.68 ± 0.44 0.87 0.01 (-0.210, 0.25) 
Change in WAZ (SDS) -0.01 ± 0.20
a, b 
0.12 ±0.09 0.15 ± 0.13 0.33 0.03 ( -0.0285, 0.08) 
Change in HAZ (SDS) 0.00 ± 0.15 0.04 ± 0.08 0.04 ± 0.08 0.91 0.00( -0.039, 0.034) 
MUAC (cm) - 0.49 ± 0.39 0.44 ± 0.29 0.54 0.05 (-0.118, 0.22) 
Triceps gain (mm) - 0.29 ± 0.24 0.31 ± 0.23 0.80 0.02 ( -0.101, 0.131) 
Sub scapular gain(mm) - 0.37 ± 0.29 0.31 ± 0.25 0.38 0.06 ( -0.189, 0.073) 
Change in Skinfold Z score  0.20 ± 0.13 0.17 ± 0.12 0.30 0.03 (-0.086, 0.025) 
 
Abbreviations: RTUF, Solid ready to use food; LRUS, liquid ready to use supplement; MUAC, mid upper arm circumference; CI, confidence interval; WAZ, 
weight-for-age Z-score; HAZ, height-for-age Z-score; 
a 
Significantly different from RTUF group; 
b 
Significantly different from LRUS group; *Significantly 
different from RTUF group. P < 0.001 (Student’s t test)
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Figure 5.3: Box plots showing changes in weight, weight-for-age Z score (WAZ) and height-for-age Z score (HAZ) and BMI Z-score at 
baseline, 14 and 28 days of supplementation and during follow up in RTUF and LRUS groups
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Table 5.6 Comparison of gain in anthropometric outcomes of mildly wasted 
children (<-1 Z score) and mildly stunted (<-1 Z score) children receiving 4 
weeks of supplementation and control group. 
 
 Control 
(n=128) 
Wasted  
(n=49) 
P Value  Stunted 
(n=14) 
P Value  
Change in WAZ 
(SDS) 
-0.01 ± 0.20 0.13 ± 0.11 0.04 0.10 ± 0.14 0.04 
Change in HAZ 
(SDS) 
0.00 ± 0.15 0.04 ± 0.07 < 0.0001 0.05 ± 0.09 0.17 
Change in BMI Z 
score (SDS) 
-0.01 ± 0.34 0.10 ± 0.18 0.03 0.06 ± 0.20 0.48 
 
Appetite Responses 
The difference in the appetite measures before the provision of the first and the 
last supplement between the two groups for hunger (RTUF, 1.91 ± 1.76mm; 
LRUS, 2.14 ± 1.08 mm, P=0.99), desire to eat (RTUF, 4.53 ± 2.53 mm; 
LRUS, 2.32 ± 2.67 mm, P=0.55), satiety (RTUF, 0.71 ± 1.93 mm; LRUS, 1.44 
± 1.23 mm, P=0.35) and fullness (RTUF, 2.56 ± 2.94 mm; LRUS, 1.50 ± 2.15 
mm, P=0.77) were also not significantly different between the two 
supplemented groups (Table 5.7). 
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Table 5.7 Appetite responses before the provision of the first and the last 
supplement between RTUF and LRUS groups. Data is presented as Mean ± 
SE. 
 
Appetite Responses Before 
provision of 
first 
supplement 
Before 
provision of 
last 
supplement  
P value 
Hunger (mm)    
       RUTF 44.97 ± 4.87 46.88 ± 4.65 0.28 
       LRUS 29.00 ± 4.24 31.14 ± 4.08 0.06 
Satiety (mm)    
       RUTF 50.76 ± 4.66 51.47 ± 5.03 0.71 
       LRUS 69.88 ± 4.36 68.44 ± 4.01 0.25 
Fullness (mm)    
       RUTF 50.23 ± 4.66 52.76 ± 4.73 0.66 
       LRUS 70 ± 4.52 71.5 ± 3.95 0.49 
Prospective Food Consumption 
(mm) 
   
       RUTF 52.17 ± 54.88 54.88 ± 4.48 0.22 
       LRUS 70.88 ± 4.11 70.91 ± 3.96 0.98 
Desire to Eat (mm)    
       RUTF 45.97 ± 4.7 50.5 ± 4.88 0.08 
       LRUS 31.32 ± 4.60 33.64 ± 4.71 0.38 
 
RTUF, Solid ready to use food; LRUS, liquid ready to use supplement  
 
Structured interviews 
 
All the parents/carers reported that their children ate/ drink the provided 
supplements, although 10/34 (29%) children from RTUF group and 14/34 
(41%) children from LRUS, P= 0.310 did not like the taste of the supplements 
much. 19/34 (56%) and 12/34 (35%) of the parents/carers observed 
height/weight gain after 4 weeks of supplementation with LRUS and RTUF 
respectively, P=0.225 (Table 5.8). Regarding appetite 6/34 (18%), 
parents/carers of both groups observed a loss of appetite for short duration in 
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their children. Moreover, 2/34 (6%) parents/ carers in RTUF group and 6/34 
(18%) in LRUS group, P=0.132 attributed side effects to the intake of these 
supplements, the most common complaints were nausea, abdominal pain and 
diarrhoea.  
The parents/carers from RTUF group 26/34 (76.4%) and LRUS 24/ 34 (70%) 
group, P=0.582 were pleased with the supplementary food  and wanted to use 
the supplements again provided that they are cheap or supplied cost-free 
(Table 5.8).  
Table 5.8 RTUF and LRUS perceived acceptability, benefits, and side effects 
among children according to their parents/carers in Abbottabad, Pakistan. 
 
Variable RTUF (%) LRUS (%) P value 
Total parents/carers 34 34  
Taste  unacceptable  10 (29.4%) 14 (41%) 0.310 
Perceived Benefits    
     Weight /height gain 14 (41%) 19 (56%) 0.225 
     Improved general health 24 (70%) 24 (70%) 1.000 
     Improved appetite 6 (18%) 4 (12%) 0.493 
Perceived side effects    
       Loss of appetite 6 (18%) 6 (18%) 1.000 
Abdominal pain, nausea, 
diarrhoea 
2/34 (6%) 6/34 (18%) 0.132 
Wants to use supplements 
again in future 
26 (76%) 24 (70%)   0.582 
 
RTUF, Solid ready to use food; LRUS, liquid ready to use supplement 
 
5.4 Discussion  
To our knowledge, this is the first community based study to explore the 
effectiveness of solid ready to eat and liquid ready to drink supplements in the 
management of mild to moderate malnutrition in the children aged between 5 – 
10 years. Commercially available high energy nutritional supplement drinks 
are very expensive  and have not been tested in the  community settings 
(Singh, Kang et al. 2010). Enrolment rate for this study was high and group 
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allocation was random. Groups were similar on enrolment, compliance with 
the supplementation appeared good, follow up for both the groups was 
identical and no loss to follow up was observed during the intervention. 
In this study both RTUF and LRUS improved the nutritional characteristics of 
the children which has also been suggested by various other studies 
investigating RTUF (Diop, Dossou et al. 2003, Defourny, Seroux et al. 2007, 
Isanaka, Nombela et al. 2009, Patel, Sandige et al. 2011). In our study, we 
have found that there was no significant difference in weight gain, change in 
WAZ, HAZ, triceps- and sub scapular–Z score between RTUF and LRUS 
groups. Our findings are consistent with other studies in which RTUF was 
compared with other nutritional supplements (Phuka, Thakwalakwa et al. 
2009, Bisimwa, Owino et al. 2012, LaGrone, Trehan et al. 2012, 
Thakwalakwa, Ashorn et al. 2012). Similar to the results of this study, a RCT 
in 6-18 months old moderately underweight Malawian children provided with 
micronutrient-fortified maize –soy flour or ready to use fortified spread for 12 
weeks. The primary outcome of the study was weight gain and other secondary 
outcomes were change in anthropometric indices HAZ, WAZ, WHZ and 
recovery from underweight, stunting and wasting. No statistically significant 
differences between the outcome measures were detected between the two 
groups after 12 weeks of supplementation (Phuka, Thakwalakwa et al. 2009).  
Similarly other community based studies conducted in Malawi and other 
African countries did not observe a significant difference in the outcomes 
measures like weight gain, recovery rate and length of stay  while comparing 
standard RTUF with whey protein concentrate RTUF (Bahwere, Banda et al. 
2014), corn- soy blend ―plus plus‖, RTUF with locally produced soy RTUF, or 
an imported soy/whey RTUF for ≤ 12 weeks (LaGrone, Trehan et al. 2012) 
and locally produced and imported RTUF (Sandige, Ndekha et al. 2004). In 
our study, when the RTUF and LRUS group was compared with control group, 
a statistically significant difference was observed in some of the nutritional 
measures, more specifically, the rate of weight gain (g/kg/d) and change in 
WAZ score. Previous studies also observed a significant improvement in some 
of the nutritional outcome measures when the intervention group was 
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compared with a control group (Thakwalakwa, Ashorn et al. 2010, Grellety, 
Shepherd et al. 2012, Huybregts, Houngbé et al. 2012). 
In our study, we observed that weight gain after 4 weeks of supplementation in 
RTUF group was 0.59 ± 0.30 kg and in LRUS group 0.65 ± 0.42 kg. Previous 
studies have also documented weight gain after supplementation (Phuka, 
Thakwalakwa et al. 2009, Singh, Kang et al. 2010, Thakwalakwa, Ashorn et 
al. 2012). In Phuka et al mean (± SD) weight gain after 12 weeks of dietary 
supplementation with either maize-soya flour or fortified spread results was 
0.89 ± 0.38 kg, and 0.84 ± 0.46 kg respectively (Phuka, Thakwalakwa et al. 
2009), while Thakwala et al  observed a weight gain of 0.75 ± 0.41 kg in 
RTUF group during 12 weeks of supplementation. Here it is worth mentioning 
that the duration of supplementation lasted only for 4 weeks in our study. 
Moreover rapid weight gain occurs in severely wasted children, when children 
approach a normal weight for height Z score that rate of weight gain falls to 1-
2 g/kg/day (Ashworth 2006).  
The healthy children in the control group were measured for height and weight 
again after 4 weeks to observe temporal changes on growth and 
anthropometry. It was found that the mean weight gain of the children in the 
control group of same age was 0.26 ± 1.54 kg and the increase in height was 
0.44 ± 0.86 cm after 4 weeks. A significantly higher rate of weight gain 
(g/kg/d) was observed in RTUF and LRUS groups as compared to the control 
group. This showed that the seasonal effect on the weight and height gain in 
the children was lower than the increase observed in this trial after 4 weeks of 
intervention. The mean gain in weight, height, and skinfold measurements 
observed in this study are comparable with other interventional studies of 
supplementary feeding as compared to non supplemented group (Kuusipalo, 
Maleta et al. 2006, Adu-Afarwuah, Lartey et al. 2007). Here it is worth 
mentioning that the excess mean weight gain in supplemented group was 0.62 
± 0.37 kg.  
The total extra energy supplied (500 kcal/day) for 4 weeks would have been 
expected to lead to an excess gain of 2 kg. Thus, at least 2/3 of the energy 
ingested appears to have been compensated for by eating less at other times. 
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Previous studies have also found that the observed weight gain rate was 
substantially less as compared to their predicted growth rate. A study on 
children receiving RTUF observed a growth rate of 5.1g/kg/d, which was 
considerably less than their predicted 20 g/kg/d (based on theoretical model) 
(Manary, Ndkeha et al. 2004).  
In contrast to weight gain, the gain in height seems to be very little by 4-weeks 
of supplementation with both RTUF and LRUS in our study. This is not 
surprising; as gain in height/length has been shown to follow the weight gain 
after a certain lag period (Walker and Golden 1988, Maleta, Virtanen et al. 
2003). Therefore, a longer period of intervention might prevent stunting or 
mild to moderate malnutrition. In our study, we have found no significant 
difference in the height gain between RTUF and LRUS groups. Similarly, in 
another randomized clinical effectiveness trial on the moderately malnourished 
Malawian children it was found that the rates of the length gain was not 
different between corn/soy blend flour (CSB),  milk peanut fortified spread ( 
FS) and soy/peanut FS (Matilsky, Maleta et al. 2009). 
In our study we have found that RTUF and LRUS both have good compliance 
among mild to moderate malnourished children, which was also demonstrated 
in other studies. Studies on RTUF in moderately underweight children showed 
good compliance (Flax, Maleta et al. 2008, Flax, Thakwalakwa et al. 2009, 
Hess, Bado et al. 2011). In this study all the supplements were provided by the 
main researcher herself to each child and then the empty sachet and bottles 
were collected again on the same day in the afternoon to look at the 
compliance but it is possible that the RTUF or LRUS may have been shared 
with other children or wasted in the school. However, if this happened to a 
large extent we may not have observed the full supplementation effect on the 
nutritional characteristics of the children. Moreover, during the distribution of 
supplements the researcher also emphasized that both the supplements (RTUF 
and LRUS) were intended for the targeted children only. In addition to that, 
both the supplements used in this study were ready to use and required no 
cooking, which further improved the compliance. In one of clinical 
effectiveness trial of two supplementary feeding regimens, one supplement 
was ready- to- use therapeutic food, and another was macronutrient fortified 
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corn/soy-blend, which required cooking and that may have made an impact on 
the compliance, due to inconvenience of the  time consuming process needed 
to cook. This supplement resulted in poorer outcomes than with the 
micronutrient fortified corn/soy-blend (Patel, Sandige et al. 2011). Similarly in 
another study the same problem was observed when ready to use food (RTUF) 
was compared with maize/soy which required time and resources to prepare 
maize/soy a disadvantage over RTUF (Manary, Ndkeha et al. 2004).  
In this study, the structured interviews with the parents/carers showed that 
29% of the children from RTUF group and 41% of the children from the 
LRUS group were dissatisfied with the consistency and the taste of the 
supplement. In one of the previous study it was found that 43% of the children 
were dissatisfied with the taste of the RTUF which is higher than in our study 
(Ali, Zachariah et al. 2013). Despite the problems with taste of the 
supplements 70% of the parents/carers from the RTUF and LRUS group 
perceived these supplements to be beneficial for their children which is less 
than another study in which 91% of the caregivers perceived RTUF to be of a 
therapeutic benefit to their severe acute malnourished or moderate acute 
malnourished children (Ali, Zachariah et al. 2013). One limitation of the study 
is that the questions regarding the taste and acceptability of the supplements 
were put to the parents/carers of the children, and the reported responses did 
not reflect the actual perception of the children themselves. Thus, the impact of 
adult perception of actual acceptability in children is not known. Moreover, 
behavioural and cultural factors might also play a role in the acceptability of 
the ready to use nutritional supplements and we have not assessed such factors 
in this study. We are unable to validate any direct relation between the RTUF 
or LRUS intake and the attributed side effects. 
As economic inequity is an independent determinant of childhood 
malnutrition, numerous studies have demonstrated that poor children are 
expected to be at greater risk of being undernourished (Van de Poel, 
Hosseinpoor et al. 2008, Janevic, Petrovic et al. 2010, Mushtaq, Gull et al. 
2011, Stalin, Bazroy et al. 2013). Therefore, in this study we also determined 
the socio-demographic characteristics of the children from the supplement 
group. We found that the parents of children from the supplement groups had 
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low monthly income, spent less on food items, had larger family sizes and 
mothers were illiterate. Studies have documented that thinness and stunting 
was significantly higher among children with illiterate parents as compared to 
educated parents. Parental education is also identified as a predictor of under 
nutrition (Mushtaq, Gull et al. 2011, Emamian, Fateh et al. 2013). Similarly, 
thinness and stunting were also found to be significantly higher in the children 
living in crowded houses and having more siblings, both of these factors are 
considered to be an indirect predictor of lower socio-economic status 
(Mushtaq, Gull et al. 2011).  
RTUF contains patent allergens , and these allergens may be enhanced during 
cooking (Maleki, Chung et al. 2000). We did not observe any incidence of 
peanut allergy in this study as we screened eligible children for food allergies 
with the help of the health questionnaire during screening. Furthermore, 
allergic reactions are rare in this population, as peanuts are the part of their 
traditional diet. Moreover clinical allergy is rare in developing countries 
(Abbassy, El-Din et al. 1974) and food allergy manifests in infancy and 
declines after three years of age (Husain and Schwartz 2013). This finding is 
consistent with another study in which peanut allergy was not observed with 
ready to use food (Manary, Ndkeha et al. 2004). In developing countries there 
is lower incidence  of  peanut allergy as compared to developed countries 
(Singh, Kang et al. 2010). It was found that 5.8% (2/34) of the parents/carers 
from RTUF and 21% (7/34) from LRUS group attributed side effects to the 
intake of the supplements, the most common complaints were nausea, 
abdominal pain and diarrhoea. Other studies have also demonstrated these side 
effects by the use of RTUF and therapeutic milk F-100 (Manary, Ndkeha et al. 
2004, Talbert, Thuo et al. 2012, Ali, Zachariah et al. 2013). 
In this study, the movement of the children into other schools at the end of the 
academic year was anticipated. Hence the study was performed in the mid part 
of academic year i.e. May to December. Thus all the children participated in 
this study and there were no drop outs in the study due to change in the school. 
A previous study performed in the early part of academic year (from January 
to the end of May 2008) to evaluate the effectiveness of locally made RTUF in 
mild to moderate malnourished pre- school children observed a higher dropout 
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rate due to movement of children into other schools (Singh, Kang et al. 2010). 
This study was not blinded as blinding would have been very difficult for two 
different interventions with one supplement being solid and other being liquid. 
The response of the children from both groups during four weeks of 
supplementation was exceptionally good and there was no dropout and all the 
34 children from each group used the supplements as the researcher daily 
collected the empty bottles and sachet from each of the participants. 
We found lower effect of RTUF and LRUS on weight for age Z score (WAZ) 
and height for age Z score (HAZ) than expected but is in the range reported in 
other trials assessing the efficacy of supplementary feeding in children 
(Isanaka, Nombela et al. 2009). The little effect of RTUF and LRUS on WAZ 
and HAZ may suggest acute compensation, which we have observed in our 
first two experimental studies. We observed that 43% of the energy provided 
by supplements is compensated by eating less during the consecutive meal 
(Fatima, Gerasimidis et al. 2013) and previous studies have also reported 
energy compensation (Mattes 2006, Stratton, Stubbs et al. 2008, Mattes and 
Campbell 2009, Almiron‐Roig, Palla et al. 2013). It might be possible that 
children eat less from their habitual diet after the intake of supplements due to 
acute suppression of appetite following supplementation. Other factors may be 
short duration of supplementation, increased energy expenditure due to 
physical activity in community setting, sharing of supplements with other 
children in the school and wastage of the supplements as compared to inpatient 
therapeutic feeding centre. Other studies have demonstrated barriers to the use 
of RTUF and its inadequate compliance due to sharing within the households 
(Maleta, Kuittinen et al. 2004, Ickes, Jilcott et al. 2012). One 24 hour dietary 
study reporting on moderately malnourished children, found that the children 
only received 30% and 43% of the provided RTUF and the maize soy flour 
respectively (Maleta, Kuittinen et al. 2004). However, in our study we tried to 
ensure that the compliance with supplements was high, as empty containers 
were collected daily in the afternoon during supplementation. 
In this study the appetite was measured using visual analogue scales before the 
start of the first supplement and before the provision of last supplement but we 
were unable to measure the dietary intake of the participants before the 
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intervention or during the intervention. Subsequently, we did not have the data 
on the habitual average energy, macronutrient and micronutrient intake. 
Therefore, we could not measure the average daily energy intake from their 
habitual diet at the baseline and during the intervention period to indicate 
whether liquid ready to drink supplement or RTUF supplemented or displaced 
habitual energy intake. Previous studies have observed that energy dense ready 
to use foods seems have little measurable impact on children‘s diet and breast 
milk intake (Galpin, Thakwalakwa et al. 2007, Owino, Bahwere et al. 2011) 
but assessment of habitual diet is difficult, so further dietary assessment 
studies are necessary, to investigate the impact of RTUF and liquid ready to 
drink supplement on habitual diet substitution in children.  
In this study, we followed the children from the supplement group up to 12 
months. Data on long term follow up after supplementation is available only 
from few previous studies (Nackers, Broillet et al. 2010, Chang, Trehan et al. 
2013). Both these studies showed high rate of relapse during follow up in 
children with moderate acute malnutrition. The Malawian study (LaGrone, 
Trehan et al. 2012) was followed up for  twelve months and was reported in 
Chang et al 2013. During twelve months follow up it was found that 63% of 
the children remained well nourished, 17% relapsed to MAM, 10 % developed 
SAM and 4% die. A study by Nackers et al 2010, found that during a six 
months follow up, 62% remained well nourished and 20% relapsed to MAM. 
In our study, we observed that, during the follow up, the children in the 
supplement group remained in WAZ between -1 and -2.  Previous evidence 
also suggested that 30% to 40% of the children recovered from MAM relapsed 
in a short period of six to twelve months (Lazzerini, Rubert et al. 2013). This 
may suggest that provision of supplements may be a short-term solution and 
for a sustained, long-term impact focus should be placed on actual problem of 
food access, dietary habits, and treatment of underlying diseases, education, 
and sanitation.    
We have found that the children who were provided with the supplements 
belong to low socio-economic status and were mildly malnourished. 
Supplementation with RTUF and LRUS for four weeks resulted in modest 
weight gain and during follow up it was found that there was a tendency to 
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relapse, which demonstrates that provision of nutritional supplements is a 
short-term solution. The findings from our study suggest that RTUF and liquid 
nutritional supplements are equally effective only for short- term nutritional 
improvement. However, for the long term emphasis should be placed on 
utilising local foods and re-educating food habits as compared to externally 
provided industrial food. Though our findings are consistent with the idea that 
both supplements promote recovery from mild to moderate malnutrition, 
poverty in Pakistan diminishes the possibility to purchase commercially 
available nutritional supplements. In spite of the fact that mild to moderate 
malnutrition is a contributing factor to morbidity in a huge proportion of child 
mortality in our country, it is not getting the attention, which it deserves. It is 
therefore, suggested that, in the developing countries like Pakistan, an 
integrated nutrition programs may have a considerable impact through 
combination of interventions involving education, health, sanitation and food. 
A school based food program focused on poor and socially disadvantaged 
population in developing countries like Pakistan is recommended. 
5.5 Conclusion 
Our results suggest that benefits of supplementation with RTUF and LRUS in 
relation to the treatment of moderate malnourished children of Pakistan are 
similar. However, the overall improvement in weight gain was less than 
expected.  
.  
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6 General Discussion and Conclusions 
Malnutrition is one of the many health inequalities, affecting millions of 
individuals worldwide, and is basically a treatable condition. Systematic 
reviews and meta-analyses consistently suggest that HENSD can improve the 
energy and nutritional intake,  body weight, and have a variety of clinical and 
functional benefits in malnourished patients, and patients at risk of becoming 
malnourished (Stratton and Elia 2010, Cawood, Elia et al. 2011, Stratton, 
Hebuterne et al. 2013). Typically, HENSD contains a mixture of protein, 
carbohydrate and fat and some micronutrients and provide from 6·3 kJ/ml to 
10·1 kJ/ml per typical serving of 125–220 ml (Stratton and Elia 2010). A 
recent meta-analysis of 8 RCTs suggest that they enhance daily energy intake 
increased by a mean of 1569 kJ/d (Hubbard, Elia et al. 2012). Increase in body 
weight due to HENSD supplementation however is usually lower than 
predicted. This implies that HENSD diminishes other food intake and that the 
energy provided by HENSD is only partially compensated by a reduction in 
the energy intake during habitual meals. Mechanisms responsible for only 
partial energy compensation during meals consumed after intake of the 
supplements used for malnutrition treatment remain to be investigated.  
 
So far, the role of metabolic and hormonal appetite modulators in amendments 
of energy intake due to malnutrition treatment has been investigated only in 
tube feeding studies (Stratton and Elia 1999, Stratton, Stubbs et al. 2008). It 
has been reported that compensation for energy provided by the intermittent 
delivery of tube feeding as bolus was only partial regardless of significant 
enhancement in the metabolic and hormonal responses involved in satiation 
(Stratton, Stubbs et al. 2008). The interaction between appetite, food intake 
and metabolic and hormonal mediators of appetite and satiety following tube 
feeding and oral supplementation may be different. Therefore, the first aim of 
this thesis was to investigate the level of energy intake compensation in lean 
adult women following HENSD consumption, and to find out how it relates to 
216 
 
the response of a range of hormonal and metabolic appetite regulators as well 
as measure of gastric emptying. 
 
In clinical practice, HENSD is not consumed on an acute basis, but is taken for 
a long duration (Hubbard, Elia et al. 2012). In addition, consumption happens 
in the evening, rather than prior to breakfast. Therefore, a first experimental 
study, applying a typical pre-load trial approach, with a requirement to 
consume the supplement in the morning prior breakfast, might not fully reflect 
the food compensatory nature related to supplement intake in the evening and 
for a longer duration. Therefore, one of the aims of the second study was to 
investigate the time scale and level of energy intake compensation after five 
days of supplementation with HENSD in the afternoon.  
An enhancement in daily energy achieved by HENSD supplementation, is 
expected to increase body mass (Cawood, Elia et al. 2012) and thus induces a 
positive energy balance. A positive energy balance induced by an increase in 
dietary energy intake impacts plasma triglyceride, insulin and glucose 
concentrations (Hill, Peters et al. 1990, Faeh, Minehira et al. 2005, Bortolotti, 
Kreis et al. 2009, Brøns, Jensen et al. 2009). The impact of short term 
overfeeding on triglyceride metabolism is uncertain, since it is difficult to 
distinguish between changes in energy intake and changes in the macronutrient 
composition. Some studies reported an elevated VLDL-TAG concentrations 
after 4 to 7 days of consuming hyper-caloric high carbohydrate diet (Ngo 
Sock, Lê et al. 2010, Sobrecases, Lê et al. 2010) while overfeeding studies 
with high fat diet found that VLDL-TAG concentrations were reduced (Brøns, 
Jensen et al. 2009, Sobrecases, Lê et al. 2010). Whereas, some studies found 
no impact of hyper-caloric feeding on very low density lipoprotein triglyceride 
(VLDL-TAG) concentrations in  healthy women (Bellou, Maraki et al. 2013) 
and in obese subjects (Smith, Magkos et al. 2013). The impact of an acute 
positive energy balance achieved by overfeeding with a mixed diet (balanced 
diet) has controversial findings with respect to plasma glucose and insulin 
levels. Some studies reported an increase in the concentration of both insulin 
and glucose (Tam, Viardot et al. 2010, Bellou, Maraki et al. 2013), some 
insulin only (Sobrecases, Lê et al. 2010, Cornford, Hinko et al. 2012) and 
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others found no change in insulin or glucose levels (Després, Poehlman et al. 
1987, McDevitt, Bott et al. 2001).  Therefore, another aim of the second 
experimental study was to investigate the impact of five days supplementation 
on plasma lipids and insulin sensitivity. 
Systemic reviews and randomized controlled trials have showed that RTUFs 
are very effective and safe in the treatment of severe malnutrition in children 
(Briend, Lacsala et al. 1999, Collins and Sadler 2002, Dossou, Ndour et al. 
2003, Sandige, Ndekha et al. 2004, Ciliberto, Sandige et al. 2005, Ashworth 
2006, Brewster 2006, Bhutta, Ahmed et al. 2008, Gera 2010). Some studies 
have demonstrated a higher increase in energy intake (808 vs. 573kJ/kg/day) 
and weight gain (15.6 vs.10.1g/kg/day) achieved by supplementation with 
RTUF compared to the changes induced by consumption of a traditional high-
energy drink based on milk (F-100) (Diop, Dossou et al. 2003). RTUFs have 
been used to supplement the dietary intake of  moderately malnourished 
children (Kuusipalo, Maleta et al. 2006, Defourny, Seroux et al. 2007, 
Matilsky, Maleta et al. 2009, Nackers, Broillet et al. 2010, Patel, Sandige et al. 
2011). RTUF have been found to be effective in preventing onset of 
malnutrition in non-wasted children from the areas of food insecurity 
(Defourny, Minetti et al. 2009, Isanaka, Nombela et al. 2009, Isanaka, 
Roederer et al. 2010, Huybregts, Houngbé et al. 2012). The majority of the 
existing evidence on the use of community-based management of 
uncomplicated, severe acute malnutrition has emerged from studies conducted 
in Africa in emergency settings (Gera 2010). There are no studies from Asia 
exploring the effectiveness of RTUF and other industrialised foods in the 
treatment of children with moderate acute malnutrition (MAM), where MAM 
is most prevalent (Lazzerini, Rubert et al. 2013). There was a need to generate 
more evidence regarding the efficacy of RTUF and other locally available 
ready to use supplements in non-emergency settings particularly in a Pakistani 
context. There was no evidence comparing the impact of RTUF and 
proprietary liquid supplements on the weight gain in mild to moderate 
malnourished children between the ages of 5-10 years. Therefore, the third 
experimental study aimed to explore the efficacy of RTUF and LRUS in 
218 
 
promoting weight gain and appetite regulation in mild to moderate 
underweight children from Pakistan. 
The first experimental chapter provides insight into the appetite, metabolic, 
hormonal and gastric emptying responses to the HENSD consumption and thus 
investigated mechanisms related to impaired adjustment of energy intake 
commonly seen during subsequent intake. We found that HENSD increased 
the net energy intake by about half the energy value of the supplement and 
thus confirmed previous evidence (Stratton, Stubbs et al. 2008) that 
suppression of energy intake during meals consumed after supplementation 
with HENSD is only partial. The novel finding of this study is that the appetite 
suppressive response following the HENSD intake was shorter than the 
response of metabolic and hormonal appetite regulators, with the result that 
compensation for the energy provided by the HENSD is partial and evident 
only during immediate hours after the supplementation. In consistence with 
other studies reporting an effect of energy content of preload on appetite 
responses (Karl, Young et al. 2013), we found that during 60 minutes post-
supplementation hunger suppression and enhancement in satiety was more 
profound after HENSD than PLACEBO intake.  
 
Several mechanisms could have been responsible for these differences. 
Enhanced satiety and reduced hunger found in the HENSD trial during the 
immediate post supplementation period can be attributed to significantly 
higher plasma concentrations of PYY and CCK, gastrointestinal hormones 
known to elicit anorexigenic effects, (Chaudhri, Field et al. 2008, Suzuki, 
Simpson et al. 2010), and insulin, known to play a role in appetite regulation 
of lean individuals (Flint, Gregersen et al. 2007). Even though the plasma 
concentration of potential appetite regulators such as CCK, PYY  (Chaudhri, 
Field et al. 2008, Suzuki, Simpson et al. 2010) and insulin (Flint, Gregersen et 
al. 2007) persisted to be different beyond breakfast, neither subjective appetite 
measures during pre-lunch nor energy intake during lunch, differed between 
the HENSD and PLACEBO trials. The finding of dissociation between 
appetite measures and expected action of these appetite regulators is consistent 
with some other studies, which found that appetite scores are not always 
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related to CCK (De Graaf, Blom et al. 2004) or PYY (Doucet, Laviolette et al. 
2008) and insulin concentration (Gielkens, Verkijk et al. 1998). Thus, data 
obtain in our and some other studies suggests that subjective appetite measures 
might be a better correlate of energy intake than circulating levels of appetite 
hormones.  
 
The thermic effect of food is another potential regulator of the appetite 
sensations, including satiety. Some studies have found that higher-diet induced 
thermogenesis was correlated with reduced hunger and more satiety (Crovetti, 
Porrini et al. 1998, Mansour, Ni et al. 2012). While others have not (Ravn, 
Gregersen et al. 2013). Since even a small positive association between TEF 
and satiety could have clinical implications for weight gain during 
supplementation with HENSD, this study also aimed to find out whether 
following HENSD consumption appetite responses were related to the 
postprandial energy expenditure. We found that during 60 minutes post-
supplementation (pre-breakfast period), energy expended above resting 
metabolic rate (a measure of thermogenesis) was significantly higher in the 
HENSD than the PLACEBO trial. This coincided with hunger and desire to eat 
being significantly lower, and satiety and fullness significantly higher in the 
HENSD than the PLACEBO trial. Thus, our data hardly support notion of the 
importance of thermogenesis in appetite and satiety regulation. Future research 
is required to look at how the composition and frequency of the HENSD 
supplementation may modify the compensation for the energy provided by the 
HENSD supplements in men and in the diseased men and women suffering 
from malnutrition. 
 
To achieve the first aim of the second experimental study HENSD was 
supplemented for five days and the  impact on energy intake consumed during 
immediate hours after supplementation, and during the ad libitum buffet 
breakfast, lunch and dinner consumed on the consecutive day was measured. It 
was found that during five days of supplementation with HENSD the averaged 
total energy intake, including energy provided from the drink, was 
significantly higher. However, during supplementation we observed an acute 
suppression of the energy intake immediately after HENSD supplementation 
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in the evening meal. It was observed that 43% of the energy provided by the 
HENSD is compensated by eating less during the evening meal in HENSD 
supplementation. Previous studies have also reported energy compensation 
(Mattes 2006, Stratton, Stubbs et al. 2008, Mattes and Campbell 2009, 
Almiron‐Roig, Palla et al. 2013) and the first experimental study of this thesis 
found that exactly the same 43% of energy was compensated by eating less 
during the breakfast after HENSD supplementation (Fatima, Gerasimidis et al. 
2013). A significant decrease in energy intake of the evening meal was seen 
during four days after consumption of the HENSD but no differences in the 
energy intake during the ad libitum breakfast, lunch and dinner was observed 
on the consecutive day. This suggests that the provision of HENSD in the 
evening for five consecutive days suppresses intake only immediately during 
the evening meal and does not suppress the appetite on the following day. 
Therefore, the results from second experimental study confirmed that the 
provision of the HENSD could be expected to increase daily energy intake as 
compensation for the energy provided was partial, immediate, short lived and 
has no impact on the appetite and energy intake during the next day. 
The second experimental study investigated the impact of HENSD 
supplementation for five consecutive days on cardio-metabolic risk factors as 
the HENSD supplements are expected to induce a positive energy balance. The 
results of the second experimental study demonstrated that positive energy 
balance induced by HENSD supplementation can be expected to reduce insulin 
sensitivity, but have no impact on fasting lipids and postprandial lipaemia, 
insulinaemia and glycaemia. The results of our study are in corroboration with 
other studies which demonstrated that the acute positive energy balance 
achieved by hypercaloric feeding does not affect VLDL-TAG concentration 
and plasma insulin concentrations (Bellou, Maraki et al. 2013, Smith, Magkos 
et al. 2013). The findings from our study suggest that the deleterious effects of 
the positive energy balance, achieved by overfeeding, on insulin homeostasis 
manifests rapidly. These results indicate that insulin resistance is sensitive to 
acute (5 days) moderate increase in net energy balance whereas lipid/ TAG 
metabolism are not. This increase in fasting insulin levels could be simply 
because of higher carbohydrate load ingested during the HENSD 
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supplementation, the mechanisms for this finding need to be investigated 
further. The results of our first two experimental studies provide information 
for clinical practice, while prescribing supplements to the malnourished 
individuals. As in both our studies, we observed that 43% of the energy 
provided by the HENSD is compensated by eating less during the consecutive 
meal.  
 
Current evidence suggests that the use of nutritional supplements increases fat 
body mass (Lazzerini, Rubert et al. 2013). Rapid gain in weight due to 
adipocyte deposits (rather than increase in lean body mass) may lead to adult 
obesity, adiposity, diabetes and cardiovascular risk factors especially in 
malnourished subjects (Adair, Fall et al. 2013). Unfortunately, there is little 
evidence to evaluate possible side effects of energy dense foods and long-term 
outcomes of the treatment in malnourished children (Lazzerini, Rubert et al. 
2013). As HENSD consumption is expected to induce the positive energy 
balance, we investigated the impact of short-term supplementation (five days) 
with HENSD on cardio-metabolic risk factors. However, more research is 
required to investigate the impact of longer duration of supplementation or 
different degrees of supplementation with the HENSD on lipoprotein, glucose 
and insulin metabolism in the healthy and obese subjects. It should be noted 
that we have performed this experimental study on very healthy young 
participants and they had very high insulin sensitivity even after five days of 
the HENSD supplementation. Therefore, future studies are required to 
investigate the impact of these HENSD supplements on elderly ill patients in 
which insulin sensitivity and lipid profile is in most cases already disturbed 
due to aging (Chang and Halter 2003, Refaie, Sayed-Ahmed et al. 2006). The 
detrimental impact of continuous supplementation should also be considered; 
as acute short-term positive energy balance have found to enhanced the insulin 
resistance which if unchecked may predisposes to type 2 diabetes mellitus and 
CVD.  
 
The third experimental study on mild to moderate underweight children from 
Pakistan explored the efficacy of RTUF and liquid supplements, on promoting 
weight gain and appetite regulation, in mild to moderate malnourished children 
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between the ages of 5-10 years. We found that both RTUF and LRUS given in 
the community showed similar impact on promoting weight gain, height, and 
skinfold thickness in mild to moderate underweight children. However, the 
overall rate of the weight gain was lower than expected. Previous studies have 
also documented that the observed growth rate was substantially less as 
compared to their predicted growth rate after the supplementation (Manary, 
Ndkeha et al. 2004). The reason might be the acute suppression of appetite 
immediately after the supplementation as has been observed by us, in our first 
two experimental studies. It was found that the children might eat less than 
from their regular habitual diet. Other factors might be the sharing of 
supplements in the school and increased energy expenditure because of 
physical activity. However, when compared to a control group a significantly 
higher rate of weight gain (g/kg/d) was observed in RTUF and LRUS groups.  
 
Studies have documented significant improvement in nutritional characteristics 
when the intervention group was compared with a control group 
(Thakwalakwa, Ashorn et al. 2010, Grellety, Shepherd et al. 2012, Huybregts, 
Houngbé et al. 2012). This suggests that although RTUFs led to clinically 
significant benefits in the number of children recovering. However, RTUFs did 
not reduce mortality or progression to severe acute malnutrition and also 
induced vomiting (Lazzerini, Rubert et al. 2013). We also found that the 
children in the supplement group belong to low socio-economic status.  Their 
parents had a low monthly income, spent less on food items, had larger family 
sizes and the mothers were illiterate. Previous studies have documented that 
thinness and stunting was significantly higher among the children with 
illiterate parents as compared to educated parents and parental education is 
also identified as a predictor of under nutrition (Mushtaq, Gull et al. 2011, 
Emamian, Fateh et al. 2013). Similarly thinness and stunting were also found 
to be significantly higher in children living in crowded houses and having 
more siblings, both of these factors are considered to be an indirect predictor 
of lower socio-economic status (Mushtaq, Gull et al. 2011). The structured 
interviews with the parents/carers showed that 29% of the children from RTUF 
group and 41% of the children from LRUS group were dissatisfied with the 
consistency and the taste of the supplement. In one of the previous study it was 
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found that 43% of the children were dissatisfied with the taste of the RTUF 
which is higher compared with our study (Ali, Zachariah et al. 2013).  
 
Despite of the problems with the taste of the supplements 70% of the 
parents/carers from RTUF and LRUS group perceived these supplements to be 
beneficial for their children. This is less compared with another study in which 
91% of the caregivers perceived RTUF to be of  therapeutic benefit to their 
severe, acutely malnourished or moderate acutely malnourished children (Ali, 
Zachariah et al. 2013). We found that there was no significant difference in 
any of the appetite measure between RTUF and LRUS groups before and after 
the supplementation. This finding is also in corroboration of our first two 
experimental studies that the appetite suppressive action of the supplements 
was only short-lived. Further dietary assessment studies are necessary, to 
investigate the impact of RTUF and the liquid ready to drink supplement on 
the habitual diet substitution in children suffering from different disease 
conditions as the appetite suppressive action of the HENSD might be different 
in the children suffering from diseases as compared to the mildly malnourished 
but healthy children from the community settings. As currently very little 
evidence is available on the possible side effects of energy rich, lipid based 
nutritional supplements such as RTUF and their long-term outcomes on the 
malnourished children so future research is also required in this regard. 
 
We chose ―underweight‖ healthy young females (BMI: 17-20 kg/m2) to 
simulate relative under-nutrition and to allow a sampling regime and study 
design which would not be ethical in a paediatric patient group. The first 
experimental study investigated the level of energy intake compensation in the 
lean adult women following HENSD consumption. The question being how it 
relates to the response of a range of hormonal and metabolic appetite 
regulators. The second study investigated the time scale and level of the 
energy intake compensation after five days of supplementation with HENSD 
in the afternoon. From both these studies we observed that 43% of the energy 
provided by the HENSD is compensated by eating less during consecutive 
meal. This informs clinical practice about prescribing supplements to 
malnourished individuals. Later on, the third non-invasive experimental study 
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was performed on mild to moderate malnourished children to explore the 
efficacy of nutritional supplements in underweight school going children, 
between the ages of 5-10 years. It measured appetite before the start of the first 
supplement and before the provision of last supplements. We have observed 
that the overall rate of weight gain was lower than expected and at least 2/3 of 
the energy ingested appears to have been compensated for by eating less at 
other time, as has been observed in the first two experimental studies.   
 
 As all studies, the experimental studies presented in this thesis have some 
limitations. In first two experimental studies, we recruited slim but healthy 
young women in order to test the likely effect of the HENSD in younger 
malnourished patients. Most prior research has been done in the elderly. Thus, 
results obtained in this study are most likely to be relevant to adolescents and 
younger adults and cannot necessarily be generalized to truly malnourished 
individuals or to males. In first experimental study only short term regulation 
of appetite and energy intake was measured, which might not be generalizable 
to clinical or home settings where HENSD are prescribed for the long term. In 
the first experimental study, HENSD was consumed in the morning, prior to 
breakfast while in clinical practice intake happens during the day. However, 
the first experimental study investigated mechanisms responsible for the 
partial energy compensation and so we used a pre-load type design requiring 
the intake in the morning (Blundell, De Graaf et al. 2010). 
 
We appreciate that some other potential short-term appetite regulators such as 
glucagon like peptide -1 and ghrelin could have also been investigated in the 
first experimental study. The decision to measure PYY and CCK was based on 
the fact that both PYY and CCK are related to the subjective measures of 
appetite and food intake (De Graaf, Blom et al. 2004, Crespo, Cachero et al. 
2014).  Numerous studies have found the suppressing impact of CCK on food 
intake or the subjective feelings of hunger (Delzenne, Blundell et al. 2010). 
Moreover PYY may be involved in the ―ileal brake‖ by slowing down gastric 
emptying (Huda, Wilding et al. 2006) and CCK also slows gastric emptying 
rate (Delzenne, Blundell et al. 2010). Appetite hormones were not investigated 
in the second experimental study because the main aim of the study was to 
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confirm that the differences in appetite and energy intake (compensation) are 
short lived. In our first experimental study we observed that the supplement 
works most likely because of both partial compensation and the disturbance in 
the appetite measures were short lived. We also noted that responses of the 
metabolic and hormonal appetite regulators were measured only in a subset of 
the study participants. This decision was made based on the power calculations 
identifying that the investigation of nine participants would allow us to pick up 
physiologically meaningful and significant differences in postprandial PYY, 
CCK, glucose, insulin, concentrations at power of 85%. Moreover, studies 
have demonstrated that appetite scores are better correlates of  energy intake 
than the circulating levels of appetite hormones like PYY or ghrelin (Doucet, 
Laviolette et al. 2008). For the same reason the appetite, regulators were not 
investigated in the third study.  
 
The strengths of first experimental study was the study design which included 
the use of a preload paradigm. This is accepted as a useful methodology to 
assess the effects of food or drink on appetite and energy intake in the short 
term under controlled condition (Almiron‐Roig, Palla et al. 2013). This design 
overcomes misreporting of food intake and thus allows precise measurement 
of energy intake. To further improve the quality of energy intake data, food 
included in breakfast and lunch and left over of breakfast and lunch were 
weighted and analyzed by two researchers. Differently from most of the other 
pre-load studies, our study investigated the impact of the HENSD consumption 
on the energy intake compensation in the longer term, and thus measured 
impact on energy intake during two consecutive meals. This allowed us to find 
out that appetite suppressive responses and energy compensation happens 
close to the HENSD supplementation, and disappears quickly with time. It 
should be noted however that the laboratory environment was artificial, and 
thus energy intake could have been influenced by deviations from normal 
eating behaviours, timing and food availability (Hetherington, Anderson et al. 
2006). In the second experimental study the energy intake during the evening 
meal was measured under free living conditions and previous studies have 
documented that food consumed in a laboratory setting under controlled 
conditions is in a reasonable approximation of energy intake as measured 
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under free living conditions (Obarzanek and Levitsky 1985). Moreover, in our 
study the free-living conditions also provided time flexibility for dinner, which 
varies considerably among the individuals and is not possible under the 
laboratory conditions. Additionally participants remained to have sedentary in 
the metabolic suite for the whole duration of the trial which was not in 
correspondence to habitual interaction (Poppitt, McCormack et al. 1998). 
 
The third experimental study was limited by the fact that we were unable to 
measure the average daily energy intake of the children from their habitual 
diet, at the baseline, and during the intervention period, to indicate whether 
liquid ready to drink supplement or RTUF supplemented or displaced habitual 
energy intake. Appetite was measured using visual analogue scales before the 
start of first supplement and before the provision of last supplement but we 
were unable to measure the dietary intake of participants before intervention or 
during intervention. Moreover, the questions regarding the taste and 
acceptability of the supplements were put to the parents/carers of the children 
and the reported responses might not reflect the actual perception of the 
children themselves. Great care should be taken while translating the results 
from this study to different local settings as contextual factors, such as local 
preferences might influence the adherence to the intervention. The results from 
this study are from a general population of children with mild to moderate 
malnutrition in the absence of any disease, therefore the results should not be 
translated directly to children with MAM with a diagnosis of some disease 
condition. The strength of this study was that the enrolment rate for this study 
was high and group allocation was random. Groups were similar at enrolment, 
compliance with the supplementation appeared well, follow up for both the 
groups were identical and no loss to follow up was observed during the 
intervention.  
 
We have performed the HOMA technique for measuring insulin resistance. 
The impact of HENSD supplementation on insulin sensitivity can be checked 
with better techniques like euglycemic hyperinsulinemic clamp or the 
frequently sampled intravenous glucose tolerance test (FSIGT). Although 
HOMA technique is relatively inexpensive and easy it did not provide nearly 
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the same degree of information as FSIGT or clamp technique (Trout, Homko 
et al. 2007), but these latter techniques are invasive and unpleasant and not 
suitable for children in a population setting. The strengths of this study include 
the participants‘ attendance, as none of the participants was eliminated due to 
non-compliance of supplementation.  All participants consumed both the 
HENSD and the PLACEBO supplements in the presence of the researchers 
ensuring compliance.  
 
In the third experimental study the short term supplementation aimed only to 
assess the benefits of supplementation in mild to moderate malnourished 
children. As dietary counselling is a fundamental and effective part in the 
treatment of mild to moderate malnutrition (Ashworth and Ferguson 2009), the 
parent/carer  obtained dietary counselling on the completion of the study. 
Parents of all the participants were educated about the role of proper dietary 
requirements in school-going children as well as the importance of healthy diet 
in growing children. Dietary supplementation beyond the duration of study 
was beyond the scope of this study, however, this study highlighted the level 
of malnourishment in the government schools and in addition parents were 
given much needed information about the nutritional level of the kids and 
ways to improve it by improving their dietary intake. For effective, long term 
benefits there is a need to place more focus on the improvement of the 
adequacy of home diet by nutritional education and by improving nutritional 
habits especially in the settings where food is available which may ensure 
maintained and sustainable improvement in prevention and treatment of mild 
to moderate malnutrition.  
 
Poverty seems to be the major contributing factor for the malnourished status 
of these children. Therefore it is recommended that Government should start a 
programme for food provision, ―healthy school meals‖ for the school going 
children and International donor agencies should help the economically 
crippled countries to address this manageable problem. This should also be 
augmented by educational programmes for the masses especially focusing on 
the parents having poor socioeconomic status.   
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Conclusions 
 
 HENSD consumed either in the morning as a single dose or in the 
evening for several days in slim healthy females induces only partial 
reduction in habitual food intake and thus may benefit daily energy 
intake and body weight gain. Further studies are required to investigate 
the impact of these supplements on energy intake in malnourished ill 
individuals. 
 
 In the short term HENSD, increased net energy intake by about half the 
energy value of the supplement. This finding should be taken into 
consideration while estimating the expected enhancement in weight 
gain of the malnourished individual. 
 
 HENSD when consumed before breakfast by slim healthy females had 
partial and a relatively short-lived suppressive action on energy intake, 
but metabolic and hormonal effects persisted longer, though their 
impact on appetite or energy intake was only during the hours 
immediately after supplementation. 
 
 Short-term supplementation with HENSD can be expected to reduce 
insulin sensitivity but had no impact on the fasting lipids and 
postprandial lipaemia, insulinaemia and glycaemia in slim healthy 
females. 
 
 RTUF and LRUS given in a community setting in Pakistan had similar 
impact on improving the nutritional status in mild to moderate 
underweight children, but the overall rate of weight gain was lower 
than expected. This implies partial compensation for energy provided 
by the supplements. 
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1. Describe the purposes of the research proposed.  Please include the background 
and scientific justification for the research.  Why is this an area of importance? 
 
High energy nutritional supplement drinks (HENSD) are widely promoted by food 
industry and used in malnourished children and adults with a significant cost  to the UK 
National Health Service (£99 million pa) http://www.ic.nhs.uk/pubs/prescostanalysis 
2007. These drinks aim to maximise energy/nutrient intake on top of the normal habitual 
diet of the patient, to prevent or correct disease associated undernutrition and improve 
clinical outcome, function and quality of life (1).  Although these, mainly diary 
supplements, mimic ordinary food their composition is significantly different. They 
usually have a substantially higher energy and protein content and are supplemented with 
large amounts of micronutrients. For example Scandishake
®
, a mainstream dairy HENSD 
has 2.5 kcal/ml, 5% protein, 13% fat, 230 mg of phosphorus and an osmolarity of 880 
mOsmol/L compared to cow‘s milk which has 0.7 kcal/ml, 3% protein, 3.7% fat and 
95mg of phosphate and an osmolarity of 270 mOsmol/L. As energy content, nutrient 
composition, concentration of electrolytes and osmolarity (i.e. gastric emptying speed and 
gastrointestinal absorption) are well established regulators of appetite, it is important to 
study how consumption of HENSD impacts on energy intake during subsequent meals.  
Although there is some evidence to support HENSD use in institutionalised 
elderly (2;3), their efficacy in paediatric patients has been barely studied, but one 
randomized trial found that use of HENSD in paediatric patients with cystic fibrosis was 
ineffective in improving markers of nutritional status or lung function  (4). This suggests 
that HENSD can be partially effective and these findings may be attributed to the known 
tendency for healthy children to regulate their habitual dietary/energy intake more closely 
than adults, so that after the consumption of a high energy drink they eat less at meals in 
compensation (5). Relevant studies in paediatric patients are missing although one study 
in patient group found no sating effect of a high energy preload in children with weight 
faltering (6). No study has yet specifically looked at the extent to which patients of any 
age regulate intake after taking HENSD.  Evidence is also needed on how HENSD 
change appetite and food intake and their impact on regulators of appetite such ghrelin 
(7), peptide YY (8), leptin (9), insulin (10) as well as changes in postprandial energy 
expenditure (diet induced thermogenesis) (11) and digestion physiology (gastric 
emptying) (12).  
           We speculate that the use of high energy supplements may suppress voluntary oral 
intake, particularly in children, and this compensation is regulated though the impact of 
these supplements on objective and subjective markers of appetite, postprandial energy 
expenditure and digestion physiology. In view of the lack of prior work in this area, this 
proof of concept study aims first to describe the impact in adults of the bolus consumption 
of a mainstream HENSD on energy intake/expenditure, metabolic responses and appetite 
regulation. In particularly we will try to answer the following questions: 
1. To what extent do healthy, lean adults compensate for the energy consumed in an 
ultra high energy HENSD, and how does this relate to subjective measures of appetite. 
2. What is the impact of an ultra high HENSD on the response of appetite hormones, 
gastric emptying and diet induced thermogenesis. 
3. To what extent do changes in appetite hormones gastric emptying and diet induced 
thermogenesis correlate with or explain the extent of individual energy compensation? 
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2. Describe the design of the study and methods to be used.  Include sample size and 
the calculation used to determine this.  Statistical advice should be obtained if in 
doubt. 
Study Design. 
This will be a single blind randomised controlled trial, with participants acting as their own 
controls. Participants will undertake two main experimental tests, 1-4 weeks apart using two 
different preloads: a) A high energy liquid mainstream nutritional supplement (Scandishake, 
Chocolate, Nutricia®) made up with full fat milk and b) The same volume of a low calorie fat free 
milk drink. Both preloads will be composed using the same flavouring and colouring. The order of 
the drinks will be randomly allocated and the participants will be blinded to type of preload. In 
both experimental test blood samples will be collected and data on appetite obtained in the fasted 
state and at 30, 60, and 90 minutes after supplement and at 30, 60, 90, 120 minutes post-breakfast. 
Two hours post breakfast (3.5 hours post pre-load) the participants will be offered ad libitum 
buffet lunch and the amount of food ingested will be recorded. Participants will be asked to keep a 
diary of their dietary intake using weighed records for the rest of the day several time at after ad 
libitum buffet breakfast. Energy consumed during breakfast and lunch and the rest of the day will 
be also measured. Participants will record of all food and drink consumed and refrain from 
physical activity for 2 days preceding their first visit to the laboratory and will be asked to 
replicated this  prior to the subsequent second visit.  
Power calculation: 19 subjects will give 80 % power at 5% level to detect a difference of around 
2/3 of standard deviation between supplements for any one measure. This would be sufficient to 
detect a difference of around 500 KJ energy intake.  
Methods  
Anthropometry 
Body weight and height will be measured using electronic scales and a rigid height measure. 
Triceps and sub scapular skinfolds will be measured using Holtain callipers and summed.  
Energy intake 
The energy consumed in the preload and at each meal will be calculated using dietary analysis 
software (Windiets 2005, The Robert Gordon University, Aberdeen, Scotland, UK).  
Appetite measurements 
Appetite sensations will be measured with validated appetite questionnaires (13). Participants will 
be asked to rate measures of appetite on 100mm lines. 
Metabolic rate and diet induced thermogenesis. Ventilated hood system (Oxycon Pro, Jaeger 
GmbH, Hoechberg, Germany). A ventilated hood will be placed over the volunteer‘s head to allow 
analysis of expired gas. Meatbolic rate in the fasted state and after drink and after  breakfast will 
be calculated. 
Appetite hormones. Venous blood samples will be collected in 9 ml vacutainers containing EDTA. 
Plasma acylated ghrelin and peptide YY will be determined  by radioimmunoassay (Millipore, 
Watford, UK). 
Gastric emptying. Participants will be asked to consume of 1500 mg of  plasma  paracetamol will 
be measured as indirect marker for the rate of liquid and semisolid gastric emptying (15).  
Statistical analysis. The total areas under the curve for appetite measurement or appetite 
biomarker response versus time curve (AUC) will be used as summary measures of the post load, 
the post-breakfast and post-lunch responses. Difference in energy intake measured in two tests will 
be compared by paired t-test or 1 Two-way repeated measures ANOVA (trial x time) will also be 
used to compare responses of appetite and appetite biomarkers, and metabolic rate between tests 
and evaluate changes over time. Post hoc Tukey‘s tests will be used to identify where differences 
lay.  
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3. Describe the research procedures as they affect the research subject and any 
other parties involved. 
It should be clear exactly what will happen to the research participant, how many 
times and in what order. 
 
On the day of the experimental test the participants will come to the metabolic 
investigation suite at ~ 08:30. The participants will be allowed 10 minutes to relax and 
acclimatize. Following measurements of anthropometry, body composition and resting 
metabolic rate (RMR), a cannula will be inserted in an antecubital vein, and a baseline 
blood sample will be collected and appetite questionnaires will be completed. Following 
this the participants will be offered 240 ml of one of the preload liquid meals and dose of 
oral paracetamol (1500 mg in 100 ml of water) and be asked to consume it within 5 
minutes. Further appetite questionnaires will be completed and blood samples will be 
obtained at 30, 60, and 90 minutes. Metabolic rate will be measured for the duration of 20 
minutes after each blood sampling. An ad libitum buffet breakfast will then be provided 
and the amount of food ingested will be recorded. Blood samples will be collected at 30, 
60, 90, 120 minutes post-breakfast and metabolic rate will be measured after each 
sampling.  Two hours post breakfast (3.5 hours post pre-load) the participants will be 
offered ad libitum buffet lunch and the amount of food ingested will be recorded by 
investigator. Participants will be asked to keep a diary of their dietary intake using 
weighed records for the rest of the day. Scales and diaries will be provided. 
 
Thus, participants will be required to participate in two experimental trials lasting for ~6 
hours. Prior their first trial they will be needed to come for anthropometric measurements, 
completion of health questionnaires and to obtain scales and food diaries (this will take 
~45 minutes) 
 
 
Tests will be conducted according to the ‗Code of Practice for Conducting Experiments 
on Non-patient Human Volunteers (including Handling and Disposal of Human Blood, 
Urine and Sputum), re-approved by the University Ethics Committee on October 26, 
2001 
 
4. How will potential participants in the study be (i) identified, (ii) approached and 
(iii) recruited?   
Give details for cases and controls separately if appropriate: 
 
Participants will be healthy adults with a body mass index <20 kg/m
2
. We will use 
―underweight‖ healthy adults to simulate relative under-nutrition and to allow a sampling 
regime and study design which would not be ethical in a paediatric patient group. 
Participants will be recruited by means of an advertisement leaflet and word of mouth in 
the campus of the University of Glasgow, and other public areas. Subjects who will be 
willing to participate will be screened by means of a detailed medical history to exclude 
chronic illness, eating disorders, and major gastrointestinal operations. All participants 
will provide written informed consent.  
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5. What are the ethical considerations involved in this proposal?  (You may wish for 
example to comment on issues to do with consent, confidentiality, risk to subjects, 
etc.) 
Blood sampling 
Venous cannulation incurs a minor risk of bruising.  There is also a risk of 
thrombophlebitis (inflammation of the vein) but this risk is small in non-smokers with no 
history of coagulation disorders.  Plastic or air embolism can occur if incorrect 
cannulation technique is employed but good practice minimizes this risk. Some 
individuals may feel faint when giving blood. 
 
 
6. Outline the reasons why the possible benefits, to be gained from the 
project, justify any risks or discomforts involved.  
 
The risks associated with participating in this study are very small.  Subjects 
will receive feedback on their habitual energy and macronutrient intakes and 
also on the impact of two supplements on energy intake during the rest of the 
day. Participants also will receive antropometric data so they will benefit from 
the study personally.  In addition, the findings of the study will help 
understanding to what extent do healthy, lean adults compensate for the energy 
consumed in an ultra high energy HENSD, and how does this relate to 
subjective measures of appetite and appetite hormones. 
 
 
7. Who are the investigators (including assistants) who will conduct the 
research?  What are their qualifications and experience? 
 
Dr Dalia Malkova, Dr K. Gerasimigis and Prof C. Wright have extensive 
experience in conducting in carrying out human  studies, without incident. Dr 
Malkova has ~12 years of experience in conducting human metabolic studies 
and has ~7 years experience in venepuncture and cannulation. Dr Gerasimidis 
has extensive experience in carrying out dietary assessment. A PhD sudent 
Sadia Fatima and Prof Wrigt are a medical practitioner. Sadia Fatima is PhD 
student, working under the supervision of Dr Malkova, C. Wright and K. 
Gerasimidis will be trained in all testing procedures involved. 
 
 
 
8. Are arrangements for the provision of clinical facilities to handle 
emergencies necessary?  If so, briefly describe the arrangements made. 
The risks associated with the procedures are extremely small.  Tests will be 
conducted according to the 'Code of Practice for Conducting Experiments in 
Non-Patient Human Volunteers (including Handling and Disposal of Human 
Blood, Urine and Sputum)', re-approved by the University Ethics Committee 
on October 26, 2001.  
 
 
9. In cases where subjects will be identified from information held by 
another party (for example, a doctor or hospital), describe how you intend 
to get this information.  Include, where appropriate, which Multi Centre 
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Research Ethics Committee or Local Research Ethics Committee will be 
applied to. 
 
 
N/A 
 
 
 
10. Specify whether subjects will include students or others in a dependent 
relationship. 
 
Some undergraduate or postgraduate students may be recruited but will not be 
placed under any pressure from staff to participate in the study. 
 
 
 
11. Specify whether the research will include children or people with 
mental illness, disability or handicap.  If so, please explain the necessity of 
involving these individuals as research subjects, and include 
documentation of the suitability of those researchers who will be in 
contact with children (eg Disclosure Scotland). 
 
N/A 
 
 
 
12. Will payment or any other incentive, such as a gift or free services, be 
made to any research subject?  If so, please specify and state the level of 
payment to be made and/or the source of the funds/gift/free service to be 
used. Please explain the justification for offering an incentive. 
 
No 
 
 
13. Please give details of how consent is to be obtained. A copy of the 
proposed consent form, along with a separate information sheet, written 
in simple, non-technical language MUST ACCOMPANY THIS 
PROPOSAL FORM. 
 
Subjects will be provided with a ‗Volunteer Information Sheet‘ to read and 
will be given a verbal explanation of the study and the opportunity to ask 
questions before providing written consent to participate in the study.  Subjects 
will also complete health history questionnaires at this time (formed attached).   
 
 
 
14. Comment on any cultural, social or gender-based characteristics of the 
subject, which have affected the design of the project or may affect its 
conduct. 
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Participants will be ―underweight‖ healthy adults with a body mass index <20 
kg/m
2
. The subjects will be aware that they have been invited to participate in 
this study on this basis. 
 
 
 
15.  Please state who will have access to the data and what measures will 
be adopted to maintain the confidentiality of the research subject and to 
comply with data protection requirements e.g. will the data be 
anonymised, how will it be stored, how will access be restricted, and for 
how long will it be retained? 
 
The information obtained will be anonymised and individual information will 
not be passed on to anyone outside the study group.  
 
 
16. Will the intended group of research subjects, to your knowledge, be 
involved in other research?  If so, please justify. 
 
Not during the duration of the study. 
 
 
 
17. Proposed starting date  
 June 2011 
      Expected completion date     
 June 2015 
 
 
 
18. Please state location(s) where the project will be carried out. 
 
Subject testing take place in the Metabolic Investigation Suite at human 
Nutrition Section, Yorkhill Hospitals  
 
 
 
19. Please state briefly any precautions being taken to protect the health 
and safety of researchers and others associated with the project (as 
distinct from the research subjects) e.g. where blood samples are being 
taken 
 
All samples will be handled according to the ‗Code of Practice for Conducting 
Experiments on Non-patient Human Volunteers (including Handling and 
Disposal of Human Blood, Urine and Sputum)‘. 
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20. Please state all relevant sources of funding or support for this study  
The student who is a graduate in medicine has a secured PhD scholarship from 
the University in Kyber, Pakistan which pays tuition fees and monthly stipend 
for 3 years, but no bench fees. 
 
 
 
 
 
 
 
 
 
 
 
 
21 a). Are there any conflicts of interest related to this project for any 
member of the research team? This includes, but is not restricted to, 
financial or commercial interests in the findings. If so, please explain these 
in detail and justify the role of the research team. For each member of the 
research team please complete a declaration of conflicts of interest below. 
 
 
There are no conflicts of interest 
 
 
 
 
 
 
 
Researcher: 
Name: _________________________________________conflict of interest 
Yes / No 
If yes, please detail below 
Researcher: 
Name: __________________________________________conflict of interest 
Yes / No 
If yes, please detail below 
Researcher: 
Name: __________________________________________conflict of interest 
Yes / No 
If yes, please detail below 
Researcher: 
Name: __________________________________________conflict of interest 
Yes / No 
If yes, please detail below 
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21 b). If there are any conflicts of interest, please describe these in detail 
and justify conducting the proposed study. 
 
 
N/A 
 
 
 
 
22. How do you intend to disseminate the findings of this research? 
 
We will use ―underweight‖ healthy adults to simulate relative undernutrition 
and to allow a sampling regime and study design which would not be ethical in 
a paediatric patient group. Therefore  
 
Findings will be disseminated as presentation in the Nutrition Society meeting 
and as pear reviewed paper. 
Findings will also be disseminated to clinitians and dieticians. 
 
 
 
I confirm that have read the University of Glasgow‟s Data Protection 
Policy  [http://www.gla.ac.uk/services/dpfoioffice/policiesandprocedures/dpa-
policy/]     
 
     Please initial box 
 
 
 
Signed _______________________________________    Date  
________________ 
(Proposer of research) 
 
 
For student projects 
 
I confirm that I have read and contributed to this submission and believe 
that the methods proposed and ethical issues discussed are appropriate. 
 
I confirm that the student will have the time and resources to complete 
this project.  
 
 
Signed _______________________________________    Date  
________________ 
(Supervisor of student) 
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1. Describe the purposes of the research proposed. Please include the background and 
scientific justification for the research. Why is this area of importance? 
 
High energy nutritional supplement drinks (HENSD) are widely promoted by the food industry 
and used in malnourished children and adults with a significant cost  to the UK National Health 
Service (£99 million pa) http://www.ic.nhs.uk/pubs/prescostanalysis 2007. These drinks aim to 
maximise energy/nutrient intake on top of the normal habitual intake of the patient and thus to 
prevent or correct disease associated under-nutrition and improve clinical outcome (Stratton and 
Elia 2010). However, evidence in relations to the benefits of HENSD remains unclear with some 
((Delmi, Rapin et al. 1990, Potter, Langhorne et al. 1998, Green 1999, Lauque, Arnaud-
Battandier et al. 2000) but not all (Poustie, Russell et al. 2006) studies  reporting that the use of 
HENSD is beneficial. 
 
In our previous study we found that in slim young females HENSD consumed 60 minutes before 
breakfast reduced hunger and increased satiety, and enhanced blood glucose, insulin and peptide 
YY (PYY) concentrations which all are known as appetite suppressors (Huda, Wilding et al. 
2006, Wren and Bloom 2007).  This increase in satiety and metabolites involved in appetite 
suppression led to compensation for energy consumed by HENSD. However the compensation 
was only partial: although energy intake during ad libitum  breakfast was significantly lower in 
the HENSD than the PLACEBO trial (HENSD, 1924 ± 168 kJ; PLACEBO, 2889 ± 230 kJ, 
P=0.001), when energy provided by supplements (HENSD, 2505kJ; PLACEBO, 432 kJ) was 
added to energy intake from breakfast and lunch, the energy intake  in the HENSD trial was 
significantly higher  (HENSD, 6576 ± 258 kJ; PLACEBO, 5541 ± 318 kJ, P=0.006). We also 
found that in HENSD trial energy provision remained higher even when corrected for the increase 
in post-prandial energy expenditure. Thus, in a well controlled study we demonstrated that in 
young, healthy, slim women consumption of HENSD in the morning does not induce full 
compensation for energy provided by this drink and concluded that supplementation with HENSD 
may be beneficial for the treatment of malnutrition. 
 
In clinical practice high energy supplements are usually provided in the evening rather than prior 
to breakfast and prescribed for several days or weeks. Therefore, from a practical point of view, it 
is important to find whether enhancement in daily energy intake can also be achieved when 
HENSD is consumed on a day by day basis and when intake of supplement takes place in the 
evening.  In addition, further investigation is needed on the mechanisms involved in the 
amendments of energy intake regulation following HENSD. Therefore the proposed study will 
aim to: 
 
 Investigate the effect of HENSD given in the evening for a period of 5 consecutive days 
on compensation for energy consumed in underweight young females 
 Investigate impact of HENSD supplement consumed in the evening for a period of 5 
consecutive days on subjective appetite measures and appetite regulating blood 
metabolites such as peptide YY, cholecystokinin, pancreatic polypeptide, insulin and 
glucose measured in the fasted state and after ad libitum breakfast, lunch and dinner.   
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2. Describe the design of the study and methods to be used.  Include sample size and the 
calculation used to determine this.  Statistical advice should be obtained if in doubt. 
This study is a single blind randomized controlled, crossover study, in which participants will act 
as their own controls. The participants will conduct two main experimental trials, HENSD and 
Placebo. Study design is presented in figure 1. These trials will be conducted in counter balanced 
order (participants will receive drinks in different order) and be separated by at least 7 days of 
wash out period during which the impact of supplements on the measurements conducted in this 
study should disappear. During five days leading up to the main experimental trial, participants 
in the evening will come to the metabolic room and consume either HENSD (Scandishake, 
Chocolate, Nutricia) prepared with full fat milk, according to the manufacturer instructions or 
Placebo (a low calorie drink made up with skimmed milk, cocoa and sweeteners and having the 
same colour, volume, flavour and texture as HENSD). On the day of the experimental trial the 
rate of energy expenditure (kcal/min) and appetite will be measured, and blood samples will be 
taken in the fasted state and at 30, 60, 90 and120 minutes after ad libitum breakfast and ad 
libitum lunch. A total of 90 ml of blood will be taken over the course of the day. Lunch will be 
provided three hours and dinner seven hours after the breakfast.  Some fruits or snacks will be 
available in case participants feel hungry before dinner. The amount of food provided and 
consumed during the breakfast, lunch, snack and dinner will be recorded. For four days prior to 
the experimental trials, participants will record food and drink intake and their physical activity. 
Power calculation: Power calculations are based on standard deviation (STDEV) for the 
difference in energy intake during breakfast and lunch between placebo and HENSD trials, the 
main outcome of our other study. We found that at 85 % power, considering STDEV of 278 kcal 
for energy intake difference, 22 subjects will allow us to detect a difference in energy intake of 
195 kcal between two trials.  This number of participants should be sufficient to detect 
differences in other imperative outcomes of the study.  
Methods 
Anthropometry 
Body height will be measured with height measuring scale (portable stadiometer) (Seca, 
Leicester, UK). Body weight and fat mass will be measured to the nearest 0.01 kg using a 
bioelectrical impedance scale (TBF-300, TANITA, Cranlea, UK). Bioelectrical impedance 
measures the resistance (impedance) to the electrical signals when they travel through water 
which is found in muscle and fat. The greater the amount of water in a person's body, the easier it 
is for the current to pass through it. The more fat, the more resistance to the current as fat has less 
water content. This method is safe and it does not hurt.  
Energy intake 
The energy consumed during the days prior to experimental trial and during ad libitum meals 
will be calculated using dietary analysis software (Windiets 2005, The Robert Gordon 
University, Aberdeen, Scotland, UK).  
Appetite measurements 
Appetite sensations will be measured with validated appetite questionnaires (Flint, Raben et al. 
2000). Participants will be asked to rate measures of appetite on Visual Analogue Scale (VAS) 
questionnaires with a line of 100 mm.  Volunteers will be asked to express their feeling of 
hunger, satiety, fullness, prospective food consumption and desire to eat by placing a vertical 
mark on the horizontal 100 mm line at a point which corresponds to their feelings at that time. 
The lines are anchored by negative respective feeling words (I am not hungry at all) on the left 
and by positive feeling words (never being hungrier) on the right. Quantification of the 
measurement is made by measuring distance from the left end of the line to the participant‘s 
mark. 
Rate of Energy expenditure and food induced thermogenesis. For measurement of rate of energy 
expenditure (EE) a ventilated hood system (Oxycon Pro, Jaeger GmbH, Hoechberg, Germany) 
will be used. A ventilated hood will be placed over the volunteer‘s head to allow collection of 
expired gas needed for measurements of oxygen consumption and carbon dioxide production. 
The rate of oxygen consumption (VO2) and rate of carbon dioxide production (VCO2) will be 
recorded every minute for the duration of 20 minutes. The mean values of VO2 and VCO2 will be 
corrected for the drift by taking the mean of pre-drift and post-drift values. The corrected values 
will be used to calculate respiratory exchange ratio and rate of energy expenditure by using 
indirect calorimetry equations (Frayn and Macdonald 1997).  
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Appetite hormones. Venous blood samples will be collected in 9 ml vacutainers 
containing EDTA and then appropriately treated with chemicals prior to preparation 
of plasma. Enzyme-linked immunosorbent assay (ELISA) kits will be used to 
determine Peptide YY (Merck, Millipore, Bioscience Division, UK), Cholecystokinin 
(Phoenix Pharmaceuticals, INC Burlingame, CA, USA), Pancreatic polypeptide 
(Millipore, Missouri, USA), and insulin (Mercodia AB, Uppsala, Sweden)      
Plasma glucose. Plasma glucose will be analysed using commercial assay kit (Life 
Sciences, Cambridge, UK) and automated Cobas Mira biochemical analyser. 
Statistical analysis. The total areas under the curve (AUC) for appetite measures and 
appetite biomarkers will be used as summary measures of the post-breakfast, post-
lunch and post-dinner responses. The difference in AUCs and energy intake between 
trials will be compared by paired t-test.  Two-way repeated measure ANOVA (trial x 
time) followed by Post hoc Tukey‘s test will also be used to compare differences 
between two trials. 
 
 
 
 
Figure 1. Schematic representation of experimental trial 
   Blood samples, appetite questionnaires, metabolic rate measurement 
  
   Ad libitum buffet meal (Breakfast, lunch and dinner)                  
  
   Supplement (Placebo or HENSD) intake in the evening 
 
 
 
 
   D   
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3. Describe the research procedures as they affect the research subject and any other parties 
involved. 
It should be clear exactly what will happen to the research participant, how many times and 
in what order 
 
During the five days leading to the experimental trial, the participants will be asked to consume 
either HENSD or Placebo drinks. The consumption of drinks will take place in the evening, after 
the very last meal and in the presence of the researcher. The order in which the drinks will be 
consumed will be random with the participant being blinded in relation to the drink offered. For 
four days prior to the experimental trials, participants will record food and drink intake and their 
physical activity. 
On each experimental day the participant will be requested to come to the metabolic investigation 
suite at Yorkhill Hospital at ~ 08:30am. Approximately 10 minutes will be given to the 
participant to rest and acclimatize with the environment. Then anthropometric measurements, 
body composition and rate of energy expenditure will be measured. After that a cannula will be 
inserted into an antecubital vein, and a baseline blood sample will be collected and appetite 
questionnaires will be completed. Breakfast will be served and following breakfast appetite 
questionnaires will be completed and blood samples obtained at 30, 60, 90 and 120 minutes. After 
each blood sample the rate of EE for the duration of 20 minutes will be measured. Ad libitum 
buffet lunch and dinner will be provided 3  and  7 hours after breakfast, respectively. After lunch 
appetite will be evaluated, blood obtained and metabolic rate measured in the same manner as 
after breakfast.  Snacks or fruit will be available between lunch and dinner.The amount of food 
ingested during breakfast lunch, snack and dinner will be recorded by the researcher. The 
experimental trial will last for ~12 hours. Before the first experimental trial the participants will 
come to the metabolic suit for anthropometric measurements, completion of health questionnaires. 
During this visit they will be provided with the food intake diaries and scales for recording their 
dietary intake. This visit will take 45-50min. 
 
Tests will be conducted according to the ‗Code of Practice for Conducting Experiments on Non-
patient Human Volunteers including Handling and Disposal of Human Blood, Urine and Sputum 
(www.legislation.gov.uk/ukpga/2004/30/contents), which has been re-approved by the University 
Ethics Committee on October 26, 2001. 
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4. How will potential participants in the study be (i) identified, (ii) approached and (iii) 
recruited?   
Give details for cases and controls separately if appropriate: 
 
Participants of the study will be healthy women with the body mass index of 17- 20 kg/m
2
.The 
recruitment will be done by word of mouth; volunteers will be approached by PhD student Dr 
Sadia Fatima at the University library, canteen and University gym and asked if they would be 
interested to take part in human nutrition related research. If the answer is ‗yes‘ then the volunteer 
information sheet will be given. Those willing to participate in the study will be screened by using 
health questionnaire to exclude any chronic illnesses, gastrointestinal problems or surgery or 
some eating disorders. Screening will be done by PhD student Dr Sadia Fatima. Written informed 
consent will be taken from the participants by Dr Sadia Fatima and Dr Dalia Malkova. 
 
 
5. What are the ethical considerations involved in this proposal?  (You may wish for 
example to comment on issues to do with consent, confidentiality, risk to subjects, etc.) 
 
Blood sampling 
There is a chance of minor bruising with venous cannulation. There is also a rare risk of 
thrombophelabitis which is very rare in non-smokers, and in healthy people with no coagulation 
disorders. With incorrect cannulation plastic or air embolism may occur but good technique 
minimizes the risks. Some people may faint while giving blood samples. Dr Sadia is a qualified 
medical doctor and she will be with the participants during the whole day of the experimental 
trial, and she will provide basic emergency care to the participants if required.  
The information obtained from the participants and the data obtained after the analysis of the 
samples will be linked anonymised and individual information will not be passed on to anyone 
outside the researchers listed in the study. The data will be kept securely on papers and on 
appropriate electronic format with researchers of the study.  
 
 
 
6. Outline the reasons why the possible benefits, to be gained from the project, 
justify any risks or discomforts involved. 
 
The participants will benefit personally by receiving feedback on their dietary intake 
and their daily micronutrient and macronutrient consumption. They will also know 
their anthropometric measurement and receive information regarding their body 
composition i.e. fat mass, %fat in the body, BMI etc. This study also helps the 
participants to know about their resting metabolic rate and daily basal metabolic 
needs. Furthermore this study will help us to understand the impact of supplements on 
appetite and appetite markers when the supplements are given for a longer duration of 
time.  
 
 
7. Who are the investigators (including assistants) who will conduct the 
research?  What are their qualifications and experience? 
 
Dr Dalia Malkova, Dr K. Gerasimidis and Prof C. Wright have extensive experience 
in conducting human studies. Dr Malkova has ~16 years of experience in conducting 
human metabolic studies and has ~8 years experience in venepuncture and 
cannulation. Dr Gerasimidis has extensive experience in carrying out dietary 
assessment. Dr Sadia Fatima PhD student and Prof Wright are medical practitioners. 
Dr Sadia Fatima is a PhD student, working under the supervision of Dr Malkova, C. 
Wright and K. Gerasimidis. She has recently completed her first study and is trained 
in all procedures. 
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8. Are arrangements for the provision of clinical facilities to handle emergencies 
necessary?  If so, briefly describe the arrangements made. 
 
The risks associated with the procedures are extremely small.  Tests will be conducted 
according to the 'Code of Practice for Conducting Experiments in Non-Patient Human 
Volunteers including Handling and Disposal of Human Blood, Urine and Sputum to 
the Human Tissue Act 2004 (Commencement No1) order 2005 
(www.legislation.gov.uk/ukpga/2004/30/contents) 
 re-approved by the University Ethics Committee on October 26, 2001 
 
 
9. In cases where subjects will be identified from information held by another 
party (for example, a doctor or hospital), describe how you intend to get this 
information.  Include, where appropriate, which Multi Centre Research Ethics 
Committee or Local Research Ethics Committee will be applied to. 
 
 N/A 
 
 
 
10. Specify whether subjects will include students or others in a dependent 
relationship and where possible avoid recruiting students who might feel to be or 
be construed to be under an obligation to volunteer for a project. This is most 
likely to be where a student is enrolled on a course where the investigator is a 
teacher. In these circumstances the recruitment could be carried out by one of 
the other investigators or a suitably qualified third party. 
 
 Some post graduate and undergraduate students will be recruited from the University 
of Glasgow for the study but they will not be on courses taught by the applicants.  
 
 
11. Specify whether the research will include children or people with mental 
illness, disability or handicap.  If so, please explain the necessity of involving 
these individuals as research subjects, and include documentation of the 
suitability of those researchers who will be in contact with children (eg 
Disclosure Scotland). 
 
N/A 
 
 
 
12. Will payment or any other incentive, such as a gift or free services, be made 
to any research subject?  If so, please specify and state the level of payment to be 
made and/or the source of the funds/gift/free service to be used. Please explain 
the justification for offering an incentive. 
 
£40 will be given to the participants for partial compensation of their time and 
travelling expenses.  
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13. Please give details of how consent is to be obtained. A copy of the proposed 
consent form, along with a separate information sheet, written in simple, non-
technical language MUST ACCOMPANY THIS PROPOSAL FORM. 
Volunteer Information Sheet will be given to the subjects to read.   Verbal explanation 
of the study will also be given by Dr Sadia Fatima and Dr Dalia Malkova. The 
participants will be provided with the opportunity to ask questions about the study 
before giving written consent. Participants will be asked to complete health history 
questionnaire to exclude those with any chronic illnesses, gastrointestinal problems or 
surgery or some eating disorders. The health questionnaire form is attached.   
 
 
 
14. Comment on any cultural, social or gender-based characteristics of the 
subject, which have affected the design of the project or may affect its conduct. 
 
 
Participants will be slim healthy women with a body mass index 17-20 kg/m
2
. The 
subjects will be aware that they have been invited to participate in this study on this 
basis. 
 
 
15.  Please state who will have access to the data and what measures will be 
adopted to maintain the confidentiality of the research subject and to comply 
with data protection requirements e.g. will the data be anonymised, how will it 
be stored, how will access be restricted, and for how long will it be retained? 
 
The information obtained from the participants will be linked anonymised and 
individual information will not be passed on to anyone outside the researchers listed 
in the study i.e. Dr Dalia Malkova, Dr Konstantinos Gerasimidis, Professor Charlotte 
Wright
 
and Dr Sadia Fatima. The data will be coded by PhD student Dr Sadia Fatima. 
Each volunteer will be assigned a research code. The record matching the volunteer 
details with the code will be kept confidential with Dr Sadia Fatima. Linked 
anonymous data will be analyzed and stored in the form of an excel sheet in secure 
network of University of Glasgow which is virtual private network (VPN) set up by 
Glasgow University IT services and is accessible to Dr Sadia Fatima only. The data 
will be kept securely on papers in locked cabinets and on appropriate electronic 
format with Dr Sadia Fatima. The data will be securely held for the duration of ten 
years after the completion of research and will be disposed off thereafter as per 
University policy. 
 
 
 
16. Will the intended group of research subjects, to your knowledge, be involved 
in other research?  If so, please justify. 
 
 
Not during the duration of the study. 
 
 
 
17. Proposed starting date 
   
           November 2012 
 
      Expected completion date 
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              June 2014 
    
 
 
 
18. Please state location(s) where the project will be carried out. 
 
Experimental trials shall be carried out in the Metabolic Investigation Suite at Human 
Nutrition Section, Yorkhill Hospital.  
 
 
 
 
 
19. Please state briefly any precautions being taken to protect the health and 
safety of researchers and others associated with the project (as distinct from the 
research subjects) e.g. where blood samples are being taken 
 
All samples will be handled according to the Human Tissue Act 2004 
(Commencement No1) order 2005 (www.legislation.gov.uk/ukpga/2004/30/contents) 
 
 
20. Please state all relevant sources of funding or support for this study  
 
Dr Sadia Fatima has a secured PhD scholarship from the Khyber Medical University, 
Pakistan which pays tuition fees and monthly stipend for 3 years, and a small research 
bursary. 
 
 
 
21 a). Are there any conflicts of interest related to this project for any member of 
the research team? This includes, but is not restricted to, financial or commercial 
interests in the findings. If so, please explain these in detail and justify the role of 
the research team. For each member of the research team please complete a 
declaration of conflicts of interest below. 
 
 
There are no conflicts of interest 
 
Researcher: 
Name: _________________________________________conflict of interest Yes / No 
If yes, please detail below 
Researcher: 
Name: __________________________________________conflict of interest Yes / 
No 
If yes, please detail below 
Researcher: 
Name: __________________________________________conflict of interest Yes / 
No 
If yes, please detail below 
Researcher: 
Name: __________________________________________conflict of interest Yes / 
No 
If yes, please detail below 
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21 b). If there are any conflicts of interest, please describe these in detail and 
justify conducting the proposed study. 
 
 
N/A 
 
 
 
22. How do you intend to disseminate the findings of this research? 
 
The results of the study shall be disseminated through presentation to the clinical 
colleagues and dieticians through research symposium, and workshops.Findings will 
also be disseminated as presentation in the Nutrition Society meeting and as peer 
reviewed paper. 
 
 
I confirm that have read the University of Glasgow‟s Data Protection Policy  
[http://www.gla.ac.uk/services/dpfoioffice/policiesandprocedures/dpa-policy/]     
 
     Please initial box 
 
 
 
Signed _______________________________________    Date  ________________ 
(Proposer of research) 
 
 
 
For student projects 
 
I confirm that I have read and contributed to this submission and believe that 
the methods proposed and ethical issues discussed are appropriate. 
 
I confirm that the student will have the time and resources to complete this 
project.  
 
 
Signed _______________________________________    Date  ________________ 
(Supervisor of student) 
 
 
 
 
Send completed signed form to 
 
Stuart Morrison 
Room 330, Wolfson Medical School Building 
University Avenue  
Glasgow  
G12 8QQ 
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Tel: 0141 330 5519 
Fax: 0141 330 4758  
 
 
Please also send electronic versions of completed form and all other paperwork to  
Stuart.Morrison@glasgow.ac.uk  
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College of Medical, Veterinary & Life Sciences Ethics Committee for Non 
Clinical Research Involving Human Subjects  
 
 
APPLICATION FORM FOR ETHICAL APPROVAL 
 
 
NOTES: 
 
THIS APPLICATION FORM SHOULD BE TYPED NOT HAND WRITTEN. 
 
ALL QUESTIONS MUST BE ANSWERED.  
“NOT APPLICABLE” IS A SATISFACTORY ANSWER WHERE 
APPROPRIATE. 
 
 
PROJECT CODE: 
 
 
 
Project Title  
Comparison of the effectiveness of solid ready-to-eat and a liquid ready-to-drink 
supplements for management of mild to moderate malnutrition in children from 
Pakistan 
 
 
Has this application had been submitted previously to this or any other ethics 
committee?   
 
      No 
 
 If Yes, please state the title and reference number. 
 
 
Is this project from a commercial source, or funded by a research grant of any 
kind?  
       
          No 
 
If yes,  
 
a) Has it been referred to Research & Enterprise?   
 
    Has it been allocated a project Number?    
 
             No 
b) Give details and ensure that this is stated on the Informed Consent form. 
 
Insurance Restrictions. 
 
The University insurance cover is restricted in certain, specific circumstances, 
e.g. the use of hazardous materials, work overseas and numbers of participants 
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in excess of 5000. All such projects must be referred to Research and Enterprise 
before ethical approval is sought. 
 
 
Date of submission  
03.04.2013 
 
Name of all person(s) submitting research proposal  
Dr Sadia Fatima
1
, Dr Dalia Malkova
2
, Dr Konstantinos Gerasimidis
3
, and Professor 
Charlotte Wright
4, 
 
 
 
Position(s) held 
 
1
Dr Sadia Fatima, PhD student 
2 
Dr Dalia
 
Malkova, Senior Lecturer,  
3
Dr Konstantinos Gerasimidis, Lecturer 
4 
Prof Charlotte Wright, Professor 
 
Department/Group/Institute/Centre 
  
1, 2, 3
Human Nutrition Section, School of Medicine, MVLS   
4
Clinical Specialities, PEACH Unit School of Medicine, MVLS  
 
Address for correspondence relating to this submission 
 
Dr Dalia Malkova 
School of Medicine, MVLS 
University of Glasgow 
Royal Hospital for Sick Children 
Glasgow, G3 8SJ  
 
 
Email address: Dalia.Malkova@.glagow.ac.uk 
 
 
Name of Principal Researcher (if different from above e.g., Student‘s Supervisor)  
 
Position held  
 
Undergraduate student project   No 
 
Postgraduate student project               Yes 
 
PhD degree being undertaken 
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1. Describe the purposes of the research proposed. Please include the background 
and scientific justification for the research. Why is this an area of importance? 
Malnutrition is a condition in which nutrients such as proteins, vitamins,  minerals and energy are 
deficient or in excess (imbalance) which causes severe measureable adverse effects on body 
composition, function and clinical outcomes (Meier and Stratton 2008, Nieuwenhuizen, Weenen 
et al. 2010). The World Health Organization cites malnutrition as the single greatest threat to the 
world‘s public health (Nieuwenhuizen, Weenen et al. 2010). Childhood malnutrition is associated 
with a number of socio-economic and environmental factors such as poverty leading to 
inadequate food intake, lack of access to food, poor hygienic practices, lack of sanitation, poor 
health, recurrent infections and large family size (Golden 2009, Babar, Muzaffar et al. 2010). Not 
surprisingly in low income countries 112 million (20%) out of 556 million children under 5 years 
of age are underweight and 36 million (6.4%) are suffering from moderate wasting (Golden 2009, 
Michaelsen, Hoppe et al. 2009).  
 
Pakistan is the world‘s seventh most populous country and 45% of its population is under 15 
years of age. Evidence suggests that malnutrition in children between 5-12 years is high in 
Pakistan and is a very serious impediment to the development of the nation (Mian, Ali et al. 2002, 
Pappas, Agha et al. 2008). In Pakistan 23.9% of  the population lives below the poverty line and 
38% of all children under 5 years of age are underweight (Pappas, Agha et al. 2008, Akram, Arif 
et al. 2010). 
 Malnutrition is identified using standard deviation scores (Z-scores), which is a statistical 
measure identifying how body weight and height compares to reference values. The World Health 
Organization (WHO) Global Database on Child Growth and Malnutrition uses a Z-score cut off 
point of <-2SD to classify undernutrion and a cutoff of >+2 SD to classify overweight in children 
(Wang and Chen 2012). Mildly underweight children (between  -1 and -2 Z score have 
approximately a twofold higher risk of death as compared to well nourished children (Fishman, 
CAULFiELD et al. 2004).  
 
According to the WHO recommendations for the treatment of malnutrition during the nutritional 
rehabilitation phase the children should receive an energy and protein dense diet fortified with 
vitamins and minerals to promote rapid weight gain. This phase of rehabilitation requires 3-4 
weeks and is usually carried out in hospital or residential therapeutic centres and the mother has 
to stay with the child (Diop, Dossou et al. 2003). This has some limitations as there are more 
chances of cross-infections and secondly it is unfavourable for other family members (Collins 
2001). Therefore, community based rehabilitation is suggested as an alternative (Ashworth and 
Khanum 1997). For this purpose, a solid ready to use food (RTUF) has been developed which is 
made up of peanut butter (Diop, Dossou et al. 2003). These RTUF can be eaten directly by the 
child without the addition of water or milk which reduces risk of bacterial contamination (Diop, 
Dossou et al. 2003). 
 
Studies have showed that RTUFs are very effective in the treatment of severe malnutrition in 
children (Briend, Lacsala et al. 1999, Collins and Sadler 2002, Dossou, Ndour et al. 2003, 
Brewster 2006). The randomized controlled trial conducted on 60 severely malnourished 
Senegalese children in a therapeutic feeding centre demonstrated that increase in energy intake 
and weight gain achieved by supplementation with RTUF was higher in comparison to changes 
induced by consumption of a traditional high-energy drink based on milk. There is no evidence 
comparing the impact of RTUF and liquid supplements on weight gain in mild to moderate 
malnourished children. 
Therefore the proposed study will aim : 
 To compare the efficacy of solid ready to eat and liquid ready to drink supplements in 
promoting weight gain in mild to moderate malnourished children.  
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2. Describe the design of the study and methods to be used. Include sample size and the 
calculation used to determine this. Statistical advice should be obtained if in doubt. 
This study will be open label randomized controlled trial. This study will be conducted in the 
primary schools of the district of Abbottabad located in the Hazara region of Khyber 
Pakhtunkhwa province in Pakistan. The purpose of the study will be explained to the principals 
and parent/carer in local language and informed consent will be obtained after clarification that 
their refusal will have no effect on how the child is treated in the school by the teachers and 
support staff. Then primary school children between the ages of 5-10 years will be randomly 
selected and then height and weight measurements will be done. These anthropometric 
measurements will be used to calculate Z-scores using WHO standards. Children with mild to 
moderate malnutrition (between -2 and -1 Z-score) will be selected for the study. After that the 
children will be randomly allocated by computerized randomization to receive either solid ready 
to use food (Plumpy‘ Nut) or liquid ready to use supplement (Fortini, Nutricia). The children will 
be provided with these supplements in their school for four weeks and will be asked to consume 
the supplements in addition to their habitual diet. The supplements will be delivered by the main 
researcher Dr Sadia Fatima daily. The children will be asked to keep the empty bottles/sachet of 
the supplements with them after drinking/eating, which will be collected by the main researcher 
next day in order to check the compliance. Any leftover in the bottle or sachet will be recorded.  
Height, weight, biceps and triceps skinfolds and mid-upper-arm circumference of the child will be 
measured before the supplementation (baseline), two weeks after initiation of the supplementation 
and at the end of the supplementation. The child will mark an appetite questionnaire before the 
provision of the first and the last supplement. Furthermore the parent/carer will be requested to 
attend a focus group regarding the appetite of their child once before the start of supplementation 
and once at the end of the study. The parents/carer of the children will be asked to continue 
regular normal habitual diet of their children during the days of supplementation as the 
supplements are not replacement to food. At the end of the study the children who were screened 
and did not meet the criteria for recruitment will be measured for height and weight. 
Statistical Analysis: Power calculations are based on data available from previous study (Diop, 
Dossou et al. 2003). We used standard deviation (STDEV) for the difference in weight gain 
between solid ready to eat supplement and liquid ready to drink supplement groups, the main 
outcome of this study. We found that at 80 % power, considering STDEV of 0.7, 32 subjects in 
each group will allow us to detect a mean difference of 0.5kg between two groups. This number 
of participants should be sufficient to detect differences in other imperative outcomes of the 
study. 
Prior data analysis Anderson-Darling test will be used to determine the normality of the data. 
Depending upon the distribution of the data, parametric or nonparametric analysis will be applied 
to the data. The difference between the body weight and appetite measures at the baseline 
between two groups will be determined using unpaired t test (for parametric data) and Mann-
Whitney (for non-parametric data). The difference in the weight gain and appetite changes  
between solid ready to eat and liquid ready to drink supplement will be assessed using two way 
analysis of variance ANOVA (for parametric data) or Kruskal–Wallis (for non-parametric data). 
The data will be analysed using Minitab (version 15.1; Minitab, State College, PA, USA).  P-
value of  ≤0.05 will be considered as significant 
Methods 
Height Measurement 
Height will be measured with a portable stadiometer (Seca, Leicester, UK) using a stretch stature 
method. The stature is the maximum distance from the ground to the uppermost point of the skull 
when the position of the head is held in Frankfort plane position. The measurement will be 
performed to the nearest 0.01m. The same height scale will be used throughout the study and the 
same researcher will perform all the measurements. 
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Weight Measurement 
The weight of the children will be measured wearing light weight clothes without 
shoes. Prior to the measurements extraneous clothing will be removed. The children 
will stand with both feet placed flat on the balance and arms positioned laterally along 
the side of the body. The measurements will be performed to the nearest 0.01kg. 
Skinfold Measurement 
Triceps and biceps skinfolds will be measured using the Harpenden skinfold calliper 
(Baty, International) to the nearest 0.2mm. For measuring triceps skinfolds the child 
will be asked to bend the left arm at 90
0
 at the elbow and place the forearm across the 
body. Then acromion process at the outer-most edge of the shoulder and tip of 
olecranon process of the ulna will be located and the distance between the two will be 
measured with the help of the measuring tape. Then the mid-point in line with the 
elbow and acromion process will be marked. After that the child‘s arm will be 
extended so that it is hanging loosely by the side. Using the thumb and forefinger a 
vertical fold of skin and underlying fat 1cm above the marked mid-point will be 
grasped. Afterwards the skinfold will be gently pulled away from the underlying 
muscle and calliper jaws will be applied at right angles exactly at the marked mid-
point. While taking the measurements the skinfold will be held in the fingers. Two 
measurements will be taken and the mean of both will be considered for the accuracy 
of results. 
 For measuring biceps skinfolds at the level of the mid-point between the acromion 
process (bony tip of shoulder) and the proximal and lateral border of  the radius bone 
(approximately the elbow joint), on the mid-line of the anterior surface of the arm 
(over the biceps muscle) will be marked. Then the child will be asked to relax his/her 
arm with the palm of the hand facing forwards. Then using thumb and forefinger a 
vertical fold of skin will be grasped at the land mark, and calliper jaws will be 
applied. Again two measurements will be taken and the mean of both will be used  
Mid upper arm circumference 
Mid upper arm circumference will be measured with a flexible measuring tape on the 
left upper arm while the arm is relaxed and hanging down the side of the body. 
Appetite measurements 
Appetite sensations will be measured with validated appetite questionnaires (Flint, 
Raben et al. 2000). Participants will be asked to rate measures of appetite on Visual 
Analogue Scale (VAS) questionnaires with a line of 100 mm.  Children will be asked 
to express their feeling of hunger, satiety, fullness, prospective food consumption and 
desire to eat by placing a vertical mark on the horizontal 100 mm line at a point which 
corresponds to their feelings at that time. The lines are anchored by negative 
respective feeling words (I am not hungry at all) on the left and by positive feeling 
words (never being hungrier) on the right. Quantification of the measurement is made 
by measuring the distance from the left end of the line to the participant‘s mark. 
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3. Describe the research procedures as they affect the research subject and any other parties 
involved. It should be clear exactly (i) what will happen to the research participant, (ii) how 
many times and (iii) in what order. 
 
 The study participants will be provided with either solid ready to eat food (Plumpy‘ Nut) or 
liquid ready to drink (Fortini, Nutricia) supplements and asked to consume these supplements 
daily for four weeks. Supplements will be provided by the main researcher Dr Sadia Fatima and 
consumed at school. The energy content of both the supplements will be same (500kcal/day). 
Height, weight, mid-upper-arm circumference and biceps and triceps skinfolds will be measured 
before the start of supplementation, two weeks after initiation and at the end of supplementation. 
These measurements will be conducted by the main researcher and will take place at the child‘s 
school. The child will mark an appetite questionnaire before the provision of the first and last 
supplement. The parent/carer will be asked to attend a focus group regarding their child‘s appetite 
once before start of supplementation and once at the end of supplementation. It will take only 15-
20 minutes of the child and parent/carer to answer the questions. 
This study  will be conducted according to the ‗Code of Practice for Conducting Experiments on 
Non-patient Human Volunteers including Handling and Disposal of Human Blood, Urine and 
Sputum (www.legislation.gov.uk/ukpga/2004/30/contents), which has been re-approved by the 
University Ethics Committee on October 26, 2001 
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4. How will potential participants in the study be (i) identified, (ii) approached and (iii) 
recruited? Give details for cases and controls separately if appropriate. 
 
This study will be conducted in the primary schools of the district of Abbottabad located in the 
Hazara region of Khyber Pakhtunkhwa province in Pakistan. The participants of this study will be 
primary school children between the ages of 5-10 years with mild to moderate malnutrition. The 
recruitment will be done by the main researcher Dr Sadia Fatima in accordance with the 
principals of the primary schools in the vicinity of Abbottabad. The study protocols will be 
explained in detail to the principals of the schools and written permission will be taken from them 
to conduct the study in their schools. Then the parent/carer of all the children will be approached 
by the main researcher Dr Sadia Fatima. The purpose of the study will be explained to the 
parent/carer of the children in the local language. The eligible children will be screened by using 
health questionnaires to exclude any chronic illnesses, gastrointestinal problems or surgery or 
some allergy or eating disorders. Screening will be done by the main researcher Dr Sadia Fatima.  
Children less than 8 years of age will be given a pictorial form of the recruitment procedure along 
with the consent or assent form. Parent/carer will be requested to give consent in the case of 
participants who are unable to give consent on their own behalf. A Volunteer information sheets 
for the participants will be given along with a written informed consent in an easy to understand 
language (it will be translated to the local language Urdu) to parent/carer and to the participants. 
An explanation will be given to the participants and the parent/carer about all aspects of the 
research study by the researcher at the same time. The illiterate parents/carers will be asked to 
take the information sheet and request their educated relatives to read it for them so that they can 
understand the study. While the parents/carer who does not consent to take part or withdraw at 
any time will be provided with some dietary counselling and their children will not be included in 
the study. Then written informed consent will be obtained from the participants and their 
parent/carer by Dr Sadia Fatima after clarification that their refusal to participate will have no 
effect on how the child is treated in the school by the teachers and support staff. 
After taking permission, the children will be randomly selected from the school and then their 
height and weight will be measurement to identify mild to moderate malnourished children. 
Standard deviation scores (Z-score) for anthropometric measurements will be calculated based on 
international growth reference data (Cole 1990, H Pan 2012).   
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5. What are the ethical considerations involved in this proposal? You may wish, for example, 
to comment on issues to do with consent, confidentiality, risk to subjects, etc. 
 
The purpose of the study will be explained to the parent/carer and children in local language and 
informed consent will be obtained before taking any measurement from the children. Those 
participants who do not meet the anthropometric criteria for inclusion will be encouraged to 
continue healthy diet and their height and weight will be measured again after 28 days. While 
those parents/carers who do not consent to take part or withdraw at any time will be provided with 
some dietary counselling and their children will not be included in the study.  
A high energy diet given for a prolonged period of time could potentially lead to obesity (Golden 
2009). We will provide these supplements with energy content of 500kcal/day for 28 days which 
may result in an approximate maximum weight gain of 1.8 kg. Thus a moderately malnourished 
child (-2 Z-score) is expected to improve towards the lower limit of normal and upper limit of 
mild malnutrition (-1 Z-score) and mildly malnourished children (-1Z-score) becomes normal (0Z-
score). Therefore there will be no chance to induce obesity by using these supplements for 28 
days. 
There might be a risk of allergic reaction from the peanut butter used in the preparation of solid 
ready to use food. Peanut butter contains patent allergens , and these allergens may be enhanced 
during cooking (Maleki, Chung et al. 2000). An allergic reaction will be rare as peanuts are part of 
the traditional diet. Furthermore the eligible children will also be screened for food allergies with 
the help of the Health questionnaire. Moreover clinical allergy is rare in developing countries 
(Abbassy, El-Din et al. 1974) and food allergy manifests in infancy and declines after three years 
of age (Husain and Schwartz 2013). 
The information obtained from the participants will be linked anonymised and individual 
information will not be passed on to anyone outside the researchers listed in the study. The data 
will be kept securely in appropriate electronic format with researchers of the study.  
 
 
 
6. Outline the reasons why the possible benefits to be gained from the project 
justify any risks or discomforts involved. 
 
The children participating in this study may benefit directly by receiving supplements 
which may improve their nutritional status. The parent/carer will find out about their 
child‘s anthropometric measurements and receive information regarding the child‘s 
nutritional status before and after supplementation. As dietary counselling is a 
fundamental and effective part in the treatment of mild to moderate malnutrition 
(Ashworth and Ferguson 2009), the parent/carer will obtain some counselling on the 
completion of the study. 
  
Furthermore this study will help us to understand and compare the efficacy of solid 
ready to eat with liquid milk based supplements in promoting weight gain in mild to 
moderate malnourished children in community settings and the impact of these rich 
energy and nutrient supplements on appetite. 
 
 
 
7. Who are the investigators (including assistants) who will conduct the 
research? What are their qualifications and experience? 
 
Dr Dalia Malkova, Dr K. Gerasimidis and Prof C. Wright have extensive experience 
in conducting human research, including research studies in children. Dr Sadia Fatima 
(PhD student) and Prof Wright are medical practitioners. Dr Sadia Fatima is a PhD 
student, working under the supervision of Dr Malkova, Prof C. Wright and Dr K. 
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Gerasimidis. She has already completed her first two studies and therefore has 
extensive experience in all relevant methods and procedures. 
 
 
 
8. Are arrangements for the provision of clinical facilities to handle emergencies 
necessary? If so, briefly describe the arrangements made. 
 
The risks associated with this study are extremely small. The study will be conducted 
according to the 'Code of Practice for Conducting Experiments in Non-Patient Human 
Volunteers including Handling and Disposal of Human Blood, Urine and Sputum to 
the Human Tissue Act 2004‘ (Commencement No1) order 2005 
(www.legislation.gov.uk/ukpga/2004/30/contents) 
re-approved by the University Ethics Committee on October 26, 2001 
 
 
 
 
9. In cases where subjects will be identified from information held by another 
party (e.g., a doctor or hospital), describe how you intend to obtain this 
information. Include, where appropriate, which Multi Centre Research Ethics 
Committee or Local Research Ethics Committee will be applied to. 
 
As the study will be conducted in the district of Abbottabad located in the Hazara 
region of Khyber Pakhtunkhwa province in Pakistan, the ethics will also be submitted 
to the research ethics committee of Ayub Medical College Abbottabad.  
 
 
 
10. Specify whether subjects will include students or others in a dependent 
relationship and, where possible, avoid recruiting students who might feel to be, 
or be construed to be, under obligation to volunteer for a project. This is most 
likely to be when a student is enrolled on a course where the investigator is a 
teacher. In these circumstances, the recruitment could be carried out by one of 
the other investigators or a suitably qualified third party. 
 
 
N/A 
 
 
11. Specify whether the research will include children or participants with 
mental illness, disability or handicap. If so, please explain the necessity of 
involving these individuals as research subjects and include documentation of 
the suitability of those researchers who will be in contact with children (e.g., 
Disclosure Scotland or membership of the PVG Scheme). 
 
The participants of this study will be primary school children from Pakistan aged 
between 5-10 years with mild to moderate malnutrition. In Pakistan prevalence of  
malnutrition including malnutrition in children between 5-12 years  is very high and 
has serious impediment to the development of the nation (Mian, Ali et al. 2002, 
Pappas, Agha et al. 2008). Investigation of benefits of high energy supplements in 
children who have not yet developed severe malnutrition is of great importance. This  
study will provide evidence on the impact of solid ready to eat  and liquid ready to 
drink supplements on weight gain in mild to moderate malnourished children and 
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suggests which type of supplement might be the best when supplementation takes 
place in community rather than hospital settings (Diop, Dossou et al. 2003). Children 
less than 8 years of age will be given a pictorial form of the recruitment procedure 
along with the consent or assent form. Parent/carer will be requested to give consent 
in the case of participants who are unable to give consent on their own behalf. A 
volunteer information sheets for the participants will be given along with a written 
informed consent in an easy to understand language (it will be translated to the local 
language Urdu) to parent/care and to the participants. An explanation will be given to 
the participants and the parent/carer about all aspects of the research study by the 
researcher at the same time. 
 
The main researcher of the study, Dr Sadia Fatima will be in contact with the 
children. Dr Sadia Fatima is a qualified doctor and is a registered medical practitioner 
in Pakistan. She has experience of one and a half year of working as a medical officer 
in Pakistan. In addition Dr Sadia Fatima is the mother of two children and knows how 
to approach and talk to children. Dr Sadia Fatima has attended a Good Clinical 
Practice (GCP) Workshop in the first year of her PhD training, through which she 
developed an understanding of ethical issues and informed consent. This GCP 
workshop was conducted by Glasgow Clinical Research Facility in Tennet Building 
Church street Glasgow. This workshop mainly focused on the fact that good clinical 
practice is the rules or guidelines by which clinical trials are conducted. These rules 
provide guarantee that the data provided and results obtained are rational and accurate 
as well as protects participant‘s confidentiality, safety and well being.    
 
 
12. Will payment or other incentive, such as a gift or free services, be made to 
any research subject? If so, please specify, and state the level of payment to be 
made and/or the source of the funds/gift/free service to be used. Please explain 
the justification for offering an incentive. 
 
 
N/A 
 
 
 
13. Please give details of how consent is to be obtained. A copy of the 
proposed consent form, along with a separate information sheet, written 
in simple, non-technical language MUST ACCOMPANY THIS 
PROPOSAL FORM. 
  
Keeping in mind the age of legal capacity, Scotland Act 1991, all participants who are 
considered mentally competent to give consent on their own behalf will be asked to 
give an informed consent. 
Competence is defined as; 
―The ability of a person, given the necessary information, to understand the nature 
and the consequences of the proposed procedure or treatment, and to use that 
information to make a valid choice in accordance with their own fundamental values‖ 
Children less than 8 years of age will be given a pictorial form of the recruitment 
procedure along with the consent or assent form. Legal guardians or parents will be 
requested to give consent in the case of participants who are unable to give consent on 
their own behalf. 
Volunteer information sheets for the participants will be given along with a written 
informed consent in an easy to understand language (it will be translated to the local 
language Urdu) to parent/care. An explanation will be given to the participant and the 
carer about all aspects of the research study by the researcher at the same time. 
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Children or the parent/carer of the children will be asked to complete a health check 
questionnaire to exclude those with any chronic illnesses, gastrointestinal problems or 
surgery or some allergies to nuts, peanuts or milk. The health check questionnaire 
form is attached. 
 
 
14. Comment on any cultural, social or gender-based characteristics of the 
subjects which have affected the design of the project or may affect its 
conduct. 
 
The participants of this study will be primary school children between the ages of 5-
10 years with mild to moderate malnutrition between -2 Z-score and -1 Z-score. 
 
 
 
 
 
 
15. Please state (i) who will have access to the data and (ii) what measures will be 
adopted to maintain the confidentiality of the research subjects and to comply 
with data protection requirements. For example, will the data be anonymised, 
how will it be stored, how will access be restricted, and for how long will it be 
retained? 
 
Every participant will be allocated an alphanumeric subject code and no names or 
personal details of the participants will be stored by electronic means. The 
information obtained from the participants will be linked anonymised and individual 
information will not be passed on to anyone outside the researchers listed in the study 
i.e. Dr Dalia Malkova, Dr Konstantinos Gerasimidis, Professor Charlotte Wright
 
and 
Dr Sadia Fatima. Linked anonymous data will be analyzed and stored in the form of 
an excel sheet within the secure network of the University of Glasgow which is a 
virtual private network (VPN) set up by Glasgow University IT services and is 
accessible to Dr Sadia Fatima only. Initially the hard copies with the participant‘s 
details will be locked in a personal cabinet with Dr Sadia Fatima. Later on the hard 
copies will be shifted to the locked cabinet within the premises of the Human 
Nutrition Unit, University of Glasgow. For long term data storage, the data will be 
stored in locked cabinets under the supervision of the principal investigator. Data will 
be stored for 10 years after completion of study and will be disposed off thereafter as 
per hospital/University policy. 
 
 
 
16. To your knowledge, will the intended group of research subjects be involved 
in other research? If so, please justify. 
 
Not during the duration of the study. 
 
 
17. Proposed starting date:  
                        May 2013 
      Expected completion date:     
 
                       June 2014 
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18. Please state location(s) where the project will be carried out. 
 
This study will be conducted in 7-10 primary schools of the district of Abbottabad 
located in the Hazara region of Khyber Pakhtunkhwa province in Pakistan. 
 
 
19. Please state briefly any precautions being taken to protect the health and 
safety of researchers and others associated with the project (as distinct from the 
research subjects), e.g., where blood samples are being taken. 
 
No blood, urinary or stools samples will be collected in this study.  
 
 
 
 
 
20. Please state all relevant sources of funding or support for this study.  
 
Dr Sadia Fatima has a secured PhD scholarship from the Khyber Medical University, 
Pakistan which pays tuition fees and a monthly stipend for 3 years, and a small 
research bursary 
 
 
 
 
21a). Are there any conflicts of interest related to this project for any member of 
the research team? This includes, but is not restricted to, financial or commercial 
interests in the findings. If so, please explain these in detail and justify the role of 
the research team. For each member of the research team please complete a 
declaration of conflicts of interest below. 
 
There are no conflicts of interest 
 
 
Researcher Name: ______Dr Sadia Fatima______________ conflict of interest Yes / 
No 
If yes, please detail below 
 
Researcher Name: ___Dr Dalia Malkova_______________________ conflict of 
interest Yes / No 
If yes, please detail below 
 
Researcher Name: _Dr Konstantinos Gerasimidis_______         conflict of interest 
Yes / No 
If yes, please detail below 
 
Researcher Name: _Prof.  Charlotte Wright________________ conflict of interest 
Yes / No 
If yes, please detail below 
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21b). If there are any conflicts of interest, please describe these in detail and 
justify conducting the proposed study. 
 
N/A 
 
 
 
 
22. How do you intend to disseminate the findings of this research? 
 
The results of the study shall be disseminated through presentations to clinical 
colleagues and dieticians through research symposium, workshops and conferences. 
Findings will also be disseminated as a presentation in the Nutrition Society meeting 
and as peer reviewed papers. 
 
I confirm that have read the University of Glasgow‟s Data Protection Policy.  
[http://www.gla.ac.uk/services/dpfoioffice/policiesandprocedures/dpa-policy/]     
 
Please initial box 
 
 
Name ______Dr Sadia Fatima______________________    Date 
_04.04.2013_______________ 
(Proposer of research) 
Please type your name on the line above. 
 
For student projects: 
 
I confirm that I have read and contributed to this submission and believe that 
the methods proposed and ethical issues discussed are appropriate. 
 
I confirm that the student will have the time and resources to complete this 
project.  
 
 
Name __Dr Dalia Malokva_____________________    Date 
___04.04.2013_____________ 
(Supervisor of student) 
Please type your name on the line above. 
 
 
Please upload the completed and signed form, along with other required 
documents by logging in to the Research Ethics System at - 
https://frontdoor.spa.gla.ac.uk/login/ 
 
 
 
 
 
  
 
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Appendix II a, b, c, d 
VOLUNTEER INFORMATION SHEET 
  
Effect of high energy nutritional supplement drinks on appetite, 
appetite hormones and dietary intake 
 
You are being invited to take part in a research study.  Before you decide 
whether or not to take part, it is important for you to understand why the 
research is being done and what it will involve.  Please take time to read the 
following information carefully and discuss it with others if you wish.  Ask us 
if there is anything that is not clear or if you would like more information.  
Take time to decide whether or not you wish to take part. Thank you for 
reading this. 
 
What is the purpose of the study? 
 
High energy nutritional supplement drinks (HENSD) are commonly prescribed 
to under-nourished patients but it is not clear if they are effective, particularly 
in children, whose appetite tends to be spoiled by snacks and drinks between 
meals.  We first need to find out what effect these ultra high energy drinks 
have on appetite, biochemical markers of appetite and food consumption 
during all day healthy slim adults, before going on to study their effect, using 
less invasive methods, in children.  We will recruit 19 slim adults and to attend 
our lab twice each and eat two meals, once after a HENSD and once after a 
similar tasting low energy drink.  Series of blood samples will be taken and 
appetite and energy intake consumed during these meals and for the rest of the 
day will be measured.  
 
Why have I been chosen? 
 
You have been chosen because you are a healthy adult aged between 18-45 
years who is somewhat slimmer than the ideal weight for your height. 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part.  If you do decide to take 
part you will be given this information sheet to keep and be asked to sign a 
consent form. If you decide to take part you are still free to withdraw at any 
time and without giving a reason.  A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
 
A. SCREENING PROCEDURES 
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Before enrolling in the study you will be asked to attend for a screening visit in 
which we will: 
 discuss with you and complete confidential questionnaires 
regarding your health  
 measure your height and weight and some of the skinfolds 
 provide an opportunity for you to ask questions 
 
These screening procedures will enable us to determine whether you fall into 
the group of people we wish to study  
 
B. EXPERIMENTAL TESTS 
 
We will ask you to undergo 2 main experimental tests lasting fro the duration 
of ~ 8 hours On the day of each experimental test you will be asked to come to 
the metabolic investigation suite at ~ 08:30. Upon arrival we will collect an 
expired air samples to measure how many calories you burn at rest. We will 
then place a tiny plastic tube called a ‗cannula‘ into a vein in your forearm, 
from which we will take blood samples This is no more painful than a simple 
blood test. A total of 200 ml of blood will be taken over the course of the day 
(a small cupful, less than half the amount when you donate a pint of blood). 
You will be given 240 ml of one of the preload liquid meals and be asked to 
consume it entirely within 5 minutes. You will be asked to take a standard 
dose of oral paracetamol (1500 mg in 100 ml of water) at the same time with 
the administration of the preload drink. In 90 minutes you will then be given 
breakfast, and later on lunch Blood, expired air, and appetite ratings will be 
collected throughout the experimental test. You will be allowed to leave after 
lunch and instructed to record all food and drink consumed during the rest of 
the day.  
 
What do I have to do? 
 
Other than the specific tasks described above, we ask you to maintain your 
usual lifestyle (i.e. don‘t change your diet or exercise habits) for the duration 
of this study. We will ask you to record your food intake throughout the day 
before the first experimental test and to replicate the food intake prior to the 
second one. We also ask you to avoid alcohol and any planned exercise 2 days 
prior to each main trial. 
 
What are the possible disadvantages and risks of taking part? 
 
Blood sampling via the cannula may cause minor bruising, an inflammation of 
the vein or haematoma (a small accumulation of blood under the skin). Good 
practice, however, minimises this risk.  Some people may feel faint when they 
give blood. 
 
What are the possible benefits of taking part? 
 
There may be no direct benefits to you but as a result of being involved in this 
study you will receive health information about yourself including body fat 
measurement. You will also receive information on your habitual intake of 
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energy, and nutrients. The findings of this study will be published in scientific 
journals so that understanding about high energy supplements can help slim 
people to improve their energy intake. This information may contribute 
towards guidelines on the consumption of high energy supplements 
We will provide you with feedback about the main study findings and also 
about your own results and would be delighted to explain our findings and 
discuss their implications with you. 
 
What if something goes wrong? 
 
The chance of something going wrong is extremely small.  All of the 
procedures involved in this study are low risk and our screening tests are 
designed to ensure that you will only participate if it is safe for you to do so. In 
the unlikely event that you are harmed due to someone's negligence, then you 
may have grounds for a legal action but you may have to pay for it.  
Regardless of this, if you wish to complain, or have any concerns about any 
aspect of the way you have been approached or treated during the course of 
this study, the normal University of Glasgow complaints mechanisms may be 
available to you. 
 
Will my taking part in this study be kept confidential? 
 
Any information which is collected about you during the course of the research 
will be kept strictly confidential. Any findings from the study that that are 
published will have your name and address removed so that you cannot be 
recognised. We will not pass on confidential personal information to others. 
 
Who has reviewed the study? 
 
This study has been reviewed and approved by Faculty of Medicine Ethics 
Committee for Non Clinical  Research Involving Human Subjects 
 
Contact for Further Information 
 
Any questions about the procedures used in this study are encouraged. If you 
have any doubts or questions, please ask for further explanations by contacting 
Sadia Fatima e- mail: s.fatima.1@gla.ac.uk   
Dr Dalia Malkova, e-mail: Dalia.Malkova@clinmed.gla.ac.uk 
 
You will be given a copy of this information sheet and a signed consent 
form to keep for your records. 
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  VOLUNTEER INFORMATION SHEET                   
Impact of High Energy Nutritional Supplement Drink (HENSD) 
consumed for five days on appetite, appetite regulators, resting 
and post prandial energy expenditure, and energy intake 
 
 
You are being invited to take part in a research study.  Before you decide 
whether or not to take part, it is important for you to understand why the 
research is being done and what it will involve.  Please take time to read the 
following information carefully and discuss it with others if you wish.  Ask us 
if there is anything that is not clear or if you would like more information.  
Take time to decide whether or not you wish to take part. Thank you for 
reading this. 
 
What is the purpose of the study? 
 
High energy nutritional supplement drinks (HENSD) are commonly prescribed 
to under-nourished patients but it is not clear if they are effective. We first 
need to find out what effect these ultra high energy drinks have on appetite, 
biomarkers of appetite and food consumption during all day in healthy slim 
individuals, before going on to study of their effect on those who are 
malnourished and have impaired health .In our previous study we found that 
consumption of HENSD in the morning   by young, healthy, slim, young 
women benefited daily energy intake. In clinical practice high energy 
supplements are consumed in the evening rather than in the morning and are 
prescribed for several days or weeks. Therefore, this study aims to find 
whether enhancement in daily energy intake can be achieved when HENSD 
supplements are consumed on day by day basis and when intake of supplement 
takes place in the evening.   
We will recruit 22 slim healthy women not suffering from any recognised 
eating disorder. Volunteers will be invited to attend our lab on two occasions 
and eat three meals, on one occasion after a five days supplementation with 
HENSD and on another after five days supplementation with similar tasting 
low energy drink.  Series of blood samples will be taken and appetite and 
energy intake consumed during three meals will be measured.  
 
Why have I been chosen? 
 
You have been chosen because you are a healthy slim women aged between 
18-45 years  
 
Do I have to take part? 
 
 
309 
 
It is up to you to decide whether or not to take part.  If you do decide to take 
part you will be given this information sheet to keep and be asked to sign a 
consent form. If you decide to take part you are still free to withdraw at any 
time and without giving a reason.  A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
 
A. SCREENING PROCEDURES 
 
Before enrolling in the study you will be asked to attend for a screening visit in 
which we will: 
 Discuss with you about this study and complete confidential 
questionnaires regarding your health  
 Measure your height and weight. Height will be measured with a 
portable stadiometer. Body weight will be measured with the help 
of digital Tanita scale. Your weight will be measured wearing light 
weight cloths without shoes. You will stand with both the feet 
placed flat on the balance without socks and arms will be 
positioned laterally along the side of the body.  
 Provide an opportunity for you to ask questions 
 
These screening procedures will enable us to determine whether you fall into 
the group of people we wish to study  
 
B. EXPERIMENTAL TESTS 
 
We will ask you to undergo 2 main experimental tests lasting for the duration 
of ~ 12 hours. Prior both experimental tests, you will be provided with 
chocolate flavoured drink and asked to consume it for five consecutive days. 
On the day of the experimental test you will be asked to come in the fasted 
state to the metabolic investigation suite of the York hill Hospital at ~ 08:30. 
Upon arrival we will collect an expired air samples to measure how many 
calories you burn at rest.   For these measurements we will ask you to lie in a 
supine position and relax for ~10 min. Then a transparent ventilated plastic 
hood will be placed over your head which is required for the measurements. 
You will be asked to stay under the ventilated plastic hood for the duration of 
20 minutes. The measurements will be recorded on computer screen. 
We will then place a tiny plastic tube called a ‗cannula‘ into a vein in your 
forearm, from which we will take blood samples. This is no more painful than 
a simple blood test. A total of 90 ml of blood will be taken over the course of 
the day (less than one fifth of the amounts when you donate a pint of blood). 
You will then be given breakfast, and later on lunch and dinner. Blood, expired 
air, and appetite ratings will be collected throughout the experimental test.  
 
What do I have to do? 
 
Other than attending screening session and participating in two experimental 
trials, during 5 days leading to the main experimental trials you will be asked 
to consume chocolate flavoured drink. Prior the first experimental trial, you 
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will also be asked to record food and drink intake and your physical activity 
and then replicated it prior your second trial.   
 
What are the possible disadvantages and risks of taking part? 
 
Blood sampling via the cannula may cause minor bruising, an inflammation of 
the vein or haematoma (a small accumulation of blood under the skin). Good 
practice, however, minimises this risk.  Some people may feel faint when they 
give blood. 
 
What are the possible benefits of taking part? 
 
There may be no direct benefits to you but as a result of being involved in this 
study you will receive some information about your current health. You will 
also receive information on your habitual intake of energy and nutrients. The 
findings of this study will be published in scientific journals so that 
understanding about high energy supplements can help slim people to improve 
their energy intake. This information may contribute towards guidelines on the 
consumption of high energy supplements. We will provide you with feedback 
about the main study findings and also about your own results and would be 
delighted to explain our findings and discuss their implications with you. 
 
What if something goes wrong? 
 
The chance of something going wrong is extremely small.  All of the 
procedures involved in this study are low risk and our screening tests are 
designed to ensure that you will only participate if it is safe for you to do so. In 
the unlikely event that you are harmed due to someone's negligence, then you 
may have grounds for a legal action but you may have to pay for it.  
Regardless of this, if you wish to complain, or have any concerns about any 
aspect of the way you have been approached or treated during the course of 
this study, the normal University of Glasgow complaints mechanisms may be 
available to you. 
 
Will my taking part in this study be kept confidential? 
 
Any information which is collected about you during the course of the research 
will be kept strictly confidential. Any findings from the study that that are 
published will have your name and address removed so that you cannot be 
recognised. We will not pass on confidential personal information to others. 
 
Who has reviewed the study? 
This study has been reviewed and approved by Faculty of Medicine Ethics 
Committee for Non Clinical Research Involving Human Subjects. 
Contact for Further Information 
Any questions about the procedures used in this study are encouraged. If you 
have any doubts or questions, please ask for further explanations by contacting 
Sadia Fatima e- mail: s.fatima.1@research.gla.ac.uk 
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Dr Dalia Malkova, e-mail: Dalia.Malkova@clinmed.gla.ac.uk 
 
You will be given a copy of this information sheet and a signed consent 
form to keep for your records. 
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INFORMATION SHEET 
 
Impact of solid and liquid supplements on weight gain of 
children 
 
(8-10 Years; CHILDERN) 
 
We are asking you to join us in our research about the impact of 
solid and liquid supplements on weight gain in children. Before you 
join us, we want you to understand why this research is important 
and why you are being asked to join in. Please consider this 
pamphlet carefully and discuss it with your parents. We will be 
happy to answer your questions.  
 
Why we are doing this research?                                                                              
 
Solid and liquid supplements are very effective in the weight gain 
of thin, slim children. We want to find out which supplement is 
better for weight gain in children.  
                                                       
Why have I been chosen? 
                                            
Your have been chosen because you are a healthy slim 
child between 5-10 years. We will be inviting 64 other 
children of your age and health. This will be a four week 
study. 
 
 
 
Do I have to take part?  
 
It is up to you to decide whether or not to take part. If you agree 
to take part, you will be given a form which says you are happy. If 
you want to stop, you can do so by telling your teacher or your 
parents. 
 
What will happen if I take part? 
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If you agree to take part, we will measure your height and weight 
and ask you some questions about your health.  
 
 
 
 
 
 
 If you are eligible for the study, than we will measure your upper 
arm, and skinfold.  
 
 
 
 
 
 
Then we will provide you supplements daily in the 
morning for 28 days.  
 
We will measure your height, weight, skinfolds and 
mid-upper-arm circumference before the 
supplementation, two weeks after the start of supplementation, and 
after the completion of supplementation. 
 
You have to mark a questionnaire about 
your appetite before the provision of first 
and last supplement. 
 
 
 
 
We will not let anybody know that you are taking part in our 
research. 
 
 
Are there any benefits or risks to taking part? 
 
There are no benefits or risks to 
you if you participate in this 
research. 
 
 
OR 
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Thank you for reading this 
315 
 
316 
 
 
 
VOLUNTEER INFORMATION SHEET 
 
Impact of solid and liquid supplements on weight gain and appetite of children 
between 5 to 10 years  
 
 
Your child is being invited to take part in a research study. Before you decide whether or 
not your child should take part, it is important for you to understand why the study is being 
done and what it will involve. Please take time to read the following information carefully  
 
and discuss it with others if you wish. Ask us if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not you wish your child to 
take part. Thank you for reading this. 
 
What is the purpose of the study? 
 
It has been shown that solid ready to eat food supplements are very effective in the 
treatment of severe malnutrition. For example, a study conducted on severely 
malnourished Senegalese children in a therapeutic feeding centre demonstrated that 
increase in energy intake and weight gain achieved by supplementation with ready to use 
food was even higher in comparison to changes induced by consumption of a traditional 
high energy drink based on milk. This study aims to compare the efficacy of the high 
energy nutritional solid ready to eat and liquid milk based supplements on the weight gain 
of mild to moderate malnourished children aged between 5 and 10 years. 
 
Why has my child been chosen? 
 
Your child has been chosen because he/she is a healthy slim child between 5-10 years not 
suffering from any recognized eating disorders. This will be a four week study. 
 
Does my child have to take part? 
 
It is up to you to decide whether or not your child should take part. If you do decide to take 
part you will be given this information sheet to keep and be asked to sign a consent form. 
If you decide to take part, you are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not affect 
the standard of care your child receives. 
 
 
What will happen to my child if he/she takes part? 
 
A. SCREENING PROCEDURES 
 
The height of your child will be measured with a height measuring scale. Body weight will 
be measured with the help of an electronic scale. The weight of the child will be measured 
wearing light weight clothes without shoes. The child will stand with both feet placed flat 
on the balance and arms positioned laterally along the side of the body. These methods are 
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safe and it does not hurt. This screening procedure will enable us to determine whether 
your child falls into the group of children we wish to study. 
 
B. INTERVENTION 
 
It is still not clear which supplement is the best for the prevention of mild to moderate 
malnutrition in children. This is why one group of recruited children will receive a solid 
supplement and the other group a liquid supplement. The groups will be decided by 
chance.  
The supplements will be provided to the child daily for the duration of four weeks. The 
supplements will be delivered to the school and given to your child on a daily basis. We 
will measure height, body weight, skinfolds and mid-upper-arm circumference of the child 
before supplementation, two weeks after initiation of supplementation, and after the 
completion of supplementation. The skinfolds of the upper arm will be measured with the 
help of a skinfold measuring caliper while mid -upper-arm circumference will be measured 
with the help of a measuring tape. The child will be asked to fill in the appetite 
questionnaire before the provision of the first and the last supplement. All these procedures 
will take no longer than 15-20 minutes and will be performed in the school. The 
parent/carer will be requested to come to school to discuss their child‘s appetite once 
before the start and once at the end of the supplementation. This will take no longer than 
15-20 minutes.  
 
What does my child have to do? 
 
Other than attending the screening session, your child will be requested to consume liquid 
or solid nutritional supplements for four weeks. Height, body weight, skinfolds and mid-
upper-arm circumference of the child will be measured before the supplementation, two 
weeks after the initiation of supplementation, and after the completion of supplementation. 
The child has to mark an appetite questionnaire before the provision of the first and the last 
supplement. Your child will be asked to keep the empty bottles/sachet of the supplements 
with him, which will be collected by the researcher next day. The parent/carer of the child 
will be requested to join two focus groups, and discuss their child‘s appetite. 
 
 
What are the possible disadvantages and risks of taking part? 
 
We do not anticipate any potential risk to children or their parent/carer in taking part in this 
study. 
 
 
What are the possible benefits of taking part? 
 
The children participating in this study will benefit directly by receiving supplements 
which will improve the nutritional needs of the children. Parent/carer will receive some 
information about their child‘s current health. Moreover dietary counselling for the 
parent/carer of the child will be done. We will provide parent/carer with feedback about 
the main study findings. The findings of this study will be published in scientific journals. 
This study will help to understand and compare the impact of liquid and solid nutritional 
supplements in preventing under-nutrition among children in their community. This 
information may contribute towards guidelines on the consumption of high energy 
supplements.  
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Will my child taking part in this study be kept confidential? 
 
Any information which is collected about your child during the course of the research will 
be kept strictly confidential. Your child will be identified by an ID number. Any 
information about your child will not contain his/her name and address so your child 
cannot be recognised. Furthermore findings from the study that are published will contain 
only the results. We will not pass on confidential personal information to others. 
 
Who has reviewed the study? 
 
This study has been reviewed and approved by the College of Medical, Veterinary and Life 
Sciences Ethics Committee for Non Clinical Research Involving Human Subjects and the 
Research Ethics Committee of Ayub Medical College Abbottabad.  
 
Contact for Further Information 
 
Any questions about the procedures used in this study are encouraged. If you have any 
doubts or questions, please ask for further explanations by contacting 
Sadia Fatima e- mail: s.fatima.1@research.gla.ac.uk 
Dr Dalia Malkova, e-mail: dalia.malkova@glasgow.ac.uk 
 
 
 
You will be given a copy of this information sheet and a signed consent form to keep 
for your records.  
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Appendix III a, b, c, d 
 
 
Centre Number: 
Study Number: 
Subject Identification Number for this trial: 
 
CONSENT FORM 
Title of Project: 
 
Effect of high energy nutritional supplement drinks on appetite, appetite hormones 
and dietary intake 
 
Name of Researchers: Dr Dalia Malkova,  Dr Konstantinos Gerasimidis,  Professor 
Charlotte Wright
 
Dr Sadia Fatima 
 
   Please initial box 
1. I confirm that I have read and understand the information sheet dated 
  for the above study and have had the opportunity to ask questions. 
  
 
2. I understand that my participation is voluntary and that I am free to    
 withdraw at any time, without giving any reason, without my legal rights  
       being affected. 
 
3.    I agree to take part in the above study.       
 
 
           
Name of subject Date Signature 
 
 
    
Name of Person taking consent             Date                         Signature 
(if different from researcher) 
 
 
   
Researcher Date Signature 
 
 
 
1 for subject; 1 for researcher 
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Centre Number: 
Study Number: 
Subject Identification Number for this trial: 
 
CONSENT FORM 
 
Title of Project: 
 
Impact of High Energy Nutritional Supplement Drinks (HENSD) consumed for five 
days on appetite, metabolic appetite regulators, resting and post prandial energy 
expenditure, and energy intake 
 
Name of Researchers: Dr Dalia Malkova, Dr Konstantinos Gerasimidis, Professor 
Charlotte Wright
 
Dr Sadia Fatima 
   Please initial box 
1. I confirm that I have read and understood the information sheet  
  for the above study and have had the opportunity to ask questions. 
  
 
2. I understand that my participation is voluntary and that I am free to    
 withdraw at any time, without giving any reason, without my legal rights  
       being affected. 
 
3.    I agree to take part in the above study.       
 
 
 
 
           
8.1.1.1 Name of subject Date Signature 
 
 
    
8.1.1.2 Name of Person taking consent  Date Signature 
(if different from researcher) 
 
 
   
8.1.1.3 Researcher Date Signature 
 
 
 
1 for subject; 1 for researcher 
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Centre Number: 
Project Number: 
Subject Identification Number for this trial: 
 
CONSENT FORM 
 
Title of Project: Impact of solid and liquid supplements on weight gain of children 
 
Name of Researcher(s): Dr Dalia Malkova, Dr Konstantinos Gerasimidis, Professor 
Charlotte Wright,
 
Dr Sadia Fatima 
  
To be completed by the child (or if unable, the parent on their behalf).Please circles your 
answers: 
Have you read or has somebody else explained this project to you?      Yes / No  
Do you understand what this project is about?                                                   Yes / No 
 
Have you asked all the questions you want?                                                       Yes / No 
 
Have you had your questions answered in a way that you understand?              Yes / No 
 
Do you understand that it‘s OK to stop taking part at any time?                         Yes / No 
 
Are you happy to take part?                                                                                  Yes / No 
 
If any answers are „no‟ or you don‟t want to take part, don‟t sign your name‼ 
 
If you do want to take part, you can sign your name below 
 
Your name    
 
Signature 
 
Date                   
 
The researcher who explained this project to you needs to sign too 
 
Print name 
 
Signature 
 
Date                                                                                                    
                                                                                                     Thank you for your help 
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Centre Number: 
Project Number: 
Subject Identification Number for this trial: 
CONSENT FORM 
 
Title of Project: Impact of solid and liquid supplements on weight gain of children. 
 
Name of Researcher(s): Dr Sadia Fatima, Dr Dalia Malkova, Dr Konstantinos 
Gerasimidis, Professor Charlotte Wright. 
                      Please initial box 
1. I confirm that I have read and understood the information sheet dated............ 
        for the above study. I have had the opportunity to consider the information, ask 
        questions and have had these answered satisfactorily. 
  
2. I understand that my child‘s participation is voluntary and that I and my child are 
       free to withdraw at any time, without giving any reason, without my child‘s legal 
       rights being affected. 
 
3.    I agree for my child to take part in the above study.       
 
 
           
Name of carer/parent of participant            Date                  Signature 
 
 
    
Name of Person taking consent             Date Signature 
(if different from researcher) 
 
 
   
Researcher Date Signature 
 
 
 
1 for subject; 1 for researcher 
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Appendix IV a, b 
 
HEALTH SCREEN FOR STUDY VOLUNTEERS 
 
Name: ………………………………………………………. 
 
It is important that volunteers participating in research studies are currently in good health 
and have had no significant medical problems in the past.  This is to ensure (i) their own 
continuing well-being and (ii) to avoid the possibility of individual health issues 
confounding study outcomes. 
 
Please complete this brief questionnaire to confirm fitness to participate: 
 
1. At present, do you have any health problem for which you are: 
(a) on medication, prescribed or otherwise  yes [ ] no [ ] 
(b) attending your general practitioner   yes [ ] no [ ] 
(c) on a hospital waiting list    yes [ ] no [ ] 
2. In the past two years, have you had any illness which required you to: 
(a) consult your GP      yes [ ] no [ ] 
(b) attend a hospital outpatient department   yes [ ] no [ ] 
(c) be admitted to hospital      yes [ ] no [ ] 
3. Have you ever had any of the following: 
(a) Convulsions/epilepsy        yes [    ]      no [    ]         
(b) Asthma         yes [    ]      no [    ]  
(c)Eczema          yes [    ]      no [    ]        
(d) Diabetes         yes [    ]      no [    ]       
(e) A blood disorder        yes [    ]      no [    ]        
(f) Head injury         yes [    ]      no [    ]      
(g)  Digestive problems        yes [    ]      no [    ]       
(h) Hearing problems        yes [    ]      no [    ]       
(i) Problems with bones or joints      yes [    ]      no [    ]        
(j) Disturbance of balance/co-ordination      yes [    ]      no [    ]       
(k) Numbness in hands or feet       yes [    ]      no [    ]        
(l) Disturbance of vision        yes [    ]      no [    ]      
(m) Thyroid problems        yes [    ]      no [    ]      
(n) Kidney or liver problems       yes [    ]      no [    ]      
(o) Chest pain or heart problems       yes [    ]      no [    ]      
(p) Any other health problems       yes [    ]      no [    ]      
(q) Are you pregnant or think that you might be pregnant  yes [    ]      no [    ]       
(r) Do you take the contraceptive pill or other hormone-based contraceptives                 
yes        [ ] no [ ] 
(s)  Are you postmenopausal     yes [   ]   no [   ]                     
(t) Are you receiving Hormone Replacement Therapy (HRT)   yes [     ]   no [     ] 
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5.  Have any of your immediate family ever had any of the following: (if yes please give 
details including age of first diagnosis) 
(a) Any heart problems     yes [ ] no [ ]           
(b) Diabetes      yes [ ] no [ ]          
(c)  Stroke       yes [ ] no [ ]         
(d)  Any other family illnesses    yes [ ] no [ ] 
6. Do you currently smoke     yes [ ] no [ ] 
 Have you ever smoked     yes [ ] no [ ] 
 If so, for how long did you smoke and when did you stop? …………………… 
5. How many units of alcohol do you typically drink in a week? …………………. 
 
If YES to any question, please describe briefly if you wish (e.g. to confirm whether 
problem was short-lived, insignificant or well controlled.) (Use a separate sheet if 
necessary) 
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………….….…………………………………………………
………………………………………………………………………………………………
…………………………………………………………………………………..……………
………………………………………………………………………………………………
………….……………………………………………………………………………………
………………………………. 
 
Name and address of GP 
………………………………………………………………………………… 
     
…………………………………………………………………………………  
 
Blood pressure measured at screening…………………..mm Hg  
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HEALTH CHECK QUESTIONNAIRE FOR PARTICIPANTS 
 
Name: ……………………………   Sex...........................      Date of birth......................... 
Date of Assessment............................................. 
Anthropometry data; 
Height (cm).....................................     Weight (kg).................................. 
It is important that volunteers participating in research studies are currently in good health 
and have had no significant medical problems in the past.  This is to ensure (i) their own 
continuing well-being and (ii) to avoid the possibility of individual health issues 
confounding study outcomes. 
Please complete this brief questionnaire to confirm fitness to participate: 
 
1. Have you used antibiotics in the past month?                                              Yes/No 
2. Have you used any other medications apart from antibiotics?                      Yes/No 
 
         Please give details 
                             .................................................................................................... 
                             ...................................................................................................... 
                                                                 
3. Have you had any recent illness or disease?                                                    Yes/No 
 
Please give detail 
                                     
 ..................................................................................................... 
              ..................................................................................................... 
                           
4. Are you allergic to any food like peanuts, nuts or milk?                         Yes/No 
 
Please give detail 
                                     
    .................................................................................................... 
    ...................................................................................................... 
                                          
5. Do you use dietary supplements like vitamins/protein shakes etc?          Yes/No 
6. Are you suffering from any chronic illness? 
 
 Please give detail 
                                     
       ..................................................................................................... 
       ...................................................................................................... 
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7. Have you ever had gut surgery?                                                      Yes/No 
Please give detail 
................................................................................................... 
            ...................................................................................................... 
 
8. Have you observed any recent weight changes?                               Yes/No                                        
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Appendix V 
Appetite Questionnaire 
 
Please answer the following questions by placing a vertical mark through the line for each 
question. Regard the end of each line as indicating the most extreme sensation you have 
ever felt and mark how you feel NOW. 
Time:                                  
 
 
 
1. How hungry do you feel (now)? 
            
                                                                                   
              
2. How satisfied do you feel (now)? 
   
 
 
                                                                                                                 
                      
 
 
3. How full do you feel (now)? 
 
 
            
 
4. How much do you think you can eat (now)? 
 
 
                    
 
            5. How strong is your desire to eat (now)? 
 
 
               
  
 
 
 
  
I am not 
hungry 
Never been 
hungrier 
I am not 
satisfied  
at all 
I cannot 
eat another 
bite 
Not at all full Totally full 
A lot 
Nothing at 
all 
Not at all  Very 
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Appendix VI 
 
FOOD INVENTORY INSTRUCTIONS 
 
It is important that you weigh and record everything that you eat and drink for the two 
days prior to your visit to the metabolic room at Yorkhill Hospital.  Please do not take any 
alcohol on these days.  Your last food and drink should be taken 12 hours before your 
arrival to the hospital.   
 
Please (i) start a separate page for each day. 
 (ii) start a separate line for each item. 
 
Column 1 
Record meal and time and place of eating. 
 
Column 2 
Describe each item as accurately as possible, stating where relevant: 
 (i) type and brand 
 (ii) whether food is fresh, dried, canned, frozen, salted, smoked, etc. 
 (iii) whether food is cooked, if so give method of cooking e.g. fried, baked, etc. 
 
Column 3 
Record the weight of each item after cooking: 
 (i) place scales on a level surface 
 (ii) place plate or container on top of scales 
 (iii) press ‗ON/Reset‘ button to turn on scales 
 (iv) once zero appears, add first item of food 
 (v) record weight displayed 
 (vi) press reset button before weighing next item 
Wherever possible, record weights in grams.  If this is not possible, record weights in 
household measures (e.g. sugar or jam in teaspoons, stating whether level, rounded, or 
heaped). 
 
Column 4 
Record the weight of any leftovers, such as food remaining on plate, weight of container in 
which food has been weighed, apple cores, etc. 
 
Columns 5 and 6 
Please leave blank. 
 
If food consists of several items, please list each on a separate line i.e. instead of writing 
‗one cheese sandwich‘, record separately the weights of bread margarine, cheese, etc. 
 
Please remember to record all drinks, as well as food, giving weights where possible, or 
volumes if these are known.  Record separately the weights of added milk and sugar. 
 
An example is shown overleaf. 
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Food Inventory - Example 
 
Name______________________________________    Date _____________________ 
 
1. 2. 3. Weight of 4. Weight of Leave 
Time/Place Description of food/drink food/drink container/ Blank 
  (g) leftovers (g)  
Breakfast Cornflakes (Kelloggs) 28    
8:30am Milk (Sainsbury‘s virtually fat-free) 48    
Home Bread (Mothers Pride, large white  76    
 sliced, toasted)     
 Flora margarine 7    
 Robinsons lemon marmalade 12    
 Coffee (instant) 2    
 Milk (whole pasteurised) 10    
      
Lunch Cheese (Cheddar) 55    
1:00pm Bread (white, crusty) 76    
Pub Butter 4    
 Chutney (2 teaspoons)     
      
Snack Coffee (instant) 2    
3:30pm Coffee-mate 6    
Office Mars Bar 35    
 Apple 76 8 (core)   
      
Dinner Turkey Fillet (frozen, grilled) 102    
6:30pm Potatoes, old, boiled 320 74   
Home   (leftover)   
 Peas (Birds Eye, frozen, boiled) 50    
 Heinz tomato ketchup 14    
 Yoghurt (Ski strawberry thick and  162 10   
 creamy)  (carton)   
 Coffee, filter 148    
 Milk (Sainsbury‘s virtually fat-free)  8    
      
Snack Banana 107    
7:45pm Orange Tango (can) 330    
Home      
      
330 
 
Food Inventory 
 
Name___________________________________           Date ____________________ 
 
1. 2. 3. Weight of 4. Weight of Leave 
Time/Place Description of food/drink food/drink container/ Blank 
  (g) leftovers (g)  
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
  
331 
 
Appendix VII 
 
 
 
 
Questionnaire Regarding Child‟s Appetite (A) 
 
Read out the following statements and tick the boxes most appropriate to the child‘s eating 
behaviour  
 
1) At present how is your child‟s appetite? 
a) Extremely good        
b) Very good 
c) Good  
d) Average 
e) Poor 
 
2) Does your child leave food on his/her plate  
a) Always 
b) Often 
c) Sometimes 
d) Never 
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Questionnaire Regarding Child‟s Appetite (B) 
 
Read out the following statements and tick the boxes most appropriate to the child‘s eating 
behaviour  
 
1) At present how is your child‟s appetite? 
a) Extremely good        
b) Very good 
c) Good  
d) Average 
e) Poor 
 
2) Does your child leave food on his/her plate  
a) Always 
b) Often 
c) Sometimes 
d) Never 
 
3) Does your child like the taste of these supplements? 
a) Extremely    
b) Very much 
c) Little bit 
d) Not at all 
 
4) Have you observed any changes in your child after the start of these 
supplements? 
a) Weight gain/growth 
b) Loss of appetite 
c) Behaviour changes 
d) Any other 
 
5) How do you rate the supplements 
a) Very good 
b) Quite good 
c) Poor 
d) Very good 
e)  
6) Would you like to use these supplements again? 
a) Definitely  
b) Maybe 
 
